
CANCER INCIDENCE IN MASSACHUSETTS 2008 – 2012:

CITY AND TOWN SUPPLEMENT

Office of Data Management and Outcomes Assessment

Massachusetts Department of Public Health

June 2016



This page intentionally left blank.

CANCER INCIDENCE IN MASSACHUSETTS 2008 – 2012:

CITY AND TOWN SUPPLEMENT

Charlie Baker, Governor
Karyn Polito, Lieutenant Governor
Marylou Sudders, Secretary of Health and Human Services
Monica Bharel, Commissioner of Public Health

Tom Land, Director, Office of Data Management and Outcomes Assessment
Susan T. Gershman, Director, Massachusetts Cancer Registry
Massachusetts Department of Public Health

June 2016

This page intentionally left blank.

ACKNOWLEDGMENTS

This report was prepared by Susan T. Gershman, Director, Massachusetts Cancer Registry, and Massachusetts Cancer Registry staff and consultants. Special thanks are extended to the following: Richard Knowlton and Annie MacMillan for their diligent work in the preparation of this report, Steve Pankowicz formerly of the Mass CHIP Program for his time and his excellent work in creating a program for formatting the tables in the report, staff of the Massachusetts Cancer Registry for their editing and data processing efforts, and Gail Merriam and the staff of the Comprehensive Cancer Control Program for updating the section on Cancer Control Initiatives and Publications.

Massachusetts Cancer Registry Staff

Susan T. Gershman, MS, MPH, PhD, CTR, <i>Director</i>	
Bruce Caldwell, <i>Research Analyst/Geocoder</i>	Jeremiah Nesser, <i>Technical Assistant to Non-Hospital Reporting</i>
Nancy Donovan, MA, CTR, <i>Cancer Registrar</i>	Jayne Nussdorfer, CTR, <i>Cancer Registrar</i>
Patricia J. Drew, CTR, <i>Cancer Registrar/Quality Assurance Coordinator</i>	Barbara J. Rhodes, CMA, CTR, <i>Cancer Registrar/Death Clearance Coordinator</i>
Loi Huynh, <i>Software Developer</i>	Pamela Shuttle, CTR, RHIT, <i>Cancer Registrar/Non-Hospital Reporting Coordinator</i>
Richard Knowlton, MS, <i>Epidemiologist</i>	Hung Tran, <i>Software Developer</i>
Ann MacMillan, MPH, <i>Epidemiologist</i>	
Mary Mroszczyk, CTR, <i>Geocoding/ Special Projects Coordinator</i>	

Massachusetts Cancer Registry Advisory Committee

	Lindsay Frazier, MD, ScM (<i>Chair</i>)
Anita Christie, RN, MHA, CPHQ	Larissa Nekhlyudov, MD, MPH
Deborah Dillon, MD	Al Ozonoff, MA, PhD
Joanna Haas, MD	Paul C. Shroy, MD, MPH
Carol Lowenstein, CTR, MBA	Mark Smith, PhD, MS
Reggie Mead	Ingrid Stendhal, CTR
Gail Merriam, MSW, MPH	Susan Sturgeon, DrPH, MPH
J. David Naparstek, ScM., CHO	Jan Sullivan, MS

The data in this report are intended for public use and may be reproduced without permission. Proper acknowledgement of the source is requested.

For further information, please contact the following:

Massachusetts Cancer Registry.....	(617) 624-5642
Research and Epidemiology.....	(617) 624-5642
Occupational Health Surveillance.....	(617) 624-5632
Bureau of Environmental Health.....	(617) 624-5757
Cancer Prevention and Control Network.....	(617) 624-5479
Massachusetts Department of Public Health website.....	www.mass.gov/dph

We acknowledge the Centers for Disease Control and Prevention for its support of the staff and the printing and distribution of this report under cooperative agreement 5 NU58 DP003920-04-00 awarded to the Massachusetts Cancer Registry at the Massachusetts Department of Public Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

This page intentionally left blank.

CONTENTS

	<u>Page</u>
INTRODUCTION AND METHODS	
Introduction	1
Content	1
Comparison with Previous Reports	1
Methods	2
Data Sources	2
Presentation of Data	3
Observed and Expected Case Counts	3
Standardized Incidence Ratios	3
Statistical Significance and Interpretation of SIRs	4
Example of Calculation of an SIR and Its Significance	5
Notes about Data Interpretation	5
Data Limitations	6
Border Areas and Neighboring States	6
Cases Diagnosed in Non-Hospital Settings	6
City/Town Misassignment	7
Small Numbers of Cases	7
TABLES	
Observed and Expected Counts, with Standardized Incidence Ratios, by Sex, for 351 Cities and Towns, 2008 - 2012	9
APPENDICES	
APPENDIX I	
International Classification of Diseases for Oncology (Third Edition) Codes Used for This Report	364
APPENDIX II	
Selected Resources for Information on Cancer	365
APPENDIX III	
Massachusetts Department of Public Health Cancer Prevention and Control Initiatives	366
REFERENCES	367

This page intentionally left blank.

INTRODUCTION

Content

The purpose of this report is to provide an estimate of cancer incidence for each of the 351 cities and towns of Massachusetts for the five-year time period 2008 through 2012. For each city and town, Standardized Incidence Ratios (SIRs) are presented for twenty-three types of invasive cancer and for all invasive cancer types combined. These ratios compare the cancer incidence experience of each city or town with the cancer experience of the state as a whole. The method involves comparing the number of cases that were observed for a city or town to the number of cases that would be expected if the city or town had the same cancer rates as the state as whole. The report is organized into the following sections:

METHODS PROVIDES a detailed explanation of the data collection, data processing, and statistical techniques employed in this report.

TABLES present data for selected types of cancer by city/town and sex.

APPENDIX I provides a listing of *International Classification of Diseases for Oncology* codes used in the preparation of this report.

APPENDIX II provides selected resources for information on cancer.

APPENDIX III describes the Massachusetts Department of Public Health's current cancer control initiatives, and provides links to bureaus within the department that address some aspect of cancer. Links to resources for publications are also provided.

Comparison with Previous Reports

This report updates previous annual reports published by the Massachusetts Cancer Registry (MCR). It is available on line at <http://www.mass.gov/dph/mcr>. For questions about the report, contact the MCR at:

Massachusetts Cancer Registry
Office of Data Management and Outcomes Assessment
Massachusetts Department of Public Health
250 Washington Street, 6th floor
Boston, MA 02108-4619
telephone 617-624-5642; fax 617-624-5695

The preceding report, *Cancer Incidence in Massachusetts 2007-2011: City and Town Supplement*, included data for diagnosis years 2007 through 2011. This report contains data for the diagnosis years 2008 through 2012. There have been no changes in this report's format from the previous report.

METHODS

Data Sources

Cancer Incidence

The MCR collects reports of newly diagnosed cancer cases from health care facilities and practitioners throughout Massachusetts. Facilities that reported the 2008-2012 diagnoses that comprise this report include 69 Massachusetts acute care hospitals, 5 radiation/oncology centers, 2 endoscopy centers, 2 surgical centers, 10 independent laboratories, 3 medical practice associations, and approximately 500 private practice physicians. The MCR signed the modified National Data Exchange Agreement on March 28, 2013. This is a single agreement that allows participating states to exchange data on cases diagnosed or treated in other areas. Together with states participating in the agreement, and states with individual agreements, the MCR now has reciprocal reporting agreements with 37 states and with Puerto Rico and Guam to obtain data on Massachusetts residents diagnosed out of state. Currently the MCR collects information on *in situ* and invasive cancers and benign tumors of the brain and associated tissues. The MCR does not collect information on basal and squamous cell carcinomas of the skin.

The MCR also collects information from reporting hospitals on cases diagnosed and treated in staff physician offices when this information is available. Not all hospitals report this type of case, however, some hospitals report such cases as if the patients had been diagnosed and treated by the hospital directly. Collecting these types of data makes the MCR's overall case ascertainment more complete. Some cancer types that may be reported to the MCR in this manner are melanoma, prostate, colon/rectum, and oral cancers.

In addition, the MCR identifies previously unreported cancer cases through review of death certificate data to further improve case completeness. This process is referred to as death clearance and identifies cancers mentioned on death certificates that were not previously reported to the MCR. In some instances, the MCR obtains additional information on these cases through follow-up activities with hospitals, nursing homes, hospice residences, and physicians' offices. In other instances, a cancer-related cause of death recorded on a Massachusetts death certificate is the only source of information for a cancer case. Thus these "death certificate only" cancer diagnoses are poorly documented and have not been confirmed by review of clinical and pathological information. Such cases are included in this report, but they comprise less than 3% of all cancer cases.

All case reports that provided the basis for this report were coded following the *International Classification of Diseases for Oncology, Third Edition* (ICD-O-3), which was implemented in North America with cases diagnosed as of January 1, 2001. (1) Please see Appendix A for the classification of cancers by ICD-O3 codes.

Each year, the North American Association of Central Cancer Registries (NAACCR) reviews cancer registry data for quality, completeness, and timeliness. For 2008-2012, the MCR's annual case count was estimated by NAACCR to be more than 95% complete for each year. The MCR has achieved the gold standard for this certification element as well as for six other certification elements for each case year since 1997.

The Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among Massachusetts residents during 2008-2012 and reported to the MCR as of December 18, 2015. These data include some additional cases diagnosed in 2008-2011 that were not counted in the previous report, *Cancer Incidence in Massachusetts 2007-2011: City and Town Supplement*. The lag time between this report and the annual statewide report of 2008-2012 cancer cases is due to the fact that data for this city and town report needed to be cleaned for accuracy of residence within Massachusetts.

The statewide report presented data at the state level and did not require such accuracy of city and town of residence. The numbers presented in this report may change slightly in future reports, reflecting late reported cases or corrections based on subsequent details from the reporting facilities. Such changes might result in slight differences in numbers and rates in future reports of MCR data, reflecting the nature of population-based cancer registries that receive case reports on an ongoing basis.

Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among Massachusetts residents during 2008-2012. The Massachusetts data presented include invasive cancers only (except cancer of the urinary bladder, where *in situ* cancers are also included). Invasive cancers have spread beyond the layer of cells where they started and have the potential to spread to other parts of the body. *In situ* cancers are neoplasms diagnosed at the earliest stage, before they have spread, when they are limited to a small number of cells and have not invaded the organ itself. Typically, published incidence rates do not combine invasive and *in situ* cancers due to differences in the biologic significance, survival prognosis and types of treatment of the tumors. Cancer of the urinary bladder is the only exception, due to the specific nature of the diagnostic techniques and treatment patterns.

Presentation of Data

Each city and town in Massachusetts is listed alphabetically in the **TABLES** section. The observed number of cases, the expected number of cases, the standardized incidence ratios, and 95% confidence intervals are presented for twenty-three main types of cancer and for all cancer types combined. The “all cancers combined” category includes the twenty-three main types presented in this report and other malignant neoplasms. This category is meant to provide a summary of the total cancer experience in a community. As different cancers have different causes, this category does not reflect any specific risk factor that may be important for this community.

Observed and Expected Case Counts

The *observed* case count (**Obs**) for a particular type of cancer in a city/town is the actual number of newly diagnosed cases among residents of that city/town for a given time period.

A city/town’s *expected* case count (**Exp**) for a certain type of cancer for this time period is a calculated number based on that city/town’s population distribution² (by sex and among eighteen age groups) for the time period 2008-2012, and the corresponding statewide average annual age-specific incidence rates. The city/town level population data for the 2008 to 2012 period in this report was calculated by multiplying 2010 city and town data by five (2).

Standardized Incidence Ratios

A Standardized Incidence Ratio (SIR) is an indirect method of adjustment for age and sex that describes in numerical terms how a city/town’s cancer experience in a given time period compares with that of the state as a whole.

- An SIR of *exactly 100* indicates that a city/town’s incidence of a certain type of cancer is *equal to that expected* based on statewide average age-specific incidence rates.
- An SIR of *more than 100* indicates that a city/town’s incidence of a certain type of cancer is *higher than expected* for that type of cancer based on statewide average annual age-specific

incidence rates. For example, an SIR of 105 indicates that a city/town's cancer incidence is 5% higher than expected based on statewide average annual age-specific incidence rates.

- An SIR of *less than 100* indicates that a city/town's incidence of a certain type of cancer is *lower than expected* based on statewide average age-specific incidence rates. For example, an SIR of 85 indicates that a city/town's cancer incidence is 15% lower than expected based on statewide average annual age-specific incidence rates.

Statistical Significance and Interpretation of SIRs

The interpretation of the SIR depends on both how large it is and how stable it is. Stability in this context refers to how much the SIR changes when there are small increases or decreases in the observed or expected number of cases. Two SIRs may have the same size but not the same stability. For example, an SIR of 150 may represent 6 observed cases and 4 expected cases, or 600 observed cases and 400 expected cases. Both represent a 50 percent excess of observed cases. However, in the first instance, one or two fewer cases would change the SIR a great deal, whereas in the second instance, even if there were several fewer cases, the SIR would only change minimally. When the observed and expected numbers of cases are relatively small, their ratio is easily affected by one or two cases. Conversely, when the observed and expected numbers of cases are relatively large, the value of the SIR is stable.

A 95 percent confidence interval (CI) has been presented for each SIR in this report (when the observed number of cases is at least 5), to indicate if the observed number of cases is significantly different from the expected number, or if the difference is most likely due to chance. A confidence interval is a range of values around a measurement that indicates the precision of the measurement. In this report, the 95% confidence interval is the range of estimated SIR values that has a 95% probability of including the true SIR for a specific city or town. If the 95% confidence interval range *does not* include the value 100.0, then the number of observed cases is significantly different from the expected number of cases. "Significantly different" means there is at most a 5% chance that the difference between the number of observed and expected cancer cases is due solely to chance alone. If the confidence interval does contain the value 100, there is no significant difference between the observed and expected numbers. Statistically, the width of the interval reflects the size of the population and the number of events; smaller populations and smaller observed numbers of cases yield less precise estimates that have wider confidence intervals. Wide confidence intervals indicate instability, meaning that small changes in the observed or expected number of cases would change the SIR a great deal.

Examples:

- SIR = 137.0; 95% CI (101.6 - 180.6) – the confidence interval does not include 100.0 and the interval is above 100.0, indicating that the number of observed cases is *statistically significantly higher* than the expected number.
- SIR = 71.0; 95% CI (56.2 – 88.4) – the confidence interval does not include 100.0 and the interval is below 100.0, indicating that the number of observed cases is *statistically significantly lower* than the expected number.
- SIR = 108.8 95% CI (71.0-159.4) – the confidence interval DOES include 100.0 indicating that the number of observed cases is *NOT statistically significantly different* from what is expected, and the difference is likely due to chance. When the interval includes 100.0, then the true SIR may be 100.0.

Example of Calculation of an SIR and Its Significance

$$\text{SIR} = \frac{\text{OBSERVED CASES}}{\text{EXPECTED CASES}} \times 100$$

The following example illustrates the method of calculation for a hypothetical town for one type of cancer and one sex for the years 2008-2012:

Age Group	<u>Town X</u> Population (A)	<u>State</u> Age-Specific Incidence Rate (B)	<u>Town X</u> Expected Cases (C) = (A) x (B)	<u>Town X</u> Observed Cases (D)
00-04	74,657	0.0001	7.47	11
05-09	134,957	0.0002	26.99	25
10-14	54,463	0.0005	27.23	30
15-19	25,136	0.0015	37.70	40
20-24	17,012	0.0018	30.62	30
UP TO				
85+	6,337	0.0010	6.34	8
Total:			136.35	144

$$\text{SIR} = \frac{\text{Observed Cases}}{\text{Expected Cases}} \times 100 = \frac{(\text{column D total})}{(\text{column C total})} \times 100 = \frac{144}{136.35} \times 100 \approx 106$$

Thus the SIR for this type of cancer in Town X is 106, indicating that the incidence of this cancer in Town X is 6% higher than the corresponding statewide average incidence for this cancer. However, the range for the 95% confidence interval (89.1-124.3) (calculation not shown) indicates that the true value may be as low as 89.1 or as high as 124.3. Also, since the range includes the value 100, it means that the observed number of cases is *not statistically significantly higher or lower* than what is expected.

Whenever the number of observed cases is less than five, the corresponding SIR is neither calculated nor tested for statistical significance. This is indicated with an (nc) (“not calculated”). However, the number of observed and expected cases is shown in these circumstances.

Notes about Data Interpretation

The SIR is a useful indication of the disease categories that have relatively high or low rates for a given community. These statistics, however, should be used with care. Such statistics provide a starting point for further research and investigation into a possible health problem, but they do not by themselves confirm or deny the existence of a particular health problem. Many factors unrelated to disease causation may contribute to an elevated SIR, including demographic factors, changes in diagnostic techniques, and changes in data collection or recording methods over time, as well as the natural variation in disease occurrence.

When reviewing the data tables, it is important to keep in mind that an SIR compares the observed cancer incidence in a particular community with the expected incidence based on statewide average annual age-specific incidence rates. This means that *valid comparisons can only be made between a community and the state as a whole. SIRs for different cities and towns CANNOT and SHOULD NOT be compared to each other.* (Comparisons between two communities would be valid only if there were no differences in the age and sex distributions of the two communities' populations.)

Another point to keep in mind when reviewing these data is the large number of statistical tests being performed in this report. For each of the 351 cities and towns, we evaluate 18 types of cancer that can occur in both males and females, 3 types that occur only in females and 2 types that occur only in males, resulting in 41 gender/cancer categories. This results in 14,391 possible calculations (351 cities and towns x 41 gender cancer categories). Note that gender/cancer categories with less than 5 observed cases are not evaluated for statistical significance, so the actual numbers of tests is slightly lower than 14,391. This is important for the reader because when multiple significance tests are performed, some will result in a significant finding due to chance alone. Based on the number of calculations in this report, we expect 720 significant findings to be due to chance alone. Half of these would be significant excesses (360) and half would be significant deficits (360). There are statistical techniques that can be used to reduce this number, however use of these techniques leads to the opposite problem – true significant differences that may be missed. We choose to err on the side of caution and identify more significant results, knowing that some will be due to chance alone.

Data Limitations

It should be emphasized that apparent increases or decreases in cancer incidence over time might reflect changes in diagnostic methods or case reporting rather than true changes in cancer incidence. Four other limitations must be considered when interpreting cancer incidence data for Massachusetts cities and towns: under-reporting in areas close to neighboring states; under-reporting for cancers that may not be diagnosed in hospitals; cases being assigned to incorrect cities/towns; and standardized incidence ratios based on small numbers of cases.

Border Areas and Neighboring States

Some areas of Massachusetts appear to have low cancer incidence, but this may be due to loss of Massachusetts resident cases who are diagnosed in neighboring or other states and not reported to the MCR. The MCR has reciprocal reporting agreements with 37 states and with Puerto Rico and Guam.

Cases Diagnosed in Non-Hospital Settings

During the time period covered by this report, the MCR's primary information source for most newly diagnosed cases of cancer was hospitals. In addition the MCR collected information from reporting hospitals on cases diagnosed and treated in staff physician offices, when this information was available. Other reporting sources include dermatologists and dermatopathology laboratories, urologists' offices and a general laboratory. Some types of cancer in this report may be under-reported because they are diagnosed primarily by private physicians, private laboratories, health maintenance organizations, radiotherapy centers that escape identification systems used by hospitals. The most common types of cancer diagnosed or treated outside of the hospital include melanoma and prostate cancer. The exact extent of this under-reporting has not been determined, but cases included in this report represent the great majority of cases statewide and provide an essential basis for evaluating statewide cancer incidence patterns.

City/Town Misassignment

In accordance with standard central cancer registry procedures, each case reported to the MCR ideally should be assigned to the city/town in which the patient lived at the time of diagnosis, based on the address provided by the reporting hospital. In practice, however, a patient may provide the hospital with his/her mailing address (e.g., a post office box located outside the patient's city/town of residence); a business address; a temporary address (e.g., the patient is staying with a relative while receiving treatment and reports the relative's address as his/her own); or a locality or post office name (e.g., "Chestnut Hill" rather than "Boston," "Brookline," or "Newton"). In addition, if a patient has moved since being diagnosed, the hospital may report the patient's current address. Because of the large number of cases reported to the MCR, and because data are reported to the MCR via electronic media, most city/town case assignments are performed by an automated computer process. This simplified matching process may misassign some cases based on the reported locality name. When MCR staff become aware of such misassignments, they manually correct the errors. Furthermore, in order to minimize such errors, cases from fifty geographic localities prone to city/town misassignment are reviewed manually.

Small Numbers of Cases

Standardized incidence ratios based on small numbers of cases result in estimates that are very unstable. This situation is common when the population of a city or town is small or if the particular cancer type is rare. SIRs and statistical significance are not calculated when the number of observed cases for a specific category is less than five. In these instances, the observed and expected cases are presented in the tables for qualitative comparison only.

This page intentionally left blank.

TABLES

This page intentionally left blank.

APPENDICES

**APPENDIX I: INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY (THIRD EDITION)
CODES USED FOR THIS REPORT ¹**

<u>Cancer Site / Type</u>	<u>Primary Site Codes</u>	<u>Histologic Type Codes ²</u>
Bladder, Urinary	C67.0 - C67.9	all except 9590 - 9989
Brain and Other Nervous System	C70.0 - C72.9	all except 9590 - 9989
Breast	C50.0 - C50.9	all except 9590 - 9989
Cervix Uteri	C53.0 - C53.9	all except 9590 - 9989
Colon / Rectum	C18.0 - C18.9, C19.9, C20.9, C26.0	all except 9590 - 9989
Esophagus	C15.0 - C15.9	all except 9590 - 9989
Hodgkin Lymphoma	C00.0 - C80.9	9650 - 9667
Kidney and Renal Pelvis ³	C64.9, C65.9	all except 9590 - 9989
Larynx	C32.0 - C32.9	all except 9590 - 9989
Leukemia	C00.0 - C80.9 C42.0, C42.1, C42.4	9733, 9742, 9800 - 9820, 9826, 9831 - 9948, 9963, 9964 9823, 9827
Liver and Intrahepatic Bile Ducts	C22.0, C22.1	all except 9590 - 9989
Lung and Bronchus	C34.0 - C34.9	all except 9590 - 9989
Melanoma of Skin	C44.0 - C44.9	8720 - 8790
Multiple Myeloma	C00.0 - C80.9	9731, 9732, 9734
Non-Hodgkin Lymphoma	C00.0 - C80.9 all except C42.0, C42.1, C42.4	9590 - 9595, 9670 - 9729 9823, 9827
Oral Cavity and Pharynx	C00.0 - C14.8	all except 9590 - 9989
Ovary	C56.9	all except 9590 - 9989
Pancreas	C25.0 - C25.9	all except 9590 - 9989
Prostate	C61.9	all except 9590 - 9989
Stomach	C16.0 - C16.9	all except 9590 - 9989
Testis	C62.0 - C62.9	all except 9590 - 9989
Thyroid	C73.9	all except 9590 - 9989
Uteri, Corpus and Uterus, NOS	C54.0 - C54.9, C55.9	all except 9590 - 9989
All Sites / Types	C00.0 - C80.9	8000 - 9989

¹includes codes added to the *International Classification of Diseases for Oncology, Third Edition* since its publication.

²Only invasive cancers (those with invasive behaviors) are included in this publication except Bladder, Urinary, which includes invasive and *in situ* behaviors. Non-invasive (*in situ*) cancers are not included.

³Massachusetts hospital coding conventions may have assigned some cases to a “not otherwise specified” site category that is not included in this cancer type.

APPENDIX II: SELECTED RESOURCES FOR INFORMATION ON CANCER

This Appendix contains a listing of selected resources for additional information on cancer. Cancers are complex diseases, many of which have multiple factors that may contribute to their development.

For information on cancer risk factors or prevention, you may wish to contact the following:

Cancer Information Service (National Cancer Institute): 1-800-4-CANCER (1-800-422-6237)

Cancer Response Line (American Cancer Society): 1-800-ACS-2345 (1-800-227-2345)

In addition, the following selected Internet websites provide information on cancer. Many of these also provide links to other sites (not listed) which may be of interest.

Massachusetts Department of Public Health: <http://www.mass.gov/dph>

American Cancer Society: <http://www.cancer.org>

Centers for Disease Control and Prevention

Home Page: <http://www.cdc.gov>

Cancer Prevention and Control Program: <http://www.cdc.gov/cancer>

Fruits and Veggies More Matters™ Campaign (nutrition – formerly 5-A-Day Program):
<http://www.FruitsandVeggiesMatter.gov>

National Cancer Institute

Information: <http://www.cancer.gov>

Cancer Literature in PubMed: http://www.cancer.gov/search/cancer_literature

Surveillance, Epidemiology, and End Results (SEER) Program data: <http://seer.cancer.gov>

Your Cancer Risk (Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; formerly at Harvard Center for Cancer Prevention):
<http://www.yourdiseaserisk.wustl.edu>

Oncolink (Abramson Cancer Center of the University of Pennsylvania):
<http://www.oncolink.upenn.edu>

Cancerquest (Emory University – Winship Cancer Institute): www.cancerquest.org

Cancer News on the Net® (information on diagnosis and treatment for cancer patients and their families): <http://www.cancernews.com>

National Coalition for Cancer Survivorship: <http://www.canceradvocacy.org>

APPENDIX III: MDPH CANCER PREVENTION AND CONTROL INITIATIVES

The Massachusetts Department of Public Health is working to reduce the incidence and mortality of cancer in the Commonwealth. Partnerships between MDPH programs, researchers, healthcare providers and nonprofit organizations collect information about cancer, lead quality improvement projects, coordinate evidenced-based workshops for managing living with chronic disease (including cancer), provide education for health professionals and bring shared messages to the public. Our collaborated efforts focus on reducing cancer risk, incidence and mortality through healthy lifestyles, early diagnosis, increased access to care, and improved quality of life for cancer survivors. The Department's programs address the impact of tobacco, alcohol, nutrition, and physical activity on cancer prevention, along with environmental and occupational hazards for cancer. Throughout all of our efforts there is an emphasis on reducing disparate health outcomes and unequal access to cancer care.

MDPH Bureaus and Programs:

Bureau of Environmental Health, www.mass.gov/dph/environmental_health

Bureau of Substance Abuse Services, www.mass.gov/dph/bsas

Comprehensive Cancer Prevention and Control Network, www.mass.gov/compcancer

Cancer Care Coordination Program, www.mass.gov/dph/cccp

Tobacco Cessation and Prevention Program, www.mass.gov/dph/mtcp

Occupational Health Surveillance Program, www.mass.gov/dph/ohsp

Office of Healthy Aging, www.mass.gov/dph/healthyaging

Oral Health Program, www.mass.gov/dph/oralhealth

Division of Prevention and Wellness www.mass.gov/dph/healthpromotion

MDPH publications on cancer prevention and screening are available at the Massachusetts Health Promotion Clearinghouse, www.maclearinghouse.com.

Massachusetts Cancer Registry Publications are available through the Massachusetts Cancer Registry, telephone: 617-624-5642 and on the web at www.mss.gov/dph/mcr.

REFERENCES

1. Fritz A, Percy C, Jack A, et al. (eds). *International Classification of Diseases for Oncology*, 3rd Ed. Geneva: World Health Organization, 2000.
2. The city and town population data for this report are from the United State Census Bureau's city and town 2010 population estimates. The website is:
http://www2.census.gov/census_2010/03-Demographic_Profile/

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	14.7	122.5	(72.6-193.7)	Male	14	10.1	138.3	(75.5-232.0)
Female	7	5.5	128.3	(51.4-264.4)	Female	13	8.6	151.6	(80.6-259.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.1	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	9	8.9	100.7	(45.9-191.1)
Female	63	65.3	96.5	(74.2-123.5)	Female	5	7.6	65.5	(21.1-152.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	6	7.5	80.1	(29.2-174.3)
<u>Colon / Rectum</u>					Female	3	3.2	nc	(nc-nc)
Male	21	17.0	123.7	(76.5-189.1)	<u>Ovary</u>				
Female	21	16.9	124.3	(76.9-190.0)	Female	8	5.9	135.9	(58.5-267.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.2	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	61	57.2	106.6	(81.5-136.9)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.6	nc	(nc-nc)
Male	20	8.8	228.6	(139.5-353.0)	Female	4	2.1	nc	(nc-nc)
Female	8	5.0	158.8	(68.4-312.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.4	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	0.8	767.0	(280.1-1669.4)	Male	3	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	21	13.1	160.4	(99.2-245.2)
Male	3	6.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	4.6	175.2	(75.4-345.3)	Female	18	14.8	121.3	(71.9-191.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.4	111.4	(40.7-242.5)	Male	250	208.0	120.2	(105.8-136.1)
Female	1	1.7	nc	(nc-nc)	Female	258	215.4	119.8	(105.6-135.3)
<u>Lung and Bronchus</u>									
Male	46	27.1	169.7	(124.3-226.4)					
Female	43	29.0	148.1	(107.2-199.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	20.3	103.5	(64.0-158.2)	Male	13	14.2	91.8	(48.8-157.0)
Female	7	7.0	99.6	(39.9-205.2)	Female	17	11.3	150.1	(87.4-240.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.4	183.3	(78.9-361.1)	Male	3	4.1	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	Female	5	3.1	161.3	(52.0-376.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	14	12.5	111.9	(61.1-187.8)
Female	102	90.3	112.9	(92.1-137.1)	Female	14	10.1	139.3	(76.1-233.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.3	nc	(nc-nc)	Male	10	10.8	92.9	(44.5-170.8)
<u>Colon / Rectum</u>					Female	5	4.3	115.5	(37.2-269.4)
Male	20	24.0	83.4	(50.9-128.8)	<u>Ovary</u>				
Female	22	22.1	99.4	(62.3-150.5)	Female	14	8.0	176.0	(96.1-295.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.8	85.5	(27.6-199.6)	Male	10	7.2	139.3	(66.7-256.1)
Female	3	1.4	nc	(nc-nc)	Female	4	6.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.8	nc	(nc-nc)	Male	81	79.7	101.6	(80.7-126.3)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	5.0	nc	(nc-nc)
Male	11	12.4	88.7	(44.2-158.8)	Female	4	2.7	nc	(nc-nc)
Female	5	6.8	73.9	(23.8-172.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.9	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	5	6.0	83.8	(27.0-195.6)
<u>Leukemia</u>					Female	14	17.7	78.9	(43.1-132.4)
Male	9	8.6	105.2	(48.0-199.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	6.0	183.6	(91.5-328.5)	Female	19	20.2	93.8	(56.5-146.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	7.7	nc	(nc-nc)	Male	250	290.2	86.1	(75.8-97.5)
Female	2	2.2	nc	(nc-nc)	Female	299	288.7	103.6	(92.1-116.0)
<u>Lung and Bronchus</u>									
Male	19	37.8	50.3	(30.3-78.6)					
Female	26	37.9	68.5	(44.8-100.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	12.5	160.5	(98.0-247.9)	Male	8	8.0	99.6	(42.9-196.3)
Female	5	4.4	112.7	(36.3-263.1)	Female	5	6.2	80.9	(26.1-188.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	2.3	310.4	(124.4-639.6)	Male	3	2.4	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.1	155.0	(77.3-277.3)
Female	44	48.0	91.6	(66.6-123.0)	Female	6	5.9	101.6	(37.1-221.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	1	5.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.5	nc	(nc-nc)
Male	15	13.7	109.5	(61.2-180.6)	<u>Ovary</u>				
Female	10	13.5	74.0	(35.4-136.1)	Female	4	4.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.4	nc	(nc-nc)	Male	8	4.2	189.2	(81.5-372.8)
Female	0	0.9	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	0.9	nc	(nc-nc)	Male	55	45.2	121.8	(91.7-158.5)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.9	nc	(nc-nc)
Male	9	6.8	133.3	(60.8-253.0)	Female	1	1.7	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	8.6	127.7	(63.7-228.6)
Male	4	4.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.5	173.1	(63.2-376.8)	Female	11	10.9	100.5	(50.1-179.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.2	nc	(nc-nc)	Male	197	166.0	118.7	(102.7-136.4)
Female	0	1.3	nc	(nc-nc)	Female	152	162.7	93.5	(79.2-109.5)
<u>Lung and Bronchus</u>									
Male	34	22.6	150.2	(104.0-209.9)					
Female	22	23.0	95.5	(59.8-144.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.6	86.1	(41.2-158.3)	Male	5	7.1	70.5	(22.7-164.4)
Female	6	4.4	137.2	(50.1-298.6)	Female	4	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	6	2.1	282.3	(103.1-614.4)
Female	2	1.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.3	111.4	(44.6-229.6)
Female	34	42.3	80.4	(55.7-112.3)	Female	9	5.6	162.0	(73.9-307.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	2.3	nc	(nc-nc)
Male	11	12.3	89.4	(44.6-159.9)	<u>Ovary</u>				
Female	12	13.2	91.1	(47.0-159.1)	Female	3	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.0	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	4.3	116.2	(37.4-271.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	45	38.5	116.8	(85.2-156.3)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.6	nc	(nc-nc)
Male	3	5.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	5	7.1	70.5	(22.7-164.6)
Male	2	4.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.3	nc	(nc-nc)	Female	7	9.7	72.5	(29.0-149.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.6	nc	(nc-nc)	Male	134	146.3	91.6	(76.7-108.5)
Female	0	1.3	nc	(nc-nc)	Female	144	149.2	96.5	(81.4-113.6)
<u>Lung and Bronchus</u>									
Male	18	20.6	87.6	(51.9-138.4)					
Female	36	21.9	164.6	(115.3-227.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	36.6	98.5	(68.9-136.3)	Male	20	22.7	88.0	(53.8-136.0)
Female	13	14.7	88.5	(47.1-151.3)	Female	14	18.6	75.2	(41.1-126.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.2	80.3	(25.9-187.5)	Male	5	6.7	74.3	(23.9-173.3)
Female	3	5.7	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	24	20.1	119.2	(76.4-177.4)
Female	156	142.4	109.5	(93.0-128.1)	Female	17	18.7	91.0	(53.0-145.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.6	151.6	(60.7-312.4)	Male	24	15.7	152.8	(97.9-227.4)
<u>Colon / Rectum</u>					Female	9	7.6	118.0	(53.8-224.0)
Male	42	39.6	106.1	(76.5-143.5)	<u>Ovary</u>				
Female	45	44.6	100.8	(73.5-134.9)	Female	11	13.3	83.0	(41.4-148.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	9.4	63.8	(23.3-138.9)	Male	12	12.3	97.9	(50.5-171.1)
Female	3	2.8	nc	(nc-nc)	Female	12	14.5	82.5	(42.6-144.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.5	nc	(nc-nc)	Male	110	123.5	89.1	(73.2-107.4)
Female	4	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	8.4	143.1	(73.8-249.9)
Male	22	18.5	118.9	(74.5-180.1)	Female	5	5.7	87.6	(28.2-204.4)
Female	8	11.7	68.6	(29.5-135.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.9	nc	(nc-nc)
Male	6	5.1	116.6	(42.6-253.9)	<u>Thyroid</u>				
Female	1	1.8	nc	(nc-nc)	Male	7	8.1	86.1	(34.5-177.5)
<u>Leukemia</u>					Female	19	23.9	79.6	(47.9-124.3)
Male	9	14.0	64.4	(29.4-122.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	11.2	80.6	(36.8-153.1)	Female	25	32.4	77.2	(50.0-114.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	11.7	59.7	(23.9-123.0)	Male	461	467.6	98.6	(89.8-108.0)
Female	2	4.2	nc	(nc-nc)	Female	479	501.2	95.6	(87.2-104.5)
<u>Lung and Bronchus</u>									
Male	81	64.6	125.4	(99.6-155.9)					
Female	77	72.1	106.8	(84.2-133.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	13.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	8	10.7	74.9	(32.2-147.5)
<u>Lung and Bronchus</u>									
Male	0	1.9	nc	(nc-nc)					
Female	0	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	15.4	149.1	(94.5-223.8)	Male	14	10.6	132.1	(72.2-221.7)
Female	10	6.2	161.9	(77.5-297.8)	Female	9	9.3	96.9	(44.2-184.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	5	3.1	163.5	(52.7-381.5)
Female	6	2.8	212.6	(77.6-462.7)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	9.3	107.0	(51.2-196.8)
Female	81	71.2	113.8	(90.4-141.5)	Female	11	8.4	130.3	(64.9-233.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	14	7.8	178.8	(97.7-300.0)
<u>Colon / Rectum</u>					Female	5	3.6	140.1	(45.2-327.0)
Male	22	17.8	123.5	(77.4-187.0)	<u>Ovary</u>				
Female	29	19.3	150.2	(100.6-215.7)	Female	8	6.4	124.4	(53.6-245.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	4.3	230.9	(110.5-424.6)	Male	10	5.4	186.0	(89.1-342.1)
Female	1	1.2	nc	(nc-nc)	Female	7	6.0	116.2	(46.6-239.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	58	58.7	98.8	(75.1-127.8)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.7	nc	(nc-nc)
Male	3	9.1	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	3	5.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.4	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	13	13.8	94.1	(50.0-160.9)
Male	9	6.4	140.5	(64.1-266.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.1	98.6	(31.8-230.1)	Female	13	16.0	81.1	(43.2-138.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.7	87.9	(28.3-205.1)	Male	243	216.1	112.4	(98.7-127.5)
Female	3	1.9	nc	(nc-nc)	Female	273	236.8	115.3	(102.0-129.8)
<u>Lung and Bronchus</u>									
Male	30	28.4	105.7	(71.3-151.0)					
Female	44	31.9	137.9	(100.2-185.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	20.6	68.0	(37.1-114.1)	Male	8	13.7	58.5	(25.2-115.2)
Female	2	8.0	nc	(nc-nc)	Female	14	13.4	104.5	(57.1-175.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.8	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	0	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	12.8	62.3	(26.8-122.7)
Female	75	83.0	90.4	(71.1-113.3)	Female	14	11.2	125.5	(68.5-210.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	10	9.3	107.7	(51.5-198.0)
<u>Colon / Rectum</u>					Female	2	4.6	nc	(nc-nc)
Male	17	22.2	76.7	(44.7-122.9)	<u>Ovary</u>				
Female	19	24.5	77.4	(46.6-120.9)	Female	12	8.5	141.1	(72.8-246.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.4	nc	(nc-nc)	Male	5	6.9	72.5	(23.4-169.2)
Female	0	1.5	nc	(nc-nc)	Female	5	7.9	63.3	(20.4-147.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	3.8	nc	(nc-nc)	Male	66	71.7	92.0	(71.1-117.0)
Female	1	3.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.7	nc	(nc-nc)
Male	6	10.7	55.9	(20.4-121.7)	Female	1	3.2	nc	(nc-nc)
Female	5	6.8	73.5	(23.7-171.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	6.6	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	5	6.2	81.3	(26.2-189.7)
<u>Leukemia</u>					Female	5	20.6	24.2	(7.8-56.5)
Male	9	9.6	93.9	(42.8-178.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.3	68.5	(22.1-160.0)	Female	14	19.3	72.6	(39.6-121.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.9	nc	(nc-nc)	Male	199	283.0	70.3	(60.9-80.8)
Female	2	2.4	nc	(nc-nc)	Female	221	303.7	72.8	(63.5-83.0)
<u>Lung and Bronchus</u>									
Male	15	36.8	40.7	(22.8-67.2)					
Female	20	40.9	48.9	(29.9-75.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	34.1	76.1	(49.7-111.6)	Male	21	22.8	92.2	(57.1-141.0)
Female	13	12.9	100.8	(53.6-172.4)	Female	24	18.6	128.9	(82.6-191.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.7	88.9	(32.5-193.6)	Male	8	6.7	119.6	(51.5-235.7)
Female	5	5.8	86.2	(27.8-201.2)	Female	6	5.5	108.6	(39.7-236.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	25	20.1	124.4	(80.5-183.7)
Female	144	145.7	98.8	(83.4-116.4)	Female	17	17.4	97.6	(56.8-156.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.1	nc	(nc-nc)	Male	24	16.8	142.8	(91.5-212.5)
<u>Colon / Rectum</u>					Female	5	7.3	68.3	(22.0-159.4)
Male	28	38.8	72.1	(47.9-104.2)	<u>Ovary</u>				
Female	33	40.1	82.4	(56.7-115.7)	Female	17	13.2	129.2	(75.2-206.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	9.5	73.6	(29.5-151.7)	Male	12	11.9	101.2	(52.3-176.9)
Female	3	2.5	nc	(nc-nc)	Female	11	12.6	87.3	(43.5-156.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.7	nc	(nc-nc)	Male	127	128.8	98.6	(82.2-117.3)
Female	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	8.1	122.7	(58.7-225.7)
Male	12	19.5	61.5	(31.7-107.4)	Female	4	5.0	nc	(nc-nc)
Female	10	11.4	88.0	(42.1-161.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.2	141.7	(51.7-308.4)
Male	2	5.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.7	nc	(nc-nc)	Male	15	9.0	166.5	(93.1-274.7)
<u>Leukemia</u>					Female	34	26.9	126.5	(87.6-176.8)
Male	20	13.8	144.5	(88.2-223.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	10.5	124.2	(66.1-212.5)	Female	28	32.7	85.6	(56.9-123.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	12.3	81.2	(38.9-149.3)	Male	432	470.4	91.8	(83.4-100.9)
Female	2	3.9	nc	(nc-nc)	Female	451	485.9	92.8	(84.5-101.8)
<u>Lung and Bronchus</u>									
Male	37	62.9	58.8	(41.4-81.1)					
Female	41	66.6	61.6	(44.2-83.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.6	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	47.8	92.1	(66.9-123.6)	Male	32	30.7	104.3	(71.4-147.3)
Female	20	19.7	101.4	(61.9-156.7)	Female	28	27.1	103.4	(68.7-149.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	8.7	nc	(nc-nc)	Male	12	9.0	134.1	(69.2-234.2)
Female	8	8.3	96.9	(41.7-191.0)	Female	8	8.3	96.6	(41.6-190.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.5	nc	(nc-nc)	Male	21	27.0	77.7	(48.1-118.7)
Female	234	204.2	114.6	(100.4-130.2)	Female	29	25.8	112.3	(75.2-161.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	7.3	nc	(nc-nc)	Male	14	21.0	66.8	(36.5-112.1)
<u>Colon / Rectum</u>					Female	17	10.6	160.2	(93.3-256.5)
Male	44	52.2	84.3	(61.2-113.2)	<u>Ovary</u>				
Female	54	60.3	89.6	(67.3-116.9)	Female	20	18.7	107.0	(65.3-165.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	12.3	121.6	(68.0-200.5)	Male	12	16.0	75.0	(38.7-131.0)
Female	1	3.8	nc	(nc-nc)	Female	19	19.3	98.2	(59.1-153.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.6	nc	(nc-nc)	Male	154	160.3	96.1	(81.5-112.5)
Female	5	3.2	156.9	(50.6-366.3)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	11.1	90.5	(43.3-166.4)
Male	24	25.1	95.7	(61.3-142.4)	Female	5	7.6	65.7	(21.2-153.3)
Female	14	16.5	84.8	(46.3-142.3)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.2	112.5	(45.1-231.8)
Male	3	6.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	2.5	nc	(nc-nc)	Male	12	11.5	104.1	(53.7-181.8)
<u>Leukemia</u>					Female	36	37.8	95.2	(66.6-131.7)
Male	16	18.8	85.2	(48.7-138.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	15.6	83.4	(44.4-142.6)	Female	41	45.8	89.6	(64.3-121.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	15.5	115.8	(68.6-183.1)	Male	557	618.8	90.0	(82.7-97.8)
Female	3	5.8	nc	(nc-nc)	Female	695	705.5	98.5	(91.3-106.1)
<u>Lung and Bronchus</u>									
Male	71	85.0	83.5	(65.2-105.3)					
Female	77	99.6	77.3	(61.0-96.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	5.7	157.1	(71.7-298.3)	Male	2	4.1	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	20	23.0	86.8	(53.0-134.0)	Female	3	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	2	6.8	nc	(nc-nc)	<u>Ovary</u>				
Female	4	5.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	22	23.6	93.2	(58.4-141.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.8	nc	(nc-nc)
Male	5	2.4	205.4	(66.2-479.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.5	nc	(nc-nc)	Female	5	5.2	95.4	(30.7-222.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	67	83.9	79.8	(61.9-101.4)
Female	0	0.6	nc	(nc-nc)	Female	66	72.9	90.5	(70.0-115.1)
<u>Lung and Bronchus</u>									
Male	6	10.8	55.7	(20.3-121.2)					
Female	8	9.3	85.9	(37.0-169.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.0	nc	(nc-nc)	Male	5	2.2	231.8	(74.7-541.0)
Female	2	0.9	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	13	12.2	106.3	(56.5-181.7)	Female	2	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.0	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	9	12.5	71.9	(32.8-136.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.8	nc	(nc-nc)	Female	5	2.8	180.2	(58.1-420.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	40	44.5	89.9	(64.2-122.4)
Female	2	0.3	nc	(nc-nc)	Female	50	39.0	128.1	(95.1-168.9)
<u>Lung and Bronchus</u>									
Male	3	5.7	nc	(nc-nc)					
Female	5	5.1	98.4	(31.7-229.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	13	9.1	143.5	(76.4-245.5)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	9.3	75.3	(30.2-155.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	22	32.1	68.6	(43.0-103.9)
Female	0	0.2	nc	(nc-nc)	Female	26	29.6	87.7	(57.3-128.6)
<u>Lung and Bronchus</u>									
Male	2	4.3	nc	(nc-nc)					
Female	1	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	14.9	100.7	(56.3-166.1)	Male	6	10.4	57.5	(21.0-125.2)
Female	4	5.4	nc	(nc-nc)	Female	5	8.8	57.1	(18.4-133.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.2	nc	(nc-nc)	Male	6	3.0	200.5	(73.2-436.4)
Female	3	2.7	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	9.2	108.9	(52.1-200.3)
Female	66	67.6	97.7	(75.6-124.3)	Female	4	7.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	3.3	nc	(nc-nc)
Male	10	17.5	57.2	(27.4-105.3)	<u>Ovary</u>				
Female	20	16.8	119.3	(72.8-184.2)	Female	10	6.0	166.0	(79.5-305.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.2	188.5	(81.2-371.5)	Male	6	5.2	114.4	(41.8-249.1)
Female	2	1.0	nc	(nc-nc)	Female	6	5.2	116.3	(42.5-253.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	48	57.7	83.1	(61.3-110.2)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.6	nc	(nc-nc)
Male	9	9.0	99.5	(45.4-189.0)	Female	4	2.1	nc	(nc-nc)
Female	3	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.4	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	5	4.4	112.6	(36.3-262.7)
<u>Leukemia</u>					Female	23	13.8	166.7	(105.6-250.2)
Male	2	6.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	4.6	173.5	(74.7-341.9)	Female	16	15.3	104.2	(59.5-169.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.6	nc	(nc-nc)	Male	179	212.2	84.4	(72.5-97.7)
Female	4	1.7	nc	(nc-nc)	Female	237	219.1	108.1	(94.8-122.8)
<u>Lung and Bronchus</u>									
Male	27	27.5	98.1	(64.6-142.7)					
Female	39	29.0	134.6	(95.7-183.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.2	128.8	(75.0-206.3)	Male	6	8.4	71.1	(26.0-154.8)
Female	4	4.9	nc	(nc-nc)	Female	4	6.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
Female	35	50.2	69.7	(48.5-96.9)	Female	4	6.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	10	5.9	170.0	(81.4-312.7)
<u>Colon / Rectum</u>					Female	4	2.6	nc	(nc-nc)
Male	19	14.5	131.4	(79.1-205.2)	<u>Ovary</u>				
Female	12	15.1	79.5	(41.0-138.8)	Female	7	4.7	150.4	(60.3-309.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.5	173.3	(63.3-377.3)	Male	5	4.5	112.2	(36.2-261.9)
Female	0	0.9	nc	(nc-nc)	Female	5	4.8	103.3	(33.3-241.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.0	nc	(nc-nc)	Male	32	45.9	69.8	(47.7-98.5)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.1	nc	(nc-nc)
Male	9	7.0	129.4	(59.0-245.7)	Female	0	1.9	nc	(nc-nc)
Female	5	4.1	123.1	(39.7-287.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	12	9.1	131.3	(67.8-229.3)
Male	3	5.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.9	128.6	(41.4-300.1)	Female	23	11.3	203.2	(128.8-304.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.4	114.2	(36.8-266.6)	Male	178	173.0	102.9	(88.3-119.2)
Female	1	1.4	nc	(nc-nc)	Female	166	174.4	95.2	(81.3-110.8)
<u>Lung and Bronchus</u>									
Male	38	23.6	160.7	(113.7-220.6)					
Female	28	24.5	114.4	(76.0-165.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	42.5	101.2	(73.2-136.3)	Male	28	28.6	98.0	(65.1-141.7)
Female	15	16.0	93.7	(52.4-154.5)	Female	17	23.7	71.8	(41.8-114.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	8.6	128.6	(64.1-230.1)	Male	5	8.2	60.7	(19.6-141.7)
Female	7	7.3	95.6	(38.3-197.0)	Female	6	6.8	87.8	(32.1-191.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	16	25.3	63.3	(36.2-102.9)
Female	175	177.8	98.4	(84.4-114.1)	Female	19	21.7	87.6	(52.7-136.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	6.5	107.6	(43.1-221.7)	Male	24	20.4	117.9	(75.5-175.5)
<u>Colon / Rectum</u>					Female	10	9.0	110.7	(53.0-203.6)
Male	50	48.2	103.8	(77.0-136.8)	<u>Ovary</u>				
Female	40	49.6	80.7	(57.6-109.9)	Female	31	16.2	191.6	(130.1-271.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	11.5	87.0	(41.7-160.1)	Male	17	14.5	116.9	(68.1-187.2)
Female	5	3.1	163.3	(52.6-381.2)	Female	16	15.6	102.3	(58.5-166.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	3.8	236.6	(108.0-449.2)	Male	143	152.6	93.7	(79.0-110.4)
Female	1	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	10.1	69.3	(27.8-142.9)
Male	18	24.0	74.9	(44.4-118.5)	Female	7	6.2	112.4	(45.0-231.6)
Female	12	14.1	85.4	(44.1-149.2)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.7	89.5	(32.7-194.8)
Male	5	6.4	78.3	(25.2-182.6)	<u>Thyroid</u>				
Female	3	2.1	nc	(nc-nc)	Male	11	11.6	94.8	(47.2-169.6)
<u>Leukemia</u>					Female	24	35.0	68.6	(44.0-102.1)
Male	8	17.5	45.8	(19.7-90.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	13.2	75.7	(36.2-139.2)	Female	43	39.8	108.2	(78.3-145.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	14.8	81.0	(41.8-141.5)	Male	563	577.7	97.5	(89.6-105.8)
Female	10	4.8	207.0	(99.1-380.8)	Female	593	602.0	98.5	(90.7-106.8)
<u>Lung and Bronchus</u>									
Male	101	76.9	131.3	(106.9-159.5)					
Female	90	82.5	109.1	(87.7-134.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	22.3	98.5	(61.7-149.1)	Male	10	13.6	73.7	(35.3-135.5)
Female	9	7.9	114.1	(52.0-216.5)	Female	6	10.3	58.4	(21.3-127.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.7	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	8	3.3	242.8	(104.5-478.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	10	12.0	83.1	(39.8-152.8)
Female	77	78.7	97.9	(77.2-122.3)	Female	13	10.1	128.1	(68.1-219.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	13	9.1	143.6	(76.4-245.6)
<u>Colon / Rectum</u>					Female	2	4.2	nc	(nc-nc)
Male	19	23.6	80.4	(48.4-125.5)	<u>Ovary</u>				
Female	24	23.9	100.6	(64.5-149.7)	Female	8	7.3	110.2	(47.5-217.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.6	89.7	(28.9-209.3)	Male	6	7.4	81.6	(29.8-177.6)
Female	2	1.5	nc	(nc-nc)	Female	7	7.7	90.3	(36.2-186.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	55	71.8	76.6	(57.7-99.7)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.0	nc	(nc-nc)
Male	13	10.8	119.8	(63.7-204.9)	Female	1	3.0	nc	(nc-nc)
Female	6	6.4	93.4	(34.1-203.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.2	nc	(nc-nc)
Male	6	3.0	197.4	(72.1-429.6)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<u>Leukemia</u>					Female	15	13.6	110.6	(61.9-182.4)
Male	10	8.4	119.0	(57.0-218.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.0	82.7	(26.7-193.1)	Female	18	17.8	101.0	(59.8-159.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	6.8	102.4	(41.0-211.0)	Male	239	277.8	86.0	(75.5-97.7)
Female	0	2.3	nc	(nc-nc)	Female	277	274.4	100.9	(89.4-113.6)
<u>Lung and Bronchus</u>									
Male	28	39.2	71.5	(47.5-103.3)					
Female	45	39.7	113.3	(82.6-151.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.4	130.0	(52.1-267.8)	Male	4	3.4	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	25	21.3	117.3	(75.9-173.2)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	4	5.9	nc	(nc-nc)	<u>Ovary</u>				
Female	3	6.2	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	8	18.4	43.4	(18.7-85.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	6	2.8	213.6	(78.0-465.0)	Female	0	0.8	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.7	136.4	(43.9-318.2)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.6	nc	(nc-nc)	Female	1	4.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	1.8	nc	(nc-nc)	Male	77	69.8	110.3	(87.0-137.8)
Female	0	0.6	nc	(nc-nc)	Female	72	73.4	98.1	(76.7-123.5)
<u>Lung and Bronchus</u>									
Male	16	9.7	165.7	(94.7-269.1)					
Female	14	10.8	129.7	(70.8-217.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.4	108.8	(43.6-224.3)	Male	3	4.5	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	4.0	nc	(nc-nc)
Female	35	28.6	122.6	(85.4-170.5)	Female	3	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.4	nc	(nc-nc)
Male	7	7.5	92.8	(37.2-191.3)	<u>Ovary</u>				
Female	6	7.7	77.4	(28.3-168.5)	Female	3	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	1.8	335.0	(122.3-729.1)	Male	3	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	21	24.0	87.5	(54.2-133.8)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.6	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.8	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	9	6.3	142.8	(65.2-271.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.4	nc	(nc-nc)	Male	83	90.7	91.5	(72.9-113.4)
Female	1	0.8	nc	(nc-nc)	Female	104	95.6	108.8	(88.9-131.9)
<u>Lung and Bronchus</u>									
Male	14	11.8	118.4	(64.7-198.7)					
Female	15	12.9	116.0	(64.9-191.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	87	70.8	122.9	(98.5-151.6)	Male	65	42.5	152.8	(117.9-194.8)
Female	26	24.3	107.0	(69.9-156.8)	Female	50	30.8	162.4	(120.5-214.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	11.1	99.3	(49.5-177.6)	Male	11	12.9	85.6	(42.7-153.1)
Female	9	9.5	95.2	(43.5-180.8)	Female	13	10.2	127.2	(67.7-217.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.1	nc	(nc-nc)	Male	39	37.4	104.2	(74.1-142.5)
Female	298	242.4	122.9	(109.4-137.7)	Female	40	31.2	128.3	(91.7-174.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	7.5	119.5	(54.5-226.9)	Male	25	28.5	87.6	(56.7-129.3)
<u>Colon / Rectum</u>					Female	14	12.8	109.2	(59.6-183.2)
Male	63	73.9	85.2	(65.5-109.0)	<u>Ovary</u>				
Female	68	71.9	94.6	(73.5-119.9)	Female	22	22.4	98.3	(61.6-148.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	19	17.9	105.9	(63.7-165.4)	Male	27	23.4	115.5	(76.1-168.0)
Female	3	4.7	nc	(nc-nc)	Female	26	23.6	110.0	(71.8-161.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	4.1	nc	(nc-nc)	Male	295	235.3	125.4	(111.5-140.5)
Female	2	3.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	15.9	106.9	(62.3-171.2)
Male	30	34.2	87.6	(59.1-125.1)	Female	8	9.1	88.3	(38.0-174.0)
Female	19	19.9	95.3	(57.4-148.8)	<u>Testis</u>				
<u>Larynx</u>					Male	9	5.9	151.7	(69.2-288.0)
Male	10	9.8	101.9	(48.8-187.4)	<u>Thyroid</u>				
Female	2	3.2	nc	(nc-nc)	Male	12	14.1	85.2	(44.0-148.8)
<u>Leukemia</u>					Female	25	39.1	64.0	(41.4-94.4)
Male	34	25.9	131.3	(90.9-183.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	26	18.1	143.6	(93.8-210.4)	Female	52	56.5	92.0	(68.7-120.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	22	21.9	100.6	(63.0-152.4)	Male	959	883.2	108.6	(101.8-115.7)
Female	8	7.2	111.7	(48.1-220.0)	Female	918	842.3	109.0	(102.1-116.3)
<u>Lung and Bronchus</u>									
Male	91	126.3	72.1	(58.0-88.5)					
Female	126	125.9	100.1	(83.3-119.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.6	106.7	(39.0-232.2)	Male	3	3.8	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	14	21.5	65.3	(35.6-109.5)	Female	0	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	8	6.4	124.9	(53.8-246.0)	<u>Ovary</u>				
Female	5	5.9	84.5	(27.2-197.2)	Female	1	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	24	21.6	111.3	(71.3-165.6)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	5	3.2	155.1	(50.0-361.8)	Female	2	0.7	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.2	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.6	nc	(nc-nc)	Female	7	4.8	145.1	(58.1-299.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.0	nc	(nc-nc)	Male	77	78.1	98.6	(77.8-123.2)
Female	0	0.6	nc	(nc-nc)	Female	58	71.7	80.9	(61.4-104.6)
<u>Lung and Bronchus</u>									
Male	12	10.3	116.4	(60.1-203.4)					
Female	7	9.6	73.0	(29.3-150.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	9	8.6	104.4	(47.6-198.2)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	2.2	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	10.0	59.7	(21.8-130.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	5	2.1	242.9	(78.3-566.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	25	34.5	72.4	(46.8-106.9)
Female	0	0.2	nc	(nc-nc)	Female	24	28.2	85.1	(54.5-126.7)
<u>Lung and Bronchus</u>									
Male	5	4.7	106.2	(34.2-247.9)					
Female	2	4.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	21.3	103.5	(64.8-156.7)	Male	18	12.5	143.6	(85.1-226.9)
Female	5	6.0	82.9	(26.7-193.4)	Female	3	8.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.3	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	11	11.2	98.6	(49.2-176.5)
Female	58	62.2	93.2	(70.8-120.5)	Female	7	7.8	89.4	(35.8-184.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.1	nc	(nc-nc)	Male	7	8.2	85.0	(34.0-175.1)
<u>Colon / Rectum</u>					Female	4	3.2	nc	(nc-nc)
Male	25	22.3	112.0	(72.5-165.4)	<u>Ovary</u>				
Female	20	18.3	109.3	(66.8-168.9)	Female	1	5.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.2	nc	(nc-nc)	Male	10	6.9	144.5	(69.2-265.7)
Female	2	1.2	nc	(nc-nc)	Female	7	5.9	118.5	(47.5-244.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	60	64.9	92.4	(70.5-118.9)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.7	nc	(nc-nc)
Male	8	9.8	81.3	(35.0-160.2)	Female	4	2.3	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	11	10.7	102.8	(51.2-183.9)
Male	7	7.9	89.0	(35.6-183.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.7	107.1	(34.5-250.0)	Female	11	14.0	78.7	(39.2-140.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.3	nc	(nc-nc)	Male	233	256.5	90.8	(79.5-103.3)
Female	0	1.8	nc	(nc-nc)	Female	187	213.7	87.5	(75.4-101.0)
<u>Lung and Bronchus</u>									
Male	24	36.7	65.4	(41.9-97.4)					
Female	30	30.8	97.5	(65.8-139.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	12.9	69.8	(31.9-132.5)	Male	9	9.2	98.2	(44.8-186.4)
Female	5	4.6	107.6	(34.7-251.2)	Female	6	7.7	77.8	(28.4-169.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.8	210.9	(77.0-459.1)	Male	2	2.6	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	8.1	161.0	(85.6-275.3)
Female	54	60.3	89.5	(67.2-116.8)	Female	7	6.7	104.3	(41.8-214.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	4	7.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	7	2.9	240.2	(96.2-494.9)
Male	14	15.4	90.9	(49.6-152.5)	<u>Ovary</u>				
Female	16	14.6	109.4	(62.5-177.7)	Female	4	5.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	3.8	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	51	52.6	96.9	(72.1-127.4)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.2	187.9	(68.6-409.0)
Male	5	8.1	62.0	(20.0-144.6)	Female	4	1.8	nc	(nc-nc)
Female	3	4.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.0	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	12.2	65.7	(28.3-129.4)
Male	6	5.5	108.9	(39.8-237.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.0	nc	(nc-nc)	Female	16	13.8	116.0	(66.2-188.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.1	nc	(nc-nc)	Male	167	188.6	88.6	(75.6-103.1)
Female	2	1.5	nc	(nc-nc)	Female	173	193.3	89.5	(76.7-103.9)
<u>Lung and Bronchus</u>									
Male	17	24.1	70.6	(41.1-113.1)					
Female	18	25.3	71.3	(42.2-112.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	15.1	72.9	(36.4-130.5)	Male	5	10.5	47.7	(15.4-111.4)
Female	7	5.5	128.0	(51.3-263.8)	Female	11	8.7	126.9	(63.3-227.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.2	187.7	(68.5-408.5)	Male	1	3.0	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	9.2	162.4	(90.8-267.8)
Female	76	66.8	113.8	(89.6-142.4)	Female	15	7.7	194.9	(109.0-321.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.5	nc	(nc-nc)	Male	7	7.7	90.6	(36.3-186.7)
<u>Colon / Rectum</u>					Female	3	3.3	nc	(nc-nc)
Male	12	17.5	68.7	(35.5-120.0)	<u>Ovary</u>				
Female	17	16.9	100.4	(58.5-160.8)	Female	2	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.3	140.6	(51.4-306.1)	Male	6	5.3	114.0	(41.6-248.1)
Female	0	1.1	nc	(nc-nc)	Female	5	5.3	94.8	(30.6-221.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	65	57.7	112.7	(87.0-143.7)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.7	136.8	(44.1-319.2)
Male	8	9.0	88.5	(38.1-174.3)	Female	2	2.1	nc	(nc-nc)
Female	5	5.1	97.2	(31.3-226.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.4	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	13	13.4	97.0	(51.6-165.8)
Male	7	6.3	110.9	(44.4-228.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.6	nc	(nc-nc)	Female	16	15.0	106.7	(61.0-173.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.6	107.4	(39.2-233.8)	Male	222	212.8	104.3	(91.0-119.0)
Female	0	1.7	nc	(nc-nc)	Female	220	218.6	100.6	(87.8-114.8)
<u>Lung and Bronchus</u>									
Male	34	27.9	121.8	(84.3-170.2)					
Female	21	29.6	71.0	(43.9-108.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	28.9	89.9	(58.7-131.8)	Male	15	18.2	82.6	(46.2-136.2)
Female	5	10.6	47.4	(15.3-110.5)	Female	9	14.8	61.0	(27.8-115.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.1	97.3	(31.4-227.1)	Male	6	5.4	112.0	(40.9-243.8)
Female	6	4.6	130.7	(47.7-284.5)	Female	5	4.5	111.6	(36.0-260.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	17	16.0	106.0	(61.7-169.7)
Female	135	113.1	119.4	(100.1-141.3)	Female	9	14.0	64.1	(29.2-121.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.0	nc	(nc-nc)	Male	4	12.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	5.8	nc	(nc-nc)
Male	22	31.3	70.3	(44.0-106.4)	<u>Ovary</u>				
Female	27	32.3	83.6	(55.1-121.6)	Female	11	10.3	106.7	(53.2-190.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.5	67.1	(21.6-156.6)	Male	9	9.7	92.9	(42.4-176.4)
Female	3	2.0	nc	(nc-nc)	Female	9	10.3	87.1	(39.8-165.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	88	97.8	90.0	(72.2-110.9)
Female	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.6	nc	(nc-nc)
Male	9	14.9	60.5	(27.6-114.8)	Female	5	4.1	123.0	(39.6-287.0)
Female	4	9.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.3	nc	(nc-nc)
Male	0	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	9	6.6	136.5	(62.3-259.1)
<u>Leukemia</u>					Female	20	20.8	96.1	(58.7-148.5)
Male	4	11.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	8.4	nc	(nc-nc)	Female	24	25.6	93.9	(60.1-139.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	9.2	nc	(nc-nc)	Male	288	371.8	77.5	(68.8-86.9)
Female	3	3.2	nc	(nc-nc)	Female	350	385.7	90.8	(81.5-100.8)
<u>Lung and Bronchus</u>									
Male	31	51.6	60.1	(40.8-85.3)					
Female	41	54.1	75.7	(54.3-102.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.1	nc	(nc-nc)	Male	5	3.8	131.5	(42.4-306.9)
Female	1	1.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	29	23.6	123.1	(82.4-176.8)	Female	4	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.1	nc	(nc-nc)
Male	6	6.3	95.7	(34.9-208.3)	<u>Ovary</u>				
Female	7	5.3	131.1	(52.5-270.1)	Female	0	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	21.5	88.5	(53.2-138.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	5	3.4	146.4	(47.2-341.7)	Female	1	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	5.1	116.9	(42.7-254.4)
Male	2	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.5	nc	(nc-nc)	Female	5	5.2	96.4	(31.1-224.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.1	nc	(nc-nc)	Male	75	77.3	97.0	(76.3-121.6)
Female	0	0.6	nc	(nc-nc)	Female	86	73.5	117.0	(93.6-144.5)
<u>Lung and Bronchus</u>									
Male	9	9.7	92.4	(42.2-175.4)					
Female	7	9.2	76.5	(30.6-157.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.9	nc	(nc-nc)	Male	5	2.5	201.8	(65.0-471.0)
Female	2	1.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	16	14.4	110.8	(63.3-180.0)	Female	2	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.1	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	12	14.3	83.9	(43.3-146.5)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.5	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	5	3.3	150.7	(48.6-351.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	59	51.7	114.1	(86.9-147.2)
Female	0	0.4	nc	(nc-nc)	Female	44	48.3	91.0	(66.1-122.2)
<u>Lung and Bronchus</u>									
Male	11	7.2	153.3	(76.4-274.3)					
Female	5	7.0	71.0	(22.9-165.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.2	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	6	1.3	447.5	(163.4-974.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	10	10.7	93.4	(44.7-171.7)	Female	3	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<u>Ovary</u>				
Female	5	3.0	169.2	(54.5-394.9)	Female	3	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	16	11.4	140.4	(80.2-228.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.8	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	42	41.9	100.4	(72.3-135.7)
Female	0	0.3	nc	(nc-nc)	Female	38	36.1	105.2	(74.4-144.4)
<u>Lung and Bronchus</u>									
Male	5	5.8	86.2	(27.8-201.2)					
Female	4	5.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	43.4	124.3	(93.4-162.2)	Male	39	27.8	140.2	(99.7-191.7)
Female	23	16.5	139.2	(88.2-208.9)	Female	34	23.1	147.0	(101.8-205.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	7.9	150.9	(77.9-263.7)	Male	9	8.2	110.3	(50.3-209.3)
Female	7	7.1	98.3	(39.4-202.6)	Female	5	7.0	71.6	(23.1-167.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.4	nc	(nc-nc)	Male	29	24.6	117.7	(78.8-169.0)
Female	177	172.9	102.3	(87.8-118.6)	Female	22	21.8	100.8	(63.1-152.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	6.0	nc	(nc-nc)	Male	27	19.5	138.4	(91.2-201.4)
<u>Colon / Rectum</u>					Female	13	9.0	143.8	(76.5-246.0)
Male	32	47.6	67.2	(46.0-94.9)	<u>Ovary</u>				
Female	53	50.6	104.8	(78.5-137.1)	Female	17	16.0	106.2	(61.8-170.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	11.4	104.9	(54.1-183.2)	Male	14	14.7	95.4	(52.1-160.0)
Female	3	3.1	nc	(nc-nc)	Female	13	16.2	80.3	(42.7-137.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.4	nc	(nc-nc)	Male	170	151.6	112.1	(95.9-130.3)
Female	1	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	10.1	49.6	(16.0-115.7)
Male	23	22.9	100.4	(63.6-150.7)	Female	4	6.4	nc	(nc-nc)
Female	15	13.9	107.9	(60.4-178.0)	<u>Testis</u>				
<u>Larynx</u>					Male	10	5.7	175.3	(83.9-322.5)
Male	6	6.3	95.0	(34.7-206.9)	<u>Thyroid</u>				
Female	3	2.1	nc	(nc-nc)	Male	11	10.5	104.8	(52.3-187.6)
<u>Leukemia</u>					Female	35	32.3	108.2	(75.4-150.5)
Male	22	17.1	128.3	(80.4-194.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	13.1	98.9	(52.6-169.1)	Female	39	39.3	99.2	(70.5-135.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	14.5	89.5	(47.6-153.0)	Male	633	571.0	110.9	(102.4-119.8)
Female	13	4.9	264.9	(140.9-452.9)	Female	662	597.0	110.9	(102.6-119.7)
<u>Lung and Bronchus</u>									
Male	87	77.8	111.8	(89.6-138.0)					
Female	97	83.7	115.8	(93.9-141.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	38.2	138.9	(104.0-181.6)	Male	35	26.6	131.7	(91.7-183.1)
Female	18	13.2	136.2	(80.7-215.2)	Female	22	20.9	105.2	(65.9-159.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	8.1	86.4	(34.6-178.1)	Male	12	7.7	156.8	(80.9-273.9)
Female	6	6.4	93.1	(34.0-202.7)	Female	5	5.8	86.3	(27.8-201.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	20	23.4	85.6	(52.2-132.1)
Female	151	161.4	93.6	(79.2-109.7)	Female	20	18.7	107.2	(65.4-165.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.9	nc	(nc-nc)	Male	18	19.7	91.1	(54.0-144.1)
<u>Colon / Rectum</u>					Female	9	7.9	113.8	(51.9-216.1)
Male	28	44.3	63.3	(42.0-91.4)	<u>Ovary</u>				
Female	55	40.7	135.2	(101.8-175.9)	Female	18	14.5	124.5	(73.8-196.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	11.0	100.2	(50.0-179.4)	Male	17	13.5	126.4	(73.6-202.3)
Female	3	2.6	nc	(nc-nc)	Female	10	12.8	78.3	(37.5-144.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.6	nc	(nc-nc)	Male	140	151.3	92.5	(77.8-109.2)
Female	1	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	9.3	97.0	(44.3-184.1)
Male	27	23.1	116.7	(76.9-169.8)	Female	6	5.0	119.7	(43.7-260.5)
Female	11	12.5	88.3	(44.0-158.1)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.3	111.0	(44.5-228.6)
Male	4	6.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	2.0	nc	(nc-nc)	Male	15	11.3	132.9	(74.3-219.2)
<u>Leukemia</u>					Female	31	32.0	96.8	(65.7-137.4)
Male	23	15.9	144.6	(91.6-216.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	20	11.1	180.8	(110.4-279.2)	Female	29	36.8	78.9	(52.8-113.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	14.2	77.6	(38.7-138.9)	Male	573	545.8	105.0	(96.6-113.9)
Female	2	4.2	nc	(nc-nc)	Female	556	528.7	105.2	(96.6-114.3)
<u>Lung and Bronchus</u>									
Male	86	71.5	120.4	(96.3-148.6)					
Female	98	72.2	135.8	(110.2-165.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.0	99.6	(42.9-196.2)	Male	4	5.6	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	5	4.8	104.7	(33.8-244.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.0	100.5	(32.4-234.6)
Female	29	36.2	80.1	(53.7-115.1)	Female	5	4.3	117.3	(37.8-273.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.8	nc	(nc-nc)
Male	6	9.5	63.3	(23.1-137.7)	<u>Ovary</u>				
Female	6	9.6	62.3	(22.7-135.6)	Female	5	3.3	153.1	(49.3-357.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	2.3	352.2	(151.6-694.0)	Male	0	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.8	nc	(nc-nc)	Male	25	30.7	81.5	(52.7-120.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	4	4.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	5	2.8	178.5	(57.5-416.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.3	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.6	193.2	(62.3-450.8)	Female	11	8.1	136.0	(67.8-243.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.0	nc	(nc-nc)	Male	119	113.9	104.5	(86.5-125.0)
Female	0	0.9	nc	(nc-nc)	Female	123	120.0	102.5	(85.2-122.2)
<u>Lung and Bronchus</u>									
Male	25	14.7	169.7	(109.8-250.6)					
Female	16	16.1	99.6	(56.9-161.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	3	5.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	6.7	104.6	(41.9-215.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.0	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	18	23.2	77.5	(45.9-122.5)
Female	0	0.1	nc	(nc-nc)	Female	17	17.5	97.0	(56.5-155.3)
<u>Lung and Bronchus</u>									
Male	3	3.1	nc	(nc-nc)					
Female	3	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	23	19.6	117.1	(74.2-175.7)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	5	5.2	96.0	(30.9-224.0)	<u>Ovary</u>				
Female	2	4.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	24	19.0	126.5	(81.0-188.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.9	nc	(nc-nc)
Male	4	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.2	nc	(nc-nc)	Female	11	4.4	248.4	(123.8-444.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	61	65.0	93.8	(71.7-120.5)
Female	0	0.5	nc	(nc-nc)	Female	57	60.8	93.8	(71.0-121.5)
<u>Lung and Bronchus</u>									
Male	5	8.1	61.6	(19.8-143.7)					
Female	5	7.6	66.1	(21.3-154.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	350	452.6	77.3	(69.4-85.9)	Male	252	313.5	80.4	(70.8-91.0)
Female	155	178.6	86.8	(73.7-101.6)	Female	202	296.3	68.2	(59.1-78.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	76	100.7	75.5	(59.5-94.5)	Male	102	87.2	117.0	(95.4-142.0)
Female	84	90.8	92.5	(73.8-114.5)	Female	115	76.3	150.7	(124.4-180.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	10	14.3	69.8	(33.4-128.3)	Male	297	279.5	106.3	(94.5-119.1)
Female	1823	1991.0	91.6	(87.4-95.9)	Female	238	248.9	95.6	(83.8-108.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	91	80.5	113.0	(91.0-138.8)	Male	251	217.8	115.3	(101.4-130.4)
<u>Colon / Rectum</u>					Female	113	102.6	110.1	(90.8-132.4)
Male	573	511.1	112.1	(103.1-121.7)	<u>Ovary</u>				
Female	587	550.9	106.6	(98.1-115.5)	Female	185	187.4	98.7	(85.0-114.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	116	122.2	94.9	(78.4-113.8)	Male	145	155.2	93.5	(78.9-110.0)
Female	37	34.4	107.7	(75.8-148.5)	Female	185	174.2	106.2	(91.5-122.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	55	57.7	95.3	(71.8-124.0)	Male	1953	1633.1	119.6	(114.3-125.0)
Female	59	53.2	110.8	(84.4-143.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	148	107.5	137.6	(116.4-161.7)
Male	232	258.3	89.8	(78.6-102.2)	Female	104	69.5	149.7	(122.3-181.4)
Female	181	159.3	113.6	(97.7-131.5)	<u>Testis</u>				
<u>Larynx</u>					Male	93	112.7	82.5	(66.6-101.1)
Male	88	67.8	129.7	(104.0-159.8)	<u>Thyroid</u>				
Female	23	24.0	95.7	(60.7-143.6)	Male	152	138.1	110.0	(93.2-129.0)
<u>Leukemia</u>					Female	506	464.2	109.0	(99.7-118.9)
Male	146	196.8	74.2	(62.7-87.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	117	155.5	75.3	(62.2-90.2)	Female	446	448.7	99.4	(90.4-109.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	272	157.0	173.3	(153.3-195.1)	Male	6719	6287.1	106.9	(104.3-109.5)
Female	96	54.5	176.1	(142.6-215.1)	Female	6722	6913.6	97.2	(94.9-99.6)
<u>Lung and Bronchus</u>									
Male	903	818.4	110.3	(103.3-117.8)					
Female	843	928.6	90.8	(84.8-97.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	27.1	125.4	(86.8-175.3)	Male	22	16.8	131.2	(82.2-198.7)
Female	11	9.8	112.0	(55.8-200.4)	Female	16	12.4	128.8	(73.6-209.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.6	131.3	(47.9-285.7)	Male	7	5.0	139.9	(56.0-288.2)
Female	6	3.8	156.4	(57.1-340.3)	Female	3	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	15	14.7	101.7	(56.9-167.8)
Female	89	96.9	91.8	(73.7-113.0)	Female	9	12.6	71.7	(32.7-136.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	14	11.5	122.2	(66.7-205.0)
<u>Colon / Rectum</u>					Female	5	5.1	97.1	(31.3-226.6)
Male	23	28.7	80.2	(50.8-120.4)	<u>Ovary</u>				
Female	20	29.1	68.8	(42.0-106.2)	Female	14	9.0	156.0	(85.2-261.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.1	113.3	(48.8-223.3)	Male	7	9.1	77.2	(30.9-159.0)
Female	6	1.9	317.9	(116.1-691.9)	Female	11	9.6	114.6	(57.1-205.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.9	nc	(nc-nc)	Male	102	93.8	108.7	(88.6-131.9)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.2	81.2	(26.2-189.5)
Male	13	13.7	95.0	(50.6-162.5)	Female	5	3.7	136.1	(43.9-317.6)
Female	7	8.0	87.4	(35.0-180.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.9	nc	(nc-nc)
Male	7	3.9	180.6	(72.4-372.1)	<u>Thyroid</u>				
Female	4	1.3	nc	(nc-nc)	Male	1	5.9	nc	(nc-nc)
<u>Leukemia</u>					Female	17	15.7	108.1	(62.9-173.0)
Male	9	10.3	87.7	(40.0-166.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	7.4	95.2	(38.1-196.1)	Female	22	22.6	97.4	(61.0-147.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.7	57.6	(18.6-134.3)	Male	365	348.4	104.8	(94.3-116.1)
Female	1	2.9	nc	(nc-nc)	Female	341	338.6	100.7	(90.3-112.0)
<u>Lung and Bronchus</u>									
Male	56	49.1	114.1	(86.2-148.1)					
Female	63	50.5	124.9	(95.9-159.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.2	nc	(nc-nc)	Male	5	3.2	157.7	(50.8-368.0)
Female	1	1.3	nc	(nc-nc)	Female	5	2.4	204.7	(66.0-477.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	22	19.8	111.1	(69.6-168.3)	Female	4	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	<u>Ovary</u>				
Female	7	4.4	159.6	(63.9-328.9)	Female	1	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	22	18.4	119.4	(74.8-180.8)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.7	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.0	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.2	nc	(nc-nc)	Female	6	4.5	134.0	(48.9-291.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	58	65.2	88.9	(67.5-115.0)
Female	0	0.5	nc	(nc-nc)	Female	74	60.6	122.0	(95.8-153.2)
<u>Lung and Bronchus</u>									
Male	5	8.1	61.7	(19.9-144.1)					
Female	9	7.5	119.3	(54.4-226.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.2	76.3	(30.6-157.2)	Male	18	6.1	295.1	(174.8-466.5)
Female	1	2.8	nc	(nc-nc)	Female	12	4.3	276.4	(142.6-482.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	4	1.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	5.4	nc	(nc-nc)
Female	45	35.6	126.5	(92.3-169.3)	Female	2	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.7	nc	(nc-nc)
Male	5	10.5	47.7	(15.4-111.3)	<u>Ovary</u>				
Female	6	8.7	68.7	(25.1-149.5)	Female	3	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.6	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	50	36.0	138.9	(103.1-183.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.2	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.5	107.0	(42.9-220.5)
Male	7	3.6	192.6	(77.2-396.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.3	nc	(nc-nc)	Female	6	8.2	73.5	(26.8-160.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.4	nc	(nc-nc)	Male	124	127.8	97.0	(80.7-115.7)
Female	0	0.9	nc	(nc-nc)	Female	114	113.6	100.4	(82.8-120.6)
<u>Lung and Bronchus</u>									
Male	6	17.1	35.0	(12.8-76.3)					
Female	7	15.3	45.8	(18.4-94.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.8	124.6	(45.5-271.2)	Male	4	3.2	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	8	2.5	316.6	(136.3-623.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	27	20.0	135.2	(89.1-196.7)	Female	0	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	3	5.5	nc	(nc-nc)	<u>Ovary</u>				
Female	8	5.2	153.6	(66.1-302.7)	Female	4	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	18.6	69.8	(37.1-119.3)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	1.2	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.7	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	58	67.1	86.5	(65.6-111.8)
Female	0	0.5	nc	(nc-nc)	Female	69	65.8	104.9	(81.6-132.8)
<u>Lung and Bronchus</u>									
Male	4	8.9	nc	(nc-nc)					
Female	6	9.1	66.3	(24.2-144.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	42.6	117.4	(87.2-154.8)	Male	29	26.5	109.3	(73.2-157.0)
Female	23	16.8	136.7	(86.6-205.1)	Female	31	22.2	139.8	(95.0-198.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.4	107.5	(46.3-211.8)	Male	4	7.8	nc	(nc-nc)
Female	7	6.9	102.0	(40.9-210.1)	Female	8	7.0	114.0	(49.1-224.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	26	23.5	110.7	(72.3-162.3)
Female	187	168.2	111.2	(95.8-128.3)	Female	21	21.7	96.8	(59.9-148.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.7	140.5	(60.5-276.9)	Male	18	17.9	100.5	(59.5-158.8)
<u>Colon / Rectum</u>					Female	8	8.8	90.5	(39.0-178.3)
Male	56	45.8	122.3	(92.4-158.8)	<u>Ovary</u>				
Female	74	50.9	145.5	(114.2-182.6)	Female	13	15.5	84.1	(44.7-143.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	10.8	120.3	(64.0-205.7)	Male	13	14.1	92.0	(48.9-157.3)
Female	5	3.2	156.1	(50.3-364.3)	Female	18	16.5	109.2	(64.7-172.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.0	167.1	(53.9-390.0)	Male	132	140.1	94.2	(78.8-111.7)
Female	5	2.7	188.1	(60.6-439.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	9.7	102.9	(49.3-189.3)
Male	18	21.5	83.9	(49.7-132.5)	Female	8	6.5	124.0	(53.4-244.3)
Female	12	13.8	87.1	(45.0-152.1)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.9	nc	(nc-nc)
Male	4	5.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	2.1	287.4	(105.0-625.6)	Male	9	9.5	94.6	(43.1-179.5)
<u>Leukemia</u>					Female	35	29.8	117.4	(81.7-163.2)
Male	11	16.4	66.9	(33.4-119.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	13.1	145.1	(87.3-226.6)	Female	37	37.6	98.3	(69.2-135.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	13.4	119.3	(68.1-193.7)	Male	536	540.7	99.1	(90.9-107.9)
Female	5	4.9	102.5	(33.0-239.3)	Female	671	587.6	114.2	(105.7-123.2)
<u>Lung and Bronchus</u>									
Male	68	75.4	90.2	(70.0-114.3)					
Female	88	85.0	103.5	(83.0-127.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	19.9	85.3	(49.7-136.6)	Male	17	11.2	151.2	(88.0-242.2)
Female	8	7.2	110.4	(47.5-217.5)	Female	16	8.1	196.7	(112.4-319.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.7	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	14	9.9	140.7	(76.9-236.1)
Female	80	64.2	124.6	(98.8-155.1)	Female	12	8.8	135.6	(70.0-236.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	8	7.3	109.7	(47.2-216.1)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	17	20.1	84.6	(49.3-135.5)	<u>Ovary</u>				
Female	16	21.4	74.8	(42.8-121.6)	Female	4	6.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.8	nc	(nc-nc)	Male	6	6.5	92.9	(33.9-202.3)
Female	3	1.4	nc	(nc-nc)	Female	4	7.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	75	62.4	120.1	(94.5-150.6)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.4	nc	(nc-nc)
Male	7	8.8	79.8	(32.0-164.4)	Female	0	2.7	nc	(nc-nc)
Female	5	5.5	91.6	(29.5-213.7)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	8	8.9	89.9	(38.7-177.2)
Male	6	7.0	86.1	(31.5-187.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	5.2	nc	(nc-nc)	Female	15	15.2	98.9	(55.3-163.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.7	nc	(nc-nc)	Male	237	236.3	100.3	(87.9-113.9)
Female	0	2.0	nc	(nc-nc)	Female	216	232.1	93.1	(81.1-106.3)
<u>Lung and Bronchus</u>									
Male	29	34.6	83.7	(56.1-120.3)					
Female	17	35.5	47.8	(27.8-76.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	23.2	116.2	(76.6-169.1)	Male	19	16.5	115.0	(69.2-179.5)
Female	12	7.5	160.4	(82.8-280.3)	Female	17	12.0	141.7	(82.5-226.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.1	117.2	(42.8-255.2)	Male	2	4.7	nc	(nc-nc)
Female	7	3.8	185.0	(74.1-381.2)	Female	3	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	10	14.6	68.4	(32.7-125.7)
Female	88	89.5	98.4	(78.9-121.2)	Female	8	10.6	75.8	(32.7-149.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.3	nc	(nc-nc)	Male	7	12.4	56.5	(22.6-116.4)
<u>Colon / Rectum</u>					Female	6	4.5	134.5	(49.1-292.8)
Male	24	27.4	87.5	(56.1-130.2)	<u>Ovary</u>				
Female	25	23.3	107.5	(69.5-158.6)	Female	10	8.2	122.6	(58.7-225.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.7	119.7	(51.6-235.9)	Male	8	8.3	96.9	(41.7-191.0)
Female	1	1.4	nc	(nc-nc)	Female	12	7.2	166.0	(85.7-289.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.5	nc	(nc-nc)	Male	88	91.6	96.1	(77.1-118.4)
Female	1	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.7	nc	(nc-nc)
Male	11	14.3	76.9	(38.3-137.5)	Female	5	2.9	172.3	(55.5-402.0)
Female	4	6.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	4.5	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	13	7.3	178.1	(94.7-304.6)
<u>Leukemia</u>					Female	27	18.6	145.2	(95.6-211.2)
Male	5	10.0	50.2	(16.2-117.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	6.4	nc	(nc-nc)	Female	15	20.2	74.4	(41.6-122.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	8.8	159.5	(87.1-267.6)	Male	332	336.0	98.8	(88.5-110.0)
Female	3	2.3	nc	(nc-nc)	Female	299	297.3	100.6	(89.5-112.6)
<u>Lung and Bronchus</u>									
Male	55	43.1	127.6	(96.1-166.1)					
Female	31	39.9	77.6	(52.7-110.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.1	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	2.4	205.6	(66.3-479.9)
Female	16	16.6	96.6	(55.2-156.9)	Female	4	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.8	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	<u>Ovary</u>				
Female	1	4.2	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	11	16.4	67.1	(33.4-120.0)
Female	2	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.1	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.1	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	49	57.9	84.6	(62.6-111.9)
Female	0	0.4	nc	(nc-nc)	Female	51	54.1	94.3	(70.2-124.0)
<u>Lung and Bronchus</u>									
Male	6	7.7	78.0	(28.5-169.7)					
Female	11	7.4	148.5	(74.0-265.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	77	82.9	92.9	(73.3-116.1)	Male	32	55.7	57.5	(39.3-81.2)
Female	28	31.8	88.0	(58.5-127.3)	Female	28	48.5	57.7	(38.3-83.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	17.3	69.3	(35.8-121.1)	Male	14	16.0	87.4	(47.7-146.6)
Female	15	15.3	98.0	(54.8-161.6)	Female	14	13.6	102.6	(56.0-172.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.7	nc	(nc-nc)	Male	43	49.4	87.1	(63.0-117.3)
Female	327	359.3	91.0	(81.4-101.4)	Female	43	43.7	98.4	(71.2-132.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	25	13.4	187.2	(121.1-276.4)	Male	39	39.7	98.1	(69.8-134.2)
<u>Colon / Rectum</u>					Female	17	18.2	93.3	(54.3-149.4)
Male	114	93.5	121.9	(100.5-146.4)	<u>Ovary</u>				
Female	109	97.7	111.5	(91.6-134.5)	Female	40	32.9	121.6	(86.9-165.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	22	22.6	97.5	(61.1-147.6)	Male	32	28.5	112.1	(76.7-158.3)
Female	8	6.1	130.8	(56.3-257.7)	Female	37	31.0	119.5	(84.1-164.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	7.8	nc	(nc-nc)	Male	320	303.4	105.5	(94.2-117.7)
Female	8	6.8	117.1	(50.4-230.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	24	19.7	122.0	(78.2-181.6)
Male	57	47.0	121.4	(91.9-157.3)	Female	15	12.3	122.4	(68.4-201.9)
Female	26	28.5	91.3	(59.7-133.9)	<u>Testis</u>				
<u>Larynx</u>					Male	12	13.6	88.1	(45.5-153.8)
Male	17	12.5	135.7	(79.0-217.2)	<u>Thyroid</u>				
Female	6	4.4	137.5	(50.2-299.3)	Male	31	22.7	136.8	(92.9-194.2)
<u>Leukemia</u>					Female	101	72.7	138.8	(113.1-168.7)
Male	26	34.9	74.6	(48.7-109.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	22	26.9	81.8	(51.2-123.8)	Female	78	81.4	95.9	(75.8-119.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	36	29.0	124.0	(86.9-171.7)	Male	1187	1136.5	104.4	(98.6-110.6)
Female	16	9.8	164.0	(93.7-266.4)	Female	1271	1216.1	104.5	(98.9-110.4)
<u>Lung and Bronchus</u>									
Male	184	150.9	122.0	(105.0-140.9)					
Female	202	166.3	121.4	(105.3-139.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.0	150.4	(54.9-327.4)	Male	4	2.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	16	15.7	101.6	(58.1-165.1)	Female	3	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	0.8	nc	(nc-nc)
Male	3	4.5	nc	(nc-nc)	<u>Ovary</u>				
Female	7	4.2	166.1	(66.5-342.2)	Female	1	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	15.8	88.7	(48.5-148.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.8	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	5	3.7	136.9	(44.1-319.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	46	55.5	82.8	(60.6-110.5)
Female	3	0.4	nc	(nc-nc)	Female	57	52.8	107.9	(81.7-139.8)
<u>Lung and Bronchus</u>									
Male	10	7.5	133.7	(64.0-245.8)					
Female	8	7.7	104.5	(45.0-205.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	55.2	97.9	(73.5-127.7)	Male	42	35.5	118.4	(85.3-160.0)
Female	14	20.9	66.9	(36.5-112.2)	Female	43	32.6	131.9	(95.4-177.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	10.5	133.9	(73.1-224.7)	Male	10	10.2	97.8	(46.8-179.8)
Female	10	9.9	100.6	(48.2-185.1)	Female	8	8.9	89.8	(38.7-176.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	40	31.4	127.4	(91.0-173.4)
Female	253	223.9	113.0	(99.5-127.8)	Female	35	28.5	122.9	(85.6-170.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	8.7	nc	(nc-nc)	Male	21	24.0	87.6	(54.2-133.9)
<u>Colon / Rectum</u>					Female	8	11.7	68.2	(29.4-134.4)
Male	38	59.4	63.9	(45.2-87.8)	<u>Ovary</u>				
Female	44	63.9	68.8	(50.0-92.4)	Female	32	21.1	151.3	(103.5-213.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	14.3	41.9	(15.3-91.2)	Male	22	18.5	118.7	(74.4-179.8)
Female	2	4.0	nc	(nc-nc)	Female	26	20.6	126.3	(82.5-185.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	5.0	nc	(nc-nc)	Male	192	189.4	101.4	(87.5-116.8)
Female	6	5.2	114.4	(41.8-249.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	12.7	78.8	(37.7-144.9)
Male	33	28.8	114.7	(79.0-161.2)	Female	9	8.1	111.2	(50.7-211.1)
Female	18	18.1	99.5	(58.9-157.2)	<u>Testis</u>				
<u>Larynx</u>					Male	13	9.4	138.6	(73.7-236.9)
Male	1	7.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	2.7	nc	(nc-nc)	Male	17	13.8	123.5	(71.9-197.7)
<u>Leukemia</u>					Female	53	48.7	108.8	(81.5-142.3)
Male	33	22.1	149.1	(102.6-209.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	26	17.5	148.6	(97.0-217.7)	Female	47	51.7	90.9	(66.8-120.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	17.7	39.5	(15.8-81.3)	Male	674	722.3	93.3	(86.4-100.6)
Female	6	6.3	94.9	(34.7-206.6)	Female	779	782.9	99.5	(92.6-106.7)
<u>Lung and Bronchus</u>									
Male	66	98.2	67.2	(52.0-85.5)					
Female	79	106.8	74.0	(58.5-92.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	12	9.7	123.7	(63.9-216.1)	Female	0	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	9.3	107.2	(51.3-197.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.7	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	26	33.0	78.8	(51.4-115.4)
Female	0	0.3	nc	(nc-nc)	Female	38	32.6	116.5	(82.5-159.9)
<u>Lung and Bronchus</u>									
Male	1	4.5	nc	(nc-nc)					
Female	5	4.7	106.3	(34.3-248.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	30.0	100.1	(67.6-143.0)	Male	15	19.0	79.1	(44.2-130.5)
Female	7	10.8	64.9	(26.0-133.8)	Female	16	14.7	108.9	(62.2-176.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.3	169.4	(77.3-321.7)	Male	6	5.6	107.3	(39.2-233.5)
Female	2	4.5	nc	(nc-nc)	Female	5	4.6	109.8	(35.4-256.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	26	16.6	156.4	(102.2-229.2)
Female	123	112.5	109.3	(90.9-130.5)	Female	15	14.2	105.9	(59.2-174.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.8	nc	(nc-nc)	Male	9	12.8	70.0	(32.0-133.0)
<u>Colon / Rectum</u>					Female	4	5.8	nc	(nc-nc)
Male	32	32.1	99.7	(68.2-140.8)	<u>Ovary</u>				
Female	30	32.1	93.6	(63.1-133.6)	Female	7	10.3	68.2	(27.3-140.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.8	nc	(nc-nc)	Male	11	10.0	109.8	(54.8-196.5)
Female	1	2.1	nc	(nc-nc)	Female	13	10.4	124.6	(66.3-213.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	99	102.1	97.0	(78.8-118.1)
Female	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.9	72.9	(23.5-170.0)
Male	18	15.5	116.0	(68.7-183.3)	Female	5	4.0	124.4	(40.1-290.3)
Female	8	9.2	87.1	(37.5-171.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.5	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	11	6.9	159.4	(79.5-285.2)
<u>Leukemia</u>					Female	28	20.2	138.5	(92.0-200.2)
Male	18	11.5	156.1	(92.4-246.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	8.4	83.2	(33.3-171.5)	Female	31	25.7	120.7	(82.0-171.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	9.6	83.1	(35.8-163.7)	Male	398	386.9	102.9	(93.0-113.5)
Female	3	3.2	nc	(nc-nc)	Female	399	387.5	103.0	(93.1-113.6)
<u>Lung and Bronchus</u>									
Male	47	54.4	86.5	(63.5-115.0)					
Female	55	56.8	96.8	(72.9-126.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	73.3	58.7	(42.4-79.0)	Male	56	51.3	109.2	(82.5-141.8)
Female	20	27.9	71.8	(43.8-110.9)	Female	41	49.6	82.7	(59.4-112.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	16.6	102.6	(59.7-164.3)	Male	16	13.9	115.1	(65.8-187.0)
Female	14	14.8	94.8	(51.8-159.1)	Female	11	12.0	91.6	(45.7-163.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.3	nc	(nc-nc)	Male	37	45.6	81.2	(57.1-111.9)
Female	300	313.8	95.6	(85.1-107.0)	Female	32	39.7	80.6	(55.1-113.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	13.6	66.1	(30.2-125.5)	Male	33	34.4	96.0	(66.0-134.8)
<u>Colon / Rectum</u>					Female	13	16.3	79.7	(42.4-136.3)
Male	77	81.5	94.5	(74.6-118.2)	<u>Ovary</u>				
Female	76	85.4	89.0	(70.1-111.4)	Female	18	30.1	59.9	(35.5-94.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	19.5	46.1	(21.1-87.6)	Male	29	25.0	116.0	(77.7-166.6)
Female	6	5.4	111.4	(40.7-242.4)	Female	25	27.2	92.0	(59.6-135.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	10.7	65.4	(26.2-134.8)	Male	243	260.8	93.2	(81.8-105.6)
Female	6	9.5	62.9	(23.0-136.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	17.3	69.4	(35.8-121.2)
Male	26	41.2	63.1	(41.2-92.5)	Female	9	10.8	83.6	(38.1-158.6)
Female	11	25.2	43.7	(21.8-78.1)	<u>Testis</u>				
<u>Larynx</u>					Male	24	22.4	107.1	(68.6-159.4)
Male	8	10.8	74.1	(31.9-146.0)	<u>Thyroid</u>				
Female	2	3.8	nc	(nc-nc)	Male	29	23.3	124.4	(83.3-178.6)
<u>Leukemia</u>					Female	79	79.8	99.0	(78.4-123.4)
Male	20	32.0	62.4	(38.1-96.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	20	24.6	81.3	(49.6-125.6)	Female	70	72.3	96.9	(75.5-122.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	20	24.7	80.9	(49.4-124.9)	Male	876	1017.3	86.1	(80.5-92.0)
Female	11	8.6	127.5	(63.5-228.1)	Female	952	1101.8	86.4	(81.0-92.1)
<u>Lung and Bronchus</u>									
Male	109	131.7	82.8	(68.0-99.8)					
Female	107	146.2	73.2	(60.0-88.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	26.5	79.1	(49.0-120.9)	Male	18	16.4	109.8	(65.0-173.5)
Female	9	10.1	88.7	(40.5-168.4)	Female	14	13.4	104.8	(57.2-175.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.6	nc	(nc-nc)	Male	6	4.9	123.1	(45.0-268.0)
Female	5	4.1	120.9	(39.0-282.2)	Female	8	4.2	189.2	(81.5-372.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	12	14.6	82.3	(42.5-143.8)
Female	95	101.6	93.5	(75.7-114.4)	Female	16	13.1	122.4	(69.9-198.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.4	nc	(nc-nc)	Male	10	11.2	89.3	(42.7-164.2)
<u>Colon / Rectum</u>					Female	10	5.4	186.9	(89.5-343.7)
Male	31	28.5	108.6	(73.8-154.2)	<u>Ovary</u>				
Female	29	31.1	93.3	(62.5-134.0)	Female	7	9.4	74.8	(29.9-154.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	6.8	88.7	(32.4-193.1)	Male	10	8.8	113.2	(54.2-208.2)
Female	1	1.9	nc	(nc-nc)	Female	9	10.0	89.8	(41.0-170.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	81	88.0	92.1	(73.1-114.4)
Female	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	6.1	nc	(nc-nc)
Male	11	13.3	82.7	(41.2-148.0)	Female	2	4.0	nc	(nc-nc)
Female	4	8.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.8	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	10	5.8	171.6	(82.2-315.7)
<u>Leukemia</u>					Female	28	17.9	156.0	(103.7-225.5)
Male	15	10.2	146.8	(82.1-242.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.9	75.7	(27.6-164.7)	Female	26	22.7	114.4	(74.7-167.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	8.4	nc	(nc-nc)	Male	322	336.7	95.6	(85.5-106.7)
Female	0	2.9	nc	(nc-nc)	Female	368	354.0	104.0	(93.6-115.1)
<u>Lung and Bronchus</u>									
Male	40	46.7	85.6	(61.1-116.6)					
Female	61	50.1	121.9	(93.2-156.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.0	nc	(nc-nc)	Male	7	4.0	174.8	(70.0-360.2)
Female	1	1.6	nc	(nc-nc)	Female	6	2.7	225.5	(82.4-490.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	23	22.3	103.0	(65.3-154.5)	Female	5	2.4	208.9	(67.3-487.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	8	6.8	117.5	(50.6-231.5)	<u>Ovary</u>				
Female	2	5.0	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.8	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	27	24.8	109.1	(71.9-158.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.4	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	7	4.0	173.5	(69.5-357.6)
Male	1	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.3	nc	(nc-nc)	Female	6	5.3	112.8	(41.2-245.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.3	nc	(nc-nc)	Male	71	85.1	83.5	(65.2-105.3)
Female	1	0.6	nc	(nc-nc)	Female	68	69.7	97.5	(75.7-123.6)
<u>Lung and Bronchus</u>									
Male	3	11.4	nc	(nc-nc)					
Female	3	9.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	13.3	112.9	(63.1-186.2)	Male	8	8.7	92.4	(39.8-182.1)
Female	11	4.8	230.8	(115.1-413.0)	Female	14	6.8	207.3	(113.2-347.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.5	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.6	92.2	(37.0-190.1)
Female	42	52.7	79.7	(57.4-107.7)	Female	14	6.4	217.9	(119.0-365.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	6.2	97.5	(35.6-212.1)
<u>Colon / Rectum</u>					Female	1	2.7	nc	(nc-nc)
Male	13	14.6	89.1	(47.4-152.4)	<u>Ovary</u>				
Female	13	14.4	90.3	(48.1-154.5)	Female	6	4.8	125.1	(45.7-272.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.6	138.7	(44.7-323.7)	Male	5	4.5	110.2	(35.5-257.1)
Female	0	0.9	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	51	48.5	105.1	(78.2-138.2)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	6	7.3	82.5	(30.1-179.7)	Female	0	1.8	nc	(nc-nc)
Female	6	4.2	143.3	(52.3-311.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.6	312.6	(100.7-729.5)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	9.5	73.6	(29.5-151.6)
Male	5	5.2	95.9	(30.9-223.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.8	nc	(nc-nc)	Female	14	12.2	114.3	(62.4-191.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.6	nc	(nc-nc)	Male	183	178.3	102.6	(88.3-118.6)
Female	2	1.5	nc	(nc-nc)	Female	197	177.5	111.0	(96.0-127.6)
<u>Lung and Bronchus</u>									
Male	33	24.4	135.2	(93.0-189.9)					
Female	34	25.2	135.1	(93.5-188.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.8	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	11	6.1	181.3	(90.4-324.5)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.3	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.1	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	24	24.2	99.1	(63.5-147.4)
Female	0	0.2	nc	(nc-nc)	Female	21	20.1	104.5	(64.7-159.8)
<u>Lung and Bronchus</u>									
Male	2	3.4	nc	(nc-nc)					
Female	1	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	12.8	109.3	(59.7-183.4)	Male	4	8.6	nc	(nc-nc)
Female	5	4.5	112.1	(36.1-261.7)	Female	4	6.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.6	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	5	1.9	260.9	(84.1-608.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.7	117.2	(53.5-222.4)
Female	56	52.3	107.0	(80.8-139.0)	Female	3	6.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	11	14.8	74.2	(37.0-132.8)	<u>Ovary</u>				
Female	13	14.3	91.1	(48.4-155.7)	Female	3	4.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.5	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	4.4	114.3	(36.8-266.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	25	45.9	54.4	(35.2-80.3)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	7	7.3	96.2	(38.5-198.2)	Female	0	1.8	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	0.6	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	10	10.4	96.0	(46.0-176.6)
Male	3	5.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.7	nc	(nc-nc)	Female	13	11.4	113.7	(60.5-194.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.5	nc	(nc-nc)	Male	136	174.5	77.9	(65.4-92.2)
Female	1	1.4	nc	(nc-nc)	Female	186	173.0	107.5	(92.6-124.1)
<u>Lung and Bronchus</u>									
Male	22	22.9	96.1	(60.2-145.6)					
Female	31	22.6	137.1	(93.1-194.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	16.1	93.3	(52.2-153.9)	Male	23	8.7	264.1	(167.4-396.4)
Female	11	5.5	201.5	(100.4-360.5)	Female	11	5.7	193.3	(96.4-345.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.0	251.5	(81.0-586.8)	Male	2	2.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	5	7.7	65.2	(21.0-152.1)
Female	58	45.2	128.3	(97.4-165.9)	Female	7	6.5	107.6	(43.1-221.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.2	nc	(nc-nc)	Male	8	5.3	151.3	(65.2-298.2)
<u>Colon / Rectum</u>					Female	1	2.6	nc	(nc-nc)
Male	17	15.6	109.2	(63.6-174.9)	<u>Ovary</u>				
Female	14	15.6	89.6	(49.0-150.4)	Female	4	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.7	nc	(nc-nc)	Male	7	5.1	137.5	(55.1-283.3)
Female	0	1.0	nc	(nc-nc)	Female	5	5.4	92.9	(29.9-216.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	47	47.4	99.2	(72.9-132.0)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.4	nc	(nc-nc)
Male	6	6.6	91.2	(33.3-198.5)	Female	0	2.0	nc	(nc-nc)
Female	5	4.0	125.3	(40.4-292.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	5.6	nc	(nc-nc)
Male	6	5.4	111.3	(40.6-242.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.7	nc	(nc-nc)	Female	9	10.7	84.3	(38.4-160.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	4.2	nc	(nc-nc)	Male	184	182.7	100.7	(86.7-116.4)
Female	2	1.5	nc	(nc-nc)	Female	193	167.7	115.1	(99.4-132.6)
<u>Lung and Bronchus</u>									
Male	20	27.8	72.0	(43.9-111.1)					
Female	28	27.3	102.7	(68.2-148.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	39.9	97.7	(69.5-133.5)	Male	25	25.6	97.5	(63.1-144.0)
Female	16	14.9	107.7	(61.5-175.0)	Female	25	20.5	122.2	(79.1-180.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.3	109.8	(47.3-216.4)	Male	10	7.6	131.9	(63.1-242.6)
Female	5	6.3	79.5	(25.6-185.5)	Female	7	6.3	110.9	(44.4-228.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	24	22.6	106.4	(68.1-158.3)
Female	180	159.5	112.8	(97.0-130.6)	Female	17	19.7	86.3	(50.3-138.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.4	92.6	(29.8-216.1)	Male	21	18.0	116.7	(72.2-178.4)
<u>Colon / Rectum</u>					Female	8	8.2	98.0	(42.2-193.2)
Male	39	43.7	89.2	(63.4-121.9)	<u>Ovary</u>				
Female	47	45.0	104.5	(76.8-138.9)	Female	16	14.5	110.3	(63.0-179.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	10.6	84.7	(38.6-160.7)	Male	12	13.5	88.6	(45.7-154.8)
Female	5	2.9	175.1	(56.4-408.7)	Female	19	14.5	131.1	(78.9-204.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.9	nc	(nc-nc)	Male	110	141.3	77.9	(64.0-93.9)
Female	5	2.4	210.2	(67.7-490.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	9.3	nc	(nc-nc)
Male	22	21.4	103.0	(64.5-155.9)	Female	6	5.6	106.3	(38.8-231.4)
Female	8	12.7	62.8	(27.0-123.7)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.6	151.7	(60.8-312.6)
Male	6	5.9	102.3	(37.3-222.6)	<u>Thyroid</u>				
Female	3	2.0	nc	(nc-nc)	Male	14	9.6	146.0	(79.8-245.0)
<u>Leukemia</u>					Female	36	28.4	127.0	(88.9-175.8)
Male	19	15.6	121.8	(73.3-190.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	11.6	215.1	(139.2-317.6)	Female	42	36.2	115.9	(83.5-156.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	13.4	82.4	(41.1-147.4)	Male	495	526.7	94.0	(85.9-102.6)
Female	3	4.4	nc	(nc-nc)	Female	596	541.5	110.1	(101.4-119.3)
<u>Lung and Bronchus</u>									
Male	71	72.4	98.0	(76.6-123.7)					
Female	76	77.4	98.2	(77.4-123.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	24.2	90.9	(57.0-137.7)	Male	7	17.4	40.1	(16.1-82.7)
Female	9	8.8	102.2	(46.6-194.0)	Female	7	14.9	47.0	(18.8-96.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.9	117.7	(47.1-242.4)	Male	4	4.8	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	17	15.6	109.3	(63.6-174.9)
Female	85	101.7	83.6	(66.8-103.4)	Female	17	12.4	136.7	(79.6-219.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	4.3	208.0	(94.9-394.8)	Male	6	12.2	49.3	(18.0-107.3)
<u>Colon / Rectum</u>					Female	7	5.1	136.3	(54.6-280.8)
Male	31	28.3	109.7	(74.5-155.8)	<u>Ovary</u>				
Female	25	27.8	89.8	(58.1-132.5)	Female	3	9.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	6.6	91.3	(33.3-198.7)	Male	9	8.4	107.6	(49.1-204.3)
Female	1	1.7	nc	(nc-nc)	Female	16	8.6	185.5	(105.9-301.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.2	nc	(nc-nc)	Male	63	86.7	72.7	(55.8-93.0)
Female	1	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	5.9	170.5	(81.6-313.6)
Male	12	14.6	82.2	(42.4-143.6)	Female	3	3.5	nc	(nc-nc)
Female	14	8.0	174.1	(95.1-292.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	6.5	nc	(nc-nc)
Male	5	3.7	136.7	(44.1-319.1)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	7	8.0	87.2	(34.9-179.7)
<u>Leukemia</u>					Female	40	24.2	165.6	(118.3-225.5)
Male	15	11.2	134.3	(75.1-221.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	8.2	97.8	(42.1-192.7)	Female	14	22.1	63.2	(34.5-106.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	8.6	198.0	(115.3-317.1)	Male	344	342.7	100.4	(90.1-111.6)
Female	5	2.7	185.7	(59.9-433.4)	Female	356	348.2	102.2	(91.9-113.4)
<u>Lung and Bronchus</u>									
Male	71	43.6	163.0	(127.3-205.6)					
Female	55	44.8	122.6	(92.4-159.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.4	114.1	(36.8-266.3)	Male	8	2.8	281.1	(121.0-553.9)
Female	3	1.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	11	15.4	71.4	(35.6-127.7)	Female	0	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	6	4.8	124.0	(45.3-269.9)	<u>Ovary</u>				
Female	2	4.2	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	22	17.1	129.0	(80.8-195.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.7	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	5	3.6	138.4	(44.6-323.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	76	59.9	126.9	(100.0-158.8)
Female	0	0.4	nc	(nc-nc)	Female	38	51.3	74.0	(52.4-101.6)
<u>Lung and Bronchus</u>									
Male	15	8.1	184.1	(103.0-303.7)					
Female	3	7.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	4	5.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	6.4	141.2	(64.4-268.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.6	nc	(nc-nc)	Male	27	23.0	117.6	(77.5-171.1)
Female	0	0.2	nc	(nc-nc)	Female	13	19.2	67.9	(36.1-116.1)
<u>Lung and Bronchus</u>									
Male	4	3.1	nc	(nc-nc)					
Female	4	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	5.7	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	14	21.1	66.4	(36.3-111.4)
Female	0	0.1	nc	(nc-nc)	Female	9	18.3	49.1	(22.4-93.3)
<u>Lung and Bronchus</u>									
Male	3	2.8	nc	(nc-nc)					
Female	1	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	67	62.8	106.7	(82.7-135.5)	Male	25	39.8	62.8	(40.6-92.7)
Female	17	24.8	68.4	(39.8-109.5)	Female	20	33.3	60.1	(36.7-92.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.3	88.2	(42.2-162.3)	Male	11	11.7	93.9	(46.8-168.1)
Female	11	10.3	106.7	(53.2-191.0)	Female	8	10.4	76.8	(33.1-151.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.9	nc	(nc-nc)	Male	31	35.2	88.0	(59.8-125.0)
Female	236	248.7	94.9	(83.2-107.8)	Female	34	32.2	105.5	(73.0-147.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.4	95.3	(41.0-187.8)	Male	29	27.5	105.5	(70.7-151.5)
<u>Colon / Rectum</u>					Female	25	13.2	189.3	(122.5-279.5)
Male	88	68.1	129.2	(103.6-159.2)	<u>Ovary</u>				
Female	82	74.9	109.5	(87.1-136.0)	Female	30	23.2	129.4	(87.3-184.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	16.4	97.7	(55.8-158.6)	Male	20	21.1	94.7	(57.8-146.3)
Female	4	4.7	nc	(nc-nc)	Female	29	24.3	119.2	(79.8-171.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	4.8	103.8	(33.5-242.3)	Male	165	216.8	76.1	(64.9-88.6)
Female	2	4.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	14.5	103.7	(58.0-171.0)
Male	33	32.6	101.2	(69.6-142.1)	Female	17	9.5	179.1	(104.3-286.8)
Female	23	20.4	112.6	(71.4-169.0)	<u>Testis</u>				
<u>Larynx</u>					Male	12	8.0	149.6	(77.2-261.4)
Male	8	9.0	88.7	(38.2-174.7)	<u>Thyroid</u>				
Female	3	3.1	nc	(nc-nc)	Male	8	14.7	54.2	(23.4-106.9)
<u>Leukemia</u>					Female	26	44.8	58.1	(37.9-85.1)
Male	25	24.6	101.7	(65.8-150.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	19.4	82.6	(47.2-134.1)	Female	55	57.0	96.6	(72.7-125.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	20.5	63.3	(33.7-108.2)	Male	789	817.6	96.5	(89.9-103.5)
Female	4	7.3	nc	(nc-nc)	Female	864	872.3	99.1	(92.6-105.9)
<u>Lung and Bronchus</u>									
Male	147	112.5	130.7	(110.4-153.6)					
Female	141	126.0	111.9	(94.2-132.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	5	4.8	103.7	(33.4-242.1)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	6	1.8	337.4	(123.2-734.4)	<u>Ovary</u>				
Female	3	1.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	5.7	175.5	(84.0-322.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	26	21.2	122.7	(80.1-179.8)
Female	0	0.1	nc	(nc-nc)	Female	14	16.5	85.1	(46.5-142.8)
<u>Lung and Bronchus</u>									
Male	1	3.1	nc	(nc-nc)					
Female	2	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	3	8.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	4	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	6	2.2	277.7	(101.4-604.4)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	8.6	92.5	(39.8-182.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	28	31.8	87.9	(58.4-127.1)
Female	0	0.2	nc	(nc-nc)	Female	25	26.7	93.5	(60.5-138.0)
<u>Lung and Bronchus</u>									
Male	5	4.5	110.7	(35.7-258.3)					
Female	5	3.9	128.3	(41.4-299.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	13.2	120.9	(69.1-196.3)	Male	6	8.9	67.5	(24.6-146.9)
Female	1	5.0	nc	(nc-nc)	Female	6	7.5	79.8	(29.1-173.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.9	nc	(nc-nc)
Female	63	56.3	112.0	(86.0-143.3)	Female	9	6.8	131.4	(60.0-249.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.1	nc	(nc-nc)	Male	6	6.4	94.2	(34.4-205.0)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	14	15.0	93.3	(51.0-156.5)	<u>Ovary</u>				
Female	18	15.7	114.9	(68.1-181.6)	Female	1	5.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.6	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	4	1.0	nc	(nc-nc)	Female	7	4.9	141.8	(56.8-292.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	52	47.9	108.5	(81.0-142.3)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.1	159.0	(51.2-371.1)
Male	2	7.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Female	7	4.4	157.9	(63.2-325.3)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.1	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	7	11.1	63.3	(25.4-130.4)
Male	5	5.4	91.8	(29.6-214.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.1	144.8	(52.9-315.1)	Female	14	12.7	110.5	(60.3-185.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.7	nc	(nc-nc)	Male	168	180.5	93.1	(79.5-108.3)
Female	2	1.5	nc	(nc-nc)	Female	202	190.3	106.2	(92.0-121.9)
<u>Lung and Bronchus</u>									
Male	31	24.0	129.2	(87.8-183.5)					
Female	35	26.0	134.7	(93.8-187.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	9.3	54.0	(17.4-125.9)	Male	9	5.9	153.7	(70.1-291.7)
Female	4	3.4	nc	(nc-nc)	Female	11	4.4	249.4	(124.3-446.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.2	96.8	(31.2-225.8)
Female	37	35.3	104.9	(73.9-144.6)	Female	1	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.8	nc	(nc-nc)
Male	15	10.1	148.1	(82.8-244.3)	<u>Ovary</u>				
Female	7	10.3	67.9	(27.2-140.0)	Female	3	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.4	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.6	nc	(nc-nc)	Male	28	32.2	86.8	(57.7-125.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.1	nc	(nc-nc)
Male	6	4.9	123.1	(45.0-268.0)	Female	0	1.3	nc	(nc-nc)
Female	5	2.8	177.0	(57.0-413.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.9	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.9	134.5	(57.9-265.0)
Male	1	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	8	7.9	101.1	(43.5-199.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.1	nc	(nc-nc)	Male	103	120.8	85.3	(69.6-103.4)
Female	1	1.0	nc	(nc-nc)	Female	122	120.0	101.6	(84.4-121.4)
<u>Lung and Bronchus</u>									
Male	8	16.7	47.8	(20.6-94.3)					
Female	8	17.1	46.8	(20.2-92.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	8	7.5	106.8	(46.0-210.4)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	7	8.5	82.1	(32.9-169.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	5	1.8	282.5	(91.0-659.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	27	30.4	88.9	(58.6-129.3)
Female	0	0.2	nc	(nc-nc)	Female	30	24.7	121.3	(81.9-173.2)
<u>Lung and Bronchus</u>									
Male	4	4.1	nc	(nc-nc)					
Female	4	3.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	26.5	98.1	(64.0-143.7)	Male	33	16.1	204.5	(140.8-287.3)
Female	6	9.6	62.7	(22.9-136.6)	Female	16	11.5	139.6	(79.7-226.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.3	116.2	(37.4-271.2)	Male	2	4.8	nc	(nc-nc)
Female	5	3.6	139.3	(44.9-325.0)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	12	14.3	83.8	(43.2-146.3)
Female	107	91.0	117.6	(96.4-142.1)	Female	12	12.0	100.0	(51.6-174.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	8	10.9	73.5	(31.7-144.8)
<u>Colon / Rectum</u>					Female	1	4.9	nc	(nc-nc)
Male	19	28.3	67.1	(40.4-104.7)	<u>Ovary</u>				
Female	33	28.9	114.4	(78.7-160.6)	Female	11	8.5	130.1	(64.9-232.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	6.6	nc	(nc-nc)	Male	14	8.7	160.1	(87.5-268.7)
Female	0	1.8	nc	(nc-nc)	Female	7	9.4	74.2	(29.7-152.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	90	85.3	105.5	(84.9-129.7)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	6.0	nc	(nc-nc)
Male	15	12.9	115.9	(64.8-191.3)	Female	0	3.7	nc	(nc-nc)
Female	7	7.5	93.4	(37.4-192.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	0	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<u>Leukemia</u>					Female	12	13.9	86.4	(44.6-151.0)
Male	10	9.9	101.0	(48.3-185.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.1	70.3	(22.7-164.1)	Female	24	20.8	115.3	(73.9-171.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.2	60.8	(19.6-142.0)	Male	299	330.1	90.6	(80.6-101.4)
Female	4	2.7	nc	(nc-nc)	Female	310	320.2	96.8	(86.3-108.2)
<u>Lung and Bronchus</u>									
Male	19	46.4	40.9	(24.6-63.9)					
Female	24	47.1	51.0	(32.7-75.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	10	9.1	110.0	(52.7-202.4)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.6	83.3	(35.8-164.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.7	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	32	32.5	98.3	(67.2-138.8)
Female	0	0.2	nc	(nc-nc)	Female	23	28.7	80.3	(50.9-120.5)
<u>Lung and Bronchus</u>									
Male	3	4.3	nc	(nc-nc)					
Female	1	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	9	4.2	213.0	(97.2-404.3)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	4	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	4.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.8	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	5	1.0	502.5	(161.9-1172.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	16.1	80.5	(42.8-137.7)
Female	0	0.1	nc	(nc-nc)	Female	24	13.8	174.1	(111.5-259.1)
<u>Lung and Bronchus</u>									
Male	1	2.2	nc	(nc-nc)					
Female	1	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.1	120.8	(60.2-216.2)	Male	11	5.6	197.0	(98.2-352.5)
Female	4	3.4	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	27	33.4	80.8	(53.2-117.5)	Female	4	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.8	nc	(nc-nc)
Male	12	9.7	123.5	(63.7-215.7)	<u>Ovary</u>				
Female	11	10.2	108.2	(53.9-193.5)	Female	4	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.3	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	32	30.2	106.0	(72.5-149.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	2	4.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.6	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	9	7.6	117.8	(53.7-223.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	102	115.0	88.7	(72.3-107.7)
Female	1	1.0	nc	(nc-nc)	Female	104	116.7	89.1	(72.8-108.0)
<u>Lung and Bronchus</u>									
Male	14	16.1	86.8	(47.4-145.7)					
Female	22	17.0	129.5	(81.1-196.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	33.9	114.9	(81.7-157.1)	Male	23	21.0	109.5	(69.4-164.2)
Female	9	13.4	67.2	(30.7-127.6)	Female	17	17.3	98.1	(57.1-157.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	5.7	209.0	(107.9-365.2)	Male	3	6.3	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)	Female	2	5.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	13	18.6	69.9	(37.2-119.6)
Female	143	132.9	107.6	(90.7-126.7)	Female	27	17.2	157.2	(103.5-228.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.4	nc	(nc-nc)	Male	14	14.3	98.1	(53.6-164.7)
<u>Colon / Rectum</u>					Female	6	7.0	85.3	(31.2-185.7)
Male	29	36.4	79.6	(53.3-114.4)	<u>Ovary</u>				
Female	40	40.8	98.1	(70.1-133.6)	Female	13	12.3	106.0	(56.4-181.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	8.6	127.7	(63.6-228.4)	Male	13	11.3	115.5	(61.4-197.4)
Female	1	2.5	nc	(nc-nc)	Female	12	13.2	91.1	(47.0-159.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	140	111.7	125.4	(105.5-147.9)
Female	4	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	7.7	64.5	(20.8-150.6)
Male	22	17.0	129.4	(81.1-195.9)	Female	7	5.2	135.3	(54.2-278.7)
Female	9	10.8	83.0	(37.9-157.6)	<u>Testis</u>				
<u>Larynx</u>					Male	9	3.5	257.3	(117.4-488.5)
Male	3	4.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	10	7.4	135.1	(64.7-248.5)
<u>Leukemia</u>					Female	19	22.8	83.4	(50.2-130.3)
Male	18	12.9	139.6	(82.7-220.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	10.3	156.0	(89.1-253.3)	Female	34	29.9	113.7	(78.8-159.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	10.8	111.6	(57.6-194.9)	Male	477	429.4	111.1	(101.3-121.5)
Female	5	3.9	129.2	(41.6-301.5)	Female	467	464.1	100.6	(91.7-110.2)
<u>Lung and Bronchus</u>									
Male	66	60.2	109.7	(84.8-139.5)					
Female	58	67.0	86.6	(65.7-111.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	39.7	136.2	(102.3-177.7)	Male	21	24.9	84.5	(52.3-129.1)
Female	19	14.6	130.0	(78.2-203.0)	Female	16	19.3	82.8	(47.3-134.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.0	113.8	(49.0-224.3)	Male	5	7.3	68.1	(21.9-158.9)
Female	6	6.0	99.9	(36.5-217.5)	Female	6	6.1	98.0	(35.8-213.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	21	22.2	94.6	(58.5-144.6)
Female	120	146.3	82.0	(68.0-98.1)	Female	23	18.9	121.4	(76.9-182.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.8	125.1	(45.7-272.3)	Male	17	17.1	99.2	(57.8-158.8)
<u>Colon / Rectum</u>					Female	10	7.8	128.7	(61.6-236.6)
Male	39	42.7	91.4	(65.0-125.0)	<u>Ovary</u>				
Female	51	44.2	115.4	(85.9-151.7)	Female	11	13.6	80.6	(40.2-144.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	10.3	106.8	(53.2-191.1)	Male	13	13.3	97.8	(52.0-167.3)
Female	2	2.8	nc	(nc-nc)	Female	7	14.4	48.6	(19.5-100.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.2	nc	(nc-nc)	Male	179	136.2	131.4	(112.8-152.1)
Female	2	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	9.1	143.1	(76.1-244.8)
Male	27	20.3	133.3	(87.8-193.9)	Female	8	5.6	142.4	(61.3-280.6)
Female	16	11.9	134.3	(76.7-218.2)	<u>Testis</u>				
<u>Larynx</u>					Male	5	5.2	95.6	(30.8-223.0)
Male	4	5.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.8	nc	(nc-nc)	Male	12	9.2	130.2	(67.2-227.5)
<u>Leukemia</u>					Female	34	25.7	132.1	(91.5-184.7)
Male	19	15.5	122.8	(73.9-191.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	11.3	79.8	(36.4-151.5)	Female	34	33.5	101.6	(70.4-142.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	12.8	62.7	(27.0-123.6)	Male	572	513.6	111.4	(102.4-120.9)
Female	2	4.3	nc	(nc-nc)	Female	467	511.5	91.3	(83.2-100.0)
<u>Lung and Bronchus</u>									
Male	74	70.5	105.0	(82.4-131.8)					
Female	43	73.6	58.4	(42.3-78.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	32.7	113.0	(79.6-155.8)	Male	21	19.9	105.3	(65.2-161.0)
Female	9	12.7	70.7	(32.3-134.2)	Female	23	15.9	144.3	(91.4-216.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.4	128.7	(51.6-265.3)	Male	5	5.9	84.5	(27.2-197.2)
Female	4	4.9	nc	(nc-nc)	Female	1	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	20	17.8	112.7	(68.8-174.0)
Female	132	120.9	109.2	(91.3-129.4)	Female	14	16.0	87.4	(47.7-146.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.9	152.1	(55.5-331.1)	Male	14	13.3	105.6	(57.7-177.2)
<u>Colon / Rectum</u>					Female	4	6.5	nc	(nc-nc)
Male	32	34.8	91.9	(62.8-129.7)	<u>Ovary</u>				
Female	34	38.6	88.0	(61.0-123.0)	Female	13	11.2	115.8	(61.6-198.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	8.1	74.1	(27.1-161.4)	Male	13	10.7	120.9	(64.3-206.8)
Female	2	2.4	nc	(nc-nc)	Female	16	12.6	127.4	(72.8-207.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	87	103.3	84.2	(67.5-103.9)
Female	3	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	7.4	108.2	(46.6-213.1)
Male	13	15.9	82.0	(43.6-140.3)	Female	6	4.9	121.4	(44.3-264.2)
Female	12	10.0	119.9	(61.9-209.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.5	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.5	nc	(nc-nc)	Male	6	6.9	86.5	(31.6-188.3)
<u>Leukemia</u>					Female	30	20.4	147.0	(99.1-209.8)
Male	9	12.4	72.4	(33.0-137.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	9.7	51.7	(16.7-120.6)	Female	26	27.0	96.4	(63.0-141.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	10.0	100.2	(48.0-184.4)	Male	386	405.6	95.2	(85.9-105.2)
Female	6	3.6	166.7	(60.9-362.8)	Female	444	429.0	103.5	(94.1-113.6)
<u>Lung and Bronchus</u>									
Male	58	56.9	102.0	(77.5-131.9)					
Female	72	62.4	115.4	(90.3-145.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	6.3	nc	(nc-nc)	Male	5	4.1	121.6	(39.2-283.7)
Female	4	2.2	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	22	25.0	88.1	(55.2-133.4)	Female	4	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	6	7.0	86.0	(31.4-187.1)	<u>Ovary</u>				
Female	2	6.7	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.8	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	23	24.3	94.7	(60.0-142.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.5	nc	(nc-nc)
Male	7	3.5	199.5	(79.9-411.1)	Female	1	0.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.4	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.7	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.2	nc	(nc-nc)	Male	64	86.2	74.2	(57.1-94.8)
Female	0	0.7	nc	(nc-nc)	Female	57	83.2	68.5	(51.9-88.8)
<u>Lung and Bronchus</u>									
Male	3	11.7	nc	(nc-nc)					
Female	4	11.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	31.1	102.8	(70.3-145.1)	Male	31	17.4	178.0	(120.9-252.7)
Female	11	11.1	98.9	(49.3-176.9)	Female	26	12.3	211.3	(138.0-309.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.1	nc	(nc-nc)	Male	5	5.4	92.5	(29.8-215.9)
Female	2	3.8	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	17	15.3	111.3	(64.8-178.1)
Female	124	98.2	126.3	(105.1-150.6)	Female	13	13.6	95.6	(50.9-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	19	10.9	174.0	(104.7-271.7)
<u>Colon / Rectum</u>					Female	4	5.4	nc	(nc-nc)
Male	32	30.7	104.1	(71.2-147.0)	<u>Ovary</u>				
Female	32	31.8	100.6	(68.8-142.0)	Female	10	9.2	108.3	(51.8-199.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.5	106.8	(46.0-210.5)	Male	13	10.0	130.1	(69.2-222.5)
Female	3	2.1	nc	(nc-nc)	Female	10	10.9	92.0	(44.0-169.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	121	96.5	125.3	(104.0-149.8)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	6.7	nc	(nc-nc)
Male	9	13.5	66.6	(30.4-126.4)	Female	4	4.0	nc	(nc-nc)
Female	8	8.5	94.2	(40.6-185.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	1	4.9	nc	(nc-nc)
<u>Leukemia</u>					Female	17	13.3	128.3	(74.7-205.4)
Male	13	10.7	122.0	(64.9-208.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	7.7	90.4	(36.2-186.3)	Female	26	23.4	111.3	(72.7-163.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	8.6	115.6	(55.3-212.6)	Male	407	365.4	111.4	(100.8-122.7)
Female	3	3.2	nc	(nc-nc)	Female	396	355.7	111.3	(100.6-122.9)
<u>Lung and Bronchus</u>									
Male	51	54.9	93.0	(69.2-122.2)					
Female	55	57.0	96.4	(72.6-125.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.2	97.1	(38.9-200.1)	Male	6	4.8	124.8	(45.6-271.6)
Female	1	2.5	nc	(nc-nc)	Female	5	3.8	133.0	(42.9-310.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	16	29.2	54.7	(31.2-88.8)	Female	0	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	13	8.2	158.2	(84.1-270.5)	<u>Ovary</u>				
Female	4	7.8	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.0	nc	(nc-nc)	Male	5	2.5	199.1	(64.2-464.6)
Female	0	0.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	30	27.4	109.5	(73.8-156.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.7	nc	(nc-nc)
Male	6	4.1	144.7	(52.8-314.9)	Female	0	1.0	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.6	88.7	(28.6-207.1)
Male	0	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.1	nc	(nc-nc)	Female	6	6.6	91.4	(33.4-198.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.5	nc	(nc-nc)	Male	98	99.6	98.3	(79.8-119.9)
Female	2	0.8	nc	(nc-nc)	Female	74	96.7	76.6	(60.1-96.1)
<u>Lung and Bronchus</u>									
Male	9	13.1	68.6	(31.3-130.1)					
Female	12	13.1	91.4	(47.2-159.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	6.2	144.4	(65.9-274.0)	Male	6	4.8	125.6	(45.9-273.4)
Female	3	2.1	nc	(nc-nc)	Female	6	3.9	155.3	(56.7-338.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	29	29.7	97.7	(65.4-140.3)	Female	2	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.4	nc	(nc-nc)
Male	6	7.9	76.1	(27.8-165.6)	<u>Ovary</u>				
Female	5	6.8	73.2	(23.6-170.9)	Female	2	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	1.9	258.4	(83.3-603.1)	Male	4	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	24	27.3	87.9	(56.3-130.8)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	6	4.4	137.9	(50.3-300.1)	Female	0	0.8	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.7	75.1	(24.2-175.3)
Male	1	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.9	nc	(nc-nc)	Female	9	6.5	138.3	(63.1-262.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.6	nc	(nc-nc)	Male	102	97.1	105.1	(85.7-127.5)
Female	0	0.7	nc	(nc-nc)	Female	91	93.0	97.8	(78.8-120.1)
<u>Lung and Bronchus</u>									
Male	11	12.0	91.9	(45.8-164.5)					
Female	13	11.3	114.9	(61.1-196.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	6.6	nc	(nc-nc)	Male	10	4.3	230.2	(110.2-423.3)
Female	0	1.9	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	3.8	209.3	(90.1-412.5)
Female	28	24.4	114.6	(76.1-165.7)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	5	7.4	67.4	(21.7-157.4)	<u>Ovary</u>				
Female	4	6.0	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	24	26.0	92.5	(59.2-137.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.6	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	4.4	113.6	(36.6-265.1)
Male	2	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.6	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.4	nc	(nc-nc)	Male	84	91.6	91.7	(73.1-113.5)
Female	0	0.6	nc	(nc-nc)	Female	66	78.2	84.4	(65.3-107.4)
<u>Lung and Bronchus</u>									
Male	5	12.4	40.2	(13.0-93.8)					
Female	6	10.7	55.8	(20.4-121.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	29.0	134.4	(95.5-183.7)	Male	11	19.5	56.4	(28.1-101.0)
Female	18	10.5	171.3	(101.5-270.8)	Female	17	16.0	106.3	(61.9-170.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.8	137.0	(59.0-270.0)	Male	6	5.6	106.2	(38.8-231.2)
Female	6	4.9	121.9	(44.5-265.3)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	18	17.2	104.4	(61.9-165.0)
Female	133	121.8	109.2	(91.4-129.4)	Female	8	14.5	55.3	(23.8-109.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.4	134.9	(49.3-293.6)	Male	9	14.1	64.0	(29.2-121.5)
<u>Colon / Rectum</u>					Female	8	6.1	131.3	(56.5-258.7)
Male	40	32.8	121.9	(87.1-166.0)	<u>Ovary</u>				
Female	44	32.4	135.7	(98.6-182.2)	Female	14	11.0	127.3	(69.5-213.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	8.0	150.4	(77.6-262.7)	Male	5	10.0	50.0	(16.1-116.6)
Female	1	2.0	nc	(nc-nc)	Female	13	10.2	127.9	(68.0-218.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.6	nc	(nc-nc)	Male	98	107.3	91.3	(74.2-111.3)
Female	3	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.9	nc	(nc-nc)
Male	20	16.5	120.9	(73.8-186.8)	Female	5	4.0	124.0	(40.0-289.3)
Female	8	9.5	84.1	(36.2-165.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	4.4	nc	(nc-nc)
Male	4	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.5	nc	(nc-nc)	Male	6	7.9	75.9	(27.7-165.3)
<u>Leukemia</u>					Female	28	24.0	116.6	(77.5-168.6)
Male	22	11.9	184.9	(115.8-279.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.7	115.3	(55.2-212.0)	Female	18	27.5	65.4	(38.8-103.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	10.2	nc	(nc-nc)	Male	401	398.2	100.7	(91.1-111.0)
Female	4	3.3	nc	(nc-nc)	Female	459	405.8	113.1	(103.0-123.9)
<u>Lung and Bronchus</u>									
Male	57	53.0	107.5	(81.4-139.3)					
Female	73	55.6	131.4	(103.0-165.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	11.0	72.8	(31.3-143.4)	Male	4	7.3	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.2	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	3	6.5	nc	(nc-nc)
Female	36	43.5	82.7	(57.9-114.5)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.2	nc	(nc-nc)
Male	14	12.4	113.2	(61.8-189.9)	<u>Ovary</u>				
Female	12	11.6	103.1	(53.2-180.2)	Female	8	3.9	202.7	(87.3-399.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.0	nc	(nc-nc)	Male	5	3.8	132.8	(42.8-309.9)
Female	2	0.7	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	32	40.0	80.0	(54.7-112.9)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.6	nc	(nc-nc)
Male	6	6.2	97.3	(35.5-211.7)	Female	0	1.5	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.7	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	12	8.7	138.0	(71.2-241.0)
Male	9	4.5	198.6	(90.6-377.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.1	nc	(nc-nc)	Female	16	9.8	162.8	(93.0-264.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.8	nc	(nc-nc)	Male	146	149.8	97.4	(82.3-114.6)
Female	0	1.2	nc	(nc-nc)	Female	147	145.1	101.3	(85.6-119.1)
<u>Lung and Bronchus</u>									
Male	28	19.9	140.7	(93.5-203.4)					
Female	23	19.5	117.9	(74.7-176.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	16	12.9	124.0	(70.8-201.3)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.6	nc	(nc-nc)
Male	7	3.4	205.5	(82.3-423.5)	<u>Ovary</u>				
Female	1	2.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	12.2	65.6	(28.2-129.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.4	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.6	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	42	42.3	99.2	(71.5-134.1)
Female	0	0.3	nc	(nc-nc)	Female	41	39.7	103.3	(74.1-140.1)
<u>Lung and Bronchus</u>									
Male	3	5.4	nc	(nc-nc)					
Female	6	5.0	119.9	(43.8-260.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	18.5	129.6	(83.0-192.8)	Male	26	11.7	221.6	(144.7-324.7)
Female	2	6.7	nc	(nc-nc)	Female	14	9.0	155.2	(84.8-260.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.3	150.1	(48.4-350.2)	Male	5	3.5	141.8	(45.7-330.9)
Female	1	2.9	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	10.4	105.8	(52.7-189.3)
Female	78	72.4	107.8	(85.2-134.5)	Female	3	8.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.4	nc	(nc-nc)	Male	5	8.5	58.6	(18.9-136.7)
<u>Colon / Rectum</u>					Female	4	3.7	nc	(nc-nc)
Male	11	20.3	54.1	(27.0-96.8)	<u>Ovary</u>				
Female	12	20.4	58.8	(30.3-102.7)	Female	9	6.6	137.0	(62.5-260.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	5.0	158.6	(68.3-312.6)	Male	4	6.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	5	6.6	76.1	(24.5-177.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.2	nc	(nc-nc)	Male	78	68.8	113.4	(89.7-141.6)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	4.3	nc	(nc-nc)
Male	12	10.0	120.3	(62.1-210.1)	Female	2	2.6	nc	(nc-nc)
Female	3	5.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	15	12.2	122.6	(68.6-202.3)
Male	6	7.2	83.5	(30.5-181.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.3	95.1	(30.6-221.9)	Female	9	16.6	54.1	(24.7-102.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	6.3	nc	(nc-nc)	Male	247	247.1	100.0	(87.9-113.2)
Female	0	2.0	nc	(nc-nc)	Female	207	243.5	85.0	(73.8-97.4)
<u>Lung and Bronchus</u>									
Male	23	33.6	68.4	(43.3-102.6)					
Female	18	34.1	52.9	(31.3-83.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	13.5	111.0	(62.1-183.1)	Male	11	9.2	119.5	(59.6-213.9)
Female	8	4.9	163.6	(70.4-322.3)	Female	11	7.4	147.9	(73.7-264.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	8.1	99.1	(42.7-195.2)
Female	47	57.7	81.5	(59.9-108.3)	Female	11	6.8	161.5	(80.5-289.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.1	nc	(nc-nc)	Male	7	6.8	103.2	(41.3-212.6)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	14	15.4	90.9	(49.6-152.4)	<u>Ovary</u>				
Female	13	15.0	86.7	(46.1-148.2)	Female	5	5.2	96.3	(31.0-224.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.8	130.6	(42.1-304.7)	Male	2	4.7	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	7	4.7	147.8	(59.2-304.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	47	52.7	89.2	(65.6-118.7)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.2	nc	(nc-nc)
Male	11	8.0	138.0	(68.8-247.0)	Female	0	1.9	nc	(nc-nc)
Female	3	4.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	6	3.8	159.5	(58.3-347.3)
<u>Leukemia</u>					Female	13	11.1	116.8	(62.1-199.7)
Male	2	5.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.0	nc	(nc-nc)	Female	15	13.2	113.5	(63.5-187.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.9	nc	(nc-nc)	Male	189	189.9	99.5	(85.9-114.8)
Female	0	1.5	nc	(nc-nc)	Female	196	190.8	102.7	(88.8-118.2)
<u>Lung and Bronchus</u>									
Male	32	25.2	127.0	(86.8-179.2)					
Female	30	26.2	114.4	(77.2-163.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	8	9.0	89.4	(38.5-176.1)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	5	2.8	178.3	(57.5-416.1)	<u>Ovary</u>				
Female	1	2.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.7	82.7	(35.6-163.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	30	34.4	87.1	(58.8-124.3)
Female	0	0.2	nc	(nc-nc)	Female	30	29.8	100.8	(68.0-144.0)
<u>Lung and Bronchus</u>									
Male	1	4.6	nc	(nc-nc)					
Female	4	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	22.0	99.8	(62.5-151.1)	Male	18	13.1	137.1	(81.2-216.6)
Female	4	8.9	nc	(nc-nc)	Female	7	10.6	66.1	(26.5-136.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	0	3.9	nc	(nc-nc)
Female	0	3.3	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	11	11.8	93.6	(46.7-167.5)
Female	73	81.0	90.1	(70.6-113.3)	Female	9	11.0	81.9	(37.4-155.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	7	8.7	80.3	(32.2-165.5)
<u>Colon / Rectum</u>					Female	5	4.4	113.2	(36.5-264.1)
Male	15	23.3	64.2	(35.9-106.0)	<u>Ovary</u>				
Female	20	27.1	73.9	(45.1-114.1)	Female	8	7.6	105.7	(45.5-208.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	5.4	nc	(nc-nc)	Male	5	7.2	69.5	(22.4-162.3)
Female	2	1.7	nc	(nc-nc)	Female	13	8.8	147.1	(78.3-251.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	66	68.2	96.7	(74.8-123.1)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.0	121.1	(44.2-263.7)
Male	13	10.4	125.2	(66.6-214.1)	Female	3	3.5	nc	(nc-nc)
Female	11	6.7	163.0	(81.3-291.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	9	13.0	69.4	(31.7-131.8)
Male	7	8.2	85.0	(34.0-175.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.7	nc	(nc-nc)	Female	12	17.9	67.1	(34.6-117.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.6	nc	(nc-nc)	Male	241	268.8	89.7	(78.7-101.7)
Female	0	2.5	nc	(nc-nc)	Female	254	290.9	87.3	(76.9-98.7)
<u>Lung and Bronchus</u>									
Male	34	38.0	89.5	(62.0-125.1)					
Female	44	42.4	103.7	(75.4-139.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	11.9	42.2	(13.6-98.4)	Male	8	6.6	121.8	(52.4-239.9)
Female	4	3.8	nc	(nc-nc)	Female	16	4.3	375.5	(214.5-609.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	46	34.5	133.2	(97.5-177.7)	Female	8	4.7	171.5	(73.8-337.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.9	nc	(nc-nc)
Male	7	11.6	60.1	(24.1-123.9)	<u>Ovary</u>				
Female	11	10.7	102.6	(51.1-183.5)	Female	5	3.2	155.4	(50.1-362.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.8	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	6	3.7	164.2	(60.0-357.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	41	36.6	112.0	(80.3-151.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.6	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.7	nc	(nc-nc)
Male	9	4.0	223.9	(102.2-425.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	7	8.3	84.0	(33.7-173.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.3	nc	(nc-nc)	Male	124	138.3	89.6	(74.6-106.9)
Female	0	1.1	nc	(nc-nc)	Female	145	123.1	117.8	(99.4-138.6)
<u>Lung and Bronchus</u>									
Male	22	20.8	105.9	(66.4-160.4)					
Female	17	19.6	86.5	(50.4-138.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	18.3	65.5	(33.8-114.4)	Male	6	12.0	50.2	(18.3-109.3)
Female	3	6.9	nc	(nc-nc)	Female	7	9.9	70.8	(28.3-145.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.4	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	6	10.6	56.8	(20.7-123.6)
Female	70	74.9	93.5	(72.9-118.1)	Female	8	9.2	86.7	(37.3-170.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	9	8.7	104.0	(47.5-197.5)
<u>Colon / Rectum</u>					Female	8	3.9	206.6	(89.0-407.1)
Male	33	20.4	161.7	(111.3-227.1)	<u>Ovary</u>				
Female	29	21.1	137.3	(92.0-197.3)	Female	2	6.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.0	100.6	(32.4-234.8)	Male	4	6.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	7	6.7	104.1	(41.7-214.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	67	66.8	100.2	(77.7-127.3)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.3	nc	(nc-nc)
Male	8	10.0	79.9	(34.4-157.4)	Female	2	2.7	nc	(nc-nc)
Female	8	5.9	135.0	(58.1-266.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.4	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	10	14.1	71.1	(34.1-130.8)
Male	7	7.2	96.7	(38.7-199.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.4	91.8	(29.6-214.2)	Female	14	17.3	81.0	(44.2-135.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.4	nc	(nc-nc)	Male	224	246.3	91.0	(79.4-103.7)
Female	2	2.1	nc	(nc-nc)	Female	235	254.5	92.4	(80.9-104.9)
<u>Lung and Bronchus</u>									
Male	31	32.9	94.2	(64.0-133.7)					
Female	32	35.2	90.9	(62.2-128.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	22.5	97.7	(61.2-147.9)	Male	19	15.1	125.6	(75.6-196.2)
Female	9	7.6	118.0	(53.9-224.1)	Female	17	11.9	142.3	(82.8-227.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.5	155.5	(62.3-320.4)	Male	4	4.4	nc	(nc-nc)
Female	6	3.8	159.3	(58.2-346.7)	Female	3	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.7	nc	(nc-nc)	Male	10	13.3	74.9	(35.9-137.8)
Female	117	92.1	127.1	(105.1-152.3)	Female	14	10.7	130.3	(71.2-218.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.3	nc	(nc-nc)	Male	9	11.1	80.8	(36.9-153.4)
<u>Colon / Rectum</u>					Female	3	4.6	nc	(nc-nc)
Male	21	25.4	82.6	(51.1-126.2)	<u>Ovary</u>				
Female	34	23.6	144.2	(99.9-201.5)	Female	8	8.3	95.9	(41.3-189.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	6.3	110.5	(44.3-227.7)	Male	6	7.9	76.4	(27.9-166.3)
Female	3	1.5	nc	(nc-nc)	Female	7	7.4	94.9	(38.0-195.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	74	87.0	85.1	(66.8-106.8)
Female	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.4	92.9	(29.9-216.7)
Male	15	13.0	115.3	(64.5-190.2)	Female	2	2.9	nc	(nc-nc)
Female	8	7.1	113.0	(48.7-222.7)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.1	159.7	(51.5-372.7)
Male	3	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	10	6.1	164.5	(78.7-302.5)
<u>Leukemia</u>					Female	24	18.2	132.1	(84.6-196.5)
Male	14	9.2	152.5	(83.3-256.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	6.4	109.2	(43.8-225.0)	Female	18	21.1	85.1	(50.4-134.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	8.1	86.1	(34.5-177.5)	Male	303	313.8	96.6	(86.0-108.1)
Female	2	2.4	nc	(nc-nc)	Female	354	302.9	116.9	(105.0-129.7)
<u>Lung and Bronchus</u>									
Male	37	41.8	88.5	(62.3-122.0)					
Female	39	40.9	95.4	(67.8-130.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.4	130.5	(52.3-268.9)	Male	11	3.5	315.1	(157.1-563.8)
Female	2	1.6	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	18	18.5	97.6	(57.8-154.2)	Female	3	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	0.9	nc	(nc-nc)
Male	5	5.9	84.9	(27.4-198.2)	<u>Ovary</u>				
Female	4	4.8	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	29	20.4	142.4	(95.3-204.5)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.3	149.8	(48.3-349.7)
Male	1	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.3	nc	(nc-nc)	Female	5	4.4	113.8	(36.7-265.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	80	72.8	109.9	(87.1-136.7)
Female	0	0.5	nc	(nc-nc)	Female	66	61.2	107.9	(83.4-137.2)
<u>Lung and Bronchus</u>									
Male	8	9.9	80.8	(34.8-159.2)					
Female	11	8.7	126.5	(63.1-226.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.3	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	3	7.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	5	2.4	210.4	(67.8-491.0)	<u>Ovary</u>				
Female	3	2.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	8.3	72.0	(26.3-156.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	27	29.6	91.2	(60.1-132.6)
Female	0	0.2	nc	(nc-nc)	Female	16	26.5	60.3	(34.5-98.0)
<u>Lung and Bronchus</u>									
Male	4	4.3	nc	(nc-nc)					
Female	4	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	4	7.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	6	2.3	262.1	(95.7-570.5)	<u>Ovary</u>				
Female	1	2.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	7.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	17	27.9	60.9	(35.5-97.5)
Female	0	0.2	nc	(nc-nc)	Female	19	26.6	71.5	(43.0-111.7)
<u>Lung and Bronchus</u>									
Male	3	3.7	nc	(nc-nc)					
Female	2	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.4	136.0	(49.7-296.0)	Male	5	2.9	174.7	(56.3-407.6)
Female	0	1.3	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	8	15.3	52.2	(22.5-102.8)	Female	0	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.5	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	<u>Ovary</u>				
Female	2	4.1	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	16.2	43.2	(17.3-89.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.9	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)	Male	55	59.3	92.8	(69.9-120.8)
Female	0	0.4	nc	(nc-nc)	Female	44	50.8	86.6	(62.9-116.3)
<u>Lung and Bronchus</u>									
Male	10	8.0	124.8	(59.8-229.6)					
Female	8	7.0	114.8	(49.4-226.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	35.2	96.6	(66.9-135.0)	Male	18	24.0	75.0	(44.4-118.5)
Female	9	13.7	65.6	(29.9-124.6)	Female	6	21.1	28.4	(10.4-61.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	7.5	66.6	(21.5-155.3)	Male	8	6.8	118.2	(50.9-233.0)
Female	3	6.5	nc	(nc-nc)	Female	5	5.8	85.8	(27.6-200.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	15	21.3	70.4	(39.4-116.1)
Female	135	152.5	88.5	(74.2-104.8)	Female	15	18.7	80.1	(44.8-132.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	15	5.9	255.8	(143.0-421.9)	Male	19	16.6	114.4	(68.9-178.7)
<u>Colon / Rectum</u>					Female	6	7.7	77.5	(28.3-168.6)
Male	42	39.7	105.7	(76.2-142.9)	<u>Ovary</u>				
Female	40	42.5	94.2	(67.3-128.3)	Female	12	13.9	86.1	(44.4-150.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	9.3	85.8	(36.9-169.0)	Male	15	12.0	125.5	(70.2-207.0)
Female	2	2.6	nc	(nc-nc)	Female	17	13.4	127.2	(74.1-203.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.7	nc	(nc-nc)	Male	101	122.1	82.7	(67.4-100.5)
Female	5	3.1	162.5	(52.4-379.3)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	8.3	191.8	(109.6-311.5)
Male	24	19.8	120.9	(77.5-179.9)	Female	9	5.4	168.2	(76.8-319.3)
Female	15	12.1	123.8	(69.2-204.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	7.0	71.0	(22.9-165.7)
Male	4	5.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.8	nc	(nc-nc)	Male	8	10.1	79.2	(34.1-156.0)
<u>Leukemia</u>					Female	27	32.1	84.1	(55.4-122.3)
Male	7	15.0	46.8	(18.7-96.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	11.6	120.2	(65.7-201.7)	Female	28	33.6	83.2	(55.3-120.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	12.0	141.5	(82.4-226.6)	Male	465	477.4	97.4	(88.7-106.7)
Female	8	4.1	193.4	(83.3-381.2)	Female	515	520.6	98.9	(90.6-107.8)
<u>Lung and Bronchus</u>									
Male	86	63.2	136.1	(108.8-168.0)					
Female	104	70.9	146.8	(119.9-177.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	22.0	118.1	(77.2-173.1)	Male	7	13.5	52.0	(20.8-107.2)
Female	15	8.7	171.4	(95.9-282.8)	Female	13	10.8	120.7	(64.2-206.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.6	nc	(nc-nc)	Male	6	4.0	149.0	(54.4-324.2)
Female	5	3.3	152.5	(49.1-355.9)	Female	2	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	9	11.9	75.4	(34.4-143.1)
Female	79	82.1	96.2	(76.2-119.9)	Female	10	11.0	91.2	(43.7-167.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.6	nc	(nc-nc)	Male	8	9.1	87.7	(37.8-172.9)
<u>Colon / Rectum</u>					Female	4	4.4	nc	(nc-nc)
Male	17	23.5	72.4	(42.2-116.0)	<u>Ovary</u>				
Female	26	26.4	98.4	(64.3-144.2)	Female	9	7.7	117.2	(53.5-222.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.6	nc	(nc-nc)	Male	6	7.3	82.3	(30.1-179.2)
Female	1	1.6	nc	(nc-nc)	Female	11	8.7	127.0	(63.3-227.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	92	72.7	126.6	(102.0-155.2)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	5.0	160.2	(69.0-315.8)
Male	17	10.9	156.5	(91.1-250.6)	Female	4	3.4	nc	(nc-nc)
Female	10	6.8	146.8	(70.3-270.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.2	nc	(nc-nc)
Male	8	3.0	262.7	(113.1-517.7)	<u>Thyroid</u>				
Female	3	1.0	nc	(nc-nc)	Male	5	4.7	106.8	(34.4-249.2)
<u>Leukemia</u>					Female	17	13.5	126.3	(73.5-202.2)
Male	13	8.3	157.3	(83.7-269.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.5	122.5	(52.7-241.3)	Female	17	18.6	91.4	(53.2-146.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.9	nc	(nc-nc)	Male	321	276.9	115.9	(103.6-129.3)
Female	1	2.5	nc	(nc-nc)	Female	319	292.3	109.1	(97.5-121.8)
<u>Lung and Bronchus</u>									
Male	60	38.7	155.0	(118.3-199.5)					
Female	54	42.7	126.4	(94.9-164.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	105	92.1	114.1	(93.3-138.1)	Male	32	59.0	54.2	(37.1-76.5)
Female	34	38.4	88.6	(61.4-123.8)	Female	22	51.9	42.4	(26.6-64.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	17.3	110.1	(66.3-172.0)	Male	14	17.2	81.6	(44.6-136.9)
Female	11	16.1	68.3	(34.0-122.2)	Female	16	16.0	100.1	(57.2-162.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.9	nc	(nc-nc)	Male	47	52.4	89.7	(65.9-119.3)
Female	287	379.7	75.6	(67.1-84.9)	Female	60	49.7	120.7	(92.1-155.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	13.3	127.9	(74.4-204.7)	Male	43	40.5	106.2	(76.9-143.1)
<u>Colon / Rectum</u>					Female	16	20.2	79.1	(45.2-128.5)
Male	123	100.5	122.4	(101.8-146.1)	<u>Ovary</u>				
Female	131	116.9	112.0	(93.7-132.9)	Female	22	35.4	62.1	(38.9-94.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	23.9	87.9	(54.4-134.3)	Male	37	30.9	119.6	(84.2-164.9)
Female	5	7.3	68.8	(22.2-160.6)	Female	33	37.8	87.3	(60.1-122.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	11	7.7	143.5	(71.5-256.8)	Male	274	314.6	87.1	(77.1-98.0)
Female	6	6.9	87.1	(31.8-189.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	39	21.3	183.2	(130.2-250.4)
Male	44	48.3	91.1	(66.2-122.3)	Female	30	14.9	201.3	(135.8-287.5)
Female	35	31.2	112.1	(78.1-155.9)	<u>Testis</u>				
<u>Larynx</u>					Male	17	13.4	126.5	(73.6-202.5)
Male	21	13.1	159.8	(98.9-244.3)	<u>Thyroid</u>				
Female	11	4.7	235.3	(117.3-421.0)	Male	19	22.5	84.3	(50.8-131.7)
<u>Leukemia</u>					Female	82	71.0	115.6	(91.9-143.4)
Male	35	36.8	95.1	(66.2-132.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	43	30.5	140.9	(102.0-189.9)	Female	99	85.3	116.1	(94.4-141.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	29	29.9	96.9	(64.9-139.1)	Male	1287	1202.6	107.0	(101.3-113.0)
Female	14	11.1	126.2	(68.9-211.8)	Female	1321	1341.5	98.5	(93.2-103.9)
<u>Lung and Bronchus</u>									
Male	250	163.9	152.6	(134.2-172.7)					
Female	212	190.7	111.2	(96.7-127.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	58	56.8	102.1	(77.5-132.0)	Male	28	33.0	84.8	(56.4-122.6)
Female	17	20.6	82.3	(47.9-131.8)	Female	33	24.3	135.8	(93.4-190.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	8.2	181.9	(101.7-300.0)	Male	9	10.1	89.0	(40.6-169.0)
Female	9	7.5	120.4	(54.9-228.5)	Female	9	8.6	104.8	(47.8-199.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.7	nc	(nc-nc)	Male	30	28.9	103.7	(69.9-148.0)
Female	215	193.0	111.4	(97.0-127.3)	Female	27	25.8	104.6	(68.9-152.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.6	88.7	(28.6-207.0)	Male	30	21.6	139.2	(93.9-198.7)
<u>Colon / Rectum</u>					Female	7	10.5	66.9	(26.8-137.9)
Male	59	57.7	102.2	(77.8-131.9)	<u>Ovary</u>				
Female	52	60.1	86.5	(64.6-113.5)	Female	22	18.0	122.4	(76.7-185.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	14.1	92.1	(49.0-157.4)	Male	13	18.6	70.0	(37.3-119.8)
Female	6	4.0	151.5	(55.3-329.8)	Female	19	20.2	94.2	(56.7-147.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.8	nc	(nc-nc)	Male	213	184.5	115.5	(100.5-132.1)
Female	3	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	12.5	87.8	(43.8-157.1)
Male	27	26.2	103.0	(67.9-149.9)	Female	3	7.6	nc	(nc-nc)
Female	12	16.3	73.8	(38.1-128.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.6	nc	(nc-nc)
Male	9	7.7	117.3	(53.5-222.8)	<u>Thyroid</u>				
Female	4	2.6	nc	(nc-nc)	Male	12	10.1	118.6	(61.2-207.2)
<u>Leukemia</u>					Female	14	28.5	49.2	(26.9-82.5)
Male	18	20.1	89.4	(52.9-141.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	14.8	60.6	(27.7-115.1)	Female	36	45.3	79.4	(55.6-110.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	16.8	107.4	(63.6-169.7)	Male	701	690.6	101.5	(94.1-109.3)
Female	3	6.0	nc	(nc-nc)	Female	666	685.0	97.2	(90.0-104.9)
<u>Lung and Bronchus</u>									
Male	68	101.1	67.2	(52.2-85.3)					
Female	112	106.1	105.6	(86.9-127.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	36.8	97.9	(68.5-135.5)	Male	16	24.3	65.8	(37.6-106.9)
Female	15	14.4	104.1	(58.2-171.7)	Female	14	20.8	67.4	(36.8-113.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.4	80.7	(29.5-175.7)	Male	13	7.0	185.3	(98.6-316.9)
Female	7	6.5	106.9	(42.8-220.3)	Female	8	6.1	131.9	(56.8-260.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	19	21.7	87.5	(52.7-136.7)
Female	130	150.5	86.4	(72.2-102.6)	Female	19	19.2	99.2	(59.7-154.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	5.4	165.2	(75.4-313.7)	Male	27	17.0	158.9	(104.7-231.2)
<u>Colon / Rectum</u>					Female	10	7.9	127.1	(60.8-233.7)
Male	31	41.0	75.7	(51.4-107.4)	<u>Ovary</u>				
Female	44	44.5	98.9	(71.9-132.8)	Female	12	14.0	85.5	(44.1-149.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	9.7	112.9	(56.3-202.1)	Male	12	12.4	96.6	(49.8-168.7)
Female	2	2.7	nc	(nc-nc)	Female	9	14.2	63.4	(28.9-120.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.5	nc	(nc-nc)	Male	112	128.3	87.3	(71.9-105.0)
Female	0	3.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	8.6	150.7	(80.1-257.7)
Male	22	20.1	109.4	(68.5-165.6)	Female	6	5.6	106.4	(38.8-231.5)
Female	11	12.2	90.4	(45.1-161.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.2	96.4	(35.2-209.8)
Male	1	5.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.8	nc	(nc-nc)	Male	4	9.8	nc	(nc-nc)
<u>Leukemia</u>					Female	23	29.8	77.2	(48.9-115.8)
Male	15	15.3	98.2	(54.9-161.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	12.0	92.0	(45.9-164.7)	Female	38	33.6	113.0	(79.9-155.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	12.5	79.8	(38.2-146.8)	Male	485	492.8	98.4	(89.8-107.6)
Female	3	4.3	nc	(nc-nc)	Female	502	524.0	95.8	(87.6-104.6)
<u>Lung and Bronchus</u>									
Male	87	66.0	131.8	(105.6-162.6)					
Female	87	72.4	120.2	(96.3-148.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	14.7	54.4	(23.4-107.3)
Female	0	0.1	nc	(nc-nc)	Female	10	10.2	98.0	(46.9-180.3)
<u>Lung and Bronchus</u>									
Male	1	2.0	nc	(nc-nc)					
Female	3	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	17.7	84.8	(47.4-139.8)	Male	22	11.8	186.1	(116.6-281.8)
Female	5	6.2	80.3	(25.9-187.4)	Female	14	9.3	150.7	(82.3-252.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.5	143.6	(46.3-335.1)	Male	3	3.5	nc	(nc-nc)
Female	5	2.9	173.7	(56.0-405.3)	Female	1	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	13	10.4	124.9	(66.4-213.6)
Female	81	72.5	111.8	(88.8-138.9)	Female	6	8.6	70.1	(25.6-152.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	7	8.6	81.5	(32.6-167.9)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	19	20.1	94.7	(57.0-147.9)	<u>Ovary</u>				
Female	16	19.1	83.7	(47.8-135.9)	Female	10	6.5	153.7	(73.6-282.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.9	nc	(nc-nc)	Male	5	6.1	81.8	(26.4-190.8)
Female	0	1.2	nc	(nc-nc)	Female	5	6.0	83.3	(26.8-194.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	70	66.4	105.5	(82.2-133.3)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.2	142.4	(52.0-309.9)
Male	8	10.1	79.1	(34.1-156.0)	Female	1	2.4	nc	(nc-nc)
Female	8	5.6	141.7	(61.0-279.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.4	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	4.7	106.3	(34.3-248.1)
<u>Leukemia</u>					Female	20	13.7	145.5	(88.8-224.8)
Male	8	7.1	112.3	(48.4-221.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.1	137.9	(55.2-284.1)	Female	18	16.4	109.9	(65.1-173.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.3	nc	(nc-nc)	Male	251	243.2	103.2	(90.8-116.8)
Female	1	1.9	nc	(nc-nc)	Female	257	240.1	107.1	(94.4-121.0)
<u>Lung and Bronchus</u>									
Male	30	32.7	91.8	(61.9-131.0)					
Female	32	33.3	96.0	(65.7-135.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	68.4	73.1	(54.3-96.4)	Male	41	44.8	91.5	(65.6-124.1)
Female	29	26.5	109.3	(73.2-156.9)	Female	29	37.8	76.7	(51.4-110.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	13.3	105.5	(57.6-177.1)	Male	17	12.9	131.6	(76.6-210.7)
Female	4	11.7	nc	(nc-nc)	Female	14	11.1	125.6	(68.6-210.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.1	nc	(nc-nc)	Male	38	39.7	95.7	(67.7-131.3)
Female	282	276.5	102.0	(90.4-114.6)	Female	36	35.1	102.6	(71.8-142.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	15	10.1	148.7	(83.2-245.3)	Male	29	30.9	93.8	(62.8-134.7)
<u>Colon / Rectum</u>					Female	7	14.4	48.6	(19.5-100.1)
Male	71	75.5	94.0	(73.4-118.6)	<u>Ovary</u>				
Female	88	82.0	107.4	(86.1-132.3)	Female	26	25.6	101.8	(66.4-149.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	17.9	83.7	(46.8-138.1)	Male	29	23.1	125.7	(84.2-180.5)
Female	8	5.0	159.1	(68.5-313.6)	Female	26	26.2	99.4	(64.9-145.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	6.0	83.1	(26.8-193.9)	Male	221	235.1	94.0	(82.0-107.3)
Female	7	5.1	136.6	(54.7-281.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	19	16.0	119.0	(71.6-185.9)
Male	44	36.9	119.3	(86.7-160.1)	Female	15	10.4	143.9	(80.5-237.4)
Female	16	22.2	72.0	(41.1-116.9)	<u>Testis</u>				
<u>Larynx</u>					Male	8	10.9	73.2	(31.5-144.3)
Male	5	9.9	50.6	(16.3-118.0)	<u>Thyroid</u>				
Female	3	3.3	nc	(nc-nc)	Male	20	17.7	113.1	(69.0-174.6)
<u>Leukemia</u>					Female	52	54.1	96.1	(71.7-126.0)
Male	29	27.8	104.5	(69.9-150.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	22	21.6	101.7	(63.7-154.0)	Female	62	61.6	100.7	(77.2-129.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	24	22.7	105.8	(67.8-157.4)	Male	852	904.6	94.2	(88.0-100.7)
Female	10	7.8	128.5	(61.5-236.3)	Female	989	959.6	103.1	(96.7-109.7)
<u>Lung and Bronchus</u>									
Male	106	122.1	86.8	(71.1-105.0)					
Female	134	132.3	101.3	(84.9-120.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	24.9	112.5	(74.7-162.5)	Male	17	17.8	95.6	(55.6-153.0)
Female	9	9.0	99.7	(45.5-189.4)	Female	17	15.1	112.4	(65.4-180.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.8	nc	(nc-nc)	Male	9	5.1	178.0	(81.2-338.0)
Female	4	4.8	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	8	15.8	50.5	(21.7-99.5)
Female	120	116.9	102.6	(85.1-122.7)	Female	14	13.0	107.4	(58.7-180.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.5	nc	(nc-nc)	Male	13	13.4	97.0	(51.6-166.0)
<u>Colon / Rectum</u>					Female	1	5.6	nc	(nc-nc)
Male	32	30.0	106.7	(72.9-150.6)	<u>Ovary</u>				
Female	32	28.9	110.6	(75.6-156.1)	Female	8	10.3	77.6	(33.4-152.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	7.1	126.9	(57.9-241.0)	Male	13	8.8	148.0	(78.7-253.0)
Female	3	1.7	nc	(nc-nc)	Female	6	8.7	68.8	(25.1-149.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.6	nc	(nc-nc)	Male	106	95.2	111.4	(91.2-134.7)
Female	6	2.1	290.6	(106.1-632.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	6.2	113.5	(45.5-233.9)
Male	13	15.5	83.8	(44.6-143.4)	Female	3	3.6	nc	(nc-nc)
Female	12	8.8	137.0	(70.7-239.4)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.4	113.2	(36.5-264.1)
Male	9	4.0	225.8	(103.0-428.7)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	12	7.8	153.1	(79.0-267.5)
<u>Leukemia</u>					Female	30	24.5	122.5	(82.6-174.9)
Male	11	11.0	100.2	(50.0-179.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.0	62.3	(20.1-145.3)	Female	29	25.6	113.2	(75.8-162.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	9.5	115.9	(57.8-207.4)	Male	369	358.4	103.0	(92.7-114.0)
Female	2	2.9	nc	(nc-nc)	Female	377	375.7	100.4	(90.5-111.0)
<u>Lung and Bronchus</u>									
Male	35	45.8	76.4	(53.2-106.2)					
Female	40	48.1	83.1	(59.3-113.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.3	75.6	(30.3-155.7)	Male	3	6.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	46	37.8	121.5	(89.0-162.1)	Female	9	4.3	209.8	(95.8-398.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.9	nc	(nc-nc)
Male	8	10.7	75.0	(32.3-147.8)	<u>Ovary</u>				
Female	9	9.2	97.9	(44.7-185.8)	Female	4	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.7	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	41	38.8	105.7	(75.9-143.4)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.3	nc	(nc-nc)
Male	7	5.7	123.5	(49.5-254.6)	Female	2	1.1	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	7	7.3	95.3	(38.2-196.3)
Male	2	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.5	nc	(nc-nc)	Female	11	8.9	122.9	(61.3-220.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.6	nc	(nc-nc)	Male	128	134.3	95.3	(79.5-113.3)
Female	0	1.0	nc	(nc-nc)	Female	143	122.2	117.0	(98.6-137.9)
<u>Lung and Bronchus</u>									
Male	22	17.5	125.4	(78.6-189.9)					
Female	22	16.4	134.3	(84.1-203.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	22.9	91.7	(56.7-140.2)	Male	6	15.0	40.1	(14.6-87.3)
Female	10	8.5	118.1	(56.6-217.3)	Female	9	11.3	79.7	(36.4-151.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.3	nc	(nc-nc)	Male	6	4.3	138.1	(50.4-300.5)
Female	5	3.5	143.3	(46.2-334.4)	Female	2	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	12	13.3	90.3	(46.6-157.8)
Female	72	84.2	85.5	(66.9-107.7)	Female	14	10.9	128.2	(70.0-215.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	14	10.5	133.1	(72.7-223.3)
<u>Colon / Rectum</u>					Female	4	4.5	nc	(nc-nc)
Male	22	25.5	86.2	(54.0-130.5)	<u>Ovary</u>				
Female	31	26.0	119.4	(81.1-169.5)	Female	7	7.8	89.7	(35.9-184.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.0	132.7	(57.1-261.4)	Male	10	7.7	129.2	(61.9-237.7)
Female	2	1.6	nc	(nc-nc)	Female	9	8.3	108.1	(49.3-205.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.9	nc	(nc-nc)	Male	70	78.9	88.7	(69.1-112.1)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	5.4	nc	(nc-nc)
Male	13	12.4	105.2	(55.9-179.9)	Female	5	3.3	151.1	(48.7-352.7)
Female	11	6.9	160.1	(79.8-286.4)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.3	152.9	(49.3-356.9)
Male	1	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
<u>Leukemia</u>					Female	12	15.3	78.3	(40.4-136.8)
Male	9	9.2	98.0	(44.7-186.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	6.7	134.9	(61.5-256.0)	Female	26	18.8	138.4	(90.4-202.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	7.7	129.3	(61.9-237.8)	Male	273	302.8	90.2	(79.8-101.5)
Female	3	2.4	nc	(nc-nc)	Female	308	295.5	104.2	(92.9-116.6)
<u>Lung and Bronchus</u>									
Male	42	40.8	102.9	(74.2-139.1)					
Female	44	41.8	105.1	(76.4-141.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.8	nc	(nc-nc)	Male	7	5.5	128.3	(51.4-264.3)
Female	2	2.6	nc	(nc-nc)	Female	5	4.2	117.9	(38.0-275.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.8	167.3	(72.0-329.7)
Female	38	33.8	112.5	(79.6-154.4)	Female	5	3.7	133.9	(43.1-312.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	9	9.1	98.4	(44.9-186.8)	<u>Ovary</u>				
Female	7	8.0	87.1	(34.9-179.4)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	39	31.8	122.7	(87.2-167.7)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	9	4.8	187.0	(85.3-355.0)	Female	2	1.0	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.7	74.5	(24.0-173.9)
Male	3	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.2	nc	(nc-nc)	Female	8	7.7	103.9	(44.7-204.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.0	nc	(nc-nc)	Male	109	113.0	96.5	(79.2-116.4)
Female	1	0.8	nc	(nc-nc)	Female	125	107.6	116.2	(96.7-138.4)
<u>Lung and Bronchus</u>									
Male	8	14.8	54.2	(23.3-106.8)					
Female	25	14.2	175.8	(113.8-259.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	7	7.2	96.8	(38.8-199.4)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	10	7.5	132.6	(63.5-243.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.3	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	29	25.6	113.2	(75.8-162.6)
Female	0	0.2	nc	(nc-nc)	Female	27	23.6	114.6	(75.5-166.8)
<u>Lung and Bronchus</u>									
Male	6	3.4	178.2	(65.1-387.8)					
Female	7	3.2	220.8	(88.5-455.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	37.7	116.6	(84.7-156.6)	Male	34	24.1	141.1	(97.7-197.2)
Female	20	14.3	140.2	(85.6-216.5)	Female	27	19.0	142.3	(93.7-207.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.6	75.7	(24.4-176.7)	Male	6	7.2	83.5	(30.5-181.7)
Female	5	5.8	86.3	(27.8-201.4)	Female	3	6.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	24	21.1	113.7	(72.8-169.2)
Female	164	148.8	110.2	(94.0-128.5)	Female	18	18.7	96.4	(57.1-152.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.8	nc	(nc-nc)	Male	23	17.3	132.7	(84.1-199.1)
<u>Colon / Rectum</u>					Female	10	7.8	128.6	(61.6-236.5)
Male	51	41.2	123.8	(92.2-162.8)	<u>Ovary</u>				
Female	33	42.8	77.0	(53.0-108.2)	Female	15	13.7	109.6	(61.3-180.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	10.3	126.5	(67.3-216.4)	Male	18	12.9	139.3	(82.5-220.1)
Female	2	2.7	nc	(nc-nc)	Female	14	13.9	100.7	(55.0-169.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.6	nc	(nc-nc)	Male	141	139.9	100.8	(84.8-118.9)
Female	4	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	8.8	102.4	(46.7-194.5)
Male	18	20.3	88.8	(52.6-140.4)	Female	4	5.4	nc	(nc-nc)
Female	16	12.0	133.4	(76.2-216.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.9	nc	(nc-nc)
Male	9	5.7	158.3	(72.2-300.4)	<u>Thyroid</u>				
Female	3	1.9	nc	(nc-nc)	Male	8	8.9	90.3	(38.9-177.9)
<u>Leukemia</u>					Female	30	25.1	119.4	(80.5-170.5)
Male	25	14.4	173.5	(112.3-256.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	10.8	55.4	(20.2-120.5)	Female	27	34.8	77.6	(51.2-113.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	13.0	84.6	(42.2-151.4)	Male	576	503.5	114.4	(105.2-124.1)
Female	4	4.3	nc	(nc-nc)	Female	542	509.5	106.4	(97.6-115.7)
<u>Lung and Bronchus</u>									
Male	87	69.0	126.0	(100.9-155.5)					
Female	99	73.9	134.1	(109.0-163.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	17.2	69.7	(36.0-121.8)
Female	0	0.1	nc	(nc-nc)	Female	9	16.0	56.1	(25.6-106.6)
<u>Lung and Bronchus</u>									
Male	0	2.3	nc	(nc-nc)					
Female	0	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	15.7	101.9	(58.2-165.5)	Male	8	10.9	73.2	(31.5-144.2)
Female	4	5.6	nc	(nc-nc)	Female	9	9.1	99.0	(45.2-187.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	3.4	266.2	(121.5-505.3)	Male	5	3.1	160.1	(51.6-373.6)
Female	3	2.8	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	5	9.7	51.7	(16.7-120.7)
Female	75	68.7	109.2	(85.9-136.9)	Female	10	7.9	126.5	(60.5-232.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	12	8.1	148.6	(76.7-259.5)
<u>Colon / Rectum</u>					Female	3	3.4	nc	(nc-nc)
Male	14	18.3	76.3	(41.7-128.1)	<u>Ovary</u>				
Female	18	17.5	103.1	(61.1-162.9)	Female	6	6.1	97.7	(35.7-212.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.4	136.1	(49.7-296.3)	Male	6	5.5	109.2	(39.9-237.6)
Female	0	1.1	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	61	59.5	102.5	(78.4-131.7)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.8	nc	(nc-nc)
Male	10	9.4	105.9	(50.7-194.8)	Female	1	2.2	nc	(nc-nc)
Female	3	5.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.6	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	6	4.7	128.9	(47.1-280.6)
<u>Leukemia</u>					Female	11	14.4	76.4	(38.1-136.7)
Male	16	6.7	239.8	(137.0-389.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	4.8	165.5	(71.2-326.0)	Female	12	15.3	78.2	(40.4-136.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.8	104.1	(38.0-226.5)	Male	229	221.4	103.4	(90.5-117.7)
Female	0	1.8	nc	(nc-nc)	Female	222	224.9	98.7	(86.1-112.6)
<u>Lung and Bronchus</u>									
Male	33	28.7	115.0	(79.2-161.5)					
Female	33	29.5	111.8	(77.0-157.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.9	nc	(nc-nc)	Male	0	4.6	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.1	122.9	(39.6-286.7)
Female	17	27.6	61.6	(35.9-98.7)	Female	2	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.4	nc	(nc-nc)
Male	7	7.8	89.6	(35.9-184.5)	<u>Ovary</u>				
Female	5	7.1	70.4	(22.7-164.3)	Female	6	2.5	243.0	(88.7-528.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.9	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	24	26.4	90.8	(58.2-135.2)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.9	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	6	5.2	115.4	(42.1-251.2)
Male	1	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.9	nc	(nc-nc)	Female	9	6.3	142.9	(65.2-271.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.5	nc	(nc-nc)	Male	78	95.7	81.5	(64.4-101.7)
Female	1	0.7	nc	(nc-nc)	Female	74	90.4	81.8	(64.3-102.7)
<u>Lung and Bronchus</u>									
Male	13	12.8	101.3	(53.9-173.2)					
Female	12	12.5	96.3	(49.7-168.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	8	7.0	114.8	(49.4-226.2)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	7.2	138.9	(66.5-255.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	1.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	31	26.0	119.4	(81.1-169.5)
Female	0	0.2	nc	(nc-nc)	Female	27	22.4	120.6	(79.5-175.5)
<u>Lung and Bronchus</u>									
Male	3	3.4	nc	(nc-nc)					
Female	4	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	9.6	155.8	(87.2-257.1)	Male	12	5.9	202.5	(104.5-353.8)
Female	7	3.7	190.9	(76.5-393.3)	Female	5	4.7	106.6	(34.3-248.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	31	36.4	85.2	(57.9-121.0)	Female	5	4.7	105.7	(34.1-246.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.0	nc	(nc-nc)
Male	6	10.3	58.5	(21.4-127.4)	<u>Ovary</u>				
Female	8	11.0	72.5	(31.2-143.0)	Female	2	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.5	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	36	33.3	108.2	(75.8-149.8)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.2	nc	(nc-nc)
Male	6	4.8	124.4	(45.4-270.7)	Female	1	1.4	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	10	5.9	168.1	(80.5-309.2)
Male	2	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.8	nc	(nc-nc)	Female	8	8.6	92.9	(40.0-183.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.1	nc	(nc-nc)	Male	127	123.4	102.9	(85.8-122.5)
Female	1	1.1	nc	(nc-nc)	Female	118	127.0	92.9	(76.9-111.3)
<u>Lung and Bronchus</u>									
Male	18	17.2	104.7	(62.0-165.5)					
Female	20	18.4	108.7	(66.3-167.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	20.7	96.6	(59.0-149.2)	Male	13	13.0	100.1	(53.2-171.2)
Female	8	8.6	93.1	(40.1-183.4)	Female	4	11.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	7	3.4	204.3	(81.8-421.0)	Female	3	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	5	11.6	43.2	(13.9-100.8)
Female	79	84.2	93.8	(74.3-117.0)	Female	11	11.0	99.9	(49.8-178.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.8	nc	(nc-nc)	Male	8	9.1	88.1	(37.9-173.6)
<u>Colon / Rectum</u>					Female	3	4.5	nc	(nc-nc)
Male	26	22.6	115.1	(75.2-168.7)	<u>Ovary</u>				
Female	29	26.3	110.4	(73.9-158.5)	Female	10	7.9	126.9	(60.8-233.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.4	93.4	(30.1-218.0)	Male	7	6.9	100.8	(40.4-207.6)
Female	0	1.6	nc	(nc-nc)	Female	6	8.5	70.3	(25.7-153.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	1.5	397.1	(145.0-864.3)	Male	60	70.4	85.2	(65.0-109.7)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.8	nc	(nc-nc)
Male	8	10.6	75.5	(32.5-148.8)	Female	5	3.4	148.7	(47.9-347.0)
Female	5	6.9	72.8	(23.4-169.8)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.5	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	14.7	nc	(nc-nc)
Male	4	8.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	6.6	90.4	(33.0-196.8)	Female	19	19.2	98.7	(59.4-154.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.8	nc	(nc-nc)	Male	236	267.1	88.3	(77.4-100.4)
Female	5	2.5	201.9	(65.1-471.3)	Female	276	296.3	93.2	(82.5-104.8)
<u>Lung and Bronchus</u>									
Male	33	36.3	90.9	(62.6-127.7)					
Female	42	41.9	100.3	(72.3-135.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.6	104.3	(49.9-191.8)	Male	3	6.8	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	2	5.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
Female	42	42.8	98.1	(70.7-132.7)	Female	3	4.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.0	nc	(nc-nc)
Male	17	11.6	146.4	(85.2-234.4)	<u>Ovary</u>				
Female	11	10.3	106.5	(53.1-190.6)	Female	5	3.8	132.9	(42.8-310.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.8	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	36	38.6	93.2	(65.2-129.0)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.4	nc	(nc-nc)
Male	4	6.0	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.4	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Leukemia</u>					Female	9	8.6	105.2	(48.0-199.6)
Male	5	4.1	121.8	(39.3-284.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.8	nc	(nc-nc)	Female	10	9.5	105.1	(50.3-193.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.8	nc	(nc-nc)	Male	129	139.7	92.3	(77.1-109.7)
Female	1	1.0	nc	(nc-nc)	Female	115	134.7	85.4	(70.5-102.5)
<u>Lung and Bronchus</u>									
Male	13	17.7	73.4	(39.0-125.5)					
Female	9	17.0	53.0	(24.2-100.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.2	125.7	(57.4-238.7)	Male	7	4.7	149.3	(59.8-307.6)
Female	2	2.7	nc	(nc-nc)	Female	9	3.8	237.0	(108.1-449.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.2	192.7	(83.0-379.8)
Female	34	30.1	112.8	(78.1-157.7)	Female	6	3.6	164.9	(60.2-359.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	4	8.1	nc	(nc-nc)	<u>Ovary</u>				
Female	9	8.3	108.7	(49.6-206.4)	Female	3	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.9	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	22	26.2	83.8	(52.5-126.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.7	nc	(nc-nc)
Male	4	4.0	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.8	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.3	149.5	(64.4-294.7)
Male	4	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	4	6.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.5	nc	(nc-nc)	Male	93	96.7	96.1	(77.6-117.8)
Female	0	0.8	nc	(nc-nc)	Female	114	101.0	112.9	(93.1-135.7)
<u>Lung and Bronchus</u>									
Male	11	13.0	84.3	(42.0-150.9)					
Female	16	14.3	111.7	(63.8-181.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.2	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	6	3.0	199.2	(72.7-433.5)	Female	3	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.9	179.5	(71.9-369.8)
Female	26	27.5	94.6	(61.8-138.6)	Female	5	3.7	134.1	(43.2-312.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	7	3.0	232.1	(93.0-478.3)
<u>Colon / Rectum</u>					Female	0	1.5	nc	(nc-nc)
Male	3	7.7	nc	(nc-nc)	<u>Ovary</u>				
Female	8	9.2	87.4	(37.6-172.3)	Female	2	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	18	24.1	74.6	(44.2-117.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.6	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.4	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.2	nc	(nc-nc)	Female	5	6.2	80.5	(25.9-187.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	68	91.1	74.7	(58.0-94.6)
Female	0	0.8	nc	(nc-nc)	Female	84	98.9	85.0	(67.8-105.2)
<u>Lung and Bronchus</u>									
Male	4	12.6	nc	(nc-nc)					
Female	10	14.4	69.2	(33.1-127.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.1	74.2	(27.1-161.4)	Male	6	5.4	111.2	(40.6-242.1)
Female	1	2.9	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.7	147.9	(59.2-304.7)
Female	37	33.9	109.1	(76.8-150.4)	Female	8	4.0	200.8	(86.5-395.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.7	nc	(nc-nc)
Male	14	9.1	153.7	(83.9-257.8)	<u>Ovary</u>				
Female	11	8.8	125.5	(62.6-224.6)	Female	5	3.1	163.7	(52.7-382.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.3	nc	(nc-nc)	Male	7	2.8	247.8	(99.3-510.6)
Female	0	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	37	31.0	119.2	(83.9-164.4)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	10	4.6	216.0	(103.4-397.2)	Female	1	1.1	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	7	2.1	327.5	(131.2-674.9)
<u>Leukemia</u>					Female	9	6.3	141.9	(64.7-269.3)
Male	1	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.3	nc	(nc-nc)	Female	11	7.9	139.8	(69.7-250.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	2.9	208.7	(76.2-454.3)	Male	145	111.8	129.7	(109.5-152.6)
Female	0	0.9	nc	(nc-nc)	Female	135	111.9	120.6	(101.2-142.8)
<u>Lung and Bronchus</u>									
Male	21	15.0	140.3	(86.8-214.5)					
Female	24	15.5	154.6	(99.0-230.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.8	114.8	(52.4-217.9)	Male	6	5.3	113.8	(41.5-247.7)
Female	3	2.7	nc	(nc-nc)	Female	5	4.1	122.2	(39.4-285.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.6	nc	(nc-nc)	Male	5	1.5	324.4	(104.5-757.1)
Female	3	1.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.6	150.6	(60.3-310.2)
Female	28	32.1	87.2	(57.9-126.0)	Female	7	3.7	187.9	(75.3-387.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	7	3.9	179.0	(71.7-368.8)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	9	9.0	100.4	(45.8-190.6)	<u>Ovary</u>				
Female	9	8.3	108.0	(49.3-205.0)	Female	3	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.2	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	25	30.0	83.3	(53.9-123.0)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.9	nc	(nc-nc)
Male	7	4.5	154.6	(62.0-318.6)	Female	0	1.0	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	5	2.1	237.2	(76.4-553.5)
<u>Leukemia</u>					Female	8	6.1	130.6	(56.3-257.4)
Male	9	3.2	280.1	(127.8-531.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.2	nc	(nc-nc)	Female	8	7.3	109.2	(47.0-215.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.9	nc	(nc-nc)	Male	122	109.1	111.8	(92.9-133.5)
Female	0	0.8	nc	(nc-nc)	Female	108	105.2	102.6	(84.2-123.9)
<u>Lung and Bronchus</u>									
Male	13	14.5	89.8	(47.8-153.6)					
Female	10	14.2	70.5	(33.8-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.0	85.7	(31.3-186.5)	Male	4	4.4	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	5	3.3	150.1	(48.4-350.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.9	128.2	(41.3-299.2)
Female	26	26.5	98.0	(64.0-143.7)	Female	0	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	2	7.6	nc	(nc-nc)	<u>Ovary</u>				
Female	5	7.6	65.4	(21.1-152.7)	Female	1	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.9	nc	(nc-nc)	Male	5	2.4	209.0	(67.4-487.8)
Female	0	0.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	26	26.3	99.0	(64.7-145.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.6	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	4.4	114.6	(36.9-267.4)
Male	3	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.9	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.4	nc	(nc-nc)	Male	89	93.5	95.2	(76.4-117.1)
Female	0	0.8	nc	(nc-nc)	Female	73	90.5	80.7	(63.3-101.5)
<u>Lung and Bronchus</u>									
Male	14	12.9	108.8	(59.4-182.5)					
Female	10	13.1	76.6	(36.7-140.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	14.3	63.1	(28.8-119.7)
Female	0	0.1	nc	(nc-nc)	Female	9	11.7	76.6	(35.0-145.5)
<u>Lung and Bronchus</u>									
Male	0	2.0	nc	(nc-nc)					
Female	2	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	13.8	72.7	(34.8-133.6)	Male	14	9.3	150.4	(82.2-252.4)
Female	3	5.2	nc	(nc-nc)	Female	8	7.6	105.3	(45.3-207.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.2	122.0	(58.4-224.4)
Female	74	60.5	122.3	(96.1-153.6)	Female	7	7.1	98.6	(39.5-203.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.1	nc	(nc-nc)	Male	6	6.9	86.6	(31.6-188.6)
<u>Colon / Rectum</u>					Female	1	3.0	nc	(nc-nc)
Male	17	15.7	108.1	(62.9-173.1)	<u>Ovary</u>				
Female	21	15.7	133.4	(82.5-203.9)	Female	4	5.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.9	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	56	53.7	104.2	(78.7-135.4)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.3	151.1	(48.7-352.5)
Male	6	8.1	74.1	(27.1-161.3)	Female	0	2.0	nc	(nc-nc)
Female	6	4.7	127.4	(46.5-277.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	5	2.2	229.3	(73.9-535.0)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	7	3.8	186.4	(74.7-384.0)
<u>Leukemia</u>					Female	12	11.1	107.9	(55.7-188.5)
Male	6	5.6	106.3	(38.8-231.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	4.2	nc	(nc-nc)	Female	16	13.8	116.1	(66.3-188.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.0	nc	(nc-nc)	Male	188	193.1	97.4	(83.9-112.3)
Female	0	1.6	nc	(nc-nc)	Female	211	199.3	105.8	(92.0-121.1)
<u>Lung and Bronchus</u>									
Male	21	25.7	81.8	(50.6-125.0)					
Female	32	27.8	115.1	(78.7-162.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	9.5	125.8	(65.0-219.8)	Male	4	6.6	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	6	5.2	115.5	(42.2-251.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	35	40.9	85.6	(59.6-119.0)	Female	5	4.6	108.9	(35.1-254.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.5	nc	(nc-nc)	Male	7	5.0	139.8	(56.0-288.0)
<u>Colon / Rectum</u>					Female	1	2.0	nc	(nc-nc)
Male	19	11.1	171.0	(102.9-267.1)	<u>Ovary</u>				
Female	10	9.9	101.5	(48.6-186.7)	Female	3	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.8	nc	(nc-nc)	Male	5	3.4	147.8	(47.6-344.8)
Female	1	0.6	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	48	38.6	124.5	(91.8-165.1)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	7	5.8	119.9	(48.0-247.0)	Female	1	1.2	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.4	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	16	8.2	196.1	(112.0-318.6)
Male	5	4.0	125.5	(40.5-293.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.7	nc	(nc-nc)	Female	20	9.4	211.9	(129.4-327.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.6	nc	(nc-nc)	Male	156	137.4	113.6	(96.4-132.8)
Female	4	1.0	nc	(nc-nc)	Female	139	131.4	105.8	(89.0-124.9)
<u>Lung and Bronchus</u>									
Male	25	18.0	139.1	(90.0-205.4)					
Female	17	17.4	97.6	(56.8-156.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.3	151.9	(48.9-354.4)	Male	2	2.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	13	11.8	110.3	(58.7-188.7)	Female	2	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	<u>Ovary</u>				
Female	5	3.1	161.7	(52.1-377.3)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	8	12.3	65.2	(28.1-128.5)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.3	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.8	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.1	nc	(nc-nc)	Male	44	44.7	98.5	(71.5-132.2)
Female	0	0.3	nc	(nc-nc)	Female	40	39.1	102.3	(73.1-139.3)
<u>Lung and Bronchus</u>									
Male	8	6.0	133.0	(57.3-262.2)					
Female	7	5.3	131.8	(52.8-271.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.5	77.1	(24.8-179.9)	Male	7	4.8	147.1	(59.0-303.2)
Female	0	1.8	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.2	190.8	(82.1-375.9)
Female	17	24.5	69.4	(40.4-111.2)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	3	7.8	nc	(nc-nc)	<u>Ovary</u>				
Female	7	5.7	123.6	(49.5-254.8)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.0	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	20	28.0	71.5	(43.7-110.5)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.6	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.5	133.3	(48.7-290.2)
Male	5	2.8	180.5	(58.2-421.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	7	5.8	120.3	(48.2-247.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.7	nc	(nc-nc)	Male	78	98.2	79.5	(62.8-99.2)
Female	0	0.6	nc	(nc-nc)	Female	56	76.8	72.9	(55.1-94.7)
<u>Lung and Bronchus</u>									
Male	4	12.4	nc	(nc-nc)					
Female	4	10.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	24.4	155.6	(110.1-213.5)	Male	16	13.8	115.7	(66.1-187.9)
Female	8	9.0	88.8	(38.2-175.0)	Female	21	10.1	207.7	(128.5-317.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.4	nc	(nc-nc)	Male	5	4.3	117.1	(37.7-273.3)
Female	3	3.1	nc	(nc-nc)	Female	5	3.7	135.2	(43.6-315.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	14	12.2	115.0	(62.8-193.0)
Female	107	79.9	133.9	(109.7-161.8)	Female	10	11.0	90.9	(43.5-167.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	8	8.8	91.0	(39.2-179.3)
<u>Colon / Rectum</u>					Female	2	4.4	nc	(nc-nc)
Male	24	24.4	98.3	(63.0-146.3)	<u>Ovary</u>				
Female	34	26.1	130.1	(90.1-181.8)	Female	10	7.5	133.3	(63.8-245.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.9	84.7	(27.3-197.8)	Male	8	7.9	101.6	(43.8-200.2)
Female	2	1.7	nc	(nc-nc)	Female	9	8.8	101.8	(46.5-193.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	1.1	462.7	(149.1-1079.8)	Male	105	75.9	138.3	(113.1-167.5)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	5.3	188.0	(90.0-345.7)
Male	9	10.8	83.5	(38.1-158.5)	Female	3	3.3	nc	(nc-nc)
Female	7	6.9	102.0	(40.9-210.1)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.1	nc	(nc-nc)	Male	5	4.0	124.5	(40.1-290.6)
<u>Leukemia</u>					Female	1	11.2	nc	(nc-nc)
Male	11	8.5	129.3	(64.5-231.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.4	nc	(nc-nc)	Female	21	18.7	112.3	(69.5-171.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.9	nc	(nc-nc)	Male	351	289.0	121.5	(109.1-134.9)
Female	3	2.5	nc	(nc-nc)	Female	321	289.0	111.1	(99.3-123.9)
<u>Lung and Bronchus</u>									
Male	52	42.9	121.3	(90.6-159.1)					
Female	35	45.4	77.1	(53.7-107.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.8	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	15	17.5	85.8	(48.0-141.5)	Female	1	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	5	5.2	95.8	(30.9-223.5)	<u>Ovary</u>				
Female	10	4.8	209.9	(100.5-386.0)	Female	3	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.3	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	16	17.7	90.2	(51.5-146.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.1	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.0	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	5	4.1	121.3	(39.1-283.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	59	63.7	92.6	(70.5-119.4)
Female	0	0.5	nc	(nc-nc)	Female	58	58.5	99.1	(75.3-128.1)
<u>Lung and Bronchus</u>									
Male	7	8.8	79.5	(31.8-163.8)					
Female	4	8.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	60	55.2	108.7	(82.9-139.9)	Male	36	37.4	96.3	(67.5-133.4)
Female	25	22.2	112.4	(72.7-165.9)	Female	27	33.3	81.0	(53.4-117.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	11.4	122.3	(66.8-205.2)	Male	8	10.7	74.5	(32.1-146.9)
Female	10	10.3	97.3	(46.6-179.0)	Female	8	9.5	84.3	(36.3-166.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.8	nc	(nc-nc)	Male	40	33.2	120.6	(86.1-164.2)
Female	253	247.4	102.2	(90.0-115.7)	Female	45	30.2	149.2	(108.8-199.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	9.2	65.4	(23.9-142.4)	Male	38	27.0	141.0	(99.8-193.5)
<u>Colon / Rectum</u>					Female	18	12.6	143.0	(84.7-226.0)
Male	81	63.2	128.2	(101.8-159.4)	<u>Ovary</u>				
Female	74	69.2	106.9	(84.0-134.2)	Female	23	22.6	101.7	(64.4-152.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	15.0	93.1	(50.8-156.2)	Male	25	19.0	131.3	(85.0-193.9)
Female	4	4.2	nc	(nc-nc)	Female	30	21.8	137.6	(92.8-196.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	5.1	136.0	(54.5-280.3)	Male	175	201.1	87.0	(74.6-100.9)
Female	4	4.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	21	13.2	159.1	(98.5-243.3)
Male	37	31.6	117.2	(82.5-161.6)	Female	8	8.7	91.7	(39.5-180.6)
Female	23	19.5	118.0	(74.8-177.1)	<u>Testis</u>				
<u>Larynx</u>					Male	9	9.1	98.4	(44.9-186.9)
Male	9	8.4	107.6	(49.1-204.3)	<u>Thyroid</u>				
Female	4	2.9	nc	(nc-nc)	Male	15	15.4	97.3	(54.4-160.5)
<u>Leukemia</u>					Female	48	49.4	97.1	(71.6-128.7)
Male	20	23.1	86.5	(52.8-133.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	18.5	102.6	(61.7-160.2)	Female	61	55.5	109.9	(84.1-141.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	19.6	91.9	(54.5-145.3)	Male	785	758.4	103.5	(96.4-111.0)
Female	4	6.7	nc	(nc-nc)	Female	908	838.5	108.3	(101.4-115.6)
<u>Lung and Bronchus</u>									
Male	106	99.7	106.3	(87.0-128.6)					
Female	145	113.2	128.1	(108.1-150.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	5	5.7	87.8	(28.3-205.0)
<u>Lung and Bronchus</u>									
Male	1	1.1	nc	(nc-nc)					
Female	1	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	3.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.4	136.1	(49.7-296.3)
Female	2	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	15	15.5	96.8	(54.1-159.7)
Female	0	0.1	nc	(nc-nc)	Female	8	12.2	65.6	(28.2-129.3)
<u>Lung and Bronchus</u>									
Male	3	2.1	nc	(nc-nc)					
Female	1	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	29.8	83.9	(54.3-123.9)	Male	37	17.9	206.3	(145.3-284.4)
Female	10	12.2	81.8	(39.2-150.5)	Female	28	14.7	191.0	(126.9-276.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	4.9	nc	(nc-nc)	Male	6	5.4	111.1	(40.6-241.8)
Female	5	4.7	107.5	(34.6-250.8)	Female	5	5.0	99.3	(32.0-231.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	18	16.0	112.7	(66.8-178.2)
Female	112	114.1	98.1	(80.8-118.1)	Female	28	15.3	183.3	(121.8-265.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.6	nc	(nc-nc)	Male	16	12.0	132.9	(75.9-215.9)
<u>Colon / Rectum</u>					Female	8	6.2	129.5	(55.7-255.1)
Male	26	31.5	82.5	(53.9-120.9)	<u>Ovary</u>				
Female	44	37.1	118.7	(86.3-159.4)	Female	14	10.6	132.4	(72.3-222.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	7.4	80.7	(29.5-175.6)	Male	5	9.8	51.1	(16.5-119.2)
Female	4	2.3	nc	(nc-nc)	Female	10	12.1	82.7	(39.6-152.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	110	95.7	114.9	(94.4-138.5)
Female	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.7	nc	(nc-nc)
Male	12	14.4	83.1	(42.9-145.1)	Female	1	4.7	nc	(nc-nc)
Female	12	9.5	126.1	(65.1-220.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.5	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	6	6.0	99.7	(36.4-217.0)
<u>Leukemia</u>					Female	26	18.0	144.3	(94.2-211.4)
Male	12	11.3	106.5	(55.0-186.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	9.3	129.4	(66.8-226.0)	Female	20	25.6	78.2	(47.8-120.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	9.1	nc	(nc-nc)	Male	354	369.2	95.9	(86.2-106.4)
Female	0	3.4	nc	(nc-nc)	Female	421	406.1	103.7	(94.0-114.1)
<u>Lung and Bronchus</u>									
Male	34	52.2	65.2	(45.1-91.1)					
Female	44	59.7	73.7	(53.5-98.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	16	10.0	160.6	(91.7-260.7)	Female	2	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	10.7	46.8	(15.1-109.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.7	nc	(nc-nc)	Female	5	2.4	212.4	(68.4-495.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.0	nc	(nc-nc)	Male	36	38.5	93.5	(65.4-129.4)
Female	0	0.3	nc	(nc-nc)	Female	44	33.1	132.8	(96.5-178.3)
<u>Lung and Bronchus</u>									
Male	11	5.4	204.4	(101.9-365.7)					
Female	7	4.8	147.2	(59.0-303.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	12.0	183.1	(114.7-277.2)	Male	4	7.8	nc	(nc-nc)
Female	9	4.3	207.2	(94.6-393.4)	Female	11	6.2	177.7	(88.6-318.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.2	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	5	1.9	269.9	(87.0-629.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	6.9	159.7	(79.6-285.8)
Female	50	47.3	105.6	(78.4-139.3)	Female	7	5.8	120.3	(48.2-247.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.7	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.4	nc	(nc-nc)
Male	17	13.3	128.2	(74.7-205.3)	<u>Ovary</u>				
Female	17	13.3	128.1	(74.6-205.1)	Female	7	4.3	162.6	(65.1-334.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.2	187.7	(68.5-408.5)	Male	6	4.1	147.4	(53.8-320.9)
Female	1	0.8	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	54	42.3	127.8	(96.0-166.7)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.8	nc	(nc-nc)
Male	8	6.5	122.9	(52.9-242.3)	Female	1	1.7	nc	(nc-nc)
Female	5	3.8	132.5	(42.7-309.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	8.8	90.5	(39.0-178.3)
Male	5	4.8	105.2	(33.9-245.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	3.5	200.8	(80.5-413.8)	Female	10	10.7	93.4	(44.7-171.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	4.1	196.5	(84.6-387.2)	Male	204	159.4	128.0	(111.0-146.8)
Female	1	1.3	nc	(nc-nc)	Female	204	160.7	126.9	(110.1-145.6)
<u>Lung and Bronchus</u>									
Male	24	21.9	109.7	(70.3-163.3)					
Female	45	22.7	198.6	(144.8-265.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	19.5	97.5	(58.7-152.3)	Male	21	12.7	165.5	(102.4-253.0)
Female	6	7.0	85.9	(31.4-187.0)	Female	6	9.9	60.4	(22.1-131.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.7	nc	(nc-nc)	Male	5	3.7	133.6	(43.1-311.9)
Female	5	3.1	160.9	(51.9-375.6)	Female	2	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	9	11.2	80.5	(36.7-152.8)
Female	81	77.3	104.8	(83.2-130.2)	Female	7	9.4	74.4	(29.8-153.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.7	nc	(nc-nc)	Male	13	9.1	142.2	(75.6-243.1)
<u>Colon / Rectum</u>					Female	5	3.9	126.8	(40.9-295.9)
Male	15	21.7	69.1	(38.7-114.0)	<u>Ovary</u>				
Female	23	21.4	107.4	(68.1-161.2)	Female	7	7.0	99.7	(39.9-205.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	5.3	151.3	(65.1-298.2)	Male	10	6.7	149.6	(71.6-275.1)
Female	1	1.3	nc	(nc-nc)	Female	2	6.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	73	71.3	102.3	(80.2-128.7)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.6	nc	(nc-nc)
Male	7	10.7	65.4	(26.2-134.7)	Female	2	2.7	nc	(nc-nc)
Female	7	6.1	114.7	(45.9-236.3)	<u>Testis</u>				
<u>Larynx</u>					Male	6	2.3	264.5	(96.6-575.6)
Male	2	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	8	14.2	56.5	(24.3-111.3)
Male	8	7.7	103.6	(44.6-204.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	5.6	nc	(nc-nc)	Female	27	17.6	153.0	(100.8-222.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.8	73.8	(23.8-172.2)	Male	269	262.1	102.6	(90.7-115.7)
Female	3	2.1	nc	(nc-nc)	Female	255	260.2	98.0	(86.3-110.8)
<u>Lung and Bronchus</u>									
Male	37	35.4	104.4	(73.5-143.9)					
Female	28	36.2	77.4	(51.4-111.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	5	9.8	51.0	(16.4-119.1)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	10	11.2	89.6	(42.9-164.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.0	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.6	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	26	38.5	67.6	(44.2-99.1)
Female	0	0.2	nc	(nc-nc)	Female	33	31.1	106.1	(73.0-149.0)
<u>Lung and Bronchus</u>									
Male	4	5.0	nc	(nc-nc)					
Female	5	4.0	124.1	(40.0-289.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	13.9	107.8	(60.3-177.8)	Male	10	9.5	105.3	(50.4-193.6)
Female	2	4.7	nc	(nc-nc)	Female	4	7.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.8	176.7	(56.9-412.3)	Male	3	2.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.4	107.7	(49.1-204.5)
Female	63	59.0	106.8	(82.1-136.7)	Female	3	6.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.1	nc	(nc-nc)	Male	7	7.2	97.5	(39.0-200.8)
<u>Colon / Rectum</u>					Female	3	2.9	nc	(nc-nc)
Male	18	16.1	111.9	(66.3-176.8)	<u>Ovary</u>				
Female	13	14.7	88.7	(47.2-151.7)	Female	4	5.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	4.0	174.7	(70.0-359.9)	Male	4	4.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	72	55.4	130.0	(101.7-163.7)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.4	nc	(nc-nc)
Male	8	8.3	96.2	(41.4-189.6)	Female	1	1.8	nc	(nc-nc)
Female	4	4.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.8	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	11	11.1	99.2	(49.5-177.5)
Male	7	5.7	123.3	(49.4-254.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.9	nc	(nc-nc)	Female	22	13.6	161.4	(101.1-244.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.2	95.5	(30.8-222.8)	Male	219	197.4	111.0	(96.7-126.7)
Female	1	1.5	nc	(nc-nc)	Female	180	190.6	94.4	(81.1-109.3)
<u>Lung and Bronchus</u>									
Male	15	26.1	57.6	(32.2-94.9)					
Female	21	25.9	81.1	(50.2-124.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	40.4	81.8	(56.3-114.9)	Male	20	25.2	79.4	(48.5-122.7)
Female	13	16.1	80.6	(42.9-137.9)	Female	15	21.9	68.4	(38.2-112.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.5	106.7	(46.0-210.4)	Male	3	7.4	nc	(nc-nc)
Female	4	7.0	nc	(nc-nc)	Female	1	6.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	19	22.5	84.3	(50.7-131.6)
Female	124	158.8	78.1	(64.9-93.1)	Female	17	20.9	81.4	(47.4-130.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	5.6	213.7	(110.3-373.4)	Male	25	17.0	146.8	(95.0-216.7)
<u>Colon / Rectum</u>					Female	6	8.5	70.7	(25.8-153.9)
Male	38	43.6	87.2	(61.7-119.7)	<u>Ovary</u>				
Female	46	49.5	93.0	(68.1-124.0)	Female	15	14.9	100.6	(56.3-166.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	10.2	78.6	(33.8-154.9)	Male	15	13.4	111.7	(62.5-184.2)
Female	3	3.0	nc	(nc-nc)	Female	25	16.0	156.4	(101.2-230.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.2	nc	(nc-nc)	Male	116	132.0	87.9	(72.6-105.4)
Female	4	3.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	9.2	nc	(nc-nc)
Male	21	20.3	103.5	(64.1-158.3)	Female	9	6.3	142.0	(64.8-269.5)
Female	8	13.1	61.2	(26.4-120.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	5.5	nc	(nc-nc)
Male	8	5.6	144.1	(62.1-284.0)	<u>Thyroid</u>				
Female	2	1.9	nc	(nc-nc)	Male	3	9.3	nc	(nc-nc)
<u>Leukemia</u>					Female	19	30.1	63.1	(38.0-98.5)
Male	12	16.3	73.8	(38.1-128.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	13.2	76.0	(36.4-139.7)	Female	42	35.6	118.1	(85.1-159.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	24	12.7	189.1	(121.1-281.4)	Male	488	514.5	94.9	(86.6-103.7)
Female	7	4.6	150.9	(60.5-311.0)	Female	499	563.4	88.6	(81.0-96.7)
<u>Lung and Bronchus</u>									
Male	74	70.5	105.0	(82.5-131.9)					
Female	71	78.8	90.1	(70.4-113.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.3	111.8	(44.8-230.5)	Male	7	4.1	172.3	(69.0-355.1)
Female	1	2.4	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	24	25.7	93.4	(59.8-139.0)	Female	0	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	5	7.1	70.8	(22.8-165.3)	<u>Ovary</u>				
Female	12	7.5	159.9	(82.5-279.3)	Female	2	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.6	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	28	21.0	133.4	(88.6-192.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.5	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.8	125.6	(45.9-273.5)
Male	4	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.9	nc	(nc-nc)	Female	7	5.7	123.7	(49.6-254.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.1	nc	(nc-nc)	Male	90	82.0	109.8	(88.3-134.9)
Female	0	0.7	nc	(nc-nc)	Female	77	87.2	88.3	(69.7-110.3)
<u>Lung and Bronchus</u>									
Male	11	11.0	100.4	(50.0-179.6)					
Female	14	11.9	118.1	(64.5-198.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	11.0	73.0	(31.4-143.8)	Male	14	8.3	169.7	(92.7-284.7)
Female	6	3.8	157.7	(57.6-343.2)	Female	11	6.9	159.2	(79.4-284.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	2.7	291.7	(125.6-574.7)	Male	1	2.3	nc	(nc-nc)
Female	5	2.2	227.9	(73.5-531.9)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.3	68.1	(21.9-158.9)
Female	52	55.2	94.2	(70.4-123.6)	Female	6	5.8	104.1	(38.0-226.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.1	nc	(nc-nc)	Male	6	6.6	90.4	(33.0-196.7)
<u>Colon / Rectum</u>					Female	1	2.5	nc	(nc-nc)
Male	7	13.8	50.6	(20.3-104.2)	<u>Ovary</u>				
Female	13	12.6	103.2	(54.9-176.5)	Female	2	4.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.4	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	6	3.7	163.8	(59.8-356.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	57	46.7	122.0	(92.4-158.1)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	2.8	176.8	(57.0-412.7)
Male	5	7.5	66.6	(21.5-155.5)	Female	0	1.5	nc	(nc-nc)
Female	1	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.9	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	5	3.8	130.4	(42.0-304.3)
<u>Leukemia</u>					Female	17	11.7	145.7	(84.8-233.3)
Male	4	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.5	nc	(nc-nc)	Female	10	12.1	82.8	(39.6-152.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.6	nc	(nc-nc)	Male	156	168.3	92.7	(78.7-108.5)
Female	2	1.3	nc	(nc-nc)	Female	171	170.7	100.2	(85.7-116.4)
<u>Lung and Bronchus</u>									
Male	9	20.8	43.4	(19.8-82.3)					
Female	19	20.9	91.0	(54.8-142.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.1	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	22	16.7	131.9	(82.6-199.7)	Female	1	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	0.8	638.0	(205.6-1489.0)
Male	1	4.9	nc	(nc-nc)	<u>Ovary</u>				
Female	6	3.8	158.5	(57.9-345.0)	Female	3	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	12	16.9	71.1	(36.7-124.2)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.0	nc	(nc-nc)
Male	4	2.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	3.5	170.8	(62.4-371.8)
Male	1	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	5	3.8	132.6	(42.7-309.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)	Male	43	59.9	71.8	(51.9-96.7)
Female	0	0.4	nc	(nc-nc)	Female	64	51.9	123.4	(95.0-157.5)
<u>Lung and Bronchus</u>									
Male	4	7.7	nc	(nc-nc)					
Female	5	6.4	77.8	(25.1-181.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	20.9	105.2	(65.9-159.2)	Male	11	13.7	80.0	(39.9-143.2)
Female	8	7.4	108.7	(46.8-214.2)	Female	9	10.8	83.7	(38.2-158.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.0	150.0	(54.8-326.4)	Male	2	4.0	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	8	12.1	66.3	(28.5-130.6)
Female	84	83.3	100.9	(80.5-124.9)	Female	7	10.0	70.0	(28.0-144.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.9	nc	(nc-nc)	Male	14	9.7	143.8	(78.6-241.3)
<u>Colon / Rectum</u>					Female	4	4.2	nc	(nc-nc)
Male	30	23.2	129.3	(87.2-184.6)	<u>Ovary</u>				
Female	23	22.2	103.7	(65.7-155.6)	Female	11	7.5	146.8	(73.2-262.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	5.7	141.3	(60.8-278.5)	Male	5	7.1	70.0	(22.5-163.3)
Female	1	1.4	nc	(nc-nc)	Female	7	7.1	98.9	(39.6-203.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	81	75.8	106.9	(84.9-132.9)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.9	nc	(nc-nc)
Male	7	11.5	60.7	(24.3-125.0)	Female	5	2.7	181.9	(58.6-424.5)
Female	9	6.6	136.0	(62.1-258.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.8	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<u>Leukemia</u>					Female	22	15.7	140.3	(87.9-212.5)
Male	9	8.4	107.8	(49.2-204.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	5.9	nc	(nc-nc)	Female	26	19.0	137.1	(89.5-200.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	7.2	69.6	(22.4-162.4)	Male	276	281.4	98.1	(86.8-110.3)
Female	0	2.3	nc	(nc-nc)	Female	281	279.0	100.7	(89.3-113.2)
<u>Lung and Bronchus</u>									
Male	36	38.3	94.0	(65.9-130.2)					
Female	36	39.7	90.6	(63.4-125.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	12.4	145.0	(85.9-229.1)	Male	11	8.3	132.7	(66.1-237.4)
Female	5	4.5	110.3	(35.5-257.3)	Female	11	6.8	162.4	(81.0-290.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	7	7.2	97.2	(38.9-200.2)
Female	56	54.6	102.6	(77.5-133.2)	Female	10	6.3	158.8	(76.0-292.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.8	nc	(nc-nc)	Male	3	6.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	6	2.7	221.1	(80.7-481.2)
Male	10	14.0	71.4	(34.2-131.4)	<u>Ovary</u>				
Female	9	13.7	65.8	(30.0-125.0)	Female	4	4.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.6	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	7	4.4	160.4	(64.3-330.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	53	50.0	105.9	(79.3-138.5)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	10	7.2	138.8	(66.5-255.3)	Female	0	1.7	nc	(nc-nc)
Female	6	4.2	142.6	(52.1-310.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.4	nc	(nc-nc)
Male	5	2.0	250.3	(80.7-584.2)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	4	9.7	nc	(nc-nc)
Male	1	4.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.5	nc	(nc-nc)	Female	15	13.0	115.1	(64.3-189.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	4.6	303.0	(165.5-508.4)	Male	198	174.2	113.6	(98.4-130.6)
Female	1	1.5	nc	(nc-nc)	Female	195	177.8	109.7	(94.8-126.2)
<u>Lung and Bronchus</u>									
Male	28	23.4	119.9	(79.6-173.3)					
Female	33	24.9	132.4	(91.1-185.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	7	9.0	78.2	(31.3-161.1)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	9.6	62.7	(22.9-136.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.8	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	38	33.1	114.8	(81.2-157.6)
Female	1	0.2	nc	(nc-nc)	Female	23	29.0	79.4	(50.3-119.2)
<u>Lung and Bronchus</u>									
Male	6	4.2	141.6	(51.7-308.1)					
Female	3	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	17.3	126.9	(79.5-192.1)	Male	15	11.0	136.4	(76.3-224.9)
Female	8	6.7	119.8	(51.6-236.1)	Female	9	8.7	103.1	(47.1-195.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.0	165.7	(53.4-386.7)	Male	2	3.3	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	8	9.7	82.7	(35.6-163.0)
Female	82	69.2	118.5	(94.3-147.2)	Female	9	8.7	103.7	(47.3-196.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	8	7.9	101.2	(43.6-199.5)
<u>Colon / Rectum</u>					Female	5	3.6	138.7	(44.7-323.6)
Male	10	18.9	52.9	(25.3-97.2)	<u>Ovary</u>				
Female	18	20.2	89.3	(52.9-141.1)	Female	9	6.3	142.1	(64.9-269.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.7	106.4	(34.3-248.3)	Male	8	5.9	135.4	(58.3-266.7)
Female	2	1.3	nc	(nc-nc)	Female	9	6.5	138.0	(63.0-261.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	77	63.5	121.2	(95.6-151.5)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.0	nc	(nc-nc)
Male	7	9.2	75.7	(30.3-155.9)	Female	6	2.5	236.6	(86.4-515.0)
Female	7	5.6	125.7	(50.3-258.9)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.7	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	4.0	124.8	(40.2-291.3)
<u>Leukemia</u>					Female	10	11.4	87.5	(41.9-160.9)
Male	8	6.6	121.1	(52.1-238.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	5.1	157.4	(67.8-310.2)	Female	18	16.0	112.5	(66.6-177.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.9	nc	(nc-nc)	Male	247	229.9	107.5	(94.5-121.7)
Female	5	2.0	252.0	(81.2-588.2)	Female	255	236.7	107.7	(94.9-121.8)
<u>Lung and Bronchus</u>									
Male	32	31.6	101.3	(69.3-143.0)					
Female	27	34.2	79.0	(52.0-114.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	13.3	97.4	(51.8-166.6)	Male	12	8.8	136.9	(70.7-239.1)
Female	6	5.6	106.8	(39.0-232.4)	Female	11	7.5	146.6	(73.1-262.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.7	nc	(nc-nc)
Female	64	57.9	110.6	(85.2-141.2)	Female	9	7.3	123.2	(56.2-233.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	6	6.3	94.6	(34.5-205.9)
<u>Colon / Rectum</u>					Female	2	3.0	nc	(nc-nc)
Male	14	15.0	93.2	(50.9-156.5)	<u>Ovary</u>				
Female	15	17.3	86.6	(48.4-142.8)	Female	2	5.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.6	nc	(nc-nc)	Male	13	4.6	283.1	(150.6-484.2)
Female	4	1.1	nc	(nc-nc)	Female	8	5.5	144.2	(62.1-284.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	47	49.0	95.9	(70.5-127.6)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	3.2	253.3	(109.1-499.1)
Male	8	7.4	107.6	(46.3-212.1)	Female	0	2.2	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.7	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	15	10.2	146.6	(82.0-241.8)
Male	7	5.3	130.9	(52.5-269.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.4	112.4	(36.2-262.3)	Female	17	12.9	131.7	(76.7-210.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.6	nc	(nc-nc)	Male	186	180.6	103.0	(88.7-118.9)
Female	1	1.6	nc	(nc-nc)	Female	215	199.2	107.9	(94.0-123.4)
<u>Lung and Bronchus</u>									
Male	30	24.3	123.6	(83.4-176.4)					
Female	23	27.8	82.8	(52.5-124.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	10.8	120.3	(64.0-205.8)	Male	7	7.4	95.2	(38.1-196.2)
Female	4	3.7	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.2	227.4	(73.3-530.8)	Male	1	2.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.5	107.9	(43.2-222.4)
Female	42	45.2	92.9	(66.9-125.6)	Female	3	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	6	5.5	108.4	(39.6-235.8)
<u>Colon / Rectum</u>					Female	4	2.2	nc	(nc-nc)
Male	17	12.4	136.8	(79.6-219.0)	<u>Ovary</u>				
Female	11	11.6	94.9	(47.3-169.8)	Female	4	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.1	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	3.6	138.8	(44.7-323.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	43	42.7	100.6	(72.8-135.6)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	2.6	191.4	(61.7-446.7)
Male	5	6.4	77.9	(25.1-181.7)	Female	1	1.4	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	12	8.7	138.4	(71.4-241.8)
Male	3	4.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.1	nc	(nc-nc)	Female	13	10.2	127.0	(67.6-217.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.0	nc	(nc-nc)	Male	157	152.7	102.8	(87.4-120.2)
Female	1	1.2	nc	(nc-nc)	Female	143	147.2	97.1	(81.9-114.4)
<u>Lung and Bronchus</u>									
Male	14	20.1	69.5	(38.0-116.6)					
Female	14	19.7	70.9	(38.7-119.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	7.3	176.9	(94.1-302.5)	Male	6	5.3	114.1	(41.7-248.4)
Female	5	2.7	187.6	(60.5-437.8)	Female	3	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.7	107.0	(34.5-249.7)
Female	28	30.0	93.3	(62.0-134.9)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.5	nc	(nc-nc)
Male	5	8.6	58.0	(18.7-135.4)	<u>Ovary</u>				
Female	3	8.1	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	46	27.9	164.6	(120.5-219.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	5	4.5	111.2	(35.8-259.5)	Female	0	1.0	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.6	nc	(nc-nc)
Male	4	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.6	89.6	(28.9-209.0)
Male	3	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.1	nc	(nc-nc)	Female	4	6.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.7	nc	(nc-nc)	Male	122	105.4	115.8	(96.1-138.2)
Female	2	0.8	nc	(nc-nc)	Female	84	100.5	83.6	(66.7-103.5)
<u>Lung and Bronchus</u>									
Male	10	13.6	73.6	(35.3-135.4)					
Female	9	14.0	64.5	(29.4-122.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.0	nc	(nc-nc)	Male	6	2.6	230.8	(84.3-502.4)
Female	0	1.3	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	9	15.0	60.1	(27.4-114.2)	Female	3	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.9	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	14	15.5	90.6	(49.5-152.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.7	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.0	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	53	54.7	96.9	(72.6-126.8)
Female	0	0.4	nc	(nc-nc)	Female	32	49.3	64.9	(44.4-91.6)
<u>Lung and Bronchus</u>									
Male	9	7.4	121.5	(55.4-230.6)					
Female	5	6.9	72.9	(23.5-170.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	49	49.7	98.7	(73.0-130.5)	Male	13	35.3	36.8	(19.6-63.0)
Female	16	19.8	80.7	(46.1-131.1)	Female	13	33.7	38.5	(20.5-65.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	12.3	65.2	(28.1-128.6)	Male	10	9.8	101.8	(48.7-187.2)
Female	10	11.0	91.1	(43.6-167.5)	Female	16	8.6	186.5	(106.5-302.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.6	nc	(nc-nc)	Male	29	31.7	91.5	(61.3-131.4)
Female	176	239.3	73.6	(63.1-85.3)	Female	33	28.4	116.3	(80.0-163.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	9.7	174.7	(101.7-279.8)	Male	28	25.5	109.9	(73.0-158.9)
<u>Colon / Rectum</u>					Female	11	11.9	92.4	(46.1-165.3)
Male	60	58.1	103.3	(78.8-132.9)	<u>Ovary</u>				
Female	59	62.5	94.4	(71.8-121.7)	Female	11	21.9	50.3	(25.1-90.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	13.8	72.5	(34.7-133.4)	Male	19	17.3	109.7	(66.0-171.4)
Female	9	3.8	236.1	(107.8-448.3)	Female	16	19.3	82.9	(47.3-134.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	6.2	nc	(nc-nc)	Male	243	185.3	131.1	(115.1-148.7)
Female	5	5.5	90.5	(29.2-211.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	22	12.1	182.4	(114.3-276.2)
Male	20	30.0	66.6	(40.7-102.9)	Female	11	7.8	140.3	(70.0-251.1)
Female	17	18.6	91.2	(53.1-146.0)	<u>Testis</u>				
<u>Larynx</u>					Male	9	11.7	77.0	(35.1-146.2)
Male	9	7.7	117.1	(53.4-222.3)	<u>Thyroid</u>				
Female	4	2.8	nc	(nc-nc)	Male	17	15.9	107.0	(62.3-171.3)
<u>Leukemia</u>					Female	60	54.5	110.0	(83.9-141.6)
Male	18	23.0	78.2	(46.3-123.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	18.4	114.1	(70.6-174.4)	Female	45	53.0	84.9	(61.9-113.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	27	18.2	148.6	(97.9-216.2)	Male	736	710.0	103.7	(96.3-111.4)
Female	14	6.2	225.0	(122.9-377.6)	Female	708	802.6	88.2	(81.8-95.0)
<u>Lung and Bronchus</u>									
Male	86	90.2	95.4	(76.3-117.8)					
Female	89	103.6	85.9	(69.0-105.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	8.2	183.3	(102.5-302.4)	Male	7	5.1	137.4	(55.1-283.2)
Female	2	3.1	nc	(nc-nc)	Female	9	3.9	229.8	(104.9-436.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	24	30.2	79.4	(50.8-118.1)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.6	nc	(nc-nc)
Male	6	8.7	68.6	(25.0-149.3)	<u>Ovary</u>				
Female	8	9.2	87.0	(37.5-171.4)	Female	0	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.1	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	32	28.7	111.5	(76.3-157.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.9	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	4	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	7	5.0	139.2	(55.8-286.7)
Male	2	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.3	nc	(nc-nc)	Female	3	7.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.6	nc	(nc-nc)	Male	114	105.7	107.8	(88.9-129.5)
Female	2	0.9	nc	(nc-nc)	Female	98	105.7	92.7	(75.2-113.0)
<u>Lung and Bronchus</u>									
Male	17	14.8	115.0	(66.9-184.1)					
Female	18	15.4	116.5	(69.0-184.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.3	88.6	(42.4-162.9)	Male	11	7.5	145.9	(72.7-261.1)
Female	3	4.1	nc	(nc-nc)	Female	10	6.0	165.8	(79.4-305.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
Female	54	46.1	117.1	(88.0-152.8)	Female	4	5.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.6	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.3	nc	(nc-nc)
Male	10	12.7	78.6	(37.7-144.6)	<u>Ovary</u>				
Female	10	12.6	79.5	(38.1-146.3)	Female	4	4.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.1	nc	(nc-nc)	Male	0	3.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	6	4.0	150.2	(54.8-326.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	30	42.6	70.4	(47.5-100.5)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.7	nc	(nc-nc)
Male	5	6.4	77.8	(25.1-181.5)	Female	0	1.6	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.6	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	8.8	nc	(nc-nc)
Male	7	4.6	153.7	(61.6-316.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.3	nc	(nc-nc)	Female	14	10.5	134.0	(73.2-224.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.0	nc	(nc-nc)	Male	139	155.5	89.4	(75.2-105.6)
Female	0	1.3	nc	(nc-nc)	Female	166	155.1	107.0	(91.3-124.6)
<u>Lung and Bronchus</u>									
Male	29	20.8	139.7	(93.5-200.6)					
Female	30	21.7	138.6	(93.5-197.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	9.1	143.4	(76.3-245.2)	Male	9	5.1	176.6	(80.6-335.2)
Female	1	4.1	nc	(nc-nc)	Female	5	4.3	116.3	(37.5-271.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	37	32.5	113.8	(80.1-156.8)	Female	3	4.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.9	nc	(nc-nc)
Male	16	9.2	174.4	(99.6-283.3)	<u>Ovary</u>				
Female	16	12.5	128.5	(73.4-208.6)	Female	5	3.2	158.6	(51.1-370.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	30	26.8	111.8	(75.4-159.6)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.3	nc	(nc-nc)
Male	7	3.2	217.9	(87.3-448.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.9	nc	(nc-nc)	Female	10	7.3	136.1	(65.2-250.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.5	nc	(nc-nc)	Male	106	105.6	100.4	(82.2-121.4)
Female	2	1.1	nc	(nc-nc)	Female	120	123.3	97.3	(80.7-116.4)
<u>Lung and Bronchus</u>									
Male	9	15.5	58.2	(26.6-110.5)					
Female	14	18.5	75.5	(41.3-126.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	42.4	122.7	(91.6-160.9)	Male	21	27.8	75.6	(46.8-115.6)
Female	27	16.6	163.0	(107.4-237.1)	Female	21	23.3	90.3	(55.9-138.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	8.2	97.9	(42.1-192.9)	Male	12	8.1	148.3	(76.6-259.1)
Female	8	7.2	111.6	(48.0-219.8)	Female	6	7.0	85.9	(31.4-187.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	28	24.6	113.8	(75.6-164.5)
Female	165	174.6	94.5	(80.6-110.1)	Female	24	21.9	109.6	(70.2-163.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	6.2	129.6	(55.8-255.4)	Male	19	19.6	96.7	(58.2-151.1)
<u>Colon / Rectum</u>					Female	12	9.0	132.7	(68.5-231.8)
Male	42	47.2	88.9	(64.1-120.2)	<u>Ovary</u>				
Female	37	50.8	72.8	(51.3-100.4)	Female	24	16.1	149.5	(95.8-222.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	11.3	97.2	(48.5-174.0)	Male	16	14.4	111.0	(63.4-180.2)
Female	3	3.1	nc	(nc-nc)	Female	16	16.2	98.5	(56.3-160.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.5	nc	(nc-nc)	Male	155	150.0	103.3	(87.7-120.9)
Female	5	3.0	168.3	(54.2-392.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	10.0	100.4	(48.1-184.7)
Male	20	23.2	86.3	(52.7-133.3)	Female	6	6.4	93.2	(34.0-202.8)
Female	14	14.0	100.1	(54.7-167.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	5.9	nc	(nc-nc)
Male	8	6.3	127.6	(54.9-251.4)	<u>Thyroid</u>				
Female	1	2.1	nc	(nc-nc)	Male	7	10.8	64.6	(25.9-133.2)
<u>Leukemia</u>					Female	19	32.9	57.8	(34.8-90.2)
Male	18	17.1	105.3	(62.4-166.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	13.3	90.5	(46.7-158.0)	Female	38	39.2	96.9	(68.5-133.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	14.5	41.5	(15.2-90.3)	Male	573	566.4	101.2	(93.1-109.8)
Female	2	4.9	nc	(nc-nc)	Female	563	600.4	93.8	(86.2-101.8)
<u>Lung and Bronchus</u>									
Male	95	76.5	124.2	(100.5-151.8)					
Female	72	83.8	85.9	(67.2-108.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	17	9.5	178.5	(103.9-285.8)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	2.3	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	11.1	72.0	(31.0-141.9)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.6	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.6	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.0	nc	(nc-nc)	Male	28	37.2	75.3	(50.0-108.8)
Female	0	0.3	nc	(nc-nc)	Female	38	30.8	123.3	(87.2-169.2)
<u>Lung and Bronchus</u>									
Male	2	5.1	nc	(nc-nc)					
Female	3	4.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	44.1	63.5	(42.2-91.7)	Male	30	26.8	112.1	(75.6-160.0)
Female	8	15.9	50.3	(21.7-99.2)	Female	24	20.2	118.7	(76.1-176.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	7.2	124.5	(56.8-236.4)	Male	8	8.1	99.1	(42.7-195.3)
Female	5	6.3	78.9	(25.4-184.2)	Female	7	6.7	105.2	(42.1-216.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.4	nc	(nc-nc)	Male	21	23.7	88.6	(54.8-135.4)
Female	175	160.2	109.2	(93.6-126.7)	Female	23	20.4	112.6	(71.3-168.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.1	nc	(nc-nc)	Male	13	18.2	71.2	(37.9-121.8)
<u>Colon / Rectum</u>					Female	7	8.4	83.2	(33.3-171.4)
Male	37	47.0	78.7	(55.4-108.5)	<u>Ovary</u>				
Female	32	48.1	66.6	(45.5-94.0)	Female	17	14.7	115.7	(67.4-185.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	11.2	nc	(nc-nc)	Male	11	14.6	75.3	(37.5-134.7)
Female	4	3.0	nc	(nc-nc)	Female	17	15.6	108.9	(63.4-174.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.5	nc	(nc-nc)	Male	152	144.6	105.1	(89.1-123.2)
Female	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	10.0	60.0	(21.9-130.6)
Male	20	21.6	92.4	(56.4-142.7)	Female	8	6.1	131.2	(56.5-258.6)
Female	7	13.0	53.9	(21.6-111.0)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.5	nc	(nc-nc)
Male	5	6.1	81.9	(26.4-191.2)	<u>Thyroid</u>				
Female	0	2.0	nc	(nc-nc)	Male	12	9.0	132.8	(68.6-232.1)
<u>Leukemia</u>					Female	38	26.2	145.3	(102.8-199.4)
Male	19	16.6	114.8	(69.1-179.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	12.1	107.3	(57.1-183.4)	Female	31	36.4	85.1	(57.8-120.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	13.8	36.2	(11.7-84.4)	Male	468	552.0	84.8	(77.3-92.8)
Female	3	4.6	nc	(nc-nc)	Female	515	553.2	93.1	(85.2-101.5)
<u>Lung and Bronchus</u>									
Male	44	77.9	56.5	(41.0-75.8)					
Female	49	80.1	61.1	(45.2-80.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	12.4	64.5	(27.8-127.2)
Female	0	0.1	nc	(nc-nc)	Female	5	10.7	46.9	(15.1-109.5)
<u>Lung and Bronchus</u>									
Male	0	1.6	nc	(nc-nc)					
Female	2	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.9	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	5	2.6	189.7	(61.1-442.8)	Female	8	3.7	217.1	(93.5-427.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.8	104.6	(33.7-244.0)
Female	36	29.4	122.6	(85.9-169.7)	Female	4	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	7	9.4	74.6	(29.9-153.7)	<u>Ovary</u>				
Female	8	7.9	101.2	(43.6-199.4)	Female	4	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.3	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	44	30.0	146.7	(106.5-196.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.1	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.1	nc	(nc-nc)	Female	8	6.9	116.7	(50.3-230.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.8	nc	(nc-nc)	Male	106	112.5	94.3	(77.2-114.0)
Female	0	0.8	nc	(nc-nc)	Female	110	98.4	111.8	(91.9-134.8)
<u>Lung and Bronchus</u>									
Male	8	16.0	50.1	(21.6-98.8)					
Female	6	14.0	42.7	(15.6-93.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.5	115.3	(57.5-206.2)	Male	5	6.3	79.3	(25.6-185.1)
Female	1	3.5	nc	(nc-nc)	Female	2	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.6	89.4	(28.8-208.7)
Female	33	40.1	82.3	(56.7-115.6)	Female	5	4.8	105.2	(33.9-245.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	2.0	nc	(nc-nc)
Male	7	10.8	64.6	(25.9-133.1)	<u>Ovary</u>				
Female	10	10.9	91.9	(44.0-169.0)	Female	4	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.6	nc	(nc-nc)	Male	5	3.3	152.2	(49.0-355.2)
Female	0	0.7	nc	(nc-nc)	Female	6	3.4	175.5	(64.1-382.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	33	34.7	95.1	(65.5-133.6)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.3	nc	(nc-nc)
Male	6	5.4	111.9	(40.9-243.5)	Female	0	1.4	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.2	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	7	7.4	95.1	(38.1-196.0)
Male	2	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.9	nc	(nc-nc)	Female	13	8.9	145.5	(77.4-248.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.3	nc	(nc-nc)	Male	118	129.2	91.3	(75.6-109.4)
Female	2	1.1	nc	(nc-nc)	Female	111	132.9	83.5	(68.7-100.6)
<u>Lung and Bronchus</u>									
Male	18	17.3	104.2	(61.7-164.6)					
Female	10	18.3	54.7	(26.2-100.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	21.9	54.7	(28.2-95.6)	Male	18	13.2	136.2	(80.7-215.3)
Female	9	8.3	108.1	(49.3-205.2)	Female	14	10.3	136.2	(74.4-228.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.6	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	10	11.7	85.1	(40.8-156.6)
Female	87	80.1	108.6	(87.0-133.9)	Female	12	10.5	114.1	(58.9-199.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	5	9.0	55.3	(17.8-129.1)
<u>Colon / Rectum</u>					Female	1	4.3	nc	(nc-nc)
Male	11	23.3	47.3	(23.6-84.6)	<u>Ovary</u>				
Female	14	25.3	55.3	(30.2-92.9)	Female	4	7.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.6	nc	(nc-nc)	Male	0	7.3	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	3	8.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	70	72.5	96.6	(75.3-122.1)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.0	100.8	(32.5-235.2)
Male	10	10.7	93.4	(44.7-171.9)	Female	3	3.2	nc	(nc-nc)
Female	4	6.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	1.7	348.2	(127.2-758.0)
Male	4	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	5	4.4	112.7	(36.3-262.9)
<u>Leukemia</u>					Female	8	12.9	62.2	(26.8-122.5)
Male	11	8.2	133.6	(66.6-239.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.3	79.1	(25.5-184.6)	Female	9	18.2	49.5	(22.6-93.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.8	nc	(nc-nc)	Male	223	274.3	81.3	(71.0-92.7)
Female	4	2.4	nc	(nc-nc)	Female	235	281.8	83.4	(73.1-94.8)
<u>Lung and Bronchus</u>									
Male	22	38.6	57.0	(35.7-86.4)					
Female	22	40.7	54.1	(33.9-81.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	85	80.9	105.1	(83.9-129.9)	Male	37	56.9	65.1	(45.8-89.7)
Female	41	31.4	130.7	(93.8-177.4)	Female	32	49.9	64.1	(43.8-90.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	18.6	70.0	(37.2-119.7)	Male	19	16.0	119.1	(71.7-185.9)
Female	15	15.8	94.9	(53.1-156.6)	Female	16	13.4	119.2	(68.1-193.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.6	nc	(nc-nc)	Male	57	50.6	112.6	(85.3-145.9)
Female	318	355.8	89.4	(79.8-99.8)	Female	33	43.5	75.9	(52.3-106.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	20	13.8	144.7	(88.4-223.5)	Male	52	41.0	126.9	(94.8-166.5)
<u>Colon / Rectum</u>					Female	12	18.1	66.3	(34.2-115.9)
Male	101	93.7	107.8	(87.8-131.0)	<u>Ovary</u>				
Female	97	97.8	99.1	(80.4-121.0)	Female	27	32.8	82.3	(54.2-119.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	20	22.5	89.0	(54.4-137.5)	Male	24	28.2	85.2	(54.6-126.8)
Female	5	6.0	83.3	(26.8-194.4)	Female	20	30.6	65.3	(39.9-100.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	11	9.5	115.7	(57.7-207.0)	Male	227	302.9	74.9	(65.5-85.4)
Female	5	7.8	64.2	(20.7-149.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	23	19.5	117.7	(74.6-176.6)
Male	47	48.2	97.6	(71.7-129.8)	Female	20	12.3	162.4	(99.2-250.8)
Female	34	28.2	120.7	(83.6-168.7)	<u>Testis</u>				
<u>Larynx</u>					Male	13	17.9	72.8	(38.7-124.5)
Male	19	12.5	151.4	(91.1-236.5)	<u>Thyroid</u>				
Female	8	4.2	189.5	(81.6-373.4)	Male	23	25.0	91.8	(58.2-137.8)
<u>Leukemia</u>					Female	76	77.0	98.7	(77.7-123.5)
Male	28	35.8	78.3	(52.0-113.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	43	27.5	156.2	(113.0-210.4)	Female	86	79.3	108.5	(86.7-133.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	64	29.5	217.3	(167.3-277.4)	Male	1179	1146.8	102.8	(97.0-108.8)
Female	9	9.6	93.7	(42.8-178.0)	Female	1213	1212.7	100.0	(94.5-105.8)
<u>Lung and Bronchus</u>									
Male	193	147.9	130.5	(112.7-150.2)					
Female	186	161.9	114.9	(99.0-132.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	25.5	133.2	(92.2-186.1)	Male	16	16.5	97.2	(55.5-157.9)
Female	5	9.5	52.6	(17.0-122.8)	Female	17	12.5	136.3	(79.4-218.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.7	150.5	(60.3-310.1)	Male	2	4.8	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	15	14.5	103.2	(57.7-170.3)
Female	89	96.3	92.4	(74.2-113.8)	Female	9	12.3	73.3	(33.4-139.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.2	nc	(nc-nc)	Male	9	11.5	78.6	(35.9-149.2)
<u>Colon / Rectum</u>					Female	2	5.0	nc	(nc-nc)
Male	36	28.0	128.7	(90.1-178.2)	<u>Ovary</u>				
Female	27	28.8	93.7	(61.8-136.4)	Female	8	8.9	90.4	(38.9-178.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.8	nc	(nc-nc)	Male	6	8.6	69.5	(25.4-151.4)
Female	3	1.8	nc	(nc-nc)	Female	10	9.3	107.4	(51.4-197.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	84	89.7	93.7	(74.7-116.0)
Female	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.9	84.3	(27.2-196.8)
Male	16	13.6	117.6	(67.2-191.1)	Female	2	3.6	nc	(nc-nc)
Female	4	7.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.5	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.2	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	16.6	36.2	(13.2-78.7)
Male	8	10.0	80.3	(34.6-158.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.3	82.3	(30.1-179.1)	Female	21	21.8	96.5	(59.7-147.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	8.5	106.4	(48.6-202.1)	Male	311	336.7	92.4	(82.4-103.2)
Female	3	2.8	nc	(nc-nc)	Female	283	333.6	84.8	(75.2-95.3)
<u>Lung and Bronchus</u>									
Male	28	46.1	60.8	(40.4-87.9)					
Female	35	48.2	72.6	(50.5-100.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	11.5	43.3	(14.0-101.1)	Male	5	7.7	65.0	(21.0-151.8)
Female	4	3.8	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	5	2.3	220.2	(71.0-513.8)
Female	3	1.8	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
Female	50	45.3	110.4	(81.9-145.6)	Female	3	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	2.2	nc	(nc-nc)
Male	15	13.0	115.2	(64.4-190.0)	<u>Ovary</u>				
Female	14	11.6	121.2	(66.2-203.4)	Female	3	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.3	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	48	44.6	107.6	(79.3-142.7)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.8	nc	(nc-nc)
Male	2	6.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	8.4	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	16	10.5	152.1	(86.9-247.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.2	nc	(nc-nc)	Male	152	159.8	95.1	(80.6-111.5)
Female	2	1.2	nc	(nc-nc)	Female	134	148.1	90.5	(75.8-107.1)
<u>Lung and Bronchus</u>									
Male	24	21.4	112.0	(71.7-166.7)					
Female	13	20.4	63.7	(33.9-109.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	69	77.1	89.5	(69.6-113.2)	Male	42	52.1	80.6	(58.1-109.0)
Female	24	29.6	81.0	(51.9-120.6)	Female	30	45.4	66.1	(44.6-94.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	16.4	91.3	(51.0-150.5)	Male	24	14.9	161.4	(103.4-240.2)
Female	17	14.3	119.0	(69.3-190.5)	Female	9	12.7	71.0	(32.4-134.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.5	nc	(nc-nc)	Male	54	46.3	116.6	(87.6-152.1)
Female	323	331.3	97.5	(87.2-108.7)	Female	46	40.6	113.4	(83.0-151.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	15	12.4	120.8	(67.5-199.2)	Male	55	36.9	149.2	(112.4-194.2)
<u>Colon / Rectum</u>					Female	18	16.9	106.6	(63.1-168.4)
Male	111	87.3	127.2	(104.6-153.2)	<u>Ovary</u>				
Female	113	91.4	123.6	(101.8-148.6)	Female	27	30.5	88.7	(58.4-129.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	27	20.8	129.9	(85.6-188.9)	Male	25	26.4	94.5	(61.2-139.6)
Female	9	5.7	158.1	(72.1-300.1)	Female	25	28.9	86.6	(56.0-127.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	7.8	64.4	(20.7-150.2)	Male	314	277.3	113.2	(101.1-126.5)
Female	3	6.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	18.3	71.1	(37.8-121.5)
Male	35	43.6	80.3	(55.9-111.7)	Female	20	11.5	174.3	(106.4-269.3)
Female	26	26.4	98.6	(64.4-144.5)	<u>Testis</u>				
<u>Larynx</u>					Male	11	14.1	77.8	(38.8-139.2)
Male	17	11.5	147.2	(85.7-235.7)	<u>Thyroid</u>				
Female	4	4.0	nc	(nc-nc)	Male	12	21.6	55.6	(28.7-97.0)
<u>Leukemia</u>					Female	51	68.2	74.8	(55.7-98.4)
Male	45	32.9	137.0	(99.9-183.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	28	25.2	111.1	(73.8-160.5)	Female	70	74.6	93.8	(73.1-118.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	56	26.9	208.5	(157.5-270.7)	Male	1229	1055.5	116.4	(110.0-123.1)
Female	11	9.0	121.6	(60.6-217.6)	Female	1156	1128.2	102.5	(96.6-108.5)
<u>Lung and Bronchus</u>									
Male	205	139.3	147.2	(127.7-168.8)					
Female	179	153.9	116.3	(99.9-134.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	15.5	84.1	(44.7-143.8)	Male	23	9.6	239.6	(151.8-359.5)
Female	9	5.4	166.9	(76.2-316.9)	Female	12	7.1	169.1	(87.3-295.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.6	nc	(nc-nc)	Male	5	2.9	174.2	(56.1-406.6)
Female	5	2.2	225.6	(72.7-526.4)	Female	4	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	14	8.5	165.3	(90.3-277.4)
Female	56	56.2	99.6	(75.3-129.4)	Female	12	7.0	170.8	(88.2-298.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	18	16.6	108.3	(64.1-171.1)	<u>Ovary</u>				
Female	22	16.3	134.7	(84.4-203.9)	Female	9	5.1	176.1	(80.4-334.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.0	nc	(nc-nc)	Male	7	5.2	135.0	(54.1-278.1)
Female	0	1.0	nc	(nc-nc)	Female	6	5.3	113.7	(41.5-247.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	57	53.0	107.6	(81.5-139.4)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.5	nc	(nc-nc)
Male	12	7.9	151.7	(78.3-265.1)	Female	2	2.1	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.4	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	12	9.5	126.7	(65.4-221.4)
Male	10	5.9	170.1	(81.4-312.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.2	144.2	(52.7-313.9)	Female	17	12.7	133.4	(77.7-213.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	5.0	nc	(nc-nc)	Male	211	198.5	106.3	(92.5-121.7)
Female	2	1.6	nc	(nc-nc)	Female	224	191.9	116.7	(101.9-133.0)
<u>Lung and Bronchus</u>									
Male	22	27.8	79.1	(49.5-119.7)					
Female	27	27.6	97.8	(64.4-142.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	51.6	77.5	(55.4-105.6)	Male	9	35.4	25.4	(11.6-48.3)
Female	32	20.3	158.0	(108.0-223.0)	Female	20	31.7	63.0	(38.5-97.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	10.9	64.2	(25.7-132.3)	Male	5	10.0	49.9	(16.1-116.5)
Female	9	9.6	93.6	(42.7-177.7)	Female	7	8.7	80.7	(32.3-166.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.6	nc	(nc-nc)	Male	32	31.2	102.5	(70.1-144.7)
Female	193	227.7	84.8	(73.2-97.6)	Female	20	27.9	71.8	(43.8-110.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	8.9	101.7	(46.4-193.0)	Male	21	24.9	84.4	(52.2-129.1)
<u>Colon / Rectum</u>					Female	8	11.6	69.1	(29.8-136.2)
Male	71	58.6	121.2	(94.6-152.9)	<u>Ovary</u>				
Female	80	62.7	127.6	(101.2-158.8)	Female	19	20.9	90.9	(54.7-141.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	20	14.0	143.1	(87.4-221.0)	Male	22	17.7	124.2	(77.8-188.0)
Female	10	3.9	256.7	(122.9-472.1)	Female	19	19.7	96.2	(57.9-150.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	5.4	93.3	(30.1-217.8)	Male	135	186.2	72.5	(60.8-85.8)
Female	3	4.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	12.3	130.3	(74.4-211.5)
Male	35	29.5	118.5	(82.5-164.8)	Female	6	7.9	76.3	(27.9-166.1)
Female	18	18.0	99.8	(59.1-157.7)	<u>Testis</u>				
<u>Larynx</u>					Male	9	10.2	88.2	(40.2-167.4)
Male	11	7.8	141.4	(70.5-253.0)	<u>Thyroid</u>				
Female	6	2.7	219.6	(80.2-478.0)	Male	17	15.0	113.7	(66.2-182.0)
<u>Leukemia</u>					Female	51	48.4	105.3	(78.4-138.5)
Male	23	21.7	106.0	(67.2-159.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	17.0	99.9	(58.2-159.9)	Female	56	51.1	109.7	(82.8-142.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	24	18.0	133.1	(85.2-198.0)	Male	671	710.1	94.5	(87.5-101.9)
Female	8	6.2	129.6	(55.8-255.4)	Female	778	775.6	100.3	(93.4-107.6)
<u>Lung and Bronchus</u>									
Male	122	93.8	130.1	(108.0-155.4)					
Female	114	105.2	108.4	(89.4-130.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.5	67.0	(21.6-156.3)	Male	16	4.6	347.2	(198.3-563.9)
Female	2	2.6	nc	(nc-nc)	Female	7	3.4	203.8	(81.7-420.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	37	28.0	132.1	(93.0-182.0)	Female	2	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.4	nc	(nc-nc)
Male	6	7.9	75.6	(27.6-164.5)	<u>Ovary</u>				
Female	3	7.7	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.0	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	35	26.7	131.0	(91.2-182.2)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.6	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	9	4.5	199.0	(90.8-377.8)
Male	2	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.0	nc	(nc-nc)	Female	5	6.6	76.0	(24.5-177.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.5	nc	(nc-nc)	Male	100	96.7	103.4	(84.1-125.8)
Female	0	0.8	nc	(nc-nc)	Female	101	94.3	107.1	(87.3-130.2)
<u>Lung and Bronchus</u>									
Male	7	13.6	51.4	(20.6-105.8)					
Female	9	14.0	64.4	(29.4-122.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	16.9	106.7	(63.2-168.6)	Male	22	12.5	175.6	(110.0-265.8)
Female	1	6.0	nc	(nc-nc)	Female	18	10.7	167.7	(99.4-265.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.2	120.0	(38.7-280.1)	Male	3	3.5	nc	(nc-nc)
Female	8	3.4	238.2	(102.6-469.5)	Female	1	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.6	nc	(nc-nc)	Male	12	11.2	107.5	(55.5-187.8)
Female	88	82.8	106.3	(85.3-131.0)	Female	3	9.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.3	nc	(nc-nc)	Male	11	9.7	113.4	(56.5-202.9)
<u>Colon / Rectum</u>					Female	2	3.9	nc	(nc-nc)
Male	27	20.9	129.0	(85.0-187.7)	<u>Ovary</u>				
Female	27	19.8	136.1	(89.7-198.1)	Female	9	7.2	124.5	(56.8-236.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.0	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	8	5.8	136.9	(59.0-269.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.9	nc	(nc-nc)	Male	60	67.6	88.8	(67.7-114.2)
Female	3	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.3	140.3	(51.2-305.4)
Male	13	11.1	117.2	(62.3-200.4)	Female	2	2.4	nc	(nc-nc)
Female	8	6.1	132.0	(56.8-260.0)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.4	177.8	(64.9-386.9)
Male	0	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	15	5.8	258.7	(144.7-426.7)
<u>Leukemia</u>					Female	19	18.0	105.7	(63.6-165.1)
Male	8	7.7	104.1	(44.8-205.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	5.5	144.4	(62.2-284.5)	Female	10	17.9	55.8	(26.7-102.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.8	nc	(nc-nc)	Male	270	251.8	107.2	(94.8-120.8)
Female	3	2.0	nc	(nc-nc)	Female	285	261.5	109.0	(96.7-122.4)
<u>Lung and Bronchus</u>									
Male	30	31.3	95.8	(64.6-136.7)					
Female	41	32.3	127.0	(91.1-172.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	25.5	78.6	(48.0-121.4)	Male	40	16.0	249.2	(178.0-339.4)
Female	13	9.1	142.1	(75.6-243.0)	Female	24	12.6	190.8	(122.2-283.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.5	nc	(nc-nc)	Male	7	4.8	145.4	(58.3-299.6)
Female	6	3.9	152.8	(55.8-332.6)	Female	7	3.9	177.9	(71.3-366.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	16	14.1	113.2	(64.7-183.8)
Female	128	101.2	126.5	(105.5-150.4)	Female	15	12.2	122.5	(68.5-202.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.3	nc	(nc-nc)	Male	12	11.5	104.0	(53.7-181.6)
<u>Colon / Rectum</u>					Female	5	5.2	96.8	(31.2-226.0)
Male	26	27.7	93.9	(61.3-137.6)	<u>Ovary</u>				
Female	18	27.6	65.2	(38.6-103.0)	Female	10	9.2	109.1	(52.2-200.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.9	nc	(nc-nc)	Male	13	8.7	149.4	(79.5-255.5)
Female	1	1.8	nc	(nc-nc)	Female	12	8.9	135.0	(69.7-235.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.6	nc	(nc-nc)	Male	103	93.8	109.8	(89.6-133.2)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.9	101.4	(37.0-220.7)
Male	11	13.6	81.0	(40.4-144.9)	Female	2	3.5	nc	(nc-nc)
Female	7	8.0	87.6	(35.1-180.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.2	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	8	5.8	138.2	(59.5-272.4)
<u>Leukemia</u>					Female	17	17.3	98.4	(57.3-157.5)
Male	15	9.8	153.8	(86.0-253.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	7.1	126.3	(57.6-239.8)	Female	16	23.6	67.8	(38.7-110.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.6	58.3	(18.8-136.0)	Male	357	337.2	105.9	(95.2-117.4)
Female	4	2.8	nc	(nc-nc)	Female	377	338.5	111.4	(100.4-123.2)
<u>Lung and Bronchus</u>									
Male	34	46.4	73.3	(50.8-102.5)					
Female	43	48.1	89.4	(64.7-120.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.4	95.2	(38.1-196.2)	Male	5	4.4	112.6	(36.3-262.7)
Female	4	2.8	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	3.9	205.1	(88.3-404.1)
Female	33	26.7	123.6	(85.0-173.6)	Female	3	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.4	nc	(nc-nc)
Male	5	7.8	64.3	(20.7-150.1)	<u>Ovary</u>				
Female	8	8.2	97.6	(42.0-192.3)	Female	2	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	28	25.0	112.1	(74.5-162.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	5	4.2	120.3	(38.8-280.7)
Male	8	2.7	294.3	(126.7-579.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.1	nc	(nc-nc)	Female	5	6.2	80.8	(26.1-188.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.3	nc	(nc-nc)	Male	91	92.7	98.2	(79.0-120.5)
Female	0	0.8	nc	(nc-nc)	Female	98	93.6	104.7	(85.0-127.6)
<u>Lung and Bronchus</u>									
Male	4	13.1	nc	(nc-nc)					
Female	17	13.9	122.2	(71.2-195.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	35.6	95.6	(66.2-133.6)	Male	22	24.4	90.3	(56.6-136.8)
Female	11	14.1	78.3	(39.0-140.0)	Female	16	20.7	77.2	(44.1-125.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	7.4	94.1	(37.7-194.0)	Male	8	6.9	115.3	(49.6-227.2)
Female	5	6.4	78.7	(25.4-183.6)	Female	6	6.0	100.8	(36.8-219.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	22	21.5	102.2	(64.0-154.7)
Female	137	153.1	89.5	(75.1-105.8)	Female	17	18.9	90.0	(52.4-144.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	5.7	158.0	(72.1-300.0)	Male	16	17.4	91.7	(52.4-149.0)
<u>Colon / Rectum</u>					Female	15	7.8	191.9	(107.3-316.5)
Male	47	40.8	115.2	(84.7-153.2)	<u>Ovary</u>				
Female	58	43.6	133.1	(101.1-172.1)	Female	16	14.0	114.4	(65.4-185.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	9.7	123.5	(63.8-215.8)	Male	9	12.3	73.3	(33.4-139.1)
Female	3	2.7	nc	(nc-nc)	Female	11	13.7	80.0	(39.9-143.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	3.5	173.1	(63.2-376.8)	Male	128	129.8	98.6	(82.3-117.3)
Female	2	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	8.5	105.6	(48.2-200.5)
Male	30	20.6	146.0	(98.5-208.4)	Female	5	5.5	90.7	(29.2-211.7)
Female	9	12.2	74.1	(33.8-140.6)	<u>Testis</u>				
<u>Larynx</u>					Male	5	6.4	78.4	(25.3-182.9)
Male	6	5.4	111.0	(40.5-241.7)	<u>Thyroid</u>				
Female	2	1.8	nc	(nc-nc)	Male	9	10.2	88.0	(40.1-167.0)
<u>Leukemia</u>					Female	40	30.6	130.8	(93.4-178.1)
Male	19	14.9	127.7	(76.8-199.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	11.6	94.8	(47.2-169.6)	Female	37	33.9	109.1	(76.8-150.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	12.6	103.4	(55.0-176.8)	Male	493	491.0	100.4	(91.7-109.7)
Female	6	4.2	143.4	(52.4-312.1)	Female	533	522.5	102.0	(93.5-111.0)
<u>Lung and Bronchus</u>									
Male	51	64.6	79.0	(58.8-103.9)					
Female	67	71.3	93.9	(72.8-119.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	26.6	86.4	(54.8-129.7)	Male	39	18.0	217.0	(154.3-296.7)
Female	12	9.3	129.4	(66.8-226.0)	Female	27	14.1	191.1	(125.9-278.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.3	132.0	(52.9-271.9)	Male	7	5.3	132.2	(53.0-272.3)
Female	7	4.4	158.4	(63.5-326.5)	Female	2	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	11	15.7	69.8	(34.8-125.0)
Female	142	113.1	125.6	(105.8-148.0)	Female	11	13.0	84.5	(42.1-151.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.9	127.4	(41.1-297.3)	Male	10	13.5	74.0	(35.4-136.1)
<u>Colon / Rectum</u>					Female	5	5.6	89.7	(28.9-209.3)
Male	34	30.3	112.2	(77.7-156.8)	<u>Ovary</u>				
Female	32	28.2	113.4	(77.5-160.1)	Female	12	10.1	118.6	(61.2-207.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.7	nc	(nc-nc)	Male	13	9.4	138.7	(73.8-237.2)
Female	2	1.8	nc	(nc-nc)	Female	7	8.9	78.5	(31.4-161.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.1	nc	(nc-nc)	Male	122	106.8	114.2	(94.9-136.4)
Female	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.4	nc	(nc-nc)
Male	25	15.7	159.1	(103.0-234.9)	Female	4	3.5	nc	(nc-nc)
Female	6	8.7	68.9	(25.2-150.0)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.3	nc	(nc-nc)
Male	0	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	7	7.2	97.3	(39.0-200.4)
<u>Leukemia</u>					Female	26	21.0	123.9	(80.9-181.5)
Male	9	10.7	83.8	(38.3-159.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	7.6	nc	(nc-nc)	Female	27	26.4	102.4	(67.5-149.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	9.9	101.1	(48.4-185.9)	Male	403	376.1	107.2	(97.0-118.2)
Female	1	3.0	nc	(nc-nc)	Female	431	368.0	117.1	(106.3-128.7)
<u>Lung and Bronchus</u>									
Male	49	50.0	98.0	(72.5-129.6)					
Female	69	50.9	135.6	(105.5-171.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	22.7	136.3	(92.6-193.4)	Male	22	13.4	164.4	(103.0-248.9)
Female	9	8.3	108.7	(49.6-206.4)	Female	15	10.1	148.0	(82.8-244.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.4	nc	(nc-nc)	Male	6	4.1	146.8	(53.6-319.6)
Female	2	3.1	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	17	11.7	144.9	(84.4-232.1)
Female	86	80.3	107.1	(85.7-132.3)	Female	14	10.5	133.4	(72.9-223.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	13	8.7	149.9	(79.8-256.4)
<u>Colon / Rectum</u>					Female	5	4.3	117.3	(37.8-273.8)
Male	19	23.1	82.1	(49.4-128.3)	<u>Ovary</u>				
Female	28	24.0	116.6	(77.5-168.5)	Female	9	7.4	121.7	(55.5-231.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.7	105.7	(38.6-230.2)	Male	8	7.4	108.0	(46.5-212.8)
Female	0	1.6	nc	(nc-nc)	Female	8	8.0	99.8	(43.0-196.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	82	73.9	110.9	(88.2-137.7)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.0	99.5	(32.1-232.2)
Male	11	10.7	103.1	(51.4-184.5)	Female	1	3.0	nc	(nc-nc)
Female	8	6.7	118.7	(51.1-234.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.7	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	1.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	11	12.5	88.3	(44.0-158.0)
Male	7	8.1	85.9	(34.4-177.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	6.1	164.9	(78.9-303.2)	Female	14	18.7	74.7	(40.8-125.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.7	nc	(nc-nc)	Male	297	278.3	106.7	(94.9-119.6)
Female	2	2.4	nc	(nc-nc)	Female	310	281.7	110.0	(98.1-123.0)
<u>Lung and Bronchus</u>									
Male	31	40.8	75.9	(51.6-107.8)					
Female	59	43.6	135.3	(103.0-174.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.2	119.1	(59.4-213.2)	Male	6	5.7	105.9	(38.7-230.6)
Female	3	3.0	nc	(nc-nc)	Female	6	4.0	149.8	(54.7-326.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	38	32.5	116.8	(82.6-160.3)	Female	5	4.0	124.6	(40.2-290.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	11	4.0	276.7	(137.9-495.1)
<u>Colon / Rectum</u>					Female	1	1.7	nc	(nc-nc)
Male	6	9.8	61.1	(22.3-133.1)	<u>Ovary</u>				
Female	11	8.9	123.1	(61.4-220.4)	Female	5	3.0	168.8	(54.4-393.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.4	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	46	33.1	139.2	(101.9-185.6)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.1	nc	(nc-nc)
Male	2	4.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.3	94.4	(30.4-220.3)
Male	4	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.3	nc	(nc-nc)	Female	11	7.7	143.2	(71.4-256.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.0	nc	(nc-nc)	Male	128	119.3	107.3	(89.5-127.5)
Female	1	0.9	nc	(nc-nc)	Female	113	109.9	102.8	(84.8-123.6)
<u>Lung and Bronchus</u>									
Male	15	16.7	89.6	(50.1-147.9)					
Female	12	16.3	73.7	(38.1-128.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.9	101.2	(48.4-186.1)	Male	4	6.7	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	Female	7	5.8	121.2	(48.6-249.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.9	118.1	(47.3-243.3)
Female	46	44.4	103.7	(75.9-138.3)	Female	3	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.2	nc	(nc-nc)
Male	20	11.3	176.3	(107.6-272.3)	<u>Ovary</u>				
Female	18	11.7	154.0	(91.2-243.5)	Female	2	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.8	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	36	37.3	96.6	(67.6-133.7)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.4	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	5	3.4	144.9	(46.7-338.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.5	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	10	8.7	114.9	(55.0-211.3)
Male	3	4.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.1	nc	(nc-nc)	Female	8	10.0	79.7	(34.3-157.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.6	nc	(nc-nc)	Male	132	137.4	96.1	(80.4-114.0)
Female	2	1.2	nc	(nc-nc)	Female	150	146.9	102.1	(86.4-119.8)
<u>Lung and Bronchus</u>									
Male	12	18.2	66.1	(34.1-115.5)					
Female	20	19.9	100.3	(61.2-154.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.6	77.5	(35.3-147.0)	Male	9	7.9	113.4	(51.8-215.4)
Female	6	4.0	150.2	(54.8-326.9)	Female	9	6.2	144.9	(66.1-275.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.4	nc	(nc-nc)	Male	5	2.3	215.0	(69.3-501.7)
Female	4	2.0	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.0	85.2	(31.1-185.5)
Female	49	50.1	97.8	(72.3-129.3)	Female	3	5.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	7	6.0	116.1	(46.5-239.2)
<u>Colon / Rectum</u>					Female	1	2.4	nc	(nc-nc)
Male	18	13.6	132.0	(78.2-208.7)	<u>Ovary</u>				
Female	16	12.6	126.5	(72.3-205.5)	Female	5	4.4	112.5	(36.2-262.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	3.3	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	60	44.9	133.7	(102.0-172.1)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.8	nc	(nc-nc)
Male	6	6.9	86.7	(31.7-188.7)	Female	1	1.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.4	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	9	9.5	95.0	(43.4-180.4)
Male	6	4.8	124.7	(45.5-271.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	3.4	207.0	(82.9-426.6)	Female	10	11.2	88.9	(42.6-163.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.4	nc	(nc-nc)	Male	164	163.6	100.2	(85.5-116.8)
Female	1	1.3	nc	(nc-nc)	Female	150	161.1	93.1	(78.8-109.2)
<u>Lung and Bronchus</u>									
Male	12	21.5	55.9	(28.8-97.6)					
Female	12	21.3	56.2	(29.0-98.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	65	60.4	107.6	(83.0-137.1)	Male	29	38.4	75.6	(50.6-108.6)
Female	22	24.3	90.7	(56.8-137.3)	Female	23	33.3	69.1	(43.8-103.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	11.0	127.8	(69.8-214.4)	Male	8	11.1	72.1	(31.0-142.0)
Female	11	10.1	109.0	(54.3-195.0)	Female	12	10.1	118.8	(61.3-207.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.8	nc	(nc-nc)	Male	29	34.0	85.3	(57.1-122.4)
Female	235	240.1	97.9	(85.8-111.2)	Female	22	31.5	69.9	(43.8-105.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	8.5	105.3	(48.1-199.9)	Male	36	25.5	141.0	(98.7-195.2)
<u>Colon / Rectum</u>					Female	13	12.8	101.7	(54.1-174.0)
Male	75	65.2	115.1	(90.5-144.3)	<u>Ovary</u>				
Female	81	73.7	109.8	(87.2-136.5)	Female	27	22.4	120.3	(79.2-175.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	15.2	78.8	(40.7-137.6)	Male	19	20.0	94.9	(57.1-148.2)
Female	5	4.6	108.5	(35.0-253.3)	Female	11	23.8	46.2	(23.0-82.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	5.2	116.1	(42.4-252.6)	Male	157	196.2	80.0	(68.0-93.6)
Female	4	4.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	13.8	101.3	(55.3-170.0)
Male	31	30.6	101.3	(68.8-143.8)	Female	10	9.4	106.6	(51.0-196.1)
Female	25	19.8	126.5	(81.8-186.7)	<u>Testis</u>				
<u>Larynx</u>					Male	11	9.4	116.5	(58.1-208.5)
Male	13	8.4	155.6	(82.7-266.0)	<u>Thyroid</u>				
Female	2	3.0	nc	(nc-nc)	Male	9	14.5	62.1	(28.3-117.9)
<u>Leukemia</u>					Female	47	46.0	102.1	(75.0-135.8)
Male	26	23.8	109.3	(71.4-160.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	19.1	130.9	(84.7-193.3)	Female	60	53.8	111.4	(85.0-143.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	19.0	89.4	(52.0-143.1)	Male	741	771.8	96.0	(89.2-103.2)
Female	8	7.0	114.1	(49.1-224.8)	Female	852	850.3	100.2	(93.6-107.2)
<u>Lung and Bronchus</u>									
Male	110	106.3	103.5	(85.0-124.7)					
Female	124	121.4	102.1	(84.9-121.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	10.9	137.2	(76.7-226.3)	Male	6	7.7	77.4	(28.3-168.6)
Female	2	4.2	nc	(nc-nc)	Female	4	6.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	6.9	188.8	(100.4-322.9)
Female	47	51.6	91.1	(66.9-121.1)	Female	7	5.9	119.2	(47.7-245.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.9	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.5	nc	(nc-nc)
Male	19	13.1	145.3	(87.5-227.0)	<u>Ovary</u>				
Female	14	13.4	104.1	(56.9-174.7)	Female	7	4.6	153.2	(61.4-315.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	3.2	221.8	(88.9-457.1)	Male	2	3.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	44	42.8	102.9	(74.8-138.1)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.7	nc	(nc-nc)
Male	4	6.8	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Female	0	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.7	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	12	10.2	117.6	(60.7-205.4)
Male	2	4.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.6	nc	(nc-nc)	Female	8	11.3	70.7	(30.4-139.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.2	nc	(nc-nc)	Male	164	157.6	104.1	(88.7-121.3)
Female	0	1.3	nc	(nc-nc)	Female	152	167.6	90.7	(76.9-106.3)
<u>Lung and Bronchus</u>									
Male	19	20.3	93.7	(56.4-146.4)					
Female	28	21.9	128.1	(85.1-185.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	29.9	80.3	(51.5-119.5)	Male	23	19.3	119.0	(75.4-178.5)
Female	17	12.3	138.6	(80.7-222.0)	Female	19	16.7	113.8	(68.5-177.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	5.5	180.6	(86.4-332.1)	Male	4	5.7	nc	(nc-nc)
Female	7	5.2	135.7	(54.4-279.6)	Female	2	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	22	17.0	129.1	(80.9-195.5)
Female	132	127.0	104.0	(87.0-123.3)	Female	16	16.1	99.5	(56.9-161.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.4	nc	(nc-nc)	Male	17	13.6	125.0	(72.8-200.1)
<u>Colon / Rectum</u>					Female	5	6.6	75.5	(24.3-176.1)
Male	44	32.9	133.7	(97.1-179.5)	<u>Ovary</u>				
Female	34	37.3	91.1	(63.1-127.3)	Female	13	11.6	111.7	(59.4-191.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	8.0	125.5	(60.1-230.8)	Male	11	10.2	108.3	(54.0-193.7)
Female	1	2.3	nc	(nc-nc)	Female	16	12.0	133.2	(76.1-216.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.3	nc	(nc-nc)	Male	95	106.3	89.4	(72.3-109.3)
Female	1	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.0	86.1	(31.4-187.3)
Male	16	16.1	99.2	(56.6-161.1)	Female	5	4.7	106.0	(34.2-247.3)
Female	9	10.3	87.7	(40.0-166.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.8	nc	(nc-nc)
Male	10	4.4	227.7	(109.0-418.8)	<u>Thyroid</u>				
Female	2	1.6	nc	(nc-nc)	Male	12	7.4	162.7	(84.0-284.3)
<u>Leukemia</u>					Female	27	23.1	117.0	(77.1-170.3)
Male	20	11.8	169.6	(103.6-262.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	9.7	62.2	(22.7-135.3)	Female	32	28.8	111.3	(76.1-157.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	10.0	49.9	(16.1-116.5)	Male	418	396.3	105.5	(95.6-116.1)
Female	2	3.6	nc	(nc-nc)	Female	431	438.3	98.3	(89.3-108.1)
<u>Lung and Bronchus</u>									
Male	54	53.9	100.2	(75.3-130.7)					
Female	50	62.2	80.4	(59.7-106.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.4	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	24	23.2	103.2	(66.1-153.6)	Female	7	2.5	277.5	(111.2-571.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	2	6.5	nc	(nc-nc)	<u>Ovary</u>				
Female	3	5.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	27	22.1	122.2	(80.5-177.8)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.7	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.5	nc	(nc-nc)	Female	5	5.2	96.4	(31.1-224.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.1	nc	(nc-nc)	Male	60	79.1	75.9	(57.9-97.7)
Female	1	0.6	nc	(nc-nc)	Female	71	73.3	96.9	(75.6-122.2)
<u>Lung and Bronchus</u>									
Male	4	10.2	nc	(nc-nc)					
Female	7	9.5	73.8	(29.6-152.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.7	74.9	(24.2-174.9)	Male	5	4.5	111.4	(35.9-259.9)
Female	2	2.4	nc	(nc-nc)	Female	5	3.6	139.3	(44.9-325.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	24	28.8	83.3	(53.4-124.0)	Female	2	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.4	nc	(nc-nc)
Male	8	7.6	105.0	(45.2-207.0)	<u>Ovary</u>				
Female	6	7.4	81.5	(29.8-177.3)	Female	5	2.6	195.8	(63.1-456.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	25	25.5	97.9	(63.3-144.5)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.8	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.4	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.9	nc	(nc-nc)	Female	4	6.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.4	nc	(nc-nc)	Male	88	92.7	95.0	(76.2-117.0)
Female	2	0.7	nc	(nc-nc)	Female	86	93.6	91.9	(73.5-113.5)
<u>Lung and Bronchus</u>									
Male	14	12.4	113.0	(61.7-189.5)					
Female	16	12.8	124.8	(71.3-202.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	47.7	113.2	(85.0-147.7)	Male	25	31.1	80.4	(52.0-118.8)
Female	25	18.9	132.1	(85.5-195.0)	Female	27	26.8	100.8	(66.4-146.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	9.2	87.0	(37.5-171.5)	Male	11	9.0	121.7	(60.7-217.7)
Female	9	8.3	108.0	(49.3-205.0)	Female	5	8.0	62.5	(20.1-145.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.5	nc	(nc-nc)	Male	27	27.6	97.8	(64.4-142.3)
Female	197	201.1	98.0	(84.8-112.6)	Female	27	25.2	107.3	(70.7-156.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	7.2	111.8	(48.1-220.2)	Male	18	21.9	82.1	(48.7-129.8)
<u>Colon / Rectum</u>					Female	8	10.4	76.9	(33.1-151.5)
Male	56	53.1	105.4	(79.6-136.9)	<u>Ovary</u>				
Female	52	58.4	89.1	(66.5-116.8)	Female	10	18.5	54.2	(25.9-99.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	12.6	95.1	(49.1-166.1)	Male	19	16.2	117.2	(70.5-183.0)
Female	1	3.6	nc	(nc-nc)	Female	17	18.6	91.5	(53.3-146.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	4.0	nc	(nc-nc)	Male	186	166.9	111.4	(96.0-128.7)
Female	3	3.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	11.2	116.3	(61.9-198.9)
Male	27	25.8	104.8	(69.0-152.4)	Female	7	7.4	94.9	(38.0-195.5)
Female	16	16.1	99.5	(56.9-161.7)	<u>Testis</u>				
<u>Larynx</u>					Male	11	6.7	163.0	(81.3-291.7)
Male	8	7.0	114.9	(49.5-226.3)	<u>Thyroid</u>				
Female	3	2.4	nc	(nc-nc)	Male	14	12.1	115.8	(63.2-194.3)
<u>Leukemia</u>					Female	34	38.2	89.1	(61.7-124.5)
Male	21	19.3	108.7	(67.3-166.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	15.3	104.4	(59.6-169.5)	Female	48	45.1	106.5	(78.5-141.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	16.1	93.1	(52.1-153.5)	Male	663	633.7	104.6	(96.8-112.9)
Female	4	5.6	nc	(nc-nc)	Female	699	690.2	101.3	(93.9-109.1)
<u>Lung and Bronchus</u>									
Male	98	85.2	115.0	(93.4-140.2)					
Female	113	95.6	118.1	(97.4-142.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	25.7	132.2	(91.6-184.8)	Male	19	16.8	113.3	(68.2-177.0)
Female	15	8.9	168.4	(94.2-277.8)	Female	14	13.0	107.3	(58.6-180.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.9	123.4	(45.1-268.7)	Male	5	4.9	101.5	(32.7-236.8)
Female	4	4.1	nc	(nc-nc)	Female	5	3.8	130.1	(41.9-303.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	17	14.8	115.2	(67.1-184.4)
Female	110	101.0	108.9	(89.5-131.3)	Female	9	12.2	74.1	(33.8-140.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	3.5	197.6	(79.2-407.1)	Male	8	12.0	66.8	(28.8-131.7)
<u>Colon / Rectum</u>					Female	9	5.1	176.8	(80.7-335.6)
Male	41	28.4	144.3	(103.5-195.8)	<u>Ovary</u>				
Female	31	26.9	115.1	(78.2-163.3)	Female	14	9.2	153.0	(83.6-256.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.0	114.0	(49.1-224.5)	Male	12	8.8	135.9	(70.1-237.4)
Female	2	1.7	nc	(nc-nc)	Female	6	8.6	69.4	(25.3-151.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	106	95.3	111.2	(91.1-134.5)
Female	0	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.0	99.4	(36.3-216.4)
Male	14	14.2	98.5	(53.8-165.2)	Female	0	3.4	nc	(nc-nc)
Female	1	8.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.2	185.3	(67.7-403.4)
Male	1	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.3	nc	(nc-nc)	Male	6	6.5	92.8	(33.9-202.0)
<u>Leukemia</u>					Female	20	18.9	105.9	(64.6-163.5)
Male	15	10.2	147.0	(82.2-242.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	7.2	194.8	(106.4-326.8)	Female	30	23.3	128.7	(86.8-183.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	8.8	148.4	(79.0-253.8)	Male	391	347.2	112.6	(101.7-124.3)
Female	8	2.7	291.3	(125.4-574.1)	Female	396	338.0	117.2	(105.9-129.3)
<u>Lung and Bronchus</u>									
Male	45	47.1	95.5	(69.7-127.8)					
Female	67	47.4	141.3	(109.5-179.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.6	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	10.0	89.9	(41.0-170.7)
Female	0	0.1	nc	(nc-nc)	Female	7	7.6	92.6	(37.1-190.7)
<u>Lung and Bronchus</u>									
Male	1	1.3	nc	(nc-nc)					
Female	2	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	9.6	167.3	(95.5-271.6)	Male	8	6.5	122.3	(52.7-241.1)
Female	6	3.2	189.7	(69.3-412.9)	Female	6	4.5	133.7	(48.8-291.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	5	1.9	267.0	(86.0-623.0)
Female	3	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	5.8	172.6	(82.6-317.4)
Female	36	35.9	100.4	(70.3-139.0)	Female	5	4.3	117.2	(37.8-273.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	5	4.7	107.1	(34.5-249.9)
<u>Colon / Rectum</u>					Female	3	1.8	nc	(nc-nc)
Male	11	10.9	100.5	(50.1-179.9)	<u>Ovary</u>				
Female	10	9.6	104.0	(49.8-191.3)	Female	0	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.6	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	45	34.6	130.0	(94.8-173.9)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.3	nc	(nc-nc)
Male	3	5.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	6.4	nc	(nc-nc)
Male	5	3.9	127.2	(41.0-296.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.5	nc	(nc-nc)	Female	6	8.0	74.8	(27.3-162.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.3	nc	(nc-nc)	Male	161	131.5	122.4	(104.2-142.9)
Female	1	1.0	nc	(nc-nc)	Female	120	119.1	100.8	(83.6-120.5)
<u>Lung and Bronchus</u>									
Male	16	17.4	91.8	(52.4-149.0)					
Female	20	16.9	118.1	(72.1-182.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	48	28.2	170.2	(125.5-225.7)	Male	10	18.7	53.3	(25.5-98.1)
Female	13	10.1	128.4	(68.3-219.5)	Female	15	15.0	100.3	(56.1-165.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.6	nc	(nc-nc)	Male	7	5.4	129.3	(51.8-266.5)
Female	0	4.6	nc	(nc-nc)	Female	7	4.3	161.9	(64.9-333.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	18	16.6	108.2	(64.1-171.0)
Female	87	112.3	77.5	(62.0-95.5)	Female	17	13.7	123.9	(72.1-198.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.1	nc	(nc-nc)	Male	13	13.3	97.5	(51.8-166.7)
<u>Colon / Rectum</u>					Female	10	5.7	174.7	(83.6-321.4)
Male	25	31.8	78.7	(50.9-116.2)	<u>Ovary</u>				
Female	29	31.4	92.4	(61.9-132.8)	Female	9	10.2	87.9	(40.1-166.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	7.6	132.0	(63.2-242.7)	Male	11	9.6	114.0	(56.8-204.0)
Female	2	1.9	nc	(nc-nc)	Female	6	9.9	60.5	(22.1-131.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	2.5	280.4	(112.3-577.7)	Male	107	101.2	105.8	(86.7-127.8)
Female	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	6.7	194.7	(103.6-333.0)
Male	17	15.7	108.2	(63.0-173.3)	Female	1	3.9	nc	(nc-nc)
Female	11	8.9	124.0	(61.8-221.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.4	nc	(nc-nc)
Male	3	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
<u>Leukemia</u>					Female	19	22.0	86.5	(52.0-135.1)
Male	12	11.6	103.9	(53.6-181.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	8.4	131.3	(65.5-235.0)	Female	25	25.3	99.0	(64.0-146.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	9.7	nc	(nc-nc)	Male	390	381.3	102.3	(92.4-112.9)
Female	2	3.1	nc	(nc-nc)	Female	358	380.4	94.1	(84.6-104.4)
<u>Lung and Bronchus</u>									
Male	49	50.6	96.8	(71.6-128.0)					
Female	60	51.9	115.6	(88.2-148.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	15.2	92.0	(50.2-154.3)	Male	4	9.9	nc	(nc-nc)
Female	8	5.7	141.0	(60.7-277.8)	Female	4	7.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	5	2.4	207.8	(67.0-484.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	14	8.7	160.9	(87.9-270.0)
Female	56	60.4	92.7	(70.0-120.4)	Female	5	7.5	66.4	(21.4-154.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.1	238.5	(76.9-556.5)	Male	8	6.9	115.3	(49.6-227.1)
<u>Colon / Rectum</u>					Female	2	3.1	nc	(nc-nc)
Male	10	16.7	59.8	(28.6-109.9)	<u>Ovary</u>				
Female	14	17.2	81.2	(44.4-136.3)	Female	7	5.5	127.0	(50.9-261.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	4.1	172.0	(68.9-354.4)	Male	6	5.2	116.2	(42.4-253.0)
Female	2	1.1	nc	(nc-nc)	Female	10	5.5	180.7	(86.5-332.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	60	54.2	110.7	(84.5-142.5)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.6	nc	(nc-nc)
Male	14	8.3	169.4	(92.5-284.3)	Female	1	2.2	nc	(nc-nc)
Female	8	4.9	164.8	(70.9-324.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.9	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<u>Leukemia</u>					Female	10	11.1	90.3	(43.2-166.0)
Male	5	6.0	83.9	(27.0-195.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.5	156.0	(62.5-321.5)	Female	12	13.7	87.6	(45.2-153.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.1	97.8	(31.5-228.2)	Male	228	202.1	112.8	(98.6-128.4)
Female	2	1.7	nc	(nc-nc)	Female	208	206.6	100.7	(87.5-115.3)
<u>Lung and Bronchus</u>									
Male	44	27.7	159.0	(115.5-213.4)					
Female	32	29.4	108.9	(74.5-153.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	7.9	152.9	(78.9-267.0)	Male	7	5.4	129.2	(51.8-266.3)
Female	4	2.7	nc	(nc-nc)	Female	5	4.3	116.8	(37.6-272.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.8	104.9	(33.8-244.8)
Female	36	33.9	106.1	(74.3-146.9)	Female	2	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	6	4.1	146.1	(53.3-317.9)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	10	9.1	110.0	(52.7-202.3)	<u>Ovary</u>				
Female	13	8.3	156.3	(83.1-267.2)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.3	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	39	31.3	124.5	(88.5-170.1)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	7	4.7	147.5	(59.1-304.0)	Female	0	1.0	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	13	6.6	197.2	(104.9-337.3)
Male	3	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.3	nc	(nc-nc)	Female	5	7.8	64.2	(20.7-149.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.0	nc	(nc-nc)	Male	133	112.0	118.7	(99.4-140.7)
Female	0	0.9	nc	(nc-nc)	Female	114	109.4	104.2	(85.9-125.2)
<u>Lung and Bronchus</u>									
Male	14	14.7	95.4	(52.1-160.1)					
Female	13	14.8	88.1	(46.8-150.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	7	11.2	62.5	(25.0-128.8)	Female	2	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	10	9.0	110.8	(53.1-203.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.6	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	32	33.2	96.3	(65.8-135.9)
Female	1	0.3	nc	(nc-nc)	Female	28	35.9	77.9	(51.8-112.6)
<u>Lung and Bronchus</u>									
Male	0	4.1	nc	(nc-nc)					
Female	8	4.6	175.3	(75.5-345.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	30.2	66.3	(40.5-102.4)	Male	34	19.0	179.4	(124.2-250.7)
Female	4	12.3	nc	(nc-nc)	Female	23	16.1	142.5	(90.3-213.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.5	91.6	(29.5-213.7)	Male	8	5.6	142.0	(61.1-279.8)
Female	6	5.1	117.6	(43.0-256.0)	Female	8	5.1	155.7	(67.1-306.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	12	16.9	71.0	(36.7-124.1)
Female	112	124.4	90.0	(74.1-108.3)	Female	12	15.9	75.5	(39.0-131.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.1	146.5	(53.5-318.8)	Male	10	13.3	75.4	(36.1-138.6)
<u>Colon / Rectum</u>					Female	5	6.6	76.2	(24.6-177.8)
Male	24	32.9	73.0	(46.8-108.7)	<u>Ovary</u>				
Female	44	37.4	117.7	(85.5-158.1)	Female	14	11.5	121.9	(66.6-204.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.8	nc	(nc-nc)	Male	7	10.1	69.1	(27.7-142.3)
Female	4	2.3	nc	(nc-nc)	Female	13	12.0	108.2	(57.5-185.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.2	nc	(nc-nc)	Male	122	103.2	118.2	(98.1-141.1)
Female	3	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	7.0	nc	(nc-nc)
Male	14	15.6	90.0	(49.2-151.0)	Female	4	4.7	nc	(nc-nc)
Female	12	10.1	118.8	(61.3-207.5)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.4	149.0	(48.0-347.7)
Male	1	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.5	nc	(nc-nc)	Male	7	6.9	101.2	(40.6-208.6)
<u>Leukemia</u>					Female	35	21.6	161.8	(112.7-225.0)
Male	11	11.9	92.4	(46.1-165.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	9.6	114.4	(57.0-204.6)	Female	31	28.2	110.1	(74.8-156.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	10.0	50.2	(16.2-117.2)	Male	351	390.9	89.8	(80.7-99.7)
Female	2	3.6	nc	(nc-nc)	Female	416	431.5	96.4	(87.4-106.1)
<u>Lung and Bronchus</u>									
Male	32	53.5	59.8	(40.9-84.5)					
Female	45	61.6	73.1	(53.3-97.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.9	78.3	(31.4-161.3)	Male	8	6.1	130.3	(56.1-256.8)
Female	2	3.1	nc	(nc-nc)	Female	1	4.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	45	37.8	118.9	(86.7-159.1)	Female	4	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.9	nc	(nc-nc)
Male	10	10.4	96.0	(46.0-176.6)	<u>Ovary</u>				
Female	7	9.6	72.9	(29.2-150.1)	Female	2	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.6	nc	(nc-nc)	Male	5	3.2	157.6	(50.8-367.8)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	31	36.4	85.2	(57.9-121.0)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.2	nc	(nc-nc)
Male	8	5.4	148.4	(63.9-292.4)	Female	1	1.2	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	2	7.2	nc	(nc-nc)
Male	5	3.6	137.9	(44.5-321.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.5	nc	(nc-nc)	Female	8	8.7	91.8	(39.5-180.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	3.4	146.4	(47.2-341.6)	Male	122	128.1	95.3	(79.1-113.7)
Female	0	1.0	nc	(nc-nc)	Female	105	123.1	85.3	(69.7-103.2)
<u>Lung and Bronchus</u>									
Male	17	16.7	101.6	(59.2-162.7)					
Female	11	16.6	66.1	(33.0-118.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.1	79.0	(34.0-155.7)	Male	7	6.5	107.2	(43.0-220.9)
Female	7	3.9	180.9	(72.5-372.8)	Female	2	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
Female	41	39.7	103.3	(74.1-140.2)	Female	3	5.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.1	nc	(nc-nc)
Male	9	11.1	81.0	(36.9-153.7)	<u>Ovary</u>				
Female	15	11.7	128.2	(71.7-211.4)	Female	5	3.7	136.4	(43.9-318.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.7	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	30	36.1	83.0	(56.0-118.5)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.4	nc	(nc-nc)
Male	6	5.4	110.7	(40.4-241.0)	Female	0	1.5	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	3	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.0	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	11	9.1	120.6	(60.1-215.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.5	nc	(nc-nc)	Male	110	134.3	81.9	(67.3-98.7)
Female	0	1.1	nc	(nc-nc)	Female	121	137.4	88.1	(73.1-105.2)
<u>Lung and Bronchus</u>									
Male	16	18.3	87.2	(49.8-141.7)					
Female	15	19.7	76.0	(42.5-125.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.8	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	5.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	10	22.5	44.4	(21.2-81.6)
Female	0	0.2	nc	(nc-nc)	Female	10	18.8	53.1	(25.4-97.7)
<u>Lung and Bronchus</u>									
Male	1	3.2	nc	(nc-nc)					
Female	1	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	4.2	188.6	(81.2-371.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	18	14.7	122.1	(72.3-193.0)
Female	0	0.1	nc	(nc-nc)	Female	8	12.1	65.9	(28.4-129.9)
<u>Lung and Bronchus</u>									
Male	1	1.9	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	2	0.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.7	87.0	(28.0-203.1)	Male	12	3.5	345.7	(178.4-603.9)
Female	3	1.9	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	18	19.7	91.2	(54.0-144.1)	Female	1	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.6	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	3	6.1	nc	(nc-nc)	<u>Ovary</u>				
Female	7	5.8	119.8	(48.0-246.9)	Female	2	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	20	20.2	99.0	(60.4-152.9)
Female	2	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	0	2.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.2	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.4	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.8	nc	(nc-nc)	Male	71	73.2	97.0	(75.8-122.4)
Female	1	0.6	nc	(nc-nc)	Female	62	67.6	91.7	(70.3-117.5)
<u>Lung and Bronchus</u>									
Male	7	10.3	68.0	(27.2-140.1)					
Female	5	9.7	51.4	(16.6-119.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	10.1	69.5	(27.8-143.1)	Male	26	7.0	372.7	(243.4-546.1)
Female	3	3.4	nc	(nc-nc)	Female	18	5.3	341.9	(202.5-540.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	55	39.5	139.3	(104.9-181.3)	Female	5	4.7	107.1	(34.5-249.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	8	5.0	158.7	(68.3-312.6)
<u>Colon / Rectum</u>					Female	4	2.0	nc	(nc-nc)
Male	13	11.5	112.8	(60.0-192.8)	<u>Ovary</u>				
Female	11	10.4	105.8	(52.7-189.2)	Female	3	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.8	nc	(nc-nc)	Male	5	3.5	142.2	(45.8-331.9)
Female	4	0.6	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.0	nc	(nc-nc)	Male	47	38.4	122.4	(90.0-162.8)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.4	nc	(nc-nc)
Male	3	6.0	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.9	169.6	(54.7-395.9)
<u>Leukemia</u>					Female	9	8.0	112.1	(51.1-212.7)
Male	8	4.2	191.5	(82.5-377.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.8	nc	(nc-nc)	Female	11	9.0	122.9	(61.2-219.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.6	nc	(nc-nc)	Male	173	141.4	122.3	(104.8-142.0)
Female	0	1.0	nc	(nc-nc)	Female	154	131.5	117.2	(99.4-137.2)
<u>Lung and Bronchus</u>									
Male	15	18.6	80.6	(45.1-133.0)					
Female	12	17.7	67.7	(34.9-118.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	35.1	111.2	(79.1-152.0)	Male	21	22.9	91.6	(56.7-140.0)
Female	11	13.2	83.6	(41.7-149.6)	Female	21	19.1	109.9	(68.0-168.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	6.7	193.7	(103.0-331.3)	Male	7	6.7	104.7	(42.0-215.8)
Female	10	5.9	170.2	(81.5-313.1)	Female	6	5.6	106.9	(39.0-232.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.1	nc	(nc-nc)	Male	17	20.3	83.9	(48.8-134.3)
Female	159	146.1	108.8	(92.6-127.1)	Female	15	17.7	84.6	(47.3-139.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	5.2	nc	(nc-nc)	Male	16	16.2	98.8	(56.4-160.5)
<u>Colon / Rectum</u>					Female	10	7.4	135.2	(64.7-248.7)
Male	47	39.1	120.2	(88.3-159.9)	<u>Ovary</u>				
Female	31	40.4	76.8	(52.2-109.0)	Female	21	13.2	158.7	(98.2-242.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	9.3	118.0	(58.8-211.1)	Male	13	11.9	109.0	(58.0-186.4)
Female	3	2.5	nc	(nc-nc)	Female	7	12.8	54.6	(21.9-112.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.7	nc	(nc-nc)	Male	121	123.2	98.2	(81.5-117.3)
Female	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	8.2	121.5	(58.2-223.4)
Male	16	19.1	83.7	(47.8-135.9)	Female	2	5.1	nc	(nc-nc)
Female	9	11.6	77.8	(35.5-147.8)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.6	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	5	1.8	282.4	(91.0-658.9)	Male	15	8.9	169.1	(94.6-278.9)
<u>Leukemia</u>					Female	24	27.8	86.4	(55.4-128.6)
Male	12	14.1	85.1	(43.9-148.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	10.7	84.3	(38.5-160.1)	Female	29	32.9	88.2	(59.1-126.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	11.9	nc	(nc-nc)	Male	477	466.5	102.2	(93.3-111.9)
Female	3	4.0	nc	(nc-nc)	Female	492	492.5	99.9	(91.3-109.1)
<u>Lung and Bronchus</u>									
Male	52	63.0	82.5	(61.6-108.2)					
Female	73	68.4	106.7	(83.6-134.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	35.5	112.6	(80.4-153.3)	Male	34	22.0	154.6	(107.1-216.1)
Female	10	13.4	74.7	(35.8-137.4)	Female	18	17.3	104.2	(61.7-164.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.2	128.7	(55.4-253.7)	Male	8	6.5	122.2	(52.6-240.8)
Female	9	5.5	163.9	(74.8-311.2)	Female	5	5.6	89.5	(28.9-209.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	26	19.6	132.7	(86.7-194.5)
Female	153	134.8	113.5	(96.2-133.0)	Female	16	17.2	93.0	(53.1-151.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.4	nc	(nc-nc)	Male	13	15.2	85.4	(45.4-146.1)
<u>Colon / Rectum</u>					Female	6	7.1	84.8	(31.0-184.6)
Male	29	38.5	75.2	(50.4-108.1)	<u>Ovary</u>				
Female	33	41.1	80.2	(55.2-112.7)	Female	12	12.4	97.1	(50.1-169.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	9.1	77.2	(30.9-159.1)	Male	11	11.8	92.8	(46.3-166.1)
Female	4	2.5	nc	(nc-nc)	Female	17	13.2	128.5	(74.8-205.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.3	nc	(nc-nc)	Male	156	117.6	132.7	(112.7-155.2)
Female	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	8.1	85.9	(34.4-177.1)
Male	14	17.9	78.0	(42.6-130.9)	Female	2	5.2	nc	(nc-nc)
Female	10	10.9	91.7	(43.9-168.6)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.4	nc	(nc-nc)
Male	5	5.0	100.9	(32.5-235.4)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	9	7.8	115.5	(52.7-219.3)
<u>Leukemia</u>					Female	39	22.8	171.0	(121.6-233.7)
Male	7	13.8	50.6	(20.3-104.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	10.5	142.4	(79.6-234.8)	Female	29	30.2	96.1	(64.3-138.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	11.4	44.0	(14.2-102.6)	Male	455	451.5	100.8	(91.7-110.5)
Female	1	3.9	nc	(nc-nc)	Female	465	466.7	99.6	(90.8-109.1)
<u>Lung and Bronchus</u>									
Male	41	62.4	65.7	(47.2-89.2)					
Female	40	65.9	60.7	(43.3-82.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	5	3.6	139.8	(45.1-326.3)
<u>Lung and Bronchus</u>									
Male	0	0.6	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	110	96.8	113.6	(93.4-136.9)	Male	33	61.9	53.3	(36.7-74.9)
Female	38	39.7	95.6	(67.7-131.3)	Female	23	53.8	42.8	(27.1-64.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	18.3	87.5	(50.0-142.1)	Male	20	18.0	111.2	(67.9-171.7)
Female	21	16.9	124.5	(77.0-190.3)	Female	14	16.5	84.6	(46.2-142.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	3.0	nc	(nc-nc)	Male	51	55.0	92.7	(69.0-121.9)
Female	339	392.8	86.3	(77.4-96.0)	Female	36	51.4	70.0	(49.0-96.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	24	13.7	174.8	(111.9-260.0)	Male	59	42.2	139.9	(106.5-180.5)
<u>Colon / Rectum</u>					Female	30	20.9	143.4	(96.7-204.7)
Male	119	105.3	113.0	(93.6-135.2)	<u>Ovary</u>				
Female	107	120.9	88.5	(72.5-106.9)	Female	37	36.7	100.8	(71.0-139.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	34	24.9	136.3	(94.4-190.5)	Male	36	32.4	111.1	(77.8-153.8)
Female	9	7.5	119.7	(54.6-227.3)	Female	63	39.1	161.1	(123.8-206.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	8.2	110.3	(50.3-209.5)	Male	379	326.2	116.2	(104.8-128.5)
Female	4	7.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	37	22.3	165.8	(116.7-228.5)
Male	71	50.4	140.9	(110.1-177.8)	Female	27	15.4	175.1	(115.4-254.8)
Female	46	32.4	142.0	(104.0-189.5)	<u>Testis</u>				
<u>Larynx</u>					Male	8	14.3	56.0	(24.1-110.3)
Male	21	13.7	153.1	(94.8-234.1)	<u>Thyroid</u>				
Female	14	4.8	288.9	(157.8-484.7)	Male	20	23.5	85.1	(51.9-131.4)
<u>Leukemia</u>					Female	74	73.5	100.6	(79.0-126.4)
Male	37	39.0	95.0	(66.9-130.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	23	31.8	72.3	(45.8-108.5)	Female	93	88.3	105.4	(85.0-129.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	69	31.3	220.3	(171.4-278.9)	Male	1477	1258.4	117.4	(111.5-123.5)
Female	11	11.5	95.7	(47.7-171.2)	Female	1365	1389.3	98.2	(93.1-103.6)
<u>Lung and Bronchus</u>									
Male	244	171.9	141.9	(124.7-160.9)					
Female	199	197.6	100.7	(87.2-115.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	14.0	78.7	(39.3-140.9)
Female	0	0.1	nc	(nc-nc)	Female	12	13.7	87.6	(45.2-153.0)
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	0	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.4	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	10	7.7	129.4	(62.0-238.0)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.4	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	9.3	54.0	(17.4-126.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	18	32.1	56.1	(33.2-88.7)
Female	0	0.2	nc	(nc-nc)	Female	23	26.1	88.1	(55.8-132.2)
<u>Lung and Bronchus</u>									
Male	0	4.5	nc	(nc-nc)					
Female	2	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	3	4.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.3	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	17.1	64.5	(32.1-115.3)
Female	0	0.1	nc	(nc-nc)	Female	10	13.8	72.3	(34.6-133.0)
<u>Lung and Bronchus</u>									
Male	1	2.2	nc	(nc-nc)					
Female	0	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.9	76.2	(27.8-165.9)	Male	16	5.3	301.0	(171.9-488.8)
Female	3	2.6	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.6	107.6	(34.7-251.2)
Female	44	32.1	137.2	(99.7-184.2)	Female	4	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	11	9.0	122.5	(61.0-219.1)	<u>Ovary</u>				
Female	10	8.0	124.4	(59.6-228.8)	Female	4	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	40	32.5	123.0	(87.8-167.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	7	5.8	121.1	(48.5-249.5)
Male	0	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.1	nc	(nc-nc)	Female	8	7.5	106.2	(45.7-209.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.0	nc	(nc-nc)	Male	113	112.3	100.7	(83.0-121.0)
Female	1	0.8	nc	(nc-nc)	Female	113	103.7	108.9	(89.8-131.0)
<u>Lung and Bronchus</u>									
Male	9	14.9	60.5	(27.6-114.9)					
Female	11	14.2	77.3	(38.5-138.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	20.7	106.3	(66.6-160.9)	Male	24	13.5	178.2	(114.2-265.2)
Female	8	8.5	93.9	(40.4-185.0)	Female	16	11.6	137.7	(78.6-223.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	6	3.6	165.0	(60.2-359.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	14	11.8	118.7	(64.9-199.2)
Female	91	91.5	99.4	(80.1-122.1)	Female	8	11.3	71.0	(30.6-139.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.0	nc	(nc-nc)	Male	17	9.8	173.7	(101.1-278.1)
<u>Colon / Rectum</u>					Female	3	4.7	nc	(nc-nc)
Male	25	23.0	108.9	(70.5-160.8)	<u>Ovary</u>				
Female	26	26.0	99.9	(65.3-146.5)	Female	9	8.4	107.6	(49.1-204.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.7	105.1	(38.4-228.8)	Male	7	7.1	98.0	(39.3-202.0)
Female	2	1.6	nc	(nc-nc)	Female	8	8.4	95.7	(41.2-188.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	85	77.7	109.5	(87.4-135.4)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.9	123.2	(45.0-268.1)
Male	11	11.5	96.0	(47.9-171.8)	Female	6	3.3	183.6	(67.1-399.7)
Female	4	7.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.2	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	9	5.1	176.6	(80.6-335.2)
<u>Leukemia</u>					Female	18	15.8	113.9	(67.5-180.1)
Male	8	8.1	99.3	(42.8-195.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.6	75.6	(24.4-176.5)	Female	16	21.2	75.3	(43.0-122.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	7.2	nc	(nc-nc)	Male	293	280.0	104.6	(93.0-117.3)
Female	3	2.6	nc	(nc-nc)	Female	306	309.8	98.8	(88.0-110.5)
<u>Lung and Bronchus</u>									
Male	30	38.1	78.8	(53.2-112.5)					
Female	43	43.6	98.7	(71.4-132.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	93	98.2	94.7	(76.4-116.0)	Male	69	61.3	112.5	(87.5-142.4)
Female	42	36.8	114.1	(82.2-154.3)	Female	67	50.3	133.3	(103.3-169.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	21	17.4	120.9	(74.8-184.9)	Male	25	18.2	137.4	(88.9-202.8)
Female	17	15.7	108.1	(62.9-173.1)	Female	18	15.5	116.1	(68.7-183.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.0	nc	(nc-nc)	Male	56	54.5	102.7	(77.6-133.4)
Female	457	381.0	119.9	(109.2-131.5)	Female	53	48.3	109.7	(82.1-143.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	12.9	92.8	(47.9-162.1)	Male	40	42.6	93.9	(67.1-127.9)
<u>Colon / Rectum</u>					Female	26	20.0	130.0	(84.9-190.5)
Male	90	105.8	85.0	(68.4-104.5)	<u>Ovary</u>				
Female	91	112.1	81.1	(65.3-99.6)	Female	39	35.3	110.4	(78.5-151.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	25.5	35.2	(16.1-66.9)	Male	34	33.0	103.2	(71.4-144.2)
Female	7	7.0	99.8	(40.0-205.7)	Female	48	36.2	132.5	(97.7-175.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	7.1	nc	(nc-nc)	Male	362	337.6	107.2	(96.5-118.9)
Female	4	6.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	18	22.5	79.9	(47.3-126.2)
Male	51	50.3	101.5	(75.6-133.4)	Female	15	14.2	105.4	(59.0-173.9)
Female	22	30.7	71.7	(44.9-108.6)	<u>Testis</u>				
<u>Larynx</u>					Male	13	11.1	117.2	(62.3-200.4)
Male	9	14.0	64.3	(29.4-122.1)	<u>Thyroid</u>				
Female	1	4.7	nc	(nc-nc)	Male	34	22.2	153.1	(106.0-214.0)
<u>Leukemia</u>					Female	82	68.8	119.3	(94.8-148.0)
Male	46	38.3	120.2	(88.0-160.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	29.2	85.7	(55.5-126.6)	Female	87	87.4	99.6	(79.8-122.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	28	31.9	87.9	(58.4-127.0)	Male	1203	1268.4	94.8	(89.6-100.4)
Female	11	10.9	100.8	(50.3-180.5)	Female	1400	1316.6	106.3	(100.8-112.1)
<u>Lung and Bronchus</u>									
Male	127	174.6	72.8	(60.6-86.6)					
Female	148	185.0	80.0	(67.6-94.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.6	75.6	(32.6-149.0)	Male	12	8.3	145.2	(75.0-253.7)
Female	3	2.6	nc	(nc-nc)	Female	6	4.4	135.5	(49.5-294.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	7	7.2	96.9	(38.8-199.7)
Female	53	35.7	148.3	(111.1-194.0)	Female	0	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.7	nc	(nc-nc)
Male	12	13.5	88.6	(45.7-154.8)	<u>Ovary</u>				
Female	7	8.2	85.4	(34.2-176.0)	Female	1	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.4	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	49	47.6	103.0	(76.2-136.2)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	2.8	217.0	(79.2-472.4)
Male	6	7.5	79.6	(29.1-173.3)	Female	2	1.0	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.2	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.2	83.8	(30.6-182.5)
Male	3	4.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.3	nc	(nc-nc)	Female	7	8.2	85.7	(34.3-176.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	4.6	151.5	(60.7-312.2)	Male	157	167.3	93.8	(79.7-109.7)
Female	0	0.9	nc	(nc-nc)	Female	113	111.6	101.3	(83.5-121.8)
<u>Lung and Bronchus</u>									
Male	20	20.4	98.1	(59.9-151.5)					
Female	10	14.2	70.3	(33.6-129.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	15.6	121.9	(73.3-190.3)	Male	6	9.8	61.5	(22.5-133.9)
Female	13	6.4	203.1	(108.0-347.3)	Female	5	8.2	60.9	(19.6-142.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.7	182.1	(58.7-424.9)	Male	5	2.9	173.4	(55.9-404.7)
Female	1	2.6	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	8	8.7	92.4	(39.8-182.0)
Female	52	60.8	85.5	(63.8-112.1)	Female	6	8.1	73.7	(26.9-160.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	8	6.7	120.2	(51.7-236.8)
<u>Colon / Rectum</u>					Female	2	3.3	nc	(nc-nc)
Male	26	16.7	155.4	(101.5-227.7)	<u>Ovary</u>				
Female	24	19.3	124.4	(79.7-185.1)	Female	6	5.7	104.7	(38.2-227.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	4.0	249.0	(119.2-458.0)	Male	2	5.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	11	6.3	174.9	(87.2-313.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	52	52.7	98.6	(73.6-129.3)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.6	140.3	(45.2-327.4)
Male	14	7.9	176.8	(96.6-296.7)	Female	3	2.5	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.0	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	0.8	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	11	10.7	103.1	(51.4-184.5)
Male	5	6.1	82.6	(26.6-192.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.0	141.4	(56.6-291.3)	Female	11	13.8	80.0	(39.9-143.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	5.0	219.1	(109.2-392.1)	Male	240	200.5	119.7	(105.0-135.8)
Female	3	1.8	nc	(nc-nc)	Female	220	217.6	101.1	(88.2-115.4)
<u>Lung and Bronchus</u>									
Male	41	27.8	147.4	(105.7-199.9)					
Female	42	31.9	131.8	(95.0-178.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	27.6	134.1	(94.4-184.8)	Male	23	18.2	126.4	(80.1-189.7)
Female	14	11.3	123.6	(67.5-207.3)	Female	15	15.8	94.9	(53.1-156.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.5	109.5	(40.0-238.4)	Male	4	5.3	nc	(nc-nc)
Female	5	5.0	100.9	(32.5-235.4)	Female	5	4.8	105.0	(33.8-245.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	0.9	nc	(nc-nc)	Male	13	16.2	80.2	(42.7-137.1)
Female	117	119.9	97.6	(80.7-117.0)	Female	17	15.0	113.7	(66.2-182.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.3	nc	(nc-nc)	Male	12	13.1	91.5	(47.2-159.8)
<u>Colon / Rectum</u>					Female	4	6.2	nc	(nc-nc)
Male	27	31.2	86.4	(56.9-125.8)	<u>Ovary</u>				
Female	40	35.4	112.9	(80.6-153.7)	Female	11	11.0	100.4	(50.1-179.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.4	94.2	(37.7-194.1)	Male	13	9.5	137.3	(73.1-234.9)
Female	1	2.1	nc	(nc-nc)	Female	13	11.2	115.9	(61.6-198.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.3	217.6	(70.1-507.8)	Male	115	98.9	116.3	(96.0-139.6)
Female	4	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.5	91.8	(33.5-199.7)
Male	19	15.3	124.0	(74.6-193.6)	Female	5	4.5	110.7	(35.7-258.3)
Female	5	9.5	52.7	(17.0-122.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.8	132.3	(42.6-308.8)
Male	1	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	9	7.2	124.9	(57.0-237.1)
<u>Leukemia</u>					Female	31	22.4	138.5	(94.1-196.5)
Male	12	11.3	105.9	(54.6-185.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	9.2	97.5	(44.5-185.1)	Female	17	26.5	64.2	(37.4-102.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	9.5	nc	(nc-nc)	Male	391	372.1	105.1	(94.9-116.0)
Female	4	3.3	nc	(nc-nc)	Female	412	410.2	100.4	(91.0-110.6)
<u>Lung and Bronchus</u>									
Male	35	49.5	70.7	(49.3-98.4)					
Female	59	55.6	106.2	(80.8-137.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	24.3	74.2	(44.0-117.3)	Male	19	17.2	110.5	(66.5-172.6)
Female	6	8.9	67.6	(24.7-147.1)	Female	20	14.5	137.6	(84.0-212.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.4	129.8	(52.0-267.5)	Male	1	4.9	nc	(nc-nc)
Female	6	4.5	132.7	(48.4-288.8)	Female	5	3.9	128.9	(41.5-300.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	18	15.2	118.5	(70.2-187.3)
Female	106	110.2	96.2	(78.7-116.3)	Female	12	12.6	95.1	(49.1-166.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.3	nc	(nc-nc)	Male	12	12.9	93.2	(48.1-162.8)
<u>Colon / Rectum</u>					Female	7	5.4	130.3	(52.2-268.4)
Male	38	28.7	132.2	(93.6-181.5)	<u>Ovary</u>				
Female	27	28.1	96.2	(63.4-140.0)	Female	7	9.8	71.1	(28.5-146.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.0	100.6	(40.3-207.3)	Male	6	8.6	69.9	(25.5-152.2)
Female	1	1.7	nc	(nc-nc)	Female	10	8.6	116.0	(55.5-213.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	103	95.0	108.4	(88.5-131.5)
Female	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.0	nc	(nc-nc)
Male	10	15.0	66.8	(32.0-122.9)	Female	1	3.5	nc	(nc-nc)
Female	7	8.4	83.4	(33.4-171.8)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.3	nc	(nc-nc)
Male	9	3.9	230.9	(105.4-438.4)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
<u>Leukemia</u>					Female	30	23.0	130.3	(87.9-186.0)
Male	8	10.4	76.7	(33.0-151.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.7	64.7	(20.8-150.9)	Female	25	24.6	101.7	(65.8-150.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	9.2	98.0	(44.7-186.1)	Male	356	349.1	102.0	(91.6-113.1)
Female	1	2.8	nc	(nc-nc)	Female	342	360.0	95.0	(85.2-105.6)
<u>Lung and Bronchus</u>									
Male	47	44.9	104.7	(76.9-139.2)					
Female	44	46.9	93.8	(68.2-126.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.1	nc	(nc-nc)	Male	5	3.4	148.6	(47.9-346.7)
Female	1	1.8	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	20	19.8	101.1	(61.7-156.2)	Female	1	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	6	5.7	104.6	(38.2-227.6)	<u>Ovary</u>				
Female	3	5.5	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	21	19.1	110.0	(68.0-168.1)
Female	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.8	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	6	4.5	134.2	(49.0-292.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	65	69.5	93.5	(72.1-119.1)
Female	0	0.5	nc	(nc-nc)	Female	53	66.8	79.4	(59.5-103.8)
<u>Lung and Bronchus</u>									
Male	7	9.2	75.8	(30.3-156.1)					
Female	6	9.2	64.9	(23.7-141.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	15.2	72.4	(36.1-129.6)	Male	17	10.3	164.8	(95.9-263.8)
Female	9	5.2	173.6	(79.2-329.6)	Female	14	8.0	175.2	(95.7-294.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.1	195.5	(71.4-425.4)	Male	3	3.0	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	11	9.1	121.3	(60.5-217.0)
Female	70	62.8	111.5	(86.9-140.8)	Female	8	7.2	110.6	(47.6-217.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	4	7.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	3.1	nc	(nc-nc)
Male	20	17.5	114.5	(69.9-176.9)	<u>Ovary</u>				
Female	16	16.1	99.2	(56.7-161.2)	Female	3	5.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.3	140.5	(51.3-305.9)	Male	2	5.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.3	nc	(nc-nc)	Male	55	58.1	94.7	(71.3-123.2)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.7	nc	(nc-nc)
Male	8	8.9	90.1	(38.8-177.5)	Female	0	2.0	nc	(nc-nc)
Female	2	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.0	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.7	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	16	12.1	132.1	(75.5-214.6)
Male	9	6.2	145.3	(66.3-275.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.3	139.3	(50.9-303.3)	Female	15	14.2	105.9	(59.3-174.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.6	nc	(nc-nc)	Male	204	211.9	96.3	(83.5-110.4)
Female	2	1.6	nc	(nc-nc)	Female	203	205.1	99.0	(85.8-113.6)
<u>Lung and Bronchus</u>									
Male	20	28.1	71.1	(43.4-109.9)					
Female	16	27.8	57.6	(32.9-93.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	30.0	100.1	(67.5-142.9)	Male	10	19.4	51.5	(24.6-94.7)
Female	9	11.6	77.6	(35.4-147.3)	Female	12	17.2	69.8	(36.0-121.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.5	109.2	(39.9-237.7)	Male	0	5.7	nc	(nc-nc)
Female	7	5.2	133.8	(53.6-275.6)	Female	6	4.9	121.4	(44.3-264.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	16	17.1	93.4	(53.4-151.7)
Female	142	125.5	113.2	(95.3-133.4)	Female	15	15.6	96.0	(53.7-158.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.5	nc	(nc-nc)	Male	10	14.0	71.4	(34.2-131.3)
<u>Colon / Rectum</u>					Female	9	6.5	137.6	(62.8-261.2)
Male	33	33.1	99.6	(68.5-139.8)	<u>Ovary</u>				
Female	33	35.7	92.3	(63.5-129.7)	Female	17	11.8	144.5	(84.1-231.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	8.2	110.4	(50.4-209.5)	Male	9	10.3	87.5	(39.9-166.2)
Female	3	2.2	nc	(nc-nc)	Female	15	11.4	131.5	(73.6-216.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.3	nc	(nc-nc)	Male	82	110.2	74.4	(59.2-92.4)
Female	2	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	7.0	nc	(nc-nc)
Male	12	16.2	73.9	(38.2-129.2)	Female	5	4.5	110.2	(35.5-257.2)
Female	12	9.9	120.9	(62.4-211.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.9	nc	(nc-nc)
Male	3	4.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	7.5	67.0	(21.6-156.4)
<u>Leukemia</u>					Female	11	24.8	44.4	(22.1-79.4)
Male	9	11.7	76.6	(35.0-145.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	9.4	85.4	(36.8-168.2)	Female	31	29.0	106.8	(72.5-151.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	10.4	105.7	(52.7-189.2)	Male	317	402.6	78.7	(70.3-87.9)
Female	1	3.5	nc	(nc-nc)	Female	425	430.5	98.7	(89.5-108.6)
<u>Lung and Bronchus</u>									
Male	40	54.1	73.9	(52.8-100.7)					
Female	53	58.5	90.5	(67.8-118.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	14.2	133.5	(80.3-208.4)	Male	6	9.7	62.2	(22.7-135.3)
Female	8	5.4	147.9	(63.7-291.4)	Female	7	7.9	89.1	(35.7-183.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	8.5	70.4	(25.7-153.2)
Female	59	61.9	95.4	(72.6-123.0)	Female	4	7.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.2	nc	(nc-nc)	Male	3	7.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	3.1	161.7	(52.1-377.4)
Male	10	16.4	61.0	(29.2-112.2)	<u>Ovary</u>				
Female	22	16.8	131.0	(82.0-198.3)	Female	4	5.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.0	125.2	(40.4-292.3)	Male	9	5.0	181.7	(82.9-345.0)
Female	0	1.0	nc	(nc-nc)	Female	5	5.3	95.0	(30.6-221.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	56	53.9	103.8	(78.4-134.8)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.4	nc	(nc-nc)
Male	4	8.3	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.9	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	8	11.4	69.9	(30.1-137.8)
Male	11	5.8	188.5	(93.9-337.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.4	nc	(nc-nc)	Female	17	13.8	122.9	(71.5-196.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.2	nc	(nc-nc)	Male	175	198.1	88.4	(75.8-102.5)
Female	0	1.6	nc	(nc-nc)	Female	186	205.3	90.6	(78.1-104.6)
<u>Lung and Bronchus</u>									
Male	17	26.2	64.8	(37.7-103.7)					
Female	18	28.2	63.9	(37.9-101.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	15.3	123.9	(74.6-193.5)	Male	5	10.1	49.5	(16.0-115.5)
Female	8	6.2	129.8	(55.9-255.8)	Female	6	8.7	69.3	(25.3-150.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.0	nc	(nc-nc)	Male	6	2.9	205.2	(74.9-446.7)
Female	1	2.7	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	6	9.0	66.6	(24.3-145.0)
Female	56	64.9	86.3	(65.2-112.1)	Female	7	8.1	86.0	(34.5-177.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	10	7.2	139.4	(66.8-256.5)
<u>Colon / Rectum</u>					Female	5	3.4	148.9	(48.0-347.6)
Male	19	17.4	109.4	(65.8-170.8)	<u>Ovary</u>				
Female	31	19.2	161.4	(109.7-229.1)	Female	6	5.9	101.0	(36.9-219.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.1	148.0	(54.0-322.1)	Male	2	5.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	10	6.1	163.9	(78.5-301.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.3	nc	(nc-nc)	Male	58	53.2	109.0	(82.7-140.9)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.6	nc	(nc-nc)
Male	18	8.4	213.8	(126.7-337.9)	Female	2	2.4	nc	(nc-nc)
Female	3	5.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.2	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	13	12.4	105.2	(56.0-180.0)
Male	9	6.3	142.5	(65.0-270.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	5.0	nc	(nc-nc)	Female	16	14.3	111.6	(63.7-181.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.2	115.1	(42.0-250.5)	Male	225	204.6	110.0	(96.1-125.3)
Female	3	1.8	nc	(nc-nc)	Female	222	223.1	99.5	(86.8-113.5)
<u>Lung and Bronchus</u>									
Male	29	27.2	106.6	(71.4-153.1)					
Female	30	30.4	98.7	(66.6-140.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.9	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	13	14.0	92.6	(49.3-158.4)	Female	0	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.7	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.8	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	14.4	69.5	(33.3-127.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.5	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.0	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	38	52.0	73.0	(51.7-100.2)
Female	1	0.4	nc	(nc-nc)	Female	40	46.8	85.4	(61.0-116.3)
<u>Lung and Bronchus</u>									
Male	4	7.1	nc	(nc-nc)					
Female	4	6.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	15.8	69.6	(34.7-124.5)	Male	13	11.2	116.3	(61.8-198.8)
Female	8	5.8	137.8	(59.3-271.5)	Female	13	9.4	137.8	(73.3-235.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.5	143.3	(46.2-334.3)	Male	4	3.2	nc	(nc-nc)
Female	5	3.0	168.4	(54.3-393.1)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	9.9	70.7	(28.3-145.6)
Female	63	72.0	87.5	(67.2-112.0)	Female	12	8.3	144.8	(74.7-252.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	9	8.5	106.3	(48.5-201.7)
<u>Colon / Rectum</u>					Female	4	3.5	nc	(nc-nc)
Male	26	18.7	138.9	(90.7-203.5)	<u>Ovary</u>				
Female	29	18.1	160.2	(107.3-230.1)	Female	7	6.5	107.8	(43.2-222.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.6	130.7	(47.7-284.4)	Male	9	5.6	159.9	(73.0-303.6)
Female	2	1.1	nc	(nc-nc)	Female	8	5.6	142.2	(61.2-280.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.6	nc	(nc-nc)	Male	65	63.4	102.5	(79.1-130.7)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.9	nc	(nc-nc)
Male	11	9.8	112.4	(56.0-201.1)	Female	2	2.3	nc	(nc-nc)
Female	7	5.5	127.9	(51.2-263.5)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.8	180.6	(58.2-421.5)
Male	3	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	8	4.9	164.1	(70.7-323.4)
<u>Leukemia</u>					Female	15	14.8	101.5	(56.8-167.5)
Male	7	6.8	103.3	(41.4-212.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.0	119.9	(43.8-260.9)	Female	23	16.3	141.1	(89.4-211.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	6.0	198.8	(102.6-347.3)	Male	252	229.5	109.8	(96.7-124.2)
Female	0	1.8	nc	(nc-nc)	Female	252	235.2	107.1	(94.3-121.2)
<u>Lung and Bronchus</u>									
Male	28	29.5	95.0	(63.1-137.2)					
Female	30	31.1	96.6	(65.2-137.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	12.3	81.3	(38.9-149.5)	Male	5	7.9	63.1	(20.3-147.3)
Female	1	4.6	nc	(nc-nc)	Female	14	6.2	226.0	(123.4-379.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	4	7.0	nc	(nc-nc)
Female	43	49.3	87.2	(63.1-117.4)	Female	7	6.1	115.0	(46.1-237.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	7	2.5	276.6	(110.8-570.0)
Male	11	13.6	80.7	(40.2-144.4)	<u>Ovary</u>				
Female	9	14.1	63.8	(29.1-121.1)	Female	8	4.5	179.0	(77.1-352.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.4	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	7	4.5	154.4	(61.9-318.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	45	45.9	98.1	(71.6-131.3)
Female	3	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.9	nc	(nc-nc)
Male	4	6.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	6	8.4	71.4	(26.1-155.3)
Male	6	4.8	123.9	(45.2-269.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.7	nc	(nc-nc)	Female	15	11.2	134.1	(75.0-221.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.3	nc	(nc-nc)	Male	132	165.6	79.7	(66.7-94.5)
Female	1	1.4	nc	(nc-nc)	Female	168	167.0	100.6	(85.9-117.0)
<u>Lung and Bronchus</u>									
Male	14	22.5	62.2	(34.0-104.4)					
Female	15	23.6	63.6	(35.6-104.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	34.6	60.6	(37.5-92.7)	Male	31	21.5	144.1	(97.9-204.5)
Female	11	13.9	79.0	(39.4-141.3)	Female	23	18.0	128.0	(81.1-192.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.0	166.5	(79.7-306.2)	Male	10	6.3	157.7	(75.5-290.1)
Female	8	5.5	145.1	(62.5-286.0)	Female	7	5.8	121.5	(48.7-250.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	24	19.1	125.9	(80.7-187.4)
Female	147	134.1	109.6	(92.6-128.9)	Female	16	17.7	90.3	(51.6-146.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.5	110.7	(35.7-258.3)	Male	15	14.3	104.6	(58.5-172.5)
<u>Colon / Rectum</u>					Female	4	7.2	nc	(nc-nc)
Male	51	37.0	137.9	(102.7-181.4)	<u>Ovary</u>				
Female	53	42.2	125.5	(94.0-164.2)	Female	15	12.5	120.3	(67.3-198.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	8.7	114.7	(54.9-211.0)	Male	16	11.4	139.9	(79.9-227.2)
Female	4	2.6	nc	(nc-nc)	Female	18	13.7	131.3	(77.8-207.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.5	198.3	(63.9-462.8)	Male	88	112.4	78.3	(62.8-96.5)
Female	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	7.9	139.9	(69.7-250.3)
Male	18	17.2	104.5	(61.9-165.1)	Female	7	5.4	130.1	(52.1-268.0)
Female	16	11.1	144.1	(82.3-234.0)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.3	162.4	(65.0-334.6)
Male	7	4.8	146.7	(58.8-302.3)	<u>Thyroid</u>				
Female	4	1.7	nc	(nc-nc)	Male	13	7.7	168.1	(89.4-287.4)
<u>Leukemia</u>					Female	28	23.6	118.6	(78.8-171.4)
Male	18	13.4	134.8	(79.8-213.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	10.8	74.4	(32.0-146.6)	Female	33	29.9	110.3	(75.9-154.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	10.8	129.6	(70.8-217.5)	Male	483	437.0	110.5	(100.9-120.8)
Female	2	4.0	nc	(nc-nc)	Female	526	475.7	110.6	(101.3-120.4)
<u>Lung and Bronchus</u>									
Male	64	61.0	104.9	(80.8-134.0)					
Female	83	69.1	120.2	(95.7-149.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.6	89.9	(29.0-209.7)	Male	10	3.6	277.2	(132.7-509.7)
Female	0	2.2	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	22	22.1	99.5	(62.3-150.7)	Female	1	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	6	6.1	97.8	(35.7-212.9)	<u>Ovary</u>				
Female	5	6.8	74.0	(23.9-172.8)	Female	2	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	19	20.2	94.3	(56.7-147.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.8	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.7	nc	(nc-nc)	Female	7	5.1	137.9	(55.2-284.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	1.9	264.4	(85.2-617.0)	Male	69	74.3	92.9	(72.3-117.6)
Female	0	0.6	nc	(nc-nc)	Female	69	77.2	89.3	(69.5-113.1)
<u>Lung and Bronchus</u>									
Male	5	10.1	49.4	(15.9-115.3)					
Female	12	11.1	108.4	(55.9-189.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.0	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	6	7.7	77.5	(28.3-168.6)	Female	2	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	8.1	147.6	(76.2-257.8)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	26	28.7	90.5	(59.1-132.6)
Female	0	0.2	nc	(nc-nc)	Female	20	24.3	82.3	(50.3-127.2)
<u>Lung and Bronchus</u>									
Male	2	3.7	nc	(nc-nc)					
Female	1	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.6	115.7	(55.4-212.8)	Male	4	5.7	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.0	140.3	(56.2-289.0)
Female	38	34.8	109.4	(77.4-150.1)	Female	3	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.8	nc	(nc-nc)
Male	7	9.6	73.1	(29.3-150.7)	<u>Ovary</u>				
Female	5	9.6	52.1	(16.8-121.6)	Female	1	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.4	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	34	32.5	104.8	(72.5-146.4)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	5	4.8	104.0	(33.5-242.6)	Female	0	1.2	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.4	109.4	(43.8-225.5)
Male	2	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.5	nc	(nc-nc)	Female	13	8.0	163.3	(86.9-279.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.0	nc	(nc-nc)	Male	120	117.7	102.0	(84.5-121.9)
Female	0	1.0	nc	(nc-nc)	Female	108	117.7	91.8	(75.3-110.8)
<u>Lung and Bronchus</u>									
Male	19	15.9	119.5	(71.9-186.6)					
Female	12	16.7	71.8	(37.0-125.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	16.3	97.9	(55.9-159.0)	Male	22	8.8	249.5	(156.3-377.8)
Female	5	5.5	91.4	(29.5-213.3)	Female	10	5.6	177.0	(84.7-325.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.0	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	7.7	129.1	(61.8-237.4)
Female	64	45.1	142.1	(109.4-181.4)	Female	5	6.5	76.9	(24.8-179.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.6	nc	(nc-nc)
Male	15	15.8	95.2	(53.2-157.0)	<u>Ovary</u>				
Female	16	15.5	102.9	(58.8-167.2)	Female	3	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.8	nc	(nc-nc)	Male	2	5.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	6	5.4	111.5	(40.7-242.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	42	48.4	86.8	(62.5-117.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.5	nc	(nc-nc)
Male	1	6.7	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Female	2	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.5	nc	(nc-nc)
Male	7	5.4	128.8	(51.6-265.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.7	nc	(nc-nc)	Female	15	10.7	140.0	(78.3-231.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.3	nc	(nc-nc)	Male	162	185.5	87.3	(74.4-101.8)
Female	1	1.5	nc	(nc-nc)	Female	175	167.4	104.6	(89.6-121.2)
<u>Lung and Bronchus</u>									
Male	14	28.4	49.3	(26.9-82.7)					
Female	19	27.5	69.1	(41.6-107.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	10	8.3	121.2	(58.0-222.9)	Female	3	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	9.4	138.8	(73.8-237.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	29	33.2	87.4	(58.5-125.5)
Female	0	0.2	nc	(nc-nc)	Female	29	27.0	107.2	(71.8-154.0)
<u>Lung and Bronchus</u>									
Male	5	4.6	108.7	(35.0-253.7)					
Female	6	3.9	155.2	(56.7-337.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	13.1	122.5	(70.0-199.0)	Male	9	9.0	100.3	(45.8-190.3)
Female	8	4.7	171.8	(74.0-338.5)	Female	7	7.4	95.2	(38.1-196.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.9	126.0	(60.3-231.8)
Female	52	56.7	91.8	(68.5-120.4)	Female	6	6.6	91.5	(33.4-199.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.1	nc	(nc-nc)	Male	8	6.7	119.4	(51.4-235.2)
<u>Colon / Rectum</u>					Female	4	2.8	nc	(nc-nc)
Male	6	15.2	39.6	(14.5-86.2)	<u>Ovary</u>				
Female	16	14.5	110.3	(63.0-179.1)	Female	5	5.1	98.3	(31.7-229.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.7	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	5	4.5	111.1	(35.8-259.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	47	50.9	92.4	(67.9-122.9)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.2	nc	(nc-nc)
Male	4	7.8	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	6	4.4	137.6	(50.2-299.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.0	nc	(nc-nc)
Male	5	2.1	240.5	(77.5-561.1)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	10	11.3	88.6	(42.4-163.0)
Male	10	5.4	184.5	(88.3-339.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.9	127.8	(41.2-298.2)	Female	20	12.9	155.3	(94.8-239.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	4.9	143.4	(57.5-295.6)	Male	192	184.6	104.0	(89.8-119.8)
Female	0	1.5	nc	(nc-nc)	Female	201	185.8	108.2	(93.8-124.2)
<u>Lung and Bronchus</u>									
Male	39	24.1	161.8	(115.0-221.1)					
Female	31	25.0	123.8	(84.1-175.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	13.3	165.9	(103.9-251.2)	Male	12	8.7	137.2	(70.8-239.7)
Female	9	5.1	175.6	(80.2-333.5)	Female	8	7.0	113.8	(49.0-224.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.5	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	7.8	nc	(nc-nc)
Female	60	53.4	112.4	(85.8-144.7)	Female	10	6.7	148.9	(71.3-273.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	6	6.3	94.7	(34.6-206.2)
<u>Colon / Rectum</u>					Female	0	2.8	nc	(nc-nc)
Male	9	15.0	60.1	(27.4-114.0)	<u>Ovary</u>				
Female	13	15.8	82.1	(43.6-140.3)	Female	4	4.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.6	nc	(nc-nc)	Male	6	4.5	132.1	(48.2-287.5)
Female	1	1.0	nc	(nc-nc)	Female	8	5.0	158.7	(68.3-312.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.1	nc	(nc-nc)	Male	36	48.1	74.9	(52.4-103.6)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.1	191.3	(69.9-416.4)
Male	8	7.3	108.9	(46.9-214.5)	Female	2	2.0	nc	(nc-nc)
Female	3	4.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.8	nc	(nc-nc)
Male	5	2.0	250.5	(80.7-584.5)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	7	9.7	71.8	(28.8-148.0)
Male	4	5.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.0	123.7	(39.9-288.6)	Female	11	12.0	92.0	(45.9-164.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.7	107.4	(34.6-250.7)	Male	171	179.3	95.4	(81.6-110.8)
Female	3	1.5	nc	(nc-nc)	Female	180	183.6	98.0	(84.2-113.4)
<u>Lung and Bronchus</u>									
Male	29	23.9	121.1	(81.1-173.9)					
Female	19	25.6	74.3	(44.7-116.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.4	nc	(nc-nc)	Male	5	3.4	145.2	(46.8-339.0)
Female	2	1.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	22	19.1	115.4	(72.3-174.7)	Female	0	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	0	5.9	nc	(nc-nc)	<u>Ovary</u>				
Female	6	5.1	117.2	(42.8-255.1)	Female	2	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	24	19.1	125.4	(80.3-186.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	3	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.6	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.4	nc	(nc-nc)	Female	5	4.4	114.6	(36.9-267.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.8	nc	(nc-nc)	Male	71	71.4	99.5	(77.7-125.5)
Female	1	0.5	nc	(nc-nc)	Female	58	63.7	91.1	(69.1-117.7)
<u>Lung and Bronchus</u>									
Male	7	9.7	71.9	(28.8-148.1)					
Female	6	8.8	67.8	(24.8-147.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	82	72.9	112.5	(89.5-139.7)	Male	38	43.6	87.2	(61.7-119.7)
Female	36	29.2	123.4	(86.4-170.8)	Female	36	35.2	102.3	(71.6-141.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	11.5	103.9	(53.6-181.6)	Male	18	13.0	138.2	(81.9-218.4)
Female	12	10.8	111.3	(57.4-194.4)	Female	20	12.0	167.2	(102.1-258.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.2	228.3	(73.6-532.8)	Male	46	38.7	118.8	(87.0-158.4)
Female	267	266.6	100.1	(88.5-112.9)	Female	53	36.2	146.4	(109.6-191.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	8.4	142.9	(73.8-249.7)	Male	37	28.5	129.7	(91.3-178.8)
<u>Colon / Rectum</u>					Female	14	14.6	96.2	(52.5-161.4)
Male	72	76.4	94.2	(73.7-118.7)	<u>Ovary</u>				
Female	91	87.8	103.6	(83.4-127.2)	Female	21	24.9	84.2	(52.1-128.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	17.8	84.3	(47.2-139.1)	Male	18	23.7	75.8	(44.9-119.8)
Female	4	5.5	nc	(nc-nc)	Female	34	28.8	118.0	(81.7-164.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	4.5	nc	(nc-nc)	Male	272	226.1	120.3	(106.4-135.5)
Female	6	4.0	150.9	(55.1-328.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	16.3	79.7	(42.4-136.3)
Male	39	34.3	113.7	(80.8-155.4)	Female	9	11.2	80.1	(36.6-152.1)
Female	19	22.4	84.7	(51.0-132.3)	<u>Testis</u>				
<u>Larynx</u>					Male	13	7.1	184.1	(97.9-314.9)
Male	17	9.7	175.8	(102.3-281.4)	<u>Thyroid</u>				
Female	2	3.4	nc	(nc-nc)	Male	17	14.6	116.8	(68.0-187.1)
<u>Leukemia</u>					Female	38	43.2	88.0	(62.3-120.8)
Male	30	27.1	110.7	(74.7-158.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	30	21.7	138.0	(93.1-197.0)	Female	56	59.8	93.7	(70.8-121.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	21.7	115.3	(74.6-170.2)	Male	996	888.9	112.0	(105.2-119.2)
Female	9	8.2	110.1	(50.2-209.0)	Female	1024	960.0	106.7	(100.2-113.4)
<u>Lung and Bronchus</u>									
Male	130	126.5	102.7	(85.8-122.0)					
Female	172	142.8	120.4	(103.1-139.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	6.9	87.5	(32.0-190.5)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	7.2	97.4	(39.0-200.6)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	16	25.7	62.2	(35.6-101.1)
Female	0	0.2	nc	(nc-nc)	Female	12	22.6	53.2	(27.4-92.9)
<u>Lung and Bronchus</u>									
Male	0	3.6	nc	(nc-nc)					
Female	0	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	16.2	148.1	(94.8-220.3)	Male	15	11.4	131.8	(73.7-217.4)
Female	6	5.6	107.3	(39.2-233.5)	Female	11	9.2	119.4	(59.5-213.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.5	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	10.0	150.2	(84.0-247.7)
Female	91	72.6	125.3	(100.9-153.8)	Female	6	8.1	74.0	(27.0-161.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	8	8.6	93.0	(40.1-183.3)
<u>Colon / Rectum</u>					Female	1	3.5	nc	(nc-nc)
Male	27	19.0	142.0	(93.6-206.6)	<u>Ovary</u>				
Female	19	17.4	109.0	(65.6-170.2)	Female	4	6.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.7	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	5	5.4	93.0	(30.0-217.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	74	65.5	113.1	(88.8-141.9)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.0	nc	(nc-nc)
Male	12	10.0	120.0	(61.9-209.6)	Female	1	2.1	nc	(nc-nc)
Female	6	5.5	109.7	(40.1-238.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	22	14.5	151.2	(94.7-229.0)
Male	9	6.8	131.9	(60.2-250.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.8	125.1	(45.7-272.3)	Female	17	16.6	102.5	(59.7-164.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.2	80.5	(26.0-188.0)	Male	262	234.3	111.8	(98.7-126.2)
Female	0	1.8	nc	(nc-nc)	Female	268	232.7	115.2	(101.8-129.8)
<u>Lung and Bronchus</u>									
Male	36	30.5	117.9	(82.6-163.2)					
Female	44	30.9	142.5	(103.5-191.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	10.1	69.2	(27.7-142.5)	Male	8	7.3	109.8	(47.3-216.4)
Female	2	3.5	nc	(nc-nc)	Female	2	5.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	6.4	124.5	(53.6-245.4)
Female	47	46.3	101.6	(74.7-135.1)	Female	5	5.1	98.8	(31.8-230.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.2	nc	(nc-nc)
Male	10	12.2	81.7	(39.1-150.3)	<u>Ovary</u>				
Female	16	11.0	145.9	(83.3-236.9)	Female	2	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.0	164.6	(53.0-384.1)	Male	3	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	3.3	150.3	(48.4-350.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	36	42.4	84.9	(59.5-117.6)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.5	nc	(nc-nc)
Male	6	6.5	92.6	(33.8-201.5)	Female	0	1.3	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	6	3.2	187.7	(68.5-408.6)
<u>Leukemia</u>					Female	4	9.3	nc	(nc-nc)
Male	7	4.4	160.6	(64.3-330.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.0	167.1	(53.8-389.9)	Female	11	10.6	104.1	(51.9-186.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.1	nc	(nc-nc)	Male	147	150.5	97.7	(82.5-114.8)
Female	0	1.1	nc	(nc-nc)	Female	138	146.7	94.1	(79.0-111.2)
<u>Lung and Bronchus</u>									
Male	19	19.1	99.5	(59.9-155.4)					
Female	16	19.0	84.2	(48.1-136.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	10	13.2	75.6	(36.2-139.1)
Female	0	0.1	nc	(nc-nc)	Female	4	10.2	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.7	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	4	6.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.4	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	13	23.8	54.7	(29.1-93.5)
Female	0	0.2	nc	(nc-nc)	Female	15	20.7	72.6	(40.6-119.8)
<u>Lung and Bronchus</u>									
Male	3	3.3	nc	(nc-nc)					
Female	0	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	5	6.5	76.5	(24.6-178.4)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	6.7	104.1	(41.7-214.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	17	23.8	71.4	(41.6-114.4)
Female	0	0.2	nc	(nc-nc)	Female	18	20.2	88.9	(52.7-140.6)
<u>Lung and Bronchus</u>									
Male	2	3.0	nc	(nc-nc)					
Female	3	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	57	57.2	99.6	(75.4-129.0)	Male	29	35.3	82.1	(54.9-117.9)
Female	26	21.6	120.1	(78.5-176.0)	Female	31	27.9	111.1	(75.4-157.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	9.7	154.0	(86.1-254.1)	Male	9	10.5	85.7	(39.1-162.7)
Female	7	8.7	80.9	(32.4-166.7)	Female	5	9.0	55.5	(17.9-129.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	34	31.3	108.7	(75.2-151.8)
Female	210	211.9	99.1	(86.2-113.5)	Female	33	27.7	119.3	(82.1-167.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	6.9	129.7	(59.2-246.3)	Male	28	23.9	117.1	(77.8-169.2)
<u>Colon / Rectum</u>					Female	6	11.3	53.2	(19.4-115.8)
Male	64	61.0	104.9	(80.7-133.9)	<u>Ovary</u>				
Female	86	65.2	131.9	(105.5-162.9)	Female	15	19.7	76.3	(42.7-125.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	26	14.5	178.8	(116.8-262.0)	Male	19	19.0	100.2	(60.3-156.5)
Female	4	4.1	nc	(nc-nc)	Female	15	21.2	70.6	(39.5-116.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.9	nc	(nc-nc)	Male	179	188.8	94.8	(81.4-109.8)
Female	2	3.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	13.0	53.8	(21.5-110.8)
Male	30	28.5	105.2	(71.0-150.2)	Female	4	8.3	nc	(nc-nc)
Female	21	17.5	120.1	(74.3-183.7)	<u>Testis</u>				
<u>Larynx</u>					Male	9	6.3	143.5	(65.5-272.4)
Male	7	8.0	87.8	(35.2-180.9)	<u>Thyroid</u>				
Female	3	2.7	nc	(nc-nc)	Male	14	12.5	112.2	(61.3-188.3)
<u>Leukemia</u>					Female	24	36.4	65.9	(42.2-98.1)
Male	19	21.9	86.9	(52.3-135.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	16.7	54.0	(24.7-102.6)	Female	43	48.0	89.5	(64.8-120.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	21	18.1	116.3	(72.0-177.8)	Male	741	724.1	102.3	(95.1-110.0)
Female	7	6.3	111.9	(44.8-230.6)	Female	759	745.4	101.8	(94.7-109.3)
<u>Lung and Bronchus</u>									
Male	112	101.4	110.5	(90.9-132.9)					
Female	144	108.7	132.4	(111.7-155.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.6	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	13.1	107.0	(58.5-179.6)
Female	0	0.1	nc	(nc-nc)	Female	8	10.4	76.7	(33.0-151.1)
<u>Lung and Bronchus</u>									
Male	5	1.8	277.4	(89.4-647.3)					
Female	1	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.1	148.8	(76.8-260.0)	Male	5	5.5	91.4	(29.4-213.2)
Female	2	3.1	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	9	4.8	186.5	(85.1-354.1)
Female	32	35.5	90.2	(61.7-127.4)	Female	3	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.8	nc	(nc-nc)
Male	8	9.1	87.5	(37.7-172.4)	<u>Ovary</u>				
Female	10	9.4	106.1	(50.8-195.1)	Female	4	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.2	nc	(nc-nc)	Male	6	2.8	214.7	(78.4-467.3)
Female	1	0.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	33	30.5	108.1	(74.4-151.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	10	4.7	213.4	(102.2-392.5)	Female	1	1.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.8	102.7	(41.2-211.7)
Male	3	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.5	198.8	(64.1-463.9)	Female	7	8.0	87.4	(35.0-180.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	131	112.0	116.9	(97.8-138.8)
Female	0	1.0	nc	(nc-nc)	Female	117	118.4	98.8	(81.7-118.5)
<u>Lung and Bronchus</u>									
Male	14	14.9	93.9	(51.3-157.5)					
Female	18	16.6	108.4	(64.2-171.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	72	60.0	120.0	(93.9-151.1)	Male	62	40.1	154.7	(118.6-198.4)
Female	21	22.2	94.5	(58.5-144.5)	Female	63	32.3	195.2	(150.0-249.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.8	85.0	(40.7-156.4)	Male	13	11.7	111.3	(59.2-190.4)
Female	11	10.0	109.9	(54.8-196.7)	Female	8	9.6	83.5	(35.9-164.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.9	nc	(nc-nc)	Male	43	35.2	122.1	(88.3-164.4)
Female	296	249.6	118.6	(105.5-132.9)	Female	35	30.2	115.8	(80.7-161.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	8.8	nc	(nc-nc)	Male	38	29.2	130.3	(92.2-178.9)
<u>Colon / Rectum</u>					Female	13	12.7	102.2	(54.4-174.8)
Male	84	67.2	124.9	(99.7-154.7)	<u>Ovary</u>				
Female	82	67.4	121.6	(96.7-150.9)	Female	26	22.8	114.1	(74.5-167.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	23	16.8	137.3	(87.0-206.0)	Male	23	20.9	110.3	(69.9-165.5)
Female	1	4.3	nc	(nc-nc)	Female	20	21.7	92.0	(56.2-142.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	5.0	nc	(nc-nc)	Male	264	229.7	115.0	(101.5-129.7)
Female	3	3.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	14.3	119.2	(69.4-190.8)
Male	31	34.3	90.4	(61.4-128.3)	Female	9	8.5	106.5	(48.6-202.1)
Female	20	19.7	101.8	(62.1-157.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	8.5	nc	(nc-nc)
Male	13	9.3	140.1	(74.5-239.5)	<u>Thyroid</u>				
Female	1	3.1	nc	(nc-nc)	Male	17	16.0	106.0	(61.7-169.8)
<u>Leukemia</u>					Female	70	46.2	151.5	(118.1-191.4)
Male	33	24.2	136.3	(93.8-191.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	17.8	89.7	(51.2-145.6)	Female	58	58.4	99.4	(75.5-128.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	21	21.3	98.8	(61.1-151.1)	Male	956	829.1	115.3	(108.1-122.9)
Female	5	6.9	72.9	(23.5-170.2)	Female	961	837.5	114.7	(107.6-122.2)
<u>Lung and Bronchus</u>									
Male	113	110.6	102.2	(84.2-122.9)					
Female	123	116.1	105.9	(88.0-126.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.2	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	9	12.6	71.2	(32.5-135.3)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	<u>Ovary</u>				
Female	4	3.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	15	13.4	112.1	(62.7-184.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.4	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	38	45.8	83.0	(58.7-113.9)
Female	0	0.3	nc	(nc-nc)	Female	39	40.3	96.8	(68.8-132.3)
<u>Lung and Bronchus</u>									
Male	3	6.1	nc	(nc-nc)					
Female	7	5.4	128.6	(51.5-265.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.8	158.7	(58.0-345.5)	Male	2	2.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	14	15.6	89.7	(49.0-150.5)	Female	3	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	5	2.1	233.7	(75.3-545.3)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	5	4.5	111.8	(36.0-261.0)	<u>Ovary</u>				
Female	1	3.7	nc	(nc-nc)	Female	6	1.4	430.1	(157.0-936.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	24	16.7	143.8	(92.1-213.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	5	1.2	431.7	(139.1-1007.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.9	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)	Male	63	56.4	111.8	(85.9-143.0)
Female	0	0.4	nc	(nc-nc)	Female	49	49.3	99.3	(73.5-131.3)
<u>Lung and Bronchus</u>									
Male	2	7.3	nc	(nc-nc)					
Female	3	6.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	5.2	nc	(nc-nc)	Male	7	3.4	205.6	(82.4-423.7)
Female	2	1.6	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	23	16.8	137.2	(87.0-205.9)	Female	1	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.6	194.1	(62.5-452.9)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	6	5.9	101.3	(37.0-220.4)	<u>Ovary</u>				
Female	5	4.7	106.1	(34.2-247.6)	Female	2	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.3	nc	(nc-nc)	Male	14	20.1	69.8	(38.1-117.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.6	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.1	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	1.9	nc	(nc-nc)	Male	77	71.0	108.4	(85.5-135.5)
Female	1	0.5	nc	(nc-nc)	Female	68	56.8	119.7	(93.0-151.8)
<u>Lung and Bronchus</u>									
Male	11	9.5	115.8	(57.7-207.3)					
Female	10	8.4	119.4	(57.1-219.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	81	98.3	82.4	(65.4-102.4)	Male	49	64.0	76.6	(56.7-101.3)
Female	31	39.7	78.2	(53.1-111.0)	Female	64	55.6	115.1	(88.6-147.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	18.4	87.0	(49.7-141.3)	Male	16	18.5	86.6	(49.4-140.6)
Female	11	16.7	66.0	(32.9-118.0)	Female	10	16.6	60.1	(28.8-110.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.1	nc	(nc-nc)	Male	49	56.4	86.8	(64.2-114.8)
Female	380	403.4	94.2	(85.0-104.2)	Female	58	51.9	111.7	(84.8-144.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	19	14.5	130.7	(78.6-204.1)	Male	61	44.0	138.8	(106.1-178.3)
<u>Colon / Rectum</u>					Female	22	21.2	103.5	(64.9-156.8)
Male	137	107.8	127.0	(106.7-150.2)	<u>Ovary</u>				
Female	117	121.0	96.7	(80.0-115.9)	Female	37	37.5	98.5	(69.4-135.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	30	25.7	116.5	(78.6-166.4)	Male	30	33.2	90.5	(61.0-129.2)
Female	9	7.5	119.5	(54.5-226.8)	Female	37	39.0	95.0	(66.9-130.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	8.5	82.8	(33.2-170.6)	Male	297	339.5	87.5	(77.8-98.0)
Female	7	7.3	95.4	(38.2-196.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	25	22.9	109.4	(70.8-161.5)
Male	51	52.4	97.4	(72.5-128.1)	Female	11	15.4	71.7	(35.7-128.2)
Female	39	32.8	118.8	(84.4-162.4)	<u>Testis</u>				
<u>Larynx</u>					Male	13	15.5	83.8	(44.6-143.3)
Male	14	14.2	98.6	(53.8-165.4)	<u>Thyroid</u>				
Female	7	5.0	140.9	(56.4-290.3)	Male	20	24.9	80.2	(49.0-123.9)
<u>Leukemia</u>					Female	75	77.9	96.3	(75.7-120.7)
Male	26	39.0	66.7	(43.5-97.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	28	31.3	89.4	(59.4-129.3)	Female	87	91.0	95.6	(76.5-117.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	58	32.4	178.8	(135.8-231.2)	Male	1290	1295.2	99.6	(94.2-105.2)
Female	13	11.6	112.3	(59.7-192.0)	Female	1413	1412.7	100.0	(94.9-105.4)
<u>Lung and Bronchus</u>									
Male	214	175.9	121.7	(105.9-139.1)					
Female	239	199.3	119.9	(105.2-136.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	32.3	111.4	(78.0-154.2)	Male	13	21.4	60.7	(32.3-103.8)
Female	6	12.6	47.8	(17.5-104.0)	Female	18	18.4	97.7	(57.9-154.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.3	94.7	(34.6-206.1)	Male	5	6.2	80.3	(25.9-187.4)
Female	7	5.6	124.1	(49.7-255.7)	Female	9	5.4	167.5	(76.4-318.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	17	18.9	90.0	(52.4-144.1)
Female	120	139.0	86.3	(71.6-103.2)	Female	17	17.0	100.2	(58.3-160.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	5.0	180.8	(82.5-343.3)	Male	5	15.4	32.4	(10.5-75.7)
<u>Colon / Rectum</u>					Female	8	7.1	112.6	(48.5-221.9)
Male	40	36.2	110.5	(78.9-150.4)	<u>Ovary</u>				
Female	42	38.5	109.1	(78.6-147.4)	Female	10	12.7	78.6	(37.6-144.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	8.8	68.0	(24.8-148.1)	Male	13	11.1	116.7	(62.1-199.5)
Female	3	2.4	nc	(nc-nc)	Female	11	12.2	90.1	(44.9-161.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.8	nc	(nc-nc)	Male	123	119.1	103.3	(85.8-123.2)
Female	0	2.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	7.6	91.7	(36.7-188.9)
Male	22	18.0	122.1	(76.5-184.8)	Female	6	4.8	124.3	(45.4-270.5)
Female	10	11.0	90.9	(43.5-167.1)	<u>Testis</u>				
<u>Larynx</u>					Male	0	4.7	nc	(nc-nc)
Male	7	4.9	143.0	(57.3-294.7)	<u>Thyroid</u>				
Female	0	1.7	nc	(nc-nc)	Male	4	8.5	nc	(nc-nc)
<u>Leukemia</u>					Female	24	26.8	89.6	(57.4-133.3)
Male	13	13.1	99.1	(52.7-169.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	10.2	49.2	(15.9-114.9)	Female	31	31.7	97.8	(66.5-138.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	11.3	132.2	(73.9-218.0)	Male	414	440.0	94.1	(85.2-103.6)
Female	7	3.8	183.3	(73.4-377.7)	Female	431	470.6	91.6	(83.1-100.7)
<u>Lung and Bronchus</u>									
Male	54	58.9	91.7	(68.9-119.7)					
Female	53	65.1	81.4	(60.9-106.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	14.4	117.8	(68.6-188.6)	Male	7	9.5	74.1	(29.7-152.6)
Female	6	5.2	116.2	(42.4-252.9)	Female	11	7.5	146.2	(72.9-261.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	8.4	95.8	(41.2-188.7)
Female	59	58.3	101.2	(77.0-130.5)	Female	8	7.0	113.7	(49.0-224.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.1	242.9	(78.3-566.9)	Male	4	6.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	3.0	nc	(nc-nc)
Male	16	16.0	99.7	(57.0-161.9)	<u>Ovary</u>				
Female	19	15.8	120.4	(72.5-188.0)	Female	4	5.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.9	127.3	(41.0-297.2)	Male	6	4.9	121.5	(44.4-264.4)
Female	4	1.0	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.1	nc	(nc-nc)	Male	53	52.8	100.4	(75.2-131.3)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.4	nc	(nc-nc)
Male	11	8.0	137.6	(68.6-246.2)	Female	4	2.0	nc	(nc-nc)
Female	9	4.6	196.6	(89.7-373.2)	<u>Testis</u>				
<u>Larynx</u>					Male	9	1.8	489.3	(223.3-928.9)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	6	3.7	163.7	(59.8-356.2)
<u>Leukemia</u>					Female	22	10.9	201.1	(126.0-304.4)
Male	5	5.8	86.5	(27.9-201.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.2	143.6	(52.5-312.7)	Female	11	13.3	82.5	(41.2-147.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.0	nc	(nc-nc)	Male	215	194.7	110.4	(96.2-126.2)
Female	2	1.6	nc	(nc-nc)	Female	235	195.2	120.4	(105.5-136.8)
<u>Lung and Bronchus</u>									
Male	33	26.3	125.5	(86.4-176.3)					
Female	33	27.1	121.8	(83.8-171.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	26.4	117.2	(79.6-166.4)	Male	25	17.3	144.8	(93.7-213.7)
Female	6	10.2	59.0	(21.6-128.5)	Female	15	14.3	105.1	(58.8-173.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.1	118.2	(43.2-257.3)	Male	4	5.1	nc	(nc-nc)
Female	5	4.4	112.7	(36.3-263.0)	Female	4	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	17	15.3	111.1	(64.7-177.8)
Female	130	110.0	118.2	(98.8-140.4)	Female	9	13.5	66.6	(30.4-126.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.8	nc	(nc-nc)	Male	6	12.3	48.6	(17.8-105.8)
<u>Colon / Rectum</u>					Female	5	5.6	88.8	(28.6-207.1)
Male	31	29.6	104.9	(71.2-148.9)	<u>Ovary</u>				
Female	31	31.3	99.0	(67.3-140.6)	Female	9	10.0	90.0	(41.1-170.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	7.1	155.2	(77.4-277.7)	Male	10	9.0	111.0	(53.1-204.1)
Female	3	1.9	nc	(nc-nc)	Female	7	9.9	70.5	(28.3-145.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	74	94.1	78.6	(61.7-98.7)
Female	4	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.2	96.4	(35.2-209.9)
Male	9	14.5	62.1	(28.4-118.0)	Female	2	3.9	nc	(nc-nc)
Female	4	8.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.3	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	9	6.7	134.9	(61.6-256.2)
<u>Leukemia</u>					Female	32	20.2	158.1	(108.1-223.2)
Male	12	10.6	112.7	(58.2-197.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	8.2	134.8	(67.2-241.2)	Female	31	24.7	125.3	(85.1-177.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	9.1	98.9	(45.1-187.7)	Male	329	353.5	93.1	(83.3-103.7)
Female	6	3.0	197.2	(72.0-429.3)	Female	407	373.2	109.1	(98.7-120.2)
<u>Lung and Bronchus</u>									
Male	45	47.6	94.5	(68.9-126.4)					
Female	50	52.0	96.2	(71.4-126.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	12.4	80.4	(38.5-147.9)	Male	8	8.5	94.2	(40.6-185.6)
Female	3	3.9	nc	(nc-nc)	Female	3	6.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.5	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	6	7.5	80.4	(29.4-175.0)
Female	48	50.1	95.8	(70.6-127.0)	Female	7	5.6	124.1	(49.7-255.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	2	6.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.4	nc	(nc-nc)
Male	11	14.3	76.8	(38.3-137.4)	<u>Ovary</u>				
Female	12	12.3	97.7	(50.4-170.6)	Female	2	4.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.6	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	3.8	131.7	(42.4-307.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	47	50.4	93.2	(68.5-123.9)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	8	7.5	107.3	(46.2-211.4)	Female	0	1.5	nc	(nc-nc)
Female	6	3.8	158.3	(57.8-344.6)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.6	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	9	9.6	94.1	(42.9-178.6)
Male	4	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.3	nc	(nc-nc)	Female	16	11.6	137.8	(78.7-223.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.7	nc	(nc-nc)	Male	144	177.5	81.1	(68.4-95.5)
Female	2	1.3	nc	(nc-nc)	Female	151	161.1	93.7	(79.4-109.9)
<u>Lung and Bronchus</u>									
Male	28	23.3	120.0	(79.7-173.4)					
Female	18	21.6	83.2	(49.3-131.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	54.8	85.7	(63.0-114.0)	Male	22	35.3	62.4	(39.1-94.4)
Female	19	20.7	91.8	(55.2-143.4)	Female	26	29.0	89.6	(58.5-131.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	10.3	126.7	(67.4-216.7)	Male	10	10.2	98.0	(46.9-180.2)
Female	8	8.9	89.7	(38.6-176.8)	Female	12	8.7	138.2	(71.3-241.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.7	nc	(nc-nc)	Male	31	31.3	99.1	(67.3-140.7)
Female	214	212.3	100.8	(87.7-115.2)	Female	28	27.2	103.0	(68.4-148.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	7.6	65.7	(21.2-153.3)	Male	24	23.8	100.8	(64.5-149.9)
<u>Colon / Rectum</u>					Female	12	11.1	108.1	(55.8-188.8)
Male	73	59.8	122.1	(95.7-153.6)	<u>Ovary</u>				
Female	43	63.3	67.9	(49.1-91.5)	Female	14	19.7	71.2	(38.9-119.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	14.1	56.8	(24.5-112.0)	Male	17	18.3	92.8	(54.0-148.6)
Female	5	3.9	126.7	(40.8-295.7)	Female	15	20.4	73.7	(41.2-121.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	4.7	148.3	(59.4-305.6)	Male	120	183.3	65.5	(54.3-78.3)
Female	4	3.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	23	12.6	181.9	(115.2-272.9)
Male	36	28.6	125.8	(88.1-174.1)	Female	6	8.0	74.9	(27.3-163.0)
Female	35	17.3	202.4	(140.9-281.5)	<u>Testis</u>				
<u>Larynx</u>					Male	9	8.5	105.3	(48.0-199.9)
Male	10	7.7	129.2	(61.9-237.6)	<u>Thyroid</u>				
Female	8	2.6	308.0	(132.6-606.8)	Male	13	13.6	95.8	(50.9-163.8)
<u>Leukemia</u>					Female	47	40.8	115.1	(84.6-153.1)
Male	30	21.9	137.2	(92.5-195.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	16.6	72.1	(37.2-125.9)	Female	39	47.5	82.0	(58.3-112.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	32	17.6	182.0	(124.5-256.9)	Male	707	711.8	99.3	(92.1-106.9)
Female	5	6.1	82.5	(26.6-192.6)	Female	758	741.2	102.3	(95.1-109.8)
<u>Lung and Bronchus</u>									
Male	127	97.3	130.6	(108.8-155.3)					
Female	143	104.5	136.8	(115.3-161.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	6	8.6	69.5	(25.4-151.4)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	13	10.2	127.1	(67.6-217.4)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	28	35.6	78.8	(52.3-113.8)
Female	0	0.2	nc	(nc-nc)	Female	21	28.7	73.2	(45.3-112.0)
<u>Lung and Bronchus</u>									
Male	2	5.1	nc	(nc-nc)					
Female	2	4.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.4	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	26	22.1	117.5	(76.7-172.1)	Female	3	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	5	6.3	79.3	(25.6-185.1)	<u>Ovary</u>				
Female	6	5.2	114.4	(41.8-249.0)	Female	2	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	29	22.7	127.7	(85.5-183.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.3	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.1	nc	(nc-nc)	Male	73	78.6	92.9	(72.8-116.8)
Female	0	0.6	nc	(nc-nc)	Female	65	70.1	92.7	(71.5-118.1)
<u>Lung and Bronchus</u>									
Male	12	10.1	118.5	(61.2-207.0)					
Female	3	9.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	17.4	126.2	(79.1-191.1)	Male	9	11.5	78.0	(35.6-148.0)
Female	12	7.0	172.3	(88.9-301.0)	Female	17	10.0	169.2	(98.5-271.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	3.4	233.5	(100.5-460.1)	Male	2	3.3	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	12	10.2	117.6	(60.7-205.5)
Female	79	76.3	103.6	(82.0-129.1)	Female	13	9.3	139.1	(74.0-237.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	10	8.3	120.9	(57.9-222.3)
<u>Colon / Rectum</u>					Female	6	3.9	154.2	(56.3-335.5)
Male	25	19.6	127.8	(82.7-188.7)	<u>Ovary</u>				
Female	28	21.3	131.5	(87.4-190.1)	Female	4	7.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.7	105.9	(34.1-247.1)	Male	7	6.0	117.0	(46.9-241.1)
Female	1	1.3	nc	(nc-nc)	Female	7	6.8	103.3	(41.4-213.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	70	63.2	110.8	(86.4-140.0)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.1	nc	(nc-nc)
Male	12	9.7	123.8	(63.9-216.2)	Female	5	2.7	187.3	(60.4-437.1)
Female	15	6.1	247.0	(138.1-407.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.5	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	22	14.5	152.1	(95.3-230.3)
Male	13	7.1	183.0	(97.4-313.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	5.6	230.7	(122.7-394.6)	Female	22	17.2	127.6	(79.9-193.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.1	nc	(nc-nc)	Male	274	236.0	116.1	(102.7-130.7)
Female	4	2.1	nc	(nc-nc)	Female	329	258.9	127.1	(113.7-141.6)
<u>Lung and Bronchus</u>									
Male	38	31.6	120.3	(85.1-165.1)					
Female	55	36.3	151.7	(114.3-197.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	10.9	100.6	(50.2-180.0)	Male	9	6.6	135.6	(61.9-257.4)
Female	3	4.4	nc	(nc-nc)	Female	8	5.4	148.3	(63.9-292.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.3	nc	(nc-nc)	Male	6	5.8	103.1	(37.7-224.4)
Female	42	43.2	97.3	(70.1-131.5)	Female	7	5.6	124.7	(49.9-256.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	7	4.7	149.8	(60.0-308.6)
<u>Colon / Rectum</u>					Female	5	2.3	215.6	(69.5-503.1)
Male	8	11.5	69.4	(29.9-136.8)	<u>Ovary</u>				
Female	12	13.0	92.0	(47.5-160.8)	Female	2	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.9	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	42	39.6	106.0	(76.4-143.3)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.5	nc	(nc-nc)
Male	7	5.5	126.9	(50.8-261.5)	Female	2	1.6	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	9	6.5	138.3	(63.1-262.5)
Male	5	4.0	125.4	(40.4-292.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.2	nc	(nc-nc)	Female	10	10.3	97.2	(46.5-178.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.5	nc	(nc-nc)	Male	140	141.0	99.3	(83.5-117.2)
Female	1	1.3	nc	(nc-nc)	Female	141	150.6	93.6	(78.8-110.4)
<u>Lung and Bronchus</u>									
Male	17	19.8	85.8	(50.0-137.4)					
Female	8	22.6	35.4	(15.2-69.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	9.7	51.6	(16.6-120.4)
Female	0	0.1	nc	(nc-nc)	Female	2	7.6	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.4	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.7	104.9	(38.3-228.3)	Male	3	4.0	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	27	24.8	108.7	(71.6-158.1)	Female	4	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	3	6.8	nc	(nc-nc)	<u>Ovary</u>				
Female	6	6.3	95.9	(35.0-208.7)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	1.7	296.3	(95.5-691.4)	Male	4	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	25	23.6	105.8	(68.5-156.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.4	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	7	4.8	145.3	(58.2-299.4)
Male	3	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.7	nc	(nc-nc)	Female	5	5.7	88.2	(28.4-205.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	73	83.5	87.4	(68.5-109.9)
Female	0	0.6	nc	(nc-nc)	Female	84	80.0	105.0	(83.7-129.9)
<u>Lung and Bronchus</u>									
Male	9	10.8	83.6	(38.2-158.8)					
Female	4	10.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	7	5.2	133.7	(53.6-275.4)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	6.2	113.0	(45.3-232.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	19	21.4	88.6	(53.3-138.4)
Female	0	0.1	nc	(nc-nc)	Female	18	16.5	109.0	(64.6-172.3)
<u>Lung and Bronchus</u>									
Male	3	2.8	nc	(nc-nc)					
Female	3	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	8	6.9	116.2	(50.0-229.0)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.3	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	5	1.7	295.9	(95.4-690.6)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	23.9	50.2	(25.9-87.7)
Female	1	0.2	nc	(nc-nc)	Female	24	22.2	108.0	(69.2-160.7)
<u>Lung and Bronchus</u>									
Male	2	3.1	nc	(nc-nc)					
Female	2	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	6.2	144.9	(66.1-275.1)	Male	4	4.5	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	1	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	34	29.1	117.0	(81.0-163.5)	Female	3	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	9	7.5	119.2	(54.4-226.4)	<u>Ovary</u>				
Female	7	6.8	102.4	(41.0-211.1)	Female	1	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.8	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	25	25.5	98.2	(63.5-145.0)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.6	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.1	nc	(nc-nc)
Male	3	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	6	6.2	96.4	(35.2-209.9)
Male	5	2.8	181.4	(58.4-423.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.9	nc	(nc-nc)	Female	9	6.4	139.9	(63.8-265.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.4	nc	(nc-nc)	Male	89	92.3	96.4	(77.4-118.6)
Female	0	0.7	nc	(nc-nc)	Female	84	92.1	91.2	(72.8-113.0)
<u>Lung and Bronchus</u>									
Male	10	11.6	86.1	(41.2-158.4)					
Female	10	11.7	85.5	(40.9-157.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	38.8	92.7	(64.9-128.3)	Male	26	25.7	101.1	(66.0-148.1)
Female	11	15.9	69.4	(34.6-124.2)	Female	25	23.6	106.1	(68.6-156.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	7.7	117.6	(53.6-223.2)	Male	4	7.4	nc	(nc-nc)
Female	5	7.2	69.4	(22.4-161.9)	Female	7	6.8	103.5	(41.5-213.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	36	22.8	158.2	(110.8-219.0)
Female	192	172.7	111.2	(96.0-128.1)	Female	21	21.4	98.1	(60.7-149.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.3	nc	(nc-nc)	Male	16	18.1	88.3	(50.5-143.5)
<u>Colon / Rectum</u>					Female	14	8.9	156.9	(85.7-263.3)
Male	49	43.2	113.3	(83.8-149.8)	<u>Ovary</u>				
Female	47	48.6	96.7	(71.1-128.6)	Female	12	16.0	75.0	(38.7-131.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	18	10.4	172.5	(102.2-272.7)	Male	10	13.3	75.4	(36.1-138.7)
Female	4	3.0	nc	(nc-nc)	Female	20	15.5	129.3	(78.9-199.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.6	140.3	(45.2-327.5)	Male	162	139.1	116.4	(99.2-135.8)
Female	8	3.4	238.2	(102.6-469.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	9.1	175.4	(100.2-284.9)
Male	31	21.4	145.0	(98.5-205.8)	Female	3	6.1	nc	(nc-nc)
Female	17	13.8	123.5	(71.9-197.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.4	94.2	(34.4-205.1)
Male	7	5.8	121.4	(48.6-250.2)	<u>Thyroid</u>				
Female	4	2.1	nc	(nc-nc)	Male	13	10.3	126.1	(67.1-215.6)
<u>Leukemia</u>					Female	36	34.4	104.6	(73.2-144.8)
Male	18	15.8	113.6	(67.3-179.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	12.9	116.1	(64.9-191.4)	Female	44	39.5	111.4	(80.9-149.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	13.3	135.4	(80.2-214.0)	Male	602	523.8	114.9	(105.9-124.5)
Female	4	4.8	nc	(nc-nc)	Female	631	591.4	106.7	(98.5-115.3)
<u>Lung and Bronchus</u>									
Male	72	70.2	102.6	(80.3-129.2)					
Female	93	81.6	114.0	(92.0-139.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	9.5	136.4	(72.6-233.3)	Male	12	6.4	188.3	(97.2-328.9)
Female	3	3.4	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.6	89.7	(28.9-209.4)
Female	45	40.1	112.2	(81.8-150.1)	Female	11	4.7	232.9	(116.1-416.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	11	4.8	231.5	(115.4-414.3)
<u>Colon / Rectum</u>					Female	0	2.0	nc	(nc-nc)
Male	18	10.8	167.1	(99.0-264.0)	<u>Ovary</u>				
Female	15	10.3	145.6	(81.4-240.1)	Female	8	3.6	221.0	(95.2-435.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.7	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	33	37.7	87.4	(60.2-122.8)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	11	5.5	199.1	(99.2-356.2)	Female	1	1.3	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	2	7.2	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.7	nc	(nc-nc)	Female	11	9.4	116.6	(58.1-208.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.5	nc	(nc-nc)	Male	147	133.2	110.4	(93.2-129.7)
Female	1	1.1	nc	(nc-nc)	Female	158	132.2	119.5	(101.6-139.7)
<u>Lung and Bronchus</u>									
Male	20	17.9	112.0	(68.4-173.0)					
Female	28	18.7	149.4	(99.3-216.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	4.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.6	nc	(nc-nc)	Male	14	22.5	62.1	(33.9-104.2)
Female	1	0.1	nc	(nc-nc)	Female	9	14.5	62.2	(28.4-118.1)
<u>Lung and Bronchus</u>									
Male	3	3.2	nc	(nc-nc)					
Female	3	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	24.3	127.4	(86.6-180.9)	Male	26	15.8	164.5	(107.4-241.0)
Female	7	8.9	79.0	(31.7-162.9)	Female	22	12.4	176.9	(110.8-267.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	4.5	200.3	(91.4-380.3)	Male	3	4.7	nc	(nc-nc)
Female	5	3.9	129.0	(41.6-301.0)	Female	1	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	18	13.9	129.6	(76.7-204.8)
Female	105	99.4	105.7	(86.4-127.9)	Female	16	12.0	133.7	(76.4-217.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.3	nc	(nc-nc)	Male	11	11.6	95.0	(47.3-169.9)
<u>Colon / Rectum</u>					Female	6	5.0	118.9	(43.4-258.7)
Male	21	27.0	77.7	(48.1-118.8)	<u>Ovary</u>				
Female	25	26.9	93.0	(60.2-137.3)	Female	8	9.0	88.8	(38.2-175.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.7	74.1	(23.9-173.0)	Male	12	8.4	142.6	(73.6-249.1)
Female	2	1.7	nc	(nc-nc)	Female	9	8.6	104.7	(47.8-198.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	111	92.4	120.1	(98.8-144.6)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	5.7	122.1	(48.9-251.6)
Male	10	13.5	74.1	(35.5-136.3)	Female	4	3.4	nc	(nc-nc)
Female	4	7.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	17.4	63.3	(31.6-113.3)
Male	15	9.5	157.8	(88.2-260.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.0	71.7	(23.1-167.4)	Female	22	23.0	95.5	(59.8-144.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	8.6	69.9	(25.5-152.2)	Male	355	330.9	107.3	(96.4-119.1)
Female	1	2.7	nc	(nc-nc)	Female	324	331.4	97.8	(87.4-109.0)
<u>Lung and Bronchus</u>									
Male	21	44.9	46.8	(28.9-71.5)					
Female	44	46.9	93.9	(68.2-126.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	34.0	117.7	(84.1-160.3)	Male	14	21.4	65.5	(35.8-109.9)
Female	20	12.7	157.1	(95.9-242.6)	Female	16	17.1	93.8	(53.6-152.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.8	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
Female	9	5.2	172.4	(78.7-327.3)	Female	3	5.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	22	18.8	117.2	(73.4-177.5)
Female	144	131.9	109.2	(92.1-128.5)	Female	17	16.6	102.1	(59.4-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.4	nc	(nc-nc)	Male	22	14.7	149.4	(93.6-226.2)
<u>Colon / Rectum</u>					Female	7	6.9	101.7	(40.7-209.5)
Male	43	36.5	117.7	(85.2-158.5)	<u>Ovary</u>				
Female	40	38.1	104.9	(74.9-142.8)	Female	8	12.1	66.1	(28.4-130.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	8.9	157.6	(86.1-264.4)	Male	8	11.4	70.2	(30.2-138.3)
Female	4	2.5	nc	(nc-nc)	Female	12	12.4	97.0	(50.1-169.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.4	211.8	(68.2-494.2)	Male	97	117.6	82.5	(66.9-100.7)
Female	1	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	7.8	102.6	(44.2-202.1)
Male	27	17.5	153.9	(101.4-224.0)	Female	2	4.8	nc	(nc-nc)
Female	11	10.7	102.6	(51.2-183.6)	<u>Testis</u>				
<u>Larynx</u>					Male	9	3.8	239.8	(109.4-455.2)
Male	6	4.9	122.6	(44.8-266.9)	<u>Thyroid</u>				
Female	3	1.7	nc	(nc-nc)	Male	11	7.7	142.6	(71.1-255.1)
<u>Leukemia</u>					Female	18	23.0	78.3	(46.4-123.7)
Male	18	12.9	139.3	(82.5-220.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	9.8	51.2	(16.5-119.6)	Female	27	30.4	88.9	(58.6-129.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	11.0	126.7	(69.2-212.7)	Male	468	439.7	106.4	(97.0-116.5)
Female	4	3.8	nc	(nc-nc)	Female	495	454.2	109.0	(99.6-119.0)
<u>Lung and Bronchus</u>									
Male	67	61.3	109.2	(84.6-138.7)					
Female	90	66.3	135.8	(109.2-167.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	13.2	37.9	(12.2-88.6)
Female	0	0.1	nc	(nc-nc)	Female	8	9.8	81.9	(35.3-161.3)
<u>Lung and Bronchus</u>									
Male	1	1.8	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	23.5	110.5	(72.2-161.9)	Male	39	14.8	264.1	(187.8-361.1)
Female	12	8.4	143.3	(74.0-250.4)	Female	32	11.2	284.5	(194.6-401.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.1	122.2	(39.4-285.3)	Male	5	4.4	112.9	(36.4-263.5)
Female	3	3.5	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	11	13.0	84.7	(42.2-151.6)
Female	98	90.1	108.8	(88.3-132.6)	Female	9	11.1	81.4	(37.1-154.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.9	nc	(nc-nc)	Male	17	10.4	163.7	(95.3-262.1)
<u>Colon / Rectum</u>					Female	6	4.6	129.9	(47.4-282.8)
Male	21	25.5	82.3	(50.9-125.9)	<u>Ovary</u>				
Female	18	25.4	71.0	(42.0-112.2)	Female	8	8.2	98.1	(42.2-193.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	6.2	96.3	(35.2-209.7)	Male	8	7.9	100.7	(43.3-198.4)
Female	0	1.6	nc	(nc-nc)	Female	9	8.1	110.6	(50.5-210.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	63	83.1	75.8	(58.3-97.0)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	5.4	129.0	(51.7-265.8)
Male	6	12.3	48.8	(17.8-106.3)	Female	3	3.2	nc	(nc-nc)
Female	6	7.2	83.3	(30.4-181.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.1	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.1	nc	(nc-nc)	Male	2	5.3	nc	(nc-nc)
<u>Leukemia</u>					Female	19	15.2	124.7	(75.0-194.8)
Male	9	9.0	100.2	(45.7-190.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.5	122.9	(52.9-242.2)	Female	14	20.6	67.8	(37.1-113.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	7.8	nc	(nc-nc)	Male	295	306.7	96.2	(85.5-107.8)
Female	2	2.5	nc	(nc-nc)	Female	321	304.4	105.5	(94.2-117.7)
<u>Lung and Bronchus</u>									
Male	37	42.7	86.7	(61.0-119.5)					
Female	47	43.9	107.1	(78.7-142.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.7	113.5	(68.3-177.2)	Male	11	10.8	101.7	(50.7-182.0)
Female	2	5.4	nc	(nc-nc)	Female	8	8.0	100.0	(43.1-197.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	9.5	126.4	(65.2-220.7)
Female	59	63.0	93.6	(71.3-120.8)	Female	5	7.5	67.1	(21.6-156.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	5	7.7	64.9	(20.9-151.4)
<u>Colon / Rectum</u>					Female	5	3.2	158.1	(50.9-368.9)
Male	10	18.4	54.3	(26.0-99.8)	<u>Ovary</u>				
Female	10	16.7	59.9	(28.7-110.2)	Female	6	5.7	105.5	(38.5-229.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.5	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	7	5.3	133.0	(53.3-274.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	42	61.0	68.8	(49.6-93.1)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.9	127.6	(41.1-297.8)
Male	7	9.1	76.9	(30.8-158.5)	Female	1	2.1	nc	(nc-nc)
Female	1	4.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.9	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	13	11.6	111.9	(59.5-191.3)
Male	7	6.5	108.1	(43.3-222.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.3	nc	(nc-nc)	Female	9	14.5	62.1	(28.3-117.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.7	nc	(nc-nc)	Male	170	223.5	76.1	(65.1-88.4)
Female	0	1.7	nc	(nc-nc)	Female	179	208.7	85.8	(73.7-99.3)
<u>Lung and Bronchus</u>									
Male	19	30.6	62.0	(37.3-96.8)					
Female	32	29.0	110.3	(75.4-155.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	19.0	73.8	(40.3-123.8)	Male	14	12.7	110.5	(60.4-185.4)
Female	5	6.4	78.6	(25.3-183.4)	Female	13	9.7	134.0	(71.3-229.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.7	nc	(nc-nc)	Male	8	3.7	213.5	(91.9-420.6)
Female	2	3.1	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	18	11.2	161.2	(95.5-254.7)
Female	87	77.4	112.4	(90.1-138.7)	Female	8	8.9	89.7	(38.6-176.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	6	9.5	62.9	(23.0-136.9)
<u>Colon / Rectum</u>					Female	1	3.8	nc	(nc-nc)
Male	13	21.7	59.9	(31.9-102.5)	<u>Ovary</u>				
Female	12	19.8	60.7	(31.3-106.0)	Female	9	6.9	129.5	(59.1-245.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.4	nc	(nc-nc)	Male	10	6.6	150.5	(72.1-276.9)
Female	2	1.2	nc	(nc-nc)	Female	8	6.2	130.0	(56.0-256.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	72	73.7	97.7	(76.5-123.1)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.6	nc	(nc-nc)
Male	6	11.0	54.7	(20.0-119.2)	Female	1	2.4	nc	(nc-nc)
Female	5	5.9	84.6	(27.3-197.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.1	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	8	5.0	160.0	(68.9-315.4)
<u>Leukemia</u>					Female	30	14.5	207.3	(139.8-295.9)
Male	4	7.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.2	nc	(nc-nc)	Female	12	17.9	67.1	(34.7-117.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	7.0	nc	(nc-nc)	Male	226	264.0	85.6	(74.8-97.5)
Female	2	2.0	nc	(nc-nc)	Female	256	252.0	101.6	(89.5-114.8)
<u>Lung and Bronchus</u>									
Male	13	35.0	37.1	(19.8-63.5)					
Female	32	34.0	94.2	(64.4-133.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.8	104.2	(33.6-243.3)	Male	4	3.0	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	22	17.2	128.1	(80.2-193.9)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<u>Ovary</u>				
Female	3	4.9	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	17	17.3	98.3	(57.3-157.5)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	46	62.7	73.3	(53.7-97.8)
Female	1	0.5	nc	(nc-nc)	Female	64	58.8	108.9	(83.9-139.1)
<u>Lung and Bronchus</u>									
Male	5	8.7	57.2	(18.4-133.6)					
Female	16	8.6	185.5	(106.0-301.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.7	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	8	10.1	79.1	(34.1-155.9)	Female	3	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	16	10.1	158.5	(90.5-257.4)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.6	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	7	2.4	289.4	(116.0-596.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	41	36.1	113.6	(81.5-154.2)
Female	0	0.3	nc	(nc-nc)	Female	41	35.1	116.7	(83.7-158.3)
<u>Lung and Bronchus</u>									
Male	4	5.0	nc	(nc-nc)					
Female	3	5.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	4.8	144.7	(58.0-298.1)	Male	5	3.2	157.9	(50.9-368.5)
Female	1	1.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	21	18.8	111.8	(69.2-170.9)	Female	3	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	8	5.5	146.6	(63.1-288.9)	<u>Ovary</u>				
Female	3	4.7	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	20	18.4	108.9	(66.5-168.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.3	149.8	(48.3-349.5)
Male	4	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	5	4.3	116.1	(37.4-271.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	65	66.2	98.2	(75.8-125.2)
Female	0	0.5	nc	(nc-nc)	Female	62	60.3	102.9	(78.9-131.9)
<u>Lung and Bronchus</u>									
Male	3	9.0	nc	(nc-nc)					
Female	7	8.3	84.7	(34.0-174.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	6.4	124.7	(53.7-245.8)	Male	4	4.9	nc	(nc-nc)
Female	5	2.0	253.9	(81.8-592.4)	Female	0	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	23	24.3	94.5	(59.9-141.8)	Female	0	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	13	7.9	164.6	(87.5-281.4)	<u>Ovary</u>				
Female	9	6.2	146.2	(66.7-277.5)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.9	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	24	24.8	96.7	(61.9-143.9)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	7	4.2	167.6	(67.2-345.4)	Female	2	0.8	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.8	nc	(nc-nc)
Male	0	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	12	5.5	216.3	(111.7-377.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	2.5	314.6	(135.5-619.9)	Male	110	95.1	115.7	(95.1-139.5)
Female	0	0.6	nc	(nc-nc)	Female	86	79.2	108.6	(86.8-134.1)
<u>Lung and Bronchus</u>									
Male	23	11.8	195.2	(123.7-292.9)					
Female	15	10.5	142.8	(79.8-235.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	36.3	118.4	(85.7-159.5)	Male	11	23.9	46.1	(23.0-82.4)
Female	10	13.5	74.2	(35.5-136.5)	Female	20	19.3	103.4	(63.1-159.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	7.1	127.1	(58.0-241.2)	Male	10	6.9	144.2	(69.1-265.3)
Female	3	6.1	nc	(nc-nc)	Female	5	5.7	87.6	(28.2-204.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	32	21.2	150.9	(103.2-213.1)
Female	151	147.4	102.5	(86.8-120.2)	Female	12	18.1	66.5	(34.3-116.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.3	nc	(nc-nc)	Male	13	16.8	77.5	(41.2-132.6)
<u>Colon / Rectum</u>					Female	5	7.5	66.9	(21.5-156.0)
Male	38	40.7	93.3	(66.0-128.1)	<u>Ovary</u>				
Female	34	41.8	81.3	(56.3-113.7)	Female	12	13.3	90.3	(46.6-157.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	9.6	145.8	(79.7-244.7)	Male	13	12.3	105.6	(56.2-180.6)
Female	2	2.6	nc	(nc-nc)	Female	8	13.2	60.8	(26.2-119.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.0	nc	(nc-nc)	Male	130	125.8	103.3	(86.3-122.7)
Female	5	2.4	204.3	(65.8-476.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	8.6	58.5	(18.8-136.5)
Male	30	19.9	150.6	(101.6-215.1)	Female	2	5.3	nc	(nc-nc)
Female	11	11.6	94.5	(47.1-169.0)	<u>Testis</u>				
<u>Larynx</u>					Male	7	5.0	138.7	(55.6-285.7)
Male	2	5.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.7	nc	(nc-nc)	Male	15	9.4	160.0	(89.5-263.9)
<u>Leukemia</u>					Female	17	28.3	60.1	(35.0-96.3)
Male	12	14.7	81.5	(42.1-142.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	11.0	81.6	(37.2-154.8)	Female	25	32.4	77.2	(49.9-113.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	12.2	73.8	(33.7-140.1)	Male	495	482.7	102.5	(93.7-112.0)
Female	1	4.0	nc	(nc-nc)	Female	425	499.3	85.1	(77.2-93.6)
<u>Lung and Bronchus</u>									
Male	56	65.2	85.9	(64.9-111.5)					
Female	57	68.7	83.0	(62.9-107.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	6	8.0	75.2	(27.4-163.6)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	7.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.6	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	14	26.4	53.0	(29.0-89.0)
Female	0	0.2	nc	(nc-nc)	Female	17	24.5	69.5	(40.5-111.3)
<u>Lung and Bronchus</u>									
Male	1	3.4	nc	(nc-nc)					
Female	1	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	26.2	95.3	(61.7-140.8)	Male	13	15.8	82.3	(43.8-140.7)
Female	12	10.7	112.3	(58.0-196.1)	Female	8	12.7	62.9	(27.1-123.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.2	119.8	(38.6-279.6)	Male	2	4.7	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	13	14.0	93.0	(49.5-159.1)
Female	90	97.5	92.3	(74.2-113.5)	Female	12	13.2	90.6	(46.8-158.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	8	10.5	76.5	(32.9-150.7)
<u>Colon / Rectum</u>					Female	7	5.3	131.7	(52.7-271.3)
Male	25	27.5	91.0	(58.9-134.4)	<u>Ovary</u>				
Female	30	32.0	93.9	(63.3-134.0)	Female	10	9.1	109.9	(52.6-202.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.5	76.5	(24.6-178.4)	Male	12	8.6	139.5	(72.0-243.7)
Female	0	2.0	nc	(nc-nc)	Female	10	10.6	94.7	(45.3-174.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.6	nc	(nc-nc)	Male	88	84.4	104.3	(83.6-128.4)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	5.9	186.7	(93.1-334.1)
Male	16	12.6	126.6	(72.3-205.6)	Female	5	4.1	121.9	(39.3-284.5)
Female	9	8.2	109.8	(50.1-208.4)	<u>Testis</u>				
<u>Larynx</u>					Male	7	2.4	290.3	(116.3-598.2)
Male	4	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<u>Leukemia</u>					Female	23	15.5	148.7	(94.2-223.2)
Male	11	9.7	113.4	(56.5-202.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	7.9	152.0	(78.5-265.6)	Female	26	22.0	118.4	(77.3-173.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	7.9	88.3	(35.4-181.9)	Male	335	324.4	103.3	(92.5-114.9)
Female	1	3.0	nc	(nc-nc)	Female	332	350.4	94.7	(84.8-105.5)
<u>Lung and Bronchus</u>									
Male	52	46.2	112.5	(84.0-147.5)					
Female	39	52.4	74.5	(53.0-101.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	50.6	85.0	(61.5-114.5)	Male	31	36.8	84.2	(57.2-119.5)
Female	20	20.1	99.6	(60.8-153.9)	Female	17	36.0	47.2	(27.5-75.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	12.1	66.1	(28.5-130.3)	Male	12	9.8	122.3	(63.1-213.7)
Female	14	10.5	133.6	(73.0-224.2)	Female	11	8.6	128.5	(64.0-229.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.6	nc	(nc-nc)	Male	37	32.6	113.4	(79.9-156.4)
Female	190	224.0	84.8	(73.2-97.8)	Female	19	28.4	66.9	(40.3-104.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	10.2	78.7	(33.9-155.0)	Male	29	24.9	116.4	(78.0-167.2)
<u>Colon / Rectum</u>					Female	8	11.6	69.2	(29.8-136.4)
Male	55	58.2	94.5	(71.2-123.0)	<u>Ovary</u>				
Female	56	62.6	89.5	(67.6-116.2)	Female	22	21.3	103.4	(64.8-156.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	13.6	88.4	(45.6-154.4)	Male	21	17.4	120.9	(74.8-184.9)
Female	6	3.9	155.8	(56.9-339.2)	Female	21	19.6	107.0	(66.2-163.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	15	7.7	194.7	(108.9-321.1)	Male	151	179.1	84.3	(71.4-98.9)
Female	4	6.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	12.2	139.7	(81.3-223.7)
Male	34	29.8	114.0	(79.0-159.3)	Female	11	7.9	138.9	(69.3-248.6)
Female	23	18.0	128.0	(81.1-192.0)	<u>Testis</u>				
<u>Larynx</u>					Male	7	16.8	41.8	(16.7-86.1)
Male	10	7.6	132.4	(63.4-243.6)	<u>Thyroid</u>				
Female	2	2.6	nc	(nc-nc)	Male	19	17.5	108.5	(65.3-169.4)
<u>Leukemia</u>					Female	53	58.8	90.1	(67.5-117.8)
Male	19	22.7	83.8	(50.4-130.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	17.8	106.6	(64.2-166.5)	Female	46	49.6	92.8	(67.9-123.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	17.6	142.4	(92.2-210.3)	Male	706	714.7	98.8	(91.6-106.4)
Female	13	6.1	214.2	(113.9-366.3)	Female	727	789.6	92.1	(85.5-99.0)
<u>Lung and Bronchus</u>									
Male	111	90.6	122.5	(100.8-147.5)					
Female	103	103.2	99.8	(81.4-121.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	21.4	88.8	(53.4-138.7)	Male	22	13.0	169.3	(106.1-256.3)
Female	13	8.4	154.0	(81.9-263.3)	Female	9	11.1	80.9	(36.9-153.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.5	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	12	11.5	104.4	(53.9-182.3)
Female	97	81.5	119.0	(96.5-145.2)	Female	10	10.8	92.3	(44.2-169.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.7	188.2	(60.6-439.2)	Male	5	8.7	57.1	(18.4-133.4)
<u>Colon / Rectum</u>					Female	7	4.4	159.1	(63.7-327.7)
Male	22	22.6	97.2	(60.9-147.2)	<u>Ovary</u>				
Female	31	25.5	121.7	(82.7-172.7)	Female	5	7.7	64.8	(20.9-151.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.4	92.7	(29.9-216.2)	Male	5	7.1	70.8	(22.8-165.3)
Female	3	1.6	nc	(nc-nc)	Female	8	8.3	96.4	(41.5-190.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	74	70.0	105.6	(82.9-132.6)
Female	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	4.8	165.6	(71.3-326.3)
Male	8	10.4	76.6	(33.0-151.0)	Female	2	3.2	nc	(nc-nc)
Female	6	6.8	88.9	(32.4-193.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.0	nc	(nc-nc)
Male	8	2.9	271.4	(116.9-534.8)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	10	14.7	67.9	(32.5-124.9)
Male	5	8.0	62.7	(20.2-146.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	6.6	106.7	(42.7-219.8)	Female	24	18.5	129.8	(83.2-193.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.6	nc	(nc-nc)	Male	263	267.4	98.4	(86.8-111.0)
Female	0	2.4	nc	(nc-nc)	Female	295	290.7	101.5	(90.2-113.7)
<u>Lung and Bronchus</u>									
Male	33	37.7	87.4	(60.2-122.8)					
Female	37	42.3	87.5	(61.6-120.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.3	79.1	(25.5-184.6)	Male	1	4.4	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	22	26.6	82.7	(51.8-125.2)	Female	1	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	9	7.3	123.0	(56.1-233.5)	<u>Ovary</u>				
Female	8	6.5	122.3	(52.6-240.9)	Female	3	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.9	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.5	nc	(nc-nc)	Male	25	26.7	93.7	(60.6-138.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.5	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.8	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	5.0	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.7	nc	(nc-nc)	Female	7	6.3	111.4	(44.6-229.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.5	nc	(nc-nc)	Male	75	91.7	81.8	(64.3-102.5)
Female	0	0.7	nc	(nc-nc)	Female	71	86.0	82.6	(64.5-104.2)
<u>Lung and Bronchus</u>									
Male	5	11.9	41.8	(13.5-97.6)					
Female	11	11.7	94.4	(47.1-168.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	9.0	134.0	(69.2-234.1)	Male	6	6.3	95.5	(34.9-207.9)
Female	2	3.1	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	5	1.8	273.4	(88.1-638.1)
Female	0	1.6	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	45	39.7	113.3	(82.6-151.6)	Female	4	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	8	4.8	166.8	(71.8-328.8)
<u>Colon / Rectum</u>					Female	2	1.9	nc	(nc-nc)
Male	6	10.6	56.6	(20.7-123.2)	<u>Ovary</u>				
Female	13	9.6	135.0	(71.8-230.9)	Female	2	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.6	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	2.9	203.4	(74.3-442.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	42	35.7	117.5	(84.7-158.9)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.2	nc	(nc-nc)
Male	6	5.5	108.1	(39.5-235.3)	Female	0	1.2	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.2	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.7	188.3	(60.7-439.4)
<u>Leukemia</u>					Female	5	7.7	65.0	(21.0-151.8)
Male	4	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	8	8.9	90.3	(38.9-178.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.4	nc	(nc-nc)	Male	138	129.1	106.9	(89.8-126.3)
Female	0	1.0	nc	(nc-nc)	Female	128	126.6	101.1	(84.4-120.2)
<u>Lung and Bronchus</u>									
Male	11	16.9	65.3	(32.5-116.8)					
Female	19	16.9	112.6	(67.8-175.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.8	112.8	(67.9-176.1)	Male	6	10.9	54.8	(20.0-119.3)
Female	9	6.7	134.1	(61.2-254.6)	Female	4	9.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	9.7	92.3	(42.1-175.3)
Female	68	69.0	98.6	(76.5-124.9)	Female	10	8.8	113.5	(54.3-208.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	12	7.7	156.3	(80.7-273.1)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	19	18.7	101.7	(61.2-158.8)	<u>Ovary</u>				
Female	20	20.6	96.9	(59.1-149.6)	Female	6	6.4	93.6	(34.2-203.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.4	nc	(nc-nc)	Male	5	5.7	87.6	(28.2-204.4)
Female	1	1.3	nc	(nc-nc)	Female	3	6.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	43	58.8	73.1	(52.9-98.5)
Female	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.9	152.4	(55.6-331.7)
Male	11	9.1	121.4	(60.5-217.2)	Female	5	2.6	190.3	(61.3-444.0)
Female	11	5.6	197.3	(98.3-353.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	5	2.4	204.6	(65.9-477.4)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	13.1	53.6	(21.5-110.4)
Male	6	6.8	87.7	(32.0-191.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	5.4	184.7	(88.4-339.7)	Female	15	15.6	96.3	(53.8-158.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.6	106.6	(38.9-232.1)	Male	220	223.3	98.5	(85.9-112.4)
Female	0	2.0	nc	(nc-nc)	Female	233	240.1	97.0	(85.0-110.3)
<u>Lung and Bronchus</u>									
Male	40	30.0	133.5	(95.4-181.8)					
Female	33	33.3	99.2	(68.3-139.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.7	93.4	(44.7-171.7)	Male	5	7.1	70.4	(22.7-164.3)
Female	3	4.0	nc	(nc-nc)	Female	4	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	6.3	nc	(nc-nc)
Female	32	43.1	74.2	(50.8-104.8)	Female	7	5.3	132.9	(53.2-273.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.2	nc	(nc-nc)
Male	7	12.2	57.5	(23.0-118.5)	<u>Ovary</u>				
Female	15	12.3	122.2	(68.4-201.6)	Female	4	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.9	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	37	39.9	92.7	(65.3-127.8)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.6	nc	(nc-nc)
Male	6	6.0	99.3	(36.2-216.0)	Female	1	1.5	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	7.8	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.1	159.2	(51.3-371.4)	Female	5	9.7	51.8	(16.7-120.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.8	nc	(nc-nc)	Male	116	146.3	79.3	(65.5-95.1)
Female	2	1.2	nc	(nc-nc)	Female	111	145.6	76.2	(62.7-91.8)
<u>Lung and Bronchus</u>									
Male	15	19.5	76.8	(43.0-126.8)					
Female	11	20.3	54.1	(27.0-96.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	13.3	143.1	(86.1-223.5)	Male	5	8.7	57.2	(18.4-133.5)
Female	12	4.5	268.0	(138.3-468.2)	Female	4	6.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.5	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.7	65.2	(21.0-152.1)
Female	45	50.6	89.0	(64.9-119.0)	Female	6	6.1	98.3	(35.9-214.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	6.3	95.1	(34.7-207.0)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	12	14.8	81.2	(41.9-141.9)	<u>Ovary</u>				
Female	17	13.6	125.2	(72.9-200.5)	Female	2	4.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.7	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	25	49.8	50.2	(32.5-74.2)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	12	7.4	162.1	(83.6-283.1)	Female	2	1.7	nc	(nc-nc)
Female	7	4.0	175.6	(70.4-361.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	9.5	nc	(nc-nc)
Male	14	5.3	265.9	(145.2-446.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.6	139.3	(44.9-325.1)	Female	15	11.7	127.7	(71.4-210.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.7	107.0	(34.5-249.8)	Male	153	180.8	84.6	(71.7-99.1)
Female	2	1.4	nc	(nc-nc)	Female	166	169.6	97.9	(83.5-113.9)
<u>Lung and Bronchus</u>									
Male	26	24.4	106.4	(69.5-156.0)					
Female	19	23.7	80.2	(48.3-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	97	123.0	78.9	(64.0-96.2)	Male	33	82.0	40.2	(27.7-56.5)
Female	40	49.1	81.5	(58.2-111.0)	Female	34	75.5	45.0	(31.2-62.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	28	26.3	106.5	(70.8-154.0)	Male	22	23.5	93.5	(58.6-141.5)
Female	24	24.3	98.7	(63.2-146.8)	Female	17	21.0	80.9	(47.1-129.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	8	3.9	204.7	(88.1-403.3)	Male	68	73.4	92.6	(71.9-117.4)
Female	528	548.2	96.3	(88.3-104.9)	Female	62	67.5	91.8	(70.4-117.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	31	20.6	150.8	(102.4-214.0)	Male	64	57.9	110.6	(85.2-141.3)
<u>Colon / Rectum</u>					Female	21	28.1	74.7	(46.2-114.1)
Male	148	137.6	107.6	(91.0-126.4)	<u>Ovary</u>				
Female	151	151.2	99.8	(84.5-117.1)	Female	39	50.6	77.1	(54.8-105.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	37	33.0	112.2	(79.0-154.7)	Male	42	42.0	100.1	(72.1-135.3)
Female	13	9.4	137.9	(73.4-235.8)	Female	41	47.8	85.8	(61.6-116.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	11	12.4	88.7	(44.2-158.6)	Male	452	439.6	102.8	(93.6-112.8)
Female	15	11.5	130.3	(72.9-215.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	38	29.0	131.1	(92.8-179.9)
Male	81	68.4	118.4	(94.0-147.1)	Female	24	19.0	126.3	(80.9-187.9)
Female	47	43.7	107.5	(79.0-143.0)	<u>Testis</u>				
<u>Larynx</u>					Male	13	21.8	59.5	(31.7-101.8)
Male	19	18.3	103.9	(62.5-162.3)	<u>Thyroid</u>				
Female	8	6.6	120.8	(52.0-238.1)	Male	14	33.5	41.8	(22.9-70.2)
<u>Leukemia</u>					Female	74	113.8	65.0	(51.1-81.7)
Male	48	52.7	91.0	(67.1-120.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	43	42.3	101.6	(73.5-136.9)	Female	116	124.1	93.4	(77.2-112.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	67	42.4	157.9	(122.4-200.6)	Male	1657	1672.5	99.1	(94.4-104.0)
Female	11	15.1	73.1	(36.4-130.8)	Female	1735	1872.6	92.7	(88.3-97.1)
<u>Lung and Bronchus</u>									
Male	248	221.6	111.9	(98.4-126.7)					
Female	258	254.8	101.3	(89.3-114.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.5	118.0	(56.5-217.1)	Male	5	5.7	87.4	(28.2-203.9)
Female	4	3.0	nc	(nc-nc)	Female	5	4.5	111.6	(36.0-260.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.0	139.3	(55.8-287.1)
Female	34	35.3	96.4	(66.8-134.8)	Female	3	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.8	nc	(nc-nc)
Male	7	9.7	72.1	(28.9-148.5)	<u>Ovary</u>				
Female	7	9.5	73.7	(29.5-151.8)	Female	5	3.2	156.4	(50.4-365.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.4	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	46	33.5	137.3	(100.5-183.1)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	5	5.0	100.5	(32.4-234.5)	Female	1	1.2	nc	(nc-nc)
Female	6	2.7	221.1	(80.7-481.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.5	108.1	(43.3-222.7)
Male	5	3.4	146.4	(47.2-341.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.5	nc	(nc-nc)	Female	10	8.1	122.9	(58.8-226.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.2	nc	(nc-nc)	Male	120	119.2	100.7	(83.5-120.4)
Female	0	0.9	nc	(nc-nc)	Female	107	116.6	91.8	(75.2-110.9)
<u>Lung and Bronchus</u>									
Male	9	15.8	57.0	(26.0-108.3)					
Female	12	15.6	76.8	(39.6-134.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.5	nc	(nc-nc)	Male	5	2.1	234.5	(75.6-547.3)
Female	2	1.3	nc	(nc-nc)	Female	5	1.6	314.3	(101.3-733.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	10	12.7	78.5	(37.6-144.4)	Female	3	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	6	3.7	163.6	(59.8-356.2)	<u>Ovary</u>				
Female	6	3.8	156.0	(57.0-339.5)	Female	2	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	12.9	100.6	(53.5-172.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.9	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	47	45.5	103.3	(75.9-137.4)
Female	0	0.4	nc	(nc-nc)	Female	46	44.7	102.9	(75.3-137.2)
<u>Lung and Bronchus</u>									
Male	2	6.5	nc	(nc-nc)					
Female	2	6.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	28.1	78.2	(49.0-118.5)	Male	13	17.4	74.6	(39.7-127.6)
Female	14	11.1	126.1	(68.9-211.6)	Female	19	14.2	133.8	(80.5-208.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.7	nc	(nc-nc)	Male	6	5.2	115.8	(42.3-252.0)
Female	4	4.4	nc	(nc-nc)	Female	5	4.6	108.2	(34.9-252.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	19	15.4	123.7	(74.5-193.2)
Female	127	108.8	116.7	(97.3-138.8)	Female	13	14.2	91.7	(48.8-156.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	3.6	253.2	(115.5-480.6)	Male	13	11.8	109.7	(58.4-187.6)
<u>Colon / Rectum</u>					Female	7	5.8	120.9	(48.4-249.1)
Male	33	30.1	109.7	(75.5-154.1)	<u>Ovary</u>				
Female	34	33.5	101.6	(70.4-142.0)	Female	11	10.1	109.3	(54.5-195.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.2	111.0	(47.8-218.7)	Male	3	9.4	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	13	10.9	119.4	(63.5-204.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.9	nc	(nc-nc)	Male	79	94.4	83.7	(66.3-104.3)
Female	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	6.4	187.3	(96.7-327.3)
Male	17	14.1	120.2	(70.0-192.4)	Female	5	4.3	117.6	(37.9-274.5)
Female	10	8.9	111.8	(53.5-205.6)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.9	nc	(nc-nc)
Male	6	4.0	151.8	(55.4-330.3)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	11	6.1	178.9	(89.2-320.2)
<u>Leukemia</u>					Female	23	18.5	124.6	(78.9-186.9)
Male	16	10.6	150.3	(85.8-244.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.4	118.7	(56.8-218.3)	Female	32	24.7	129.6	(88.6-183.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	8.9	89.6	(38.6-176.5)	Male	368	357.7	102.9	(92.6-113.9)
Female	4	3.2	nc	(nc-nc)	Female	418	381.8	109.5	(99.2-120.5)
<u>Lung and Bronchus</u>									
Male	46	50.1	91.8	(67.2-122.5)					
Female	47	55.7	84.3	(62.0-112.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	31.3	89.5	(59.4-129.3)	Male	16	20.0	79.8	(45.6-129.6)
Female	13	12.3	105.6	(56.2-180.6)	Female	24	16.7	143.5	(91.9-213.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.7	105.4	(38.5-229.5)	Male	4	5.9	nc	(nc-nc)
Female	6	5.1	116.5	(42.6-253.7)	Female	6	5.2	115.0	(42.0-250.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	15	17.7	84.7	(47.4-139.7)
Female	142	129.2	109.9	(92.6-129.6)	Female	23	16.2	141.9	(89.9-212.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.3	115.0	(37.1-268.5)	Male	19	14.1	134.3	(80.8-209.8)
<u>Colon / Rectum</u>					Female	7	6.7	104.4	(41.8-215.0)
Male	36	34.3	104.8	(73.4-145.2)	<u>Ovary</u>				
Female	43	37.2	115.7	(83.7-155.9)	Female	15	11.8	126.9	(70.9-209.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	8.3	107.8	(49.2-204.7)	Male	11	10.6	103.5	(51.6-185.2)
Female	7	2.4	295.1	(118.2-608.1)	Female	16	12.0	133.3	(76.1-216.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.3	214.1	(69.0-499.5)	Male	107	111.6	95.9	(78.6-115.9)
Female	6	2.0	301.0	(109.9-655.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.3	82.4	(30.1-179.3)
Male	23	16.7	137.5	(87.2-206.4)	Female	10	4.7	214.4	(102.6-394.3)
Female	16	10.4	153.5	(87.7-249.3)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.8	nc	(nc-nc)
Male	10	4.6	217.7	(104.2-400.4)	<u>Thyroid</u>				
Female	2	1.6	nc	(nc-nc)	Male	10	7.5	132.7	(63.5-244.1)
<u>Leukemia</u>					Female	37	22.9	161.7	(113.9-222.9)
Male	8	12.2	65.4	(28.1-128.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	9.6	62.6	(22.9-136.3)	Female	22	29.6	74.4	(46.6-112.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	10.4	47.9	(15.4-111.7)	Male	425	413.7	102.7	(93.2-113.0)
Female	1	3.7	nc	(nc-nc)	Female	513	443.1	115.8	(106.0-126.2)
<u>Lung and Bronchus</u>									
Male	68	56.5	120.3	(93.4-152.5)					
Female	63	63.8	98.7	(75.8-126.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	7.2	139.3	(66.7-256.2)	Male	3	4.8	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	32	29.1	109.8	(75.1-155.0)	Female	5	3.3	153.8	(49.6-359.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.4	nc	(nc-nc)
Male	5	8.2	61.0	(19.7-142.4)	<u>Ovary</u>				
Female	6	7.0	85.1	(31.1-185.3)	Female	6	2.6	233.4	(85.2-508.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.0	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	36	27.7	130.1	(91.1-180.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.5	nc	(nc-nc)
Male	5	2.9	172.1	(55.5-401.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	9	6.7	134.7	(61.4-255.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.6	nc	(nc-nc)	Male	91	99.7	91.2	(73.5-112.0)
Female	1	0.7	nc	(nc-nc)	Female	100	93.2	107.3	(87.3-130.5)
<u>Lung and Bronchus</u>									
Male	3	13.3	nc	(nc-nc)					
Female	12	12.6	95.3	(49.2-166.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.5	133.3	(72.8-223.6)	Male	9	6.8	131.6	(60.0-249.8)
Female	6	3.6	168.3	(61.4-366.3)	Female	6	5.2	115.3	(42.1-251.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
Female	42	40.5	103.7	(74.8-140.2)	Female	5	4.9	103.0	(33.2-240.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.0	nc	(nc-nc)
Male	10	11.6	86.1	(41.2-158.4)	<u>Ovary</u>				
Female	5	10.8	46.1	(14.9-107.7)	Female	2	3.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.9	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	6	3.5	173.7	(63.4-378.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.8	nc	(nc-nc)	Male	41	38.7	106.1	(76.1-143.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.5	nc	(nc-nc)
Male	7	5.8	120.7	(48.4-248.8)	Female	2	1.3	nc	(nc-nc)
Female	6	3.2	187.8	(68.6-408.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	7.6	66.0	(21.3-154.0)
Male	4	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.9	nc	(nc-nc)	Female	20	9.3	215.5	(131.6-332.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.6	nc	(nc-nc)	Male	137	141.5	96.9	(81.3-114.5)
Female	2	1.1	nc	(nc-nc)	Female	139	135.3	102.7	(86.4-121.3)
<u>Lung and Bronchus</u>									
Male	18	19.2	93.6	(55.4-147.9)					
Female	15	18.9	79.2	(44.3-130.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	17.9	89.5	(51.1-145.3)	Male	21	12.0	174.5	(108.0-266.8)
Female	2	6.0	nc	(nc-nc)	Female	11	9.2	120.1	(59.9-214.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.6	192.1	(77.0-395.9)	Male	4	3.6	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.7	112.7	(58.1-196.8)
Female	112	74.2	150.9	(124.2-181.6)	Female	12	8.4	142.4	(73.5-248.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	4	9.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	22	20.6	106.6	(66.8-161.5)	<u>Ovary</u>				
Female	11	18.9	58.3	(29.0-104.3)	Female	5	6.6	76.2	(24.6-177.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.0	nc	(nc-nc)	Male	7	6.2	112.1	(44.9-231.0)
Female	0	1.2	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	76	68.4	111.1	(87.5-139.0)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.3	nc	(nc-nc)
Male	11	10.5	105.2	(52.4-188.2)	Female	2	2.3	nc	(nc-nc)
Female	6	5.6	106.6	(38.9-232.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.0	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	5	4.8	104.2	(33.6-243.2)
<u>Leukemia</u>					Female	15	13.8	108.3	(60.6-178.6)
Male	8	7.3	109.0	(46.9-214.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	5.1	157.7	(67.9-310.7)	Female	14	16.6	84.3	(46.0-141.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.6	nc	(nc-nc)	Male	228	249.0	91.6	(80.1-104.3)
Female	3	1.9	nc	(nc-nc)	Female	281	239.6	117.3	(104.0-131.8)
<u>Lung and Bronchus</u>									
Male	11	33.1	33.3	(16.6-59.5)					
Female	35	32.0	109.2	(76.1-151.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.0	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	13	12.9	100.9	(53.7-172.6)	Female	0	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	3.5	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	14	11.3	124.4	(67.9-208.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.8	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	40	42.2	94.7	(67.6-129.0)
Female	0	0.3	nc	(nc-nc)	Female	24	43.6	55.0	(35.3-81.9)
<u>Lung and Bronchus</u>									
Male	4	5.4	nc	(nc-nc)					
Female	1	5.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.7	115.3	(55.2-212.0)	Male	10	6.1	163.4	(78.2-300.5)
Female	5	2.7	182.9	(58.9-426.8)	Female	4	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	7	5.4	130.3	(52.2-268.5)
Female	40	36.7	108.9	(77.8-148.3)	Female	5	4.0	124.5	(40.1-290.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	1.8	285.4	(92.0-666.0)
Male	7	10.2	68.3	(27.4-140.7)	<u>Ovary</u>				
Female	8	8.6	92.9	(40.0-183.0)	Female	1	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.6	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	30	36.8	81.6	(55.0-116.5)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	7	5.5	127.7	(51.2-263.2)	Female	2	1.1	nc	(nc-nc)
Female	5	2.7	183.2	(59.0-427.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	8	7.3	109.2	(47.0-215.1)
Male	5	3.6	138.0	(44.5-322.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.4	nc	(nc-nc)	Female	14	8.4	166.2	(90.8-278.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.4	nc	(nc-nc)	Male	123	127.8	96.2	(80.0-114.8)
Female	0	0.9	nc	(nc-nc)	Female	123	116.2	105.8	(88.0-126.3)
<u>Lung and Bronchus</u>									
Male	17	16.5	103.2	(60.1-165.3)					
Female	13	15.2	85.8	(45.6-146.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	18.1	121.7	(76.2-184.2)	Male	11	11.1	98.8	(49.2-176.8)
Female	14	7.1	198.4	(108.4-333.0)	Female	12	9.1	131.9	(68.1-230.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.1	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	19	9.9	192.2	(115.7-300.2)
Female	83	70.6	117.6	(93.6-145.7)	Female	12	9.1	132.5	(68.4-231.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	6	7.7	77.7	(28.4-169.1)
<u>Colon / Rectum</u>					Female	3	3.7	nc	(nc-nc)
Male	17	19.5	87.4	(50.9-139.9)	<u>Ovary</u>				
Female	25	21.6	115.7	(74.8-170.7)	Female	5	6.5	76.6	(24.7-178.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.7	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	7	7.0	100.2	(40.1-206.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	58	61.0	95.0	(72.2-122.8)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.1	nc	(nc-nc)
Male	11	9.1	120.9	(60.3-216.3)	Female	2	2.8	nc	(nc-nc)
Female	7	5.7	122.7	(49.2-252.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	8	3.9	204.8	(88.2-403.5)
<u>Leukemia</u>					Female	15	11.9	126.5	(70.7-208.6)
Male	6	6.9	86.9	(31.7-189.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	5.4	184.7	(88.4-339.7)	Female	23	16.1	143.2	(90.7-214.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.8	nc	(nc-nc)	Male	226	230.3	98.2	(85.8-111.8)
Female	2	2.0	nc	(nc-nc)	Female	287	245.0	117.1	(104.0-131.5)
<u>Lung and Bronchus</u>									
Male	32	31.9	100.3	(68.6-141.5)					
Female	36	34.7	103.8	(72.7-143.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	20.3	98.7	(60.2-152.4)	Male	9	12.9	69.8	(31.8-132.5)
Female	13	7.4	176.3	(93.8-301.4)	Female	4	9.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	5	3.0	164.5	(53.0-383.9)	Female	3	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	11.4	105.3	(54.4-184.0)
Female	75	77.3	97.0	(76.3-121.6)	Female	6	9.7	62.0	(22.6-134.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.6	193.1	(62.2-450.5)	Male	8	9.2	87.4	(37.6-172.3)
<u>Colon / Rectum</u>					Female	2	4.0	nc	(nc-nc)
Male	17	22.1	77.0	(44.8-123.3)	<u>Ovary</u>				
Female	19	22.3	85.1	(51.2-132.9)	Female	8	7.1	113.3	(48.8-223.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.4	129.1	(51.7-266.0)	Male	5	6.9	72.7	(23.4-169.6)
Female	0	1.4	nc	(nc-nc)	Female	8	7.2	111.0	(47.8-218.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.4	nc	(nc-nc)	Male	89	72.9	122.0	(98.0-150.1)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.7	106.1	(34.2-247.5)
Male	15	10.8	139.2	(77.8-229.6)	Female	3	2.8	nc	(nc-nc)
Female	4	6.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.2	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.0	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	9	13.5	66.7	(30.4-126.6)
Male	3	7.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.7	88.0	(28.4-205.4)	Female	17	17.7	95.8	(55.8-153.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.8	88.4	(32.3-192.5)	Male	261	267.5	97.6	(86.1-110.2)
Female	1	2.2	nc	(nc-nc)	Female	248	264.4	93.8	(82.5-106.2)
<u>Lung and Bronchus</u>									
Male	28	36.5	76.6	(50.9-110.8)					
Female	36	37.8	95.2	(66.7-131.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	55.2	96.0	(71.9-125.6)	Male	26	36.6	71.1	(46.4-104.2)
Female	25	21.5	116.1	(75.1-171.4)	Female	29	31.3	92.5	(62.0-132.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	10.9	82.7	(37.7-157.0)	Male	10	10.6	94.4	(45.2-173.7)
Female	6	9.7	62.0	(22.7-135.0)	Female	16	9.2	174.8	(99.9-283.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.8	nc	(nc-nc)	Male	40	32.4	123.6	(88.3-168.3)
Female	242	234.3	103.3	(90.7-117.1)	Female	41	28.9	141.7	(101.7-192.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	8.5	82.7	(33.1-170.5)	Male	32	25.9	123.7	(84.6-174.6)
<u>Colon / Rectum</u>					Female	10	12.0	83.3	(39.9-153.3)
Male	74	61.9	119.5	(93.9-150.1)	<u>Ovary</u>				
Female	90	66.3	135.7	(109.1-166.8)	Female	19	21.4	88.6	(53.3-138.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	17	14.8	114.8	(66.9-183.9)	Male	28	18.9	148.5	(98.7-214.7)
Female	3	4.1	nc	(nc-nc)	Female	25	21.1	118.7	(76.8-175.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	4.8	188.5	(86.0-357.8)	Male	183	196.7	93.0	(80.1-107.5)
Female	6	4.1	145.6	(53.2-316.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	13.0	130.5	(76.0-209.0)
Male	31	30.6	101.3	(68.8-143.8)	Female	7	8.3	83.9	(33.6-172.9)
Female	26	18.7	139.4	(91.0-204.2)	<u>Testis</u>				
<u>Larynx</u>					Male	11	8.3	132.1	(65.8-236.3)
Male	14	8.2	170.7	(93.3-286.5)	<u>Thyroid</u>				
Female	3	2.8	nc	(nc-nc)	Male	15	14.6	103.0	(57.6-169.9)
<u>Leukemia</u>					Female	75	45.5	164.9	(129.7-206.7)
Male	19	22.5	84.5	(50.9-132.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	17.6	73.9	(39.3-126.5)	Female	47	52.6	89.3	(65.6-118.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	20	18.9	105.8	(64.6-163.5)	Male	807	743.2	108.6	(101.2-116.3)
Female	5	6.5	77.4	(24.9-180.7)	Female	885	799.1	110.7	(103.6-118.3)
<u>Lung and Bronchus</u>									
Male	133	99.7	133.4	(111.7-158.1)					
Female	122	110.7	110.2	(91.5-131.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.0	122.0	(60.8-218.3)	Male	5	6.0	83.0	(26.7-193.7)
Female	3	2.9	nc	(nc-nc)	Female	0	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.3	94.2	(30.4-219.9)
Female	28	32.5	86.0	(57.1-124.3)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.2	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	9	10.2	88.4	(40.3-167.8)	<u>Ovary</u>				
Female	13	8.9	146.2	(77.8-250.0)	Female	6	3.0	203.2	(74.2-442.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.5	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	29	34.5	84.2	(56.4-120.9)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.2	nc	(nc-nc)
Male	7	5.2	135.0	(54.1-278.2)	Female	1	1.1	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.2	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.4	nc	(nc-nc)	Female	8	7.4	108.6	(46.8-214.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.2	nc	(nc-nc)	Male	115	124.6	92.3	(76.2-110.8)
Female	0	0.9	nc	(nc-nc)	Female	110	109.3	100.6	(82.7-121.3)
<u>Lung and Bronchus</u>									
Male	18	16.7	107.9	(63.9-170.5)					
Female	24	15.1	158.8	(101.7-236.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	32.3	136.1	(98.9-182.8)	Male	20	21.2	94.2	(57.5-145.4)
Female	11	11.6	94.7	(47.2-169.5)	Female	16	16.9	94.9	(54.2-154.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.1	114.5	(45.9-235.9)	Male	6	6.2	96.2	(35.1-209.4)
Female	4	5.2	nc	(nc-nc)	Female	5	5.0	100.0	(32.2-233.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.0	nc	(nc-nc)	Male	15	18.7	80.3	(44.9-132.4)
Female	136	131.8	103.2	(86.6-122.1)	Female	18	15.8	114.2	(67.6-180.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.6	153.1	(61.4-315.5)	Male	14	15.3	91.5	(50.0-153.6)
<u>Colon / Rectum</u>					Female	8	6.6	120.6	(51.9-237.6)
Male	35	36.0	97.1	(67.6-135.1)	<u>Ovary</u>				
Female	29	35.4	82.0	(54.9-117.8)	Female	15	11.9	126.0	(70.5-207.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	8.9	113.0	(54.1-207.8)	Male	15	11.1	134.9	(75.5-222.6)
Female	4	2.2	nc	(nc-nc)	Female	11	11.2	97.8	(48.8-175.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.5	nc	(nc-nc)	Male	117	119.6	97.8	(80.9-117.2)
Female	3	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.6	78.7	(28.7-171.3)
Male	29	18.0	161.1	(107.8-231.3)	Female	8	4.4	181.5	(78.1-357.6)
Female	9	10.3	87.0	(39.7-165.2)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.0	148.3	(54.2-322.9)
Male	6	4.9	122.3	(44.7-266.2)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	7	8.2	84.9	(34.0-175.0)
<u>Leukemia</u>					Female	26	24.3	106.9	(69.8-156.6)
Male	22	12.8	171.7	(107.6-260.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	9.3	161.7	(90.4-266.6)	Female	35	30.2	115.8	(80.7-161.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	11.2	71.2	(30.7-140.4)	Male	469	438.0	107.1	(97.6-117.2)
Female	1	3.6	nc	(nc-nc)	Female	493	439.6	112.2	(102.5-122.5)
<u>Lung and Bronchus</u>									
Male	62	59.3	104.6	(80.2-134.1)					
Female	88	61.5	143.1	(114.8-176.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.7	nc	(nc-nc)	Male	5	3.0	164.5	(53.0-383.8)
Female	0	1.9	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	31	19.6	157.9	(107.3-224.1)	Female	2	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<u>Ovary</u>				
Female	6	5.6	107.1	(39.1-233.1)	Female	2	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	20	17.2	116.4	(71.1-179.8)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.1	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.4	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	5	4.6	108.6	(35.0-253.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.6	nc	(nc-nc)	Male	71	62.9	113.0	(88.2-142.5)
Female	0	0.6	nc	(nc-nc)	Female	74	67.3	109.9	(86.3-138.0)
<u>Lung and Bronchus</u>									
Male	4	8.4	nc	(nc-nc)					
Female	8	9.7	82.3	(35.4-162.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	10.1	59.3	(21.6-129.0)
Female	0	0.1	nc	(nc-nc)	Female	2	7.2	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.4	nc	(nc-nc)					
Female	0	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.0	99.7	(42.9-196.5)	Male	2	5.0	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	6	3.8	158.9	(58.0-345.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.4	157.6	(63.1-324.7)
Female	33	30.0	109.9	(75.7-154.4)	Female	4	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	5	8.7	57.2	(18.4-133.4)	<u>Ovary</u>				
Female	7	9.0	77.4	(31.0-159.4)	Female	5	2.7	182.2	(58.7-425.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	36	28.4	127.0	(88.9-175.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.9	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.9	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.3	nc	(nc-nc)	Female	8	6.8	118.2	(50.9-233.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.7	nc	(nc-nc)	Male	103	104.5	98.6	(80.5-119.6)
Female	1	0.9	nc	(nc-nc)	Female	106	103.1	102.8	(84.2-124.4)
<u>Lung and Bronchus</u>									
Male	12	14.4	83.1	(42.9-145.2)					
Female	15	14.6	102.4	(57.3-169.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	7.8	140.8	(70.2-251.9)	Male	5	5.7	88.0	(28.4-205.4)
Female	1	2.6	nc	(nc-nc)	Female	7	4.5	155.3	(62.2-320.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.0	160.3	(69.0-315.9)
Female	34	35.4	95.9	(66.4-134.0)	Female	3	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	13	9.4	137.8	(73.3-235.7)	<u>Ovary</u>				
Female	12	8.3	144.9	(74.8-253.1)	Female	6	3.2	190.2	(69.5-414.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.4	208.9	(67.3-487.4)	Male	1	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.8	nc	(nc-nc)	Male	18	33.9	53.1	(31.5-83.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	5	5.1	97.9	(31.6-228.6)	Female	0	1.0	nc	(nc-nc)
Female	5	2.6	191.8	(61.8-447.6)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	8	7.3	110.0	(47.4-216.8)
Male	1	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.3	nc	(nc-nc)	Female	5	8.2	61.3	(19.7-143.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.2	nc	(nc-nc)	Male	109	118.0	92.4	(75.8-111.4)
Female	2	0.9	nc	(nc-nc)	Female	114	111.8	102.0	(84.1-122.5)
<u>Lung and Bronchus</u>									
Male	18	14.9	120.4	(71.3-190.3)					
Female	15	14.2	105.7	(59.1-174.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.8	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	18	12.5	144.5	(85.6-228.4)	Female	2	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	5	4.0	124.8	(40.2-291.3)	<u>Ovary</u>				
Female	3	3.3	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	14.4	55.5	(23.9-109.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.9	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.3	nc	(nc-nc)	Male	35	49.9	70.1	(48.8-97.5)
Female	0	0.4	nc	(nc-nc)	Female	52	41.9	124.0	(92.6-162.6)
<u>Lung and Bronchus</u>									
Male	2	7.0	nc	(nc-nc)					
Female	4	6.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	9.0	156.0	(85.2-261.8)	Male	7	6.7	105.2	(42.1-216.7)
Female	5	3.2	157.8	(50.9-368.3)	Female	6	5.6	107.4	(39.2-233.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Female	32	43.7	73.3	(50.1-103.4)	Female	3	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	5	5.3	95.2	(30.7-222.1)
<u>Colon / Rectum</u>					Female	3	2.1	nc	(nc-nc)
Male	12	11.1	108.1	(55.8-188.8)	<u>Ovary</u>				
Female	8	10.2	78.1	(33.6-154.0)	Female	4	3.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.7	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	31	37.8	82.1	(55.8-116.5)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.3	nc	(nc-nc)
Male	5	6.0	83.9	(27.0-195.8)	Female	1	1.3	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.6	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	10	9.2	108.4	(51.9-199.4)
Male	6	4.0	151.9	(55.5-330.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.8	nc	(nc-nc)	Female	8	9.7	82.2	(35.4-161.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	3.7	214.7	(92.5-423.1)	Male	139	135.7	102.4	(86.1-121.0)
Female	0	1.0	nc	(nc-nc)	Female	126	137.6	91.6	(76.3-109.0)
<u>Lung and Bronchus</u>									
Male	22	17.0	129.6	(81.2-196.2)					
Female	22	17.4	126.5	(79.3-191.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.0	89.4	(38.5-176.1)
Female	0	0.1	nc	(nc-nc)	Female	6	7.6	78.9	(28.8-171.7)
<u>Lung and Bronchus</u>									
Male	3	1.3	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.5	108.4	(43.4-223.4)	Male	4	4.7	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	7	4.1	170.3	(68.2-350.8)
Female	36	30.1	119.6	(83.7-165.6)	Female	2	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	5	3.6	138.5	(44.6-323.3)
<u>Colon / Rectum</u>					Female	2	1.4	nc	(nc-nc)
Male	6	7.8	76.8	(28.0-167.1)	<u>Ovary</u>				
Female	3	7.3	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.9	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	18	26.2	68.7	(40.7-108.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.6	nc	(nc-nc)
Male	1	4.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.1	nc	(nc-nc)
Male	4	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.0	nc	(nc-nc)	Female	9	6.7	134.4	(61.3-255.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	2.6	196.0	(63.1-457.3)	Male	86	94.9	90.6	(72.4-111.9)
Female	0	0.7	nc	(nc-nc)	Female	99	95.7	103.4	(84.0-125.9)
<u>Lung and Bronchus</u>									
Male	13	12.1	107.3	(57.1-183.5)					
Female	12	12.4	96.6	(49.9-168.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	13.4	89.2	(46.1-155.9)	Male	13	9.2	141.8	(75.4-242.5)
Female	6	4.7	127.7	(46.6-278.0)	Female	5	7.2	69.8	(22.5-162.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	9	8.1	111.0	(50.7-210.7)
Female	63	55.7	113.2	(87.0-144.8)	Female	4	6.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	12	6.7	178.1	(91.9-311.0)
<u>Colon / Rectum</u>					Female	1	2.7	nc	(nc-nc)
Male	17	15.5	109.6	(63.8-175.5)	<u>Ovary</u>				
Female	16	14.6	109.8	(62.7-178.3)	Female	3	5.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.7	nc	(nc-nc)	Male	6	4.7	128.3	(46.9-279.4)
Female	2	0.9	nc	(nc-nc)	Female	5	4.6	109.9	(35.4-256.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	60	50.4	119.1	(90.9-153.4)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.2	nc	(nc-nc)
Male	8	7.9	101.7	(43.8-200.5)	Female	0	1.8	nc	(nc-nc)
Female	6	4.3	139.3	(50.9-303.2)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.0	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<u>Leukemia</u>					Female	9	10.8	83.3	(38.0-158.2)
Male	6	5.5	108.1	(39.5-235.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.9	154.0	(56.2-335.2)	Female	16	12.5	128.2	(73.2-208.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.9	nc	(nc-nc)	Male	221	186.8	118.3	(103.2-135.0)
Female	1	1.5	nc	(nc-nc)	Female	190	183.4	103.6	(89.4-119.5)
<u>Lung and Bronchus</u>									
Male	31	24.6	126.0	(85.6-178.8)					
Female	24	25.0	96.2	(61.6-143.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	27.8	111.5	(75.7-158.2)	Male	22	18.1	121.8	(76.3-184.4)
Female	8	10.4	76.9	(33.1-151.5)	Female	27	14.8	182.5	(120.2-265.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.2	135.0	(54.1-278.2)	Male	4	5.3	nc	(nc-nc)
Female	5	4.5	110.4	(35.6-257.7)	Female	3	4.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	11	16.0	68.9	(34.4-123.3)
Female	124	112.9	109.8	(91.3-130.9)	Female	23	13.9	165.5	(104.9-248.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.0	nc	(nc-nc)	Male	12	12.7	94.1	(48.6-164.5)
<u>Colon / Rectum</u>					Female	3	5.8	nc	(nc-nc)
Male	37	30.7	120.4	(84.7-165.9)	<u>Ovary</u>				
Female	36	31.9	112.9	(79.0-156.3)	Female	6	10.3	58.2	(21.3-126.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.4	107.8	(46.4-212.5)	Male	7	9.4	74.3	(29.7-153.0)
Female	2	2.0	nc	(nc-nc)	Female	10	10.2	98.3	(47.1-180.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.2	nc	(nc-nc)	Male	82	98.6	83.2	(66.2-103.2)
Female	0	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.5	nc	(nc-nc)
Male	8	15.1	53.1	(22.9-104.7)	Female	2	4.0	nc	(nc-nc)
Female	8	9.0	89.1	(38.4-175.6)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.6	137.3	(44.2-320.4)
Male	5	4.1	121.8	(39.2-284.2)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	6	6.9	86.5	(31.6-188.2)
<u>Leukemia</u>					Female	25	21.0	118.9	(76.9-175.5)
Male	11	11.0	100.0	(49.8-178.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	8.3	84.4	(33.8-173.9)	Female	16	25.6	62.5	(35.7-101.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	9.4	53.0	(17.1-123.8)	Male	335	369.4	90.7	(81.2-100.9)
Female	5	3.1	159.8	(51.5-373.0)	Female	396	383.5	103.3	(93.3-113.9)
<u>Lung and Bronchus</u>									
Male	42	50.1	83.8	(60.4-113.3)					
Female	53	53.6	98.9	(74.1-129.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	8	7.6	105.2	(45.3-207.2)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	6	1.8	333.5	(121.8-725.9)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	8.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	2	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	5	1.8	276.1	(89.0-644.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.8	nc	(nc-nc)	Male	26	28.6	91.0	(59.5-133.4)
Female	0	0.2	nc	(nc-nc)	Female	32	24.4	131.3	(89.8-185.4)
<u>Lung and Bronchus</u>									
Male	5	3.8	132.5	(42.7-309.2)					
Female	5	3.2	154.3	(49.7-360.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	27.4	65.7	(38.9-103.8)	Male	27	17.7	152.8	(100.7-222.4)
Female	11	10.0	109.6	(54.6-196.1)	Female	14	13.7	102.1	(55.8-171.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.1	118.0	(43.1-256.8)	Male	6	5.2	115.6	(42.2-251.5)
Female	3	4.3	nc	(nc-nc)	Female	5	4.2	118.0	(38.0-275.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	11	15.7	70.3	(35.0-125.8)
Female	133	106.5	124.9	(104.5-148.0)	Female	14	13.2	105.9	(57.8-177.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.6	nc	(nc-nc)	Male	12	12.4	96.4	(49.8-168.4)
<u>Colon / Rectum</u>					Female	4	5.5	nc	(nc-nc)
Male	31	30.5	101.8	(69.1-144.5)	<u>Ovary</u>				
Female	32	30.8	104.0	(71.1-146.9)	Female	9	9.7	93.0	(42.4-176.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.2	69.3	(22.3-161.6)	Male	13	9.3	140.3	(74.6-239.9)
Female	2	1.9	nc	(nc-nc)	Female	10	9.8	102.0	(48.8-187.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.1	nc	(nc-nc)	Male	111	94.8	117.1	(96.3-141.0)
Female	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.4	93.8	(34.3-204.3)
Male	18	14.6	122.9	(72.8-194.3)	Female	3	3.9	nc	(nc-nc)
Female	4	8.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.4	179.1	(65.4-389.7)
Male	6	4.0	150.6	(55.0-327.9)	<u>Thyroid</u>				
Female	2	1.3	nc	(nc-nc)	Male	6	6.7	89.5	(32.7-194.8)
<u>Leukemia</u>					Female	20	19.0	105.1	(64.2-162.3)
Male	7	10.9	64.5	(25.8-132.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.0	125.2	(60.0-230.3)	Female	26	23.9	108.9	(71.1-159.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	9.2	76.1	(30.5-156.9)	Male	374	360.4	103.8	(93.5-114.9)
Female	4	3.0	nc	(nc-nc)	Female	382	363.1	105.2	(94.9-116.3)
<u>Lung and Bronchus</u>									
Male	43	49.0	87.7	(63.5-118.2)					
Female	48	51.1	93.9	(69.2-124.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	54.5	102.7	(77.5-133.3)	Male	32	36.6	87.5	(59.8-123.5)
Female	20	21.0	95.0	(58.0-146.8)	Female	15	31.5	47.7	(26.7-78.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	11.1	99.4	(49.5-177.9)	Male	11	10.4	106.2	(52.9-190.0)
Female	14	9.6	146.3	(79.9-245.4)	Female	4	8.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.7	nc	(nc-nc)	Male	27	32.5	83.1	(54.8-121.0)
Female	229	221.0	103.6	(90.6-117.9)	Female	36	28.2	127.5	(89.3-176.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	8.3	132.6	(66.1-237.2)	Male	23	25.2	91.3	(57.8-136.9)
<u>Colon / Rectum</u>					Female	6	11.6	51.7	(18.9-112.5)
Male	57	60.5	94.3	(71.4-122.1)	<u>Ovary</u>				
Female	62	64.3	96.4	(73.9-123.6)	Female	19	20.8	91.5	(55.1-142.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	14.5	96.7	(52.8-162.2)	Male	20	18.5	107.9	(65.9-166.7)
Female	2	4.0	nc	(nc-nc)	Female	23	20.6	111.6	(70.7-167.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	5.9	nc	(nc-nc)	Male	162	192.5	84.2	(71.7-98.2)
Female	6	4.9	122.1	(44.6-265.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	12.8	125.1	(71.5-203.1)
Male	35	29.9	116.9	(81.4-162.6)	Female	9	8.1	110.5	(50.4-209.9)
Female	15	17.9	83.8	(46.9-138.2)	<u>Testis</u>				
<u>Larynx</u>					Male	11	11.2	98.0	(48.8-175.3)
Male	8	8.0	99.8	(43.0-196.6)	<u>Thyroid</u>				
Female	2	2.7	nc	(nc-nc)	Male	15	15.2	98.8	(55.3-163.0)
<u>Leukemia</u>					Female	46	46.1	99.7	(73.0-133.0)
Male	20	22.6	88.4	(54.0-136.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	17.3	92.6	(52.9-150.4)	Female	39	50.2	77.7	(55.2-106.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	18.4	97.6	(57.8-154.3)	Male	692	737.4	93.8	(87.0-101.1)
Female	6	6.3	95.6	(34.9-208.0)	Female	753	773.2	97.4	(90.6-104.6)
<u>Lung and Bronchus</u>									
Male	102	98.2	103.9	(84.7-126.1)					
Female	113	107.2	105.4	(86.8-126.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	11.2	53.7	(19.6-117.0)	Male	4	7.3	nc	(nc-nc)
Female	5	4.0	126.4	(40.7-295.0)	Female	3	5.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	6	6.4	93.7	(34.2-203.9)
Female	30	42.9	70.0	(47.2-99.9)	Female	6	5.3	113.2	(41.3-246.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	5.2	96.6	(31.1-225.4)
<u>Colon / Rectum</u>					Female	2	2.2	nc	(nc-nc)
Male	14	12.4	112.9	(61.7-189.5)	<u>Ovary</u>				
Female	15	12.1	124.2	(69.5-204.8)	Female	5	3.9	126.8	(40.9-295.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.0	nc	(nc-nc)	Male	7	3.8	182.8	(73.2-376.7)
Female	2	0.8	nc	(nc-nc)	Female	6	3.9	155.3	(56.7-338.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	30	40.5	74.2	(50.0-105.9)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.6	nc	(nc-nc)
Male	6	6.1	98.6	(36.0-214.6)	Female	0	1.5	nc	(nc-nc)
Female	8	3.4	233.8	(100.7-460.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	8.0	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.2	nc	(nc-nc)	Female	7	9.9	71.0	(28.4-146.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.8	nc	(nc-nc)	Male	134	149.5	89.6	(75.1-106.2)
Female	1	1.2	nc	(nc-nc)	Female	132	146.0	90.4	(75.7-107.2)
<u>Lung and Bronchus</u>									
Male	20	20.2	99.2	(60.6-153.2)					
Female	20	20.4	97.8	(59.7-151.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	28.0	150.0	(108.1-202.8)	Male	16	17.7	90.3	(51.6-146.7)
Female	11	9.9	110.6	(55.1-197.9)	Female	15	13.6	110.0	(61.5-181.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.9	102.0	(32.9-238.1)	Male	7	5.3	132.4	(53.0-272.8)
Female	3	4.2	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	22	15.5	141.9	(88.9-214.8)
Female	94	106.6	88.2	(71.3-107.9)	Female	9	13.2	68.1	(31.1-129.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.5	nc	(nc-nc)	Male	17	12.4	136.7	(79.6-218.9)
<u>Colon / Rectum</u>					Female	6	5.5	109.0	(39.8-237.3)
Male	42	30.1	139.6	(100.6-188.7)	<u>Ovary</u>				
Female	39	29.8	131.0	(93.1-179.1)	Female	11	9.8	112.7	(56.2-201.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	7.5	146.5	(73.0-262.1)	Male	16	9.5	168.4	(96.2-273.4)
Female	2	1.9	nc	(nc-nc)	Female	11	9.7	113.8	(56.7-203.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.9	nc	(nc-nc)	Male	93	101.4	91.7	(74.0-112.3)
Female	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	6.5	108.4	(43.4-223.3)
Male	17	14.8	114.9	(66.9-184.0)	Female	2	3.7	nc	(nc-nc)
Female	11	8.6	128.6	(64.1-230.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.9	nc	(nc-nc)
Male	6	4.2	144.5	(52.8-314.5)	<u>Thyroid</u>				
Female	4	1.4	nc	(nc-nc)	Male	5	6.4	78.1	(25.2-182.3)
<u>Leukemia</u>					Female	16	18.6	85.9	(49.1-139.5)
Male	11	10.7	102.9	(51.3-184.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	7.7	181.8	(99.3-305.1)	Female	21	24.8	84.5	(52.3-129.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	9.4	139.0	(73.9-237.7)	Male	446	369.0	120.9	(109.9-132.6)
Female	6	3.0	198.9	(72.6-432.9)	Female	397	362.4	109.5	(99.0-120.9)
<u>Lung and Bronchus</u>									
Male	82	51.4	159.6	(126.9-198.1)					
Female	83	52.4	158.5	(126.3-196.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.3	112.2	(41.0-244.2)	Male	1	3.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	19	20.1	94.7	(57.0-148.0)	Female	1	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	4	6.0	nc	(nc-nc)	<u>Ovary</u>				
Female	2	5.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	7	1.8	379.3	(152.0-781.5)
Female	0	0.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	19.8	65.6	(34.9-112.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.0	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.4	nc	(nc-nc)	Female	6	4.5	133.0	(48.6-289.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.9	nc	(nc-nc)	Male	59	73.3	80.5	(61.3-103.9)
Female	0	0.5	nc	(nc-nc)	Female	54	66.1	81.7	(61.4-106.6)
<u>Lung and Bronchus</u>									
Male	12	9.8	122.2	(63.0-213.4)					
Female	12	8.9	134.6	(69.5-235.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	4.2	118.0	(38.0-275.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	14.8	87.9	(46.7-150.3)
Female	0	0.1	nc	(nc-nc)	Female	11	12.2	90.2	(45.0-161.4)
<u>Lung and Bronchus</u>									
Male	3	2.0	nc	(nc-nc)					
Female	2	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	10.9	46.0	(14.8-107.4)
Female	1	0.1	nc	(nc-nc)	Female	8	8.4	95.3	(41.1-187.9)
<u>Lung and Bronchus</u>									
Male	1	1.4	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	33.1	126.9	(91.4-171.5)	Male	15	21.5	69.8	(39.0-115.1)
Female	12	13.8	86.9	(44.8-151.8)	Female	19	19.8	96.2	(57.9-150.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.2	162.3	(77.7-298.5)	Male	7	6.2	113.5	(45.5-233.9)
Female	10	5.9	170.0	(81.4-312.7)	Female	6	5.8	103.2	(37.7-224.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	16	18.9	84.5	(48.3-137.3)
Female	146	141.9	102.9	(86.9-121.0)	Female	20	18.2	109.7	(67.0-169.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.3	151.9	(65.4-299.3)	Male	17	14.4	117.9	(68.6-188.7)
<u>Colon / Rectum</u>					Female	4	7.5	nc	(nc-nc)
Male	41	36.0	113.7	(81.6-154.3)	<u>Ovary</u>				
Female	38	41.8	90.9	(64.3-124.8)	Female	18	13.2	136.7	(81.0-216.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	8.5	105.7	(48.2-200.7)	Male	14	11.1	126.5	(69.1-212.2)
Female	2	2.6	nc	(nc-nc)	Female	22	13.5	163.4	(102.4-247.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.9	nc	(nc-nc)	Male	96	111.0	86.5	(70.0-105.6)
Female	2	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	7.6	104.6	(45.0-206.1)
Male	22	17.4	126.7	(79.3-191.8)	Female	9	5.3	170.7	(77.9-324.1)
Female	4	11.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	5.5	109.3	(39.9-237.9)
Male	6	4.7	127.9	(46.7-278.4)	<u>Thyroid</u>				
Female	1	1.8	nc	(nc-nc)	Male	12	8.3	143.7	(74.2-251.1)
<u>Leukemia</u>					Female	23	28.2	81.6	(51.7-122.4)
Male	10	13.1	76.3	(36.5-140.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	10.9	100.7	(50.2-180.2)	Female	31	32.2	96.4	(65.5-136.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	10.7	93.8	(44.9-172.5)	Male	431	431.0	100.0	(90.8-109.9)
Female	7	4.1	171.5	(68.7-353.3)	Female	503	496.8	101.3	(92.6-110.5)
<u>Lung and Bronchus</u>									
Male	60	58.9	101.9	(77.8-131.2)					
Female	71	70.6	100.5	(78.5-126.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	17.2	46.4	(20.0-91.5)	Male	14	10.7	130.8	(71.5-219.5)
Female	6	5.7	104.8	(38.3-228.1)	Female	13	7.8	166.2	(88.4-284.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	5	3.2	155.0	(50.0-361.7)
Female	5	2.5	203.1	(65.4-473.9)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	9.5	115.9	(57.8-207.4)
Female	75	62.7	119.5	(94.0-149.8)	Female	12	7.6	157.4	(81.3-275.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	3	7.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	3.2	nc	(nc-nc)
Male	13	18.6	69.7	(37.1-119.2)	<u>Ovary</u>				
Female	10	17.4	57.4	(27.5-105.5)	Female	4	5.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.5	nc	(nc-nc)	Male	5	5.8	86.5	(27.9-201.9)
Female	0	1.1	nc	(nc-nc)	Female	5	5.6	89.5	(28.8-208.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.1	nc	(nc-nc)	Male	63	59.6	105.7	(81.2-135.2)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.0	nc	(nc-nc)
Male	9	8.9	101.5	(46.3-192.6)	Female	0	2.2	nc	(nc-nc)
Female	5	5.0	100.9	(32.5-235.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	7	3.8	185.6	(74.4-382.5)
<u>Leukemia</u>					Female	13	10.7	121.4	(64.6-207.6)
Male	8	6.6	122.0	(52.5-240.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.5	nc	(nc-nc)	Female	10	14.5	69.1	(33.1-127.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.7	nc	(nc-nc)	Male	193	222.2	86.9	(75.0-100.0)
Female	3	1.7	nc	(nc-nc)	Female	194	210.5	92.2	(79.7-106.1)
<u>Lung and Bronchus</u>									
Male	18	30.9	58.3	(34.5-92.1)					
Female	18	29.6	60.7	(36.0-96.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	19.2	166.8	(114.0-235.4)	Male	11	12.2	90.0	(44.9-161.0)
Female	9	7.5	119.7	(54.6-227.3)	Female	5	10.0	50.0	(16.1-116.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.5	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	0.6	nc	(nc-nc)	Male	11	10.9	101.3	(50.5-181.3)
Female	83	74.3	111.6	(88.9-138.4)	Female	7	9.7	72.4	(29.0-149.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	4	8.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	4.0	126.5	(40.8-295.3)
Male	27	21.1	128.2	(84.5-186.6)	<u>Ovary</u>				
Female	27	23.1	116.8	(77.0-170.0)	Female	9	6.9	129.8	(59.2-246.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.0	99.8	(32.2-232.9)	Male	7	6.5	108.1	(43.3-222.7)
Female	1	1.4	nc	(nc-nc)	Female	6	7.5	80.4	(29.4-175.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.5	nc	(nc-nc)	Male	61	66.2	92.1	(70.4-118.3)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.5	nc	(nc-nc)
Male	9	10.1	89.3	(40.8-169.6)	Female	1	3.0	nc	(nc-nc)
Female	9	6.1	148.4	(67.7-281.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	5	2.7	181.9	(58.6-424.4)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	7	4.6	152.2	(61.0-313.5)
<u>Leukemia</u>					Female	15	13.4	111.9	(62.6-184.5)
Male	13	7.6	172.0	(91.5-294.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.9	118.2	(47.4-243.6)	Female	20	16.7	119.5	(72.9-184.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	6.3	127.4	(54.8-251.0)	Male	281	250.6	112.1	(99.4-126.1)
Female	7	2.2	324.5	(130.0-668.6)	Female	288	261.3	110.2	(97.9-123.7)
<u>Lung and Bronchus</u>									
Male	42	34.1	123.3	(88.9-166.7)					
Female	43	36.6	117.3	(84.9-158.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	28.4	74.0	(45.8-113.1)	Male	28	18.0	155.3	(103.2-224.5)
Female	9	10.8	83.6	(38.1-158.6)	Female	27	15.1	179.3	(118.2-260.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.3	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	3	4.9	nc	(nc-nc)	Female	8	4.6	175.7	(75.6-346.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	23	16.0	143.5	(91.0-215.4)
Female	129	114.7	112.5	(93.9-133.7)	Female	13	14.3	90.7	(48.2-155.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.8	nc	(nc-nc)	Male	5	12.8	39.0	(12.6-91.0)
<u>Colon / Rectum</u>					Female	5	5.9	84.2	(27.1-196.5)
Male	17	31.0	54.8	(31.9-87.7)	<u>Ovary</u>				
Female	22	32.9	66.8	(41.9-101.2)	Female	7	10.6	66.1	(26.5-136.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	7.6	nc	(nc-nc)	Male	8	9.6	83.0	(35.8-163.7)
Female	2	2.1	nc	(nc-nc)	Female	7	10.5	66.4	(26.6-136.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	118	101.3	116.5	(96.4-139.5)
Female	5	2.3	221.1	(71.3-516.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.6	75.8	(24.4-176.9)
Male	8	15.1	52.8	(22.7-104.1)	Female	3	4.2	nc	(nc-nc)
Female	9	9.2	97.9	(44.7-185.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.0	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	12	6.6	180.5	(93.2-315.3)
<u>Leukemia</u>					Female	22	21.2	104.0	(65.1-157.4)
Male	11	11.3	97.6	(48.7-174.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	8.9	146.8	(78.1-251.1)	Female	16	25.9	61.8	(35.3-100.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	9.5	63.1	(23.0-137.4)	Male	328	374.8	87.5	(78.3-97.5)
Female	2	3.2	nc	(nc-nc)	Female	368	393.5	93.5	(84.2-103.6)
<u>Lung and Bronchus</u>									
Male	20	51.4	38.9	(23.8-60.1)					
Female	33	55.2	59.8	(41.1-83.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.1	156.2	(67.2-307.7)	Male	3	3.0	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	5	2.2	222.6	(71.7-519.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	19	18.2	104.5	(62.9-163.2)	Female	2	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	11	5.3	208.0	(103.7-372.3)	<u>Ovary</u>				
Female	6	5.4	110.9	(40.5-241.4)	Female	3	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	21	18.2	115.6	(71.5-176.7)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.3	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.6	nc	(nc-nc)	Male	64	64.9	98.7	(76.0-126.0)
Female	0	0.6	nc	(nc-nc)	Female	66	63.6	103.8	(80.3-132.0)
<u>Lung and Bronchus</u>									
Male	2	9.3	nc	(nc-nc)					
Female	12	10.0	120.4	(62.1-210.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	4.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	14.8	74.5	(37.1-133.3)
Female	1	0.1	nc	(nc-nc)	Female	9	12.6	71.4	(32.6-135.5)
<u>Lung and Bronchus</u>									
Male	4	1.9	nc	(nc-nc)					
Female	4	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.0	159.5	(68.7-314.4)	Male	7	3.1	226.8	(90.9-467.4)
Female	2	1.8	nc	(nc-nc)	Female	6	2.4	245.7	(89.7-534.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	17	18.2	93.4	(54.4-149.6)	Female	2	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	2	5.4	nc	(nc-nc)	<u>Ovary</u>				
Female	6	5.4	110.9	(40.5-241.4)	Female	1	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	18	16.5	109.3	(64.8-172.8)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	4	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.4	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.4	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	63	63.7	98.9	(76.0-126.6)
Female	0	0.5	nc	(nc-nc)	Female	72	63.5	113.4	(88.8-142.9)
<u>Lung and Bronchus</u>									
Male	5	8.8	56.5	(18.2-131.9)					
Female	12	9.0	133.3	(68.8-232.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	11.1	143.5	(82.0-233.1)	Male	3	7.1	nc	(nc-nc)
Female	5	3.6	139.5	(45.0-325.5)	Female	0	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	6.3	79.4	(25.6-185.2)
Female	37	34.1	108.4	(76.3-149.4)	Female	3	4.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	5.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.8	nc	(nc-nc)
Male	5	12.4	40.4	(13.0-94.3)	<u>Ovary</u>				
Female	4	10.8	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.9	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	26	37.7	69.0	(45.0-101.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.6	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	9	5.5	162.5	(74.2-308.5)
Male	3	4.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.7	nc	(nc-nc)	Female	7	7.8	90.2	(36.1-185.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.7	nc	(nc-nc)	Male	111	144.4	76.9	(63.2-92.6)
Female	2	1.0	nc	(nc-nc)	Female	111	120.7	92.0	(75.7-110.7)
<u>Lung and Bronchus</u>									
Male	19	19.6	96.7	(58.2-151.1)					
Female	15	17.7	84.9	(47.5-140.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.4	85.5	(36.8-168.5)	Male	9	5.8	155.2	(70.8-294.7)
Female	2	3.3	nc	(nc-nc)	Female	5	4.3	117.0	(37.7-273.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.1	117.4	(42.9-255.6)
Female	23	32.9	69.9	(44.3-104.8)	Female	7	4.3	164.6	(65.9-339.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	8	10.0	80.2	(34.5-158.0)	<u>Ovary</u>				
Female	16	10.1	159.2	(90.9-258.5)	Female	2	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.4	208.6	(67.2-486.7)	Male	2	3.1	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	32	31.4	102.0	(69.8-144.0)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.0	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	9	5.6	159.6	(72.8-303.0)
Male	0	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.5	nc	(nc-nc)	Female	7	7.4	94.4	(37.8-194.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	115	119.0	96.7	(79.8-116.0)
Female	0	1.0	nc	(nc-nc)	Female	118	114.8	102.8	(85.1-123.1)
<u>Lung and Bronchus</u>									
Male	16	16.7	95.7	(54.7-155.4)					
Female	21	16.4	127.7	(79.0-195.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.2	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	15	19.6	76.6	(42.8-126.3)	Female	2	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.1	nc	(nc-nc)
Male	6	5.5	108.2	(39.5-235.4)	<u>Ovary</u>				
Female	3	6.2	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	13	18.2	71.4	(38.0-122.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.2	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	5	4.5	111.2	(35.8-259.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.7	nc	(nc-nc)	Male	45	66.9	67.3	(49.1-90.0)
Female	0	0.6	nc	(nc-nc)	Female	59	69.2	85.3	(64.9-110.0)
<u>Lung and Bronchus</u>									
Male	10	9.3	107.2	(51.3-197.2)					
Female	15	10.1	148.1	(82.8-244.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	5	2.3	216.6	(69.8-505.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.9	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	21	18.9	111.0	(68.7-169.7)	Female	0	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	3	5.3	nc	(nc-nc)	<u>Ovary</u>				
Female	1	4.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	17	18.8	90.4	(52.6-144.8)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.5	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	6	4.4	135.3	(49.4-294.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	49	65.1	75.3	(55.7-99.5)
Female	0	0.5	nc	(nc-nc)	Female	53	59.8	88.6	(66.4-115.9)
<u>Lung and Bronchus</u>									
Male	3	8.4	nc	(nc-nc)					
Female	7	7.8	89.4	(35.8-184.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	32.1	112.2	(78.6-155.4)	Male	14	20.7	67.8	(37.0-113.7)
Female	10	12.0	83.6	(40.0-153.8)	Female	14	16.5	85.1	(46.5-142.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.9	84.2	(27.1-196.5)	Male	4	6.1	nc	(nc-nc)
Female	4	5.1	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	12	18.2	65.8	(34.0-115.0)
Female	113	123.4	91.6	(75.5-110.1)	Female	11	15.7	70.1	(35.0-125.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	4.2	282.9	(146.0-494.3)	Male	22	14.5	152.2	(95.3-230.4)
<u>Colon / Rectum</u>					Female	9	6.5	139.1	(63.5-264.1)
Male	32	35.1	91.2	(62.3-128.7)	<u>Ovary</u>				
Female	35	36.3	96.4	(67.1-134.0)	Female	7	11.4	61.3	(24.6-126.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	8.5	152.8	(81.3-261.3)	Male	10	10.9	92.1	(44.1-169.5)
Female	1	2.3	nc	(nc-nc)	Female	8	11.7	68.4	(29.4-134.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.5	nc	(nc-nc)	Male	92	113.0	81.4	(65.7-99.9)
Female	1	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.4	80.5	(29.4-175.3)
Male	12	17.1	70.2	(36.3-122.7)	Female	3	4.6	nc	(nc-nc)
Female	8	10.0	80.0	(34.4-157.6)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.2	117.8	(38.0-274.8)
Male	4	4.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.5	nc	(nc-nc)	Male	8	7.8	102.1	(44.0-201.3)
<u>Leukemia</u>					Female	19	22.7	83.8	(50.4-130.9)
Male	9	12.7	71.1	(32.4-134.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	9.5	63.4	(23.1-137.9)	Female	28	28.1	99.6	(66.2-144.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	10.8	111.3	(57.5-194.5)	Male	379	423.7	89.5	(80.7-98.9)
Female	0	3.5	nc	(nc-nc)	Female	403	427.9	94.2	(85.2-103.8)
<u>Lung and Bronchus</u>									
Male	54	58.0	93.2	(70.0-121.6)					
Female	76	60.8	125.0	(98.5-156.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	8	7.7	103.4	(44.5-203.8)	Female	4	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	11	8.2	134.1	(66.9-240.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.5	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	30	29.4	101.9	(68.8-145.5)
Female	0	0.2	nc	(nc-nc)	Female	26	25.7	101.3	(66.2-148.4)
<u>Lung and Bronchus</u>									
Male	4	4.1	nc	(nc-nc)					
Female	3	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.6	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	17	13.4	126.6	(73.7-202.8)	Female	3	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.7	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	14.4	90.1	(47.9-154.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.8	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.3	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.5	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	46	49.5	93.0	(68.1-124.0)
Female	0	0.4	nc	(nc-nc)	Female	50	43.3	115.6	(85.8-152.4)
<u>Lung and Bronchus</u>									
Male	2	6.6	nc	(nc-nc)					
Female	6	5.9	102.3	(37.4-222.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.7	96.0	(55.9-153.7)	Male	9	11.9	75.8	(34.6-144.0)
Female	7	6.9	101.6	(40.7-209.4)	Female	5	9.9	50.6	(16.3-118.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	6	3.4	175.0	(63.9-380.9)
Female	3	3.1	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.6	113.6	(58.6-198.4)
Female	75	74.0	101.3	(79.7-127.0)	Female	7	9.2	76.4	(30.6-157.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	6	8.5	70.2	(25.6-152.8)
<u>Colon / Rectum</u>					Female	1	3.8	nc	(nc-nc)
Male	17	20.3	83.9	(48.8-134.3)	<u>Ovary</u>				
Female	31	21.7	143.0	(97.1-202.9)	Female	6	6.8	88.8	(32.4-193.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.8	104.8	(33.8-244.5)	Male	4	6.1	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	5	6.8	73.3	(23.6-171.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	45	63.1	71.3	(52.0-95.4)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.2	nc	(nc-nc)
Male	8	10.0	80.1	(34.5-157.9)	Female	1	2.8	nc	(nc-nc)
Female	2	5.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.7	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	9	4.8	186.9	(85.3-354.8)
<u>Leukemia</u>					Female	9	14.3	63.0	(28.8-119.7)
Male	9	7.3	122.7	(56.0-232.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.7	106.0	(38.7-230.7)	Female	19	16.2	117.5	(70.7-183.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.2	80.6	(26.0-188.1)	Male	203	240.3	84.5	(73.3-96.9)
Female	1	2.0	nc	(nc-nc)	Female	236	252.5	93.5	(81.9-106.2)
<u>Lung and Bronchus</u>									
Male	19	31.7	59.9	(36.1-93.6)					
Female	34	34.0	100.1	(69.3-139.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	42.1	95.0	(67.8-129.3)	Male	24	27.4	87.5	(56.0-130.2)
Female	9	15.7	57.2	(26.1-108.5)	Female	18	22.3	80.9	(47.9-127.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	8.1	nc	(nc-nc)	Male	9	8.0	112.3	(51.3-213.2)
Female	7	7.0	100.1	(40.1-206.3)	Female	3	6.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	17	24.4	69.7	(40.6-111.6)
Female	183	167.2	109.5	(94.2-126.5)	Female	17	21.0	81.1	(47.2-129.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.8	138.9	(59.8-273.6)	Male	13	19.6	66.4	(35.3-113.6)
<u>Colon / Rectum</u>					Female	8	8.7	91.9	(39.6-181.1)
Male	46	46.7	98.4	(72.1-131.3)	<u>Ovary</u>				
Female	55	48.0	114.6	(86.3-149.2)	Female	17	15.5	109.8	(63.9-175.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	11.3	123.4	(67.4-207.1)	Male	7	14.4	48.6	(19.5-100.2)
Female	3	3.0	nc	(nc-nc)	Female	12	15.4	77.9	(40.2-136.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	3.6	219.9	(94.7-433.3)	Male	128	152.7	83.8	(69.9-99.7)
Female	3	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	9.9	141.8	(77.5-237.9)
Male	14	22.9	61.0	(33.3-102.4)	Female	4	6.1	nc	(nc-nc)
Female	13	13.4	97.0	(51.6-165.8)	<u>Testis</u>				
<u>Larynx</u>					Male	4	6.0	nc	(nc-nc)
Male	4	6.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	2.1	nc	(nc-nc)	Male	5	10.7	46.7	(15.1-109.0)
<u>Leukemia</u>					Female	19	31.3	60.7	(36.5-94.8)
Male	16	17.0	94.1	(53.7-152.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	12.7	102.4	(54.5-175.2)	Female	34	38.3	88.8	(61.5-124.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	14.4	76.4	(38.1-136.7)	Male	499	566.4	88.1	(80.5-96.2)
Female	4	4.7	nc	(nc-nc)	Female	546	574.7	95.0	(87.2-103.3)
<u>Lung and Bronchus</u>									
Male	79	76.1	103.8	(82.2-129.4)					
Female	78	80.5	96.8	(76.6-120.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	18.9	58.2	(29.0-104.2)	Male	19	13.7	139.1	(83.7-217.2)
Female	2	6.3	nc	(nc-nc)	Female	10	10.8	92.8	(44.4-170.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.3	115.3	(37.2-269.2)	Male	7	3.9	177.3	(71.0-365.3)
Female	5	3.4	148.2	(47.8-345.8)	Female	3	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.6	nc	(nc-nc)	Male	12	12.1	99.6	(51.4-174.0)
Female	89	86.9	102.4	(82.2-126.0)	Female	7	9.3	75.3	(30.2-155.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.2	nc	(nc-nc)	Male	14	10.7	130.2	(71.1-218.5)
<u>Colon / Rectum</u>					Female	3	4.1	nc	(nc-nc)
Male	23	23.1	99.7	(63.2-149.6)	<u>Ovary</u>				
Female	18	20.0	89.8	(53.2-142.0)	Female	5	7.6	66.0	(21.3-154.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.7	nc	(nc-nc)	Male	7	6.8	102.3	(41.0-210.7)
Female	0	1.2	nc	(nc-nc)	Female	7	6.0	116.4	(46.6-239.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.8	nc	(nc-nc)	Male	80	79.2	101.1	(80.1-125.8)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	4.7	147.6	(59.1-304.1)
Male	10	12.3	81.4	(39.0-149.7)	Female	2	2.4	nc	(nc-nc)
Female	2	6.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.8	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	7	6.0	116.3	(46.6-239.6)
<u>Leukemia</u>					Female	19	17.5	108.5	(65.3-169.4)
Male	11	8.2	134.6	(67.1-240.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	5.5	199.2	(99.3-356.4)	Female	32	19.4	164.7	(112.6-232.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.6	78.7	(28.7-171.2)	Male	286	281.7	101.5	(90.1-114.0)
Female	0	2.1	nc	(nc-nc)	Female	267	271.7	98.3	(86.8-110.8)
<u>Lung and Bronchus</u>									
Male	32	36.0	89.0	(60.9-125.7)					
Female	29	34.9	83.0	(55.6-119.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.8	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	10	7.6	130.8	(62.6-240.6)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	7.5	132.9	(63.6-244.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	25	26.3	94.9	(61.4-140.1)
Female	0	0.2	nc	(nc-nc)	Female	14	24.5	57.2	(31.2-95.9)
<u>Lung and Bronchus</u>									
Male	2	3.5	nc	(nc-nc)					
Female	0	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.6	105.9	(45.6-208.6)	Male	8	5.2	153.8	(66.2-303.0)
Female	0	2.4	nc	(nc-nc)	Female	8	3.9	206.1	(88.7-406.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	4.6	153.0	(61.3-315.2)
Female	40	30.5	131.0	(93.6-178.4)	Female	2	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.5	nc	(nc-nc)
Male	11	8.8	125.6	(62.6-224.7)	<u>Ovary</u>				
Female	6	7.6	78.5	(28.7-170.8)	Female	3	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.2	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	3	0.5	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	26	30.7	84.7	(55.3-124.1)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.8	nc	(nc-nc)
Male	3	4.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.0	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.0	nc	(nc-nc)	Female	6	7.1	84.7	(30.9-184.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	108	108.3	99.7	(81.8-120.4)
Female	0	0.8	nc	(nc-nc)	Female	103	98.6	104.5	(85.3-126.7)
<u>Lung and Bronchus</u>									
Male	11	14.1	77.9	(38.9-139.5)					
Female	14	12.9	108.5	(59.3-182.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	16.5	90.8	(50.8-149.8)	Male	12	9.8	122.3	(63.1-213.6)
Female	3	5.1	nc	(nc-nc)	Female	11	6.6	165.4	(82.5-296.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.6	227.4	(83.0-495.0)	Male	3	3.0	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	8	8.7	91.7	(39.5-180.7)
Female	60	52.9	113.5	(86.6-146.1)	Female	4	6.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	6	6.6	90.4	(33.0-196.9)
<u>Colon / Rectum</u>					Female	1	2.7	nc	(nc-nc)
Male	9	17.4	51.8	(23.6-98.3)	<u>Ovary</u>				
Female	15	15.6	96.2	(53.8-158.7)	Female	3	4.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	4.1	nc	(nc-nc)	Male	5	5.4	92.0	(29.7-214.8)
Female	1	1.0	nc	(nc-nc)	Female	10	5.0	199.3	(95.4-366.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	59	53.6	110.2	(83.9-142.1)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.7	nc	(nc-nc)
Male	3	7.9	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.1	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	8	8.7	91.9	(39.6-181.1)
Male	9	6.1	146.7	(67.0-278.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	4.0	225.9	(103.1-428.9)	Female	5	12.0	41.7	(13.4-97.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.1	nc	(nc-nc)	Male	188	204.1	92.1	(79.4-106.3)
Female	1	1.5	nc	(nc-nc)	Female	179	181.0	98.9	(85.0-114.5)
<u>Lung and Bronchus</u>									
Male	23	29.2	78.9	(50.0-118.4)					
Female	24	25.9	92.6	(59.3-137.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	22.3	134.2	(90.6-191.7)	Male	16	13.9	114.8	(65.6-186.4)
Female	11	7.4	149.5	(74.5-267.4)	Female	14	9.9	141.3	(77.2-237.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.7	nc	(nc-nc)	Male	6	4.2	143.2	(52.3-311.7)
Female	0	3.1	nc	(nc-nc)	Female	5	3.1	159.0	(51.3-371.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	12	12.2	98.2	(50.7-171.5)
Female	68	78.4	86.8	(67.4-110.0)	Female	15	9.7	153.9	(86.1-253.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	2.6	234.5	(85.6-510.4)	Male	7	9.7	71.9	(28.8-148.2)
<u>Colon / Rectum</u>					Female	6	4.1	148.1	(54.1-322.4)
Male	23	23.8	96.6	(61.2-145.0)	<u>Ovary</u>				
Female	14	21.8	64.1	(35.0-107.6)	Female	3	7.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.0	151.0	(68.9-286.7)	Male	9	7.6	119.2	(54.4-226.2)
Female	1	1.4	nc	(nc-nc)	Female	6	7.2	83.8	(30.6-182.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	91	80.7	112.8	(90.8-138.5)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.1	97.5	(31.4-227.5)
Male	13	11.6	111.7	(59.4-191.1)	Female	3	2.7	nc	(nc-nc)
Female	6	6.3	95.2	(34.8-207.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	5	3.3	152.6	(49.2-356.1)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	8	4.9	162.1	(69.8-319.4)
<u>Leukemia</u>					Female	14	13.3	105.0	(57.3-176.2)
Male	8	8.3	96.0	(41.3-189.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.6	nc	(nc-nc)	Female	17	18.4	92.5	(53.9-148.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	7.3	68.5	(22.1-159.9)	Male	298	291.6	102.2	(90.9-114.5)
Female	1	2.2	nc	(nc-nc)	Female	242	266.5	90.8	(79.7-103.0)
<u>Lung and Bronchus</u>									
Male	30	40.7	73.7	(49.7-105.2)					
Female	32	39.0	82.1	(56.2-115.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	19.6	91.7	(54.3-145.0)	Male	22	11.8	186.3	(116.7-282.0)
Female	2	7.3	nc	(nc-nc)	Female	22	9.0	243.3	(152.4-368.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.2	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	5	3.0	165.6	(53.4-386.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	8	10.5	76.1	(32.7-149.9)
Female	95	70.6	134.6	(108.9-164.6)	Female	6	9.2	65.0	(23.7-141.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	4	7.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	7	3.7	187.1	(75.0-385.5)
Male	25	20.9	119.4	(77.2-176.2)	<u>Ovary</u>				
Female	26	22.4	116.1	(75.8-170.1)	Female	9	6.5	138.8	(63.3-263.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.8	nc	(nc-nc)	Male	9	6.5	139.4	(63.6-264.6)
Female	2	1.4	nc	(nc-nc)	Female	3	7.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.1	nc	(nc-nc)	Male	66	61.5	107.4	(83.1-136.6)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.4	nc	(nc-nc)
Male	10	9.4	106.1	(50.8-195.1)	Female	1	2.9	nc	(nc-nc)
Female	4	5.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	7	4.0	177.0	(70.9-364.7)
<u>Leukemia</u>					Female	20	11.5	173.9	(106.2-268.6)
Male	6	7.5	80.5	(29.4-175.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.6	124.1	(49.7-255.8)	Female	18	15.5	115.9	(68.6-183.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.0	nc	(nc-nc)	Male	249	241.5	103.1	(90.7-116.7)
Female	3	2.1	nc	(nc-nc)	Female	290	247.9	117.0	(103.9-131.2)
<u>Lung and Bronchus</u>									
Male	24	34.1	70.4	(45.1-104.7)					
Female	38	35.8	106.2	(75.2-145.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	58.8	95.2	(71.9-123.6)	Male	42	38.2	109.9	(79.2-148.6)
Female	42	23.1	181.5	(130.8-245.4)	Female	41	32.6	125.7	(90.2-170.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	10.9	91.3	(43.7-168.0)	Male	16	11.2	143.2	(81.8-232.6)
Female	13	10.0	129.8	(69.1-222.0)	Female	8	9.9	81.2	(35.0-160.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.9	nc	(nc-nc)	Male	45	33.7	133.6	(97.5-178.8)
Female	266	248.5	107.0	(94.6-120.7)	Female	26	30.9	84.2	(55.0-123.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.7	92.3	(39.7-181.8)	Male	34	26.8	126.7	(87.7-177.1)
<u>Colon / Rectum</u>					Female	20	12.8	155.8	(95.1-240.7)
Male	76	65.0	117.0	(92.1-146.4)	<u>Ovary</u>				
Female	82	70.5	116.4	(92.6-144.5)	Female	29	22.8	127.4	(85.3-183.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	17	15.7	108.6	(63.2-173.9)	Male	21	20.0	105.2	(65.1-160.8)
Female	1	4.4	nc	(nc-nc)	Female	21	22.6	93.0	(57.6-142.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	4.6	130.2	(47.6-283.5)	Male	191	208.0	91.8	(79.3-105.8)
Female	1	4.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	13.7	94.6	(50.3-161.7)
Male	34	31.8	107.0	(74.1-149.6)	Female	5	8.8	56.6	(18.2-132.0)
Female	29	19.9	145.9	(97.7-209.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	7.8	nc	(nc-nc)
Male	15	8.7	173.2	(96.9-285.7)	<u>Thyroid</u>				
Female	4	3.1	nc	(nc-nc)	Male	21	14.6	143.6	(88.8-219.5)
<u>Leukemia</u>					Female	54	46.0	117.4	(88.2-153.2)
Male	21	23.3	90.3	(55.9-138.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	18.4	70.8	(37.6-121.0)	Female	59	56.7	104.0	(79.1-134.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	19	19.8	95.8	(57.6-149.6)	Male	832	780.7	106.6	(99.5-114.1)
Female	7	7.0	100.3	(40.2-206.7)	Female	954	848.2	112.5	(105.4-119.8)
<u>Lung and Bronchus</u>									
Male	122	106.3	114.7	(95.3-137.0)					
Female	153	119.8	127.7	(108.3-149.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	2	7.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	7.7	64.8	(20.9-151.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	19	27.6	68.8	(41.4-107.5)
Female	0	0.2	nc	(nc-nc)	Female	14	24.7	56.7	(31.0-95.1)
<u>Lung and Bronchus</u>									
Male	1	3.7	nc	(nc-nc)					
Female	1	3.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	12.4	185.8	(117.7-278.7)	Male	8	8.6	92.5	(39.8-182.3)
Female	5	4.5	111.4	(35.9-259.9)	Female	11	7.4	149.6	(74.6-267.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.7	nc	(nc-nc)
Female	49	56.1	87.3	(64.6-115.5)	Female	5	6.4	77.9	(25.1-181.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	2.1	283.3	(103.4-616.6)	Male	6	6.4	93.5	(34.1-203.4)
<u>Colon / Rectum</u>					Female	7	2.7	255.8	(102.5-527.0)
Male	16	14.4	110.9	(63.4-180.2)	<u>Ovary</u>				
Female	20	14.0	143.3	(87.5-221.4)	Female	1	5.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	3.5	198.0	(79.3-408.0)	Male	4	4.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	51	48.2	105.8	(78.8-139.1)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.0	nc	(nc-nc)
Male	15	7.5	200.0	(111.8-329.9)	Female	1	1.7	nc	(nc-nc)
Female	3	4.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.2	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	12	11.5	103.9	(53.6-181.5)
Male	8	5.3	151.0	(65.0-297.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.9	nc	(nc-nc)	Female	16	12.8	125.4	(71.6-203.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	4.6	131.0	(47.8-285.1)	Male	203	176.6	114.9	(99.7-131.9)
Female	0	1.4	nc	(nc-nc)	Female	190	183.1	103.8	(89.6-119.6)
<u>Lung and Bronchus</u>									
Male	31	22.9	135.4	(92.0-192.2)					
Female	36	24.4	147.3	(103.2-203.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	20.0	74.9	(41.9-123.6)	Male	22	12.2	180.5	(113.1-273.2)
Female	8	7.3	109.3	(47.1-215.3)	Female	9	9.3	97.0	(44.2-184.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.3	153.2	(49.4-357.6)	Male	5	3.7	136.1	(43.9-317.6)
Female	6	2.9	208.1	(76.0-452.9)	Female	1	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.8	111.1	(57.3-194.0)
Female	69	73.1	94.4	(73.4-119.5)	Female	10	9.4	106.7	(51.1-196.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.3	nc	(nc-nc)	Male	5	8.4	59.6	(19.2-139.0)
<u>Colon / Rectum</u>					Female	0	3.9	nc	(nc-nc)
Male	16	21.4	74.8	(42.7-121.5)	<u>Ovary</u>				
Female	21	22.2	94.6	(58.5-144.6)	Female	5	6.7	74.4	(24.0-173.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.1	nc	(nc-nc)	Male	7	6.7	105.2	(42.1-216.8)
Female	1	1.4	nc	(nc-nc)	Female	15	7.2	208.6	(116.7-344.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	63	66.8	94.4	(72.5-120.7)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.6	nc	(nc-nc)
Male	7	9.9	70.8	(28.4-145.8)	Female	0	2.8	nc	(nc-nc)
Female	6	5.9	100.9	(36.8-219.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.6	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	11	11.9	92.2	(46.0-165.0)
Male	3	7.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.6	108.0	(39.4-235.0)	Female	12	16.6	72.3	(37.3-126.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.4	94.3	(34.4-205.2)	Male	220	252.3	87.2	(76.0-99.5)
Female	2	2.1	nc	(nc-nc)	Female	225	253.5	88.8	(77.5-101.2)
<u>Lung and Bronchus</u>									
Male	22	35.5	62.1	(38.9-94.0)					
Female	23	36.8	62.5	(39.6-93.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.1	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	16	13.3	120.6	(68.9-195.8)	Female	2	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	<u>Ovary</u>				
Female	6	3.5	172.6	(63.0-375.7)	Female	5	1.2	415.2	(133.8-968.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	12.1	58.1	(23.3-119.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.3	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	27	42.5	63.5	(41.8-92.3)
Female	0	0.4	nc	(nc-nc)	Female	53	43.6	121.5	(91.0-158.9)
<u>Lung and Bronchus</u>									
Male	2	5.7	nc	(nc-nc)					
Female	5	6.0	83.3	(26.8-194.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.9	73.2	(31.5-144.3)	Male	4	6.2	nc	(nc-nc)
Female	5	4.3	115.9	(37.4-270.6)	Female	1	5.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.6	125.4	(50.2-258.3)
Female	27	36.6	73.8	(48.6-107.4)	Female	6	5.2	114.3	(41.7-248.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.1	nc	(nc-nc)
Male	6	11.0	54.4	(19.9-118.4)	<u>Ovary</u>				
Female	10	12.8	78.1	(37.4-143.6)	Female	3	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.6	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	52	33.3	156.1	(116.6-204.7)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.4	nc	(nc-nc)
Male	5	4.7	105.4	(34.0-246.0)	Female	1	1.7	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.7	nc	(nc-nc)
Male	4	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.2	nc	(nc-nc)	Female	4	8.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.1	nc	(nc-nc)	Male	118	129.7	91.0	(75.3-109.0)
Female	3	1.2	nc	(nc-nc)	Female	101	136.4	74.0	(60.3-90.0)
<u>Lung and Bronchus</u>									
Male	11	18.7	58.9	(29.4-105.4)					
Female	18	20.6	87.4	(51.8-138.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	22.7	127.9	(85.7-183.7)	Male	9	15.1	59.4	(27.1-112.9)
Female	12	8.1	148.7	(76.7-259.7)	Female	16	12.0	133.1	(76.0-216.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.5	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	8	3.5	231.1	(99.5-455.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	8	13.4	59.7	(25.7-117.6)
Female	109	93.0	117.2	(96.2-141.4)	Female	16	11.0	145.2	(83.0-235.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.3	nc	(nc-nc)	Male	11	10.9	100.6	(50.1-179.9)
<u>Colon / Rectum</u>					Female	7	4.6	151.3	(60.6-311.8)
Male	23	25.8	89.2	(56.5-133.8)	<u>Ovary</u>				
Female	23	25.1	91.7	(58.1-137.6)	Female	7	8.3	84.0	(33.6-173.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	6.2	nc	(nc-nc)	Male	6	7.8	77.0	(28.1-167.6)
Female	0	1.5	nc	(nc-nc)	Female	10	7.8	127.6	(61.1-234.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.9	nc	(nc-nc)	Male	70	82.4	84.9	(66.2-107.3)
Female	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.4	111.1	(40.6-241.9)
Male	17	12.8	132.4	(77.1-212.0)	Female	5	3.1	159.2	(51.3-371.6)
Female	9	7.2	124.5	(56.8-236.3)	<u>Testis</u>				
<u>Larynx</u>					Male	1	3.1	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	8	6.1	132.1	(56.9-260.4)
<u>Leukemia</u>					Female	13	17.9	72.6	(38.6-124.2)
Male	18	9.2	194.8	(115.4-307.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	6.7	nc	(nc-nc)	Female	24	20.6	116.4	(74.6-173.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	8.0	nc	(nc-nc)	Male	299	308.7	96.9	(86.2-108.5)
Female	4	2.5	nc	(nc-nc)	Female	349	309.0	112.9	(101.4-125.4)
<u>Lung and Bronchus</u>									
Male	46	41.3	111.5	(81.6-148.7)					
Female	51	42.1	121.1	(90.1-159.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	9.7	144.7	(79.0-242.7)	Male	1	6.6	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	2	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	5	1.9	260.9	(84.1-608.9)
Female	0	1.6	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Female	31	39.3	78.8	(53.6-111.9)	Female	4	4.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.4	nc	(nc-nc)	Male	6	4.9	123.5	(45.1-268.8)
<u>Colon / Rectum</u>					Female	2	1.9	nc	(nc-nc)
Male	8	11.2	71.7	(30.9-141.3)	<u>Ovary</u>				
Female	16	10.1	157.9	(90.2-256.4)	Female	4	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.7	nc	(nc-nc)	Male	5	3.4	148.3	(47.8-346.1)
Female	2	0.6	nc	(nc-nc)	Female	7	3.1	222.2	(89.0-457.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	33	36.5	90.5	(62.3-127.1)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.3	nc	(nc-nc)
Male	4	5.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	5	3.0	164.3	(52.9-383.4)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	7	7.9	88.8	(35.6-182.9)
Male	4	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.8	nc	(nc-nc)	Female	9	8.8	102.4	(46.7-194.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.5	nc	(nc-nc)	Male	124	135.2	91.7	(76.3-109.3)
Female	0	1.0	nc	(nc-nc)	Female	136	129.6	104.9	(88.0-124.1)
<u>Lung and Bronchus</u>									
Male	15	17.8	84.1	(47.0-138.7)					
Female	24	17.7	135.6	(86.9-201.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	25.1	91.7	(58.1-137.6)	Male	19	15.8	120.3	(72.4-187.8)
Female	5	9.7	51.4	(16.6-119.9)	Female	16	12.7	125.8	(71.9-204.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.5	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	10	4.0	248.6	(119.0-457.2)	Female	6	4.1	148.0	(54.0-322.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	16	14.0	114.3	(65.3-185.6)
Female	99	98.9	100.1	(81.4-121.9)	Female	11	12.6	87.6	(43.7-156.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.3	nc	(nc-nc)	Male	5	11.0	45.5	(14.7-106.2)
<u>Colon / Rectum</u>					Female	5	5.1	97.2	(31.3-226.8)
Male	31	27.4	113.3	(76.9-160.8)	<u>Ovary</u>				
Female	23	29.9	76.9	(48.7-115.4)	Female	8	9.0	88.5	(38.1-174.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.5	76.7	(24.7-178.9)	Male	5	8.4	59.4	(19.1-138.7)
Female	1	1.8	nc	(nc-nc)	Female	8	9.6	83.1	(35.8-163.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	98	85.3	114.9	(93.2-140.0)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.8	nc	(nc-nc)
Male	7	13.1	53.6	(21.5-110.4)	Female	5	3.8	130.9	(42.2-305.6)
Female	8	8.0	100.3	(43.2-197.6)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.5	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	1	5.7	nc	(nc-nc)
<u>Leukemia</u>					Female	22	17.1	128.7	(80.6-194.9)
Male	12	9.8	122.2	(63.1-213.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.7	78.0	(28.5-169.7)	Female	19	21.9	86.6	(52.1-135.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	8.2	73.4	(26.8-159.8)	Male	304	324.1	93.8	(83.6-105.0)
Female	2	2.8	nc	(nc-nc)	Female	330	341.3	96.7	(86.5-107.7)
<u>Lung and Bronchus</u>									
Male	34	44.8	75.9	(52.6-106.1)					
Female	43	48.0	89.7	(64.9-120.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	5	1.4	367.2	(118.3-856.9)	<u>Ovary</u>				
Female	1	1.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	5.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.8	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	17.1	58.4	(28.0-107.4)
Female	0	0.1	nc	(nc-nc)	Female	12	13.3	90.5	(46.7-158.1)
<u>Lung and Bronchus</u>									
Male	1	2.2	nc	(nc-nc)					
Female	2	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	21.6	106.4	(67.4-159.6)	Male	24	13.9	173.1	(110.9-257.6)
Female	8	7.9	101.8	(43.8-200.6)	Female	20	11.0	182.6	(111.5-282.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.8	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	7	3.4	208.4	(83.5-429.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	5	12.2	41.1	(13.2-95.9)
Female	91	84.7	107.5	(86.5-132.0)	Female	10	10.5	95.5	(45.7-175.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.9	nc	(nc-nc)	Male	11	9.7	112.8	(56.3-201.9)
<u>Colon / Rectum</u>					Female	1	4.4	nc	(nc-nc)
Male	27	23.6	114.2	(75.2-166.1)	<u>Ovary</u>				
Female	22	23.8	92.6	(58.0-140.2)	Female	12	7.7	155.1	(80.1-271.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.8	104.1	(38.0-226.6)	Male	11	7.3	149.7	(74.6-267.9)
Female	0	1.5	nc	(nc-nc)	Female	8	7.6	104.7	(45.1-206.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	70	77.3	90.5	(70.6-114.4)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.0	nc	(nc-nc)
Male	22	11.5	190.6	(119.4-288.6)	Female	2	3.0	nc	(nc-nc)
Female	14	6.8	206.8	(113.0-347.0)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.6	nc	(nc-nc)
Male	5	3.2	157.4	(50.7-367.2)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	8	5.2	154.1	(66.4-303.6)
<u>Leukemia</u>					Female	16	15.2	105.0	(60.0-170.6)
Male	8	8.4	95.8	(41.2-188.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.1	81.9	(26.4-191.1)	Female	22	19.5	112.6	(70.5-170.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	7.2	110.8	(47.7-218.4)	Male	320	285.6	112.0	(100.1-125.0)
Female	3	2.4	nc	(nc-nc)	Female	322	287.8	111.9	(100.0-124.8)
<u>Lung and Bronchus</u>									
Male	58	39.1	148.3	(112.6-191.7)					
Female	46	41.1	111.9	(81.9-149.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	55	43.1	127.6	(96.1-166.1)	Male	33	27.6	119.6	(82.3-168.0)
Female	22	17.1	128.3	(80.4-194.3)	Female	21	23.0	91.2	(56.5-139.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.8	76.6	(28.0-166.7)	Male	7	8.0	87.2	(34.9-179.7)
Female	10	7.0	142.0	(68.0-261.1)	Female	7	7.2	97.8	(39.2-201.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	29	24.3	119.2	(79.8-171.2)
Female	190	171.6	110.7	(95.5-127.6)	Female	27	22.2	121.8	(80.2-177.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	5.9	118.2	(47.4-243.5)	Male	21	18.7	112.5	(69.6-172.0)
<u>Colon / Rectum</u>					Female	11	9.0	121.6	(60.6-217.5)
Male	62	46.9	132.1	(101.3-169.4)	<u>Ovary</u>				
Female	51	52.0	98.1	(73.0-129.0)	Female	20	15.9	126.1	(77.0-194.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	11.1	108.6	(56.0-189.7)	Male	17	14.4	118.4	(68.9-189.5)
Female	1	3.3	nc	(nc-nc)	Female	20	16.8	119.3	(72.8-184.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.4	nc	(nc-nc)	Male	124	143.3	86.5	(72.0-103.2)
Female	2	2.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	9.9	100.7	(48.2-185.2)
Male	26	22.4	116.2	(75.9-170.2)	Female	8	6.6	121.4	(52.3-239.3)
Female	17	14.1	120.8	(70.3-193.4)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.0	116.5	(46.7-240.0)
Male	1	6.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	2.1	nc	(nc-nc)	Male	11	10.4	106.0	(52.8-189.7)
<u>Leukemia</u>					Female	34	31.3	108.5	(75.1-151.7)
Male	20	16.9	118.4	(72.3-182.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	13.4	126.9	(73.9-203.1)	Female	41	38.5	106.6	(76.5-144.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	13.9	100.7	(55.0-169.0)	Male	618	556.3	111.1	(102.5-120.2)
Female	1	5.0	nc	(nc-nc)	Female	670	601.2	111.4	(103.2-120.2)
<u>Lung and Bronchus</u>									
Male	97	76.8	126.2	(102.4-154.0)					
Female	83	86.5	95.9	(76.4-118.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	176	156.5	112.4	(96.4-130.3)	Male	61	104.0	58.7	(44.9-75.4)
Female	68	61.5	110.6	(85.9-140.2)	Female	53	90.9	58.3	(43.7-76.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	28	32.3	86.8	(57.6-125.4)	Male	28	29.6	94.4	(62.7-136.5)
Female	24	28.6	84.0	(53.8-124.9)	Female	25	25.9	96.5	(62.4-142.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	4.9	nc	(nc-nc)	Male	103	93.0	110.8	(90.4-134.4)
Female	559	647.6	86.3	(79.3-93.8)	Female	84	82.3	102.0	(81.4-126.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	34	24.1	141.3	(97.9-197.5)	Male	73	72.3	101.0	(79.1-126.9)
<u>Colon / Rectum</u>					Female	38	33.8	112.3	(79.5-154.1)
Male	154	175.3	87.8	(74.5-102.9)	<u>Ovary</u>				
Female	186	190.2	97.8	(84.2-112.9)	Female	63	60.5	104.2	(80.1-133.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	56	41.1	136.2	(102.9-176.8)	Male	48	53.0	90.5	(66.7-120.0)
Female	12	11.7	102.8	(53.1-179.6)	Female	64	60.4	105.9	(81.6-135.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	14	16.0	87.7	(47.9-147.2)	Male	522	540.4	96.6	(88.5-105.3)
Female	15	14.0	107.3	(60.0-177.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	37	36.8	100.7	(70.9-138.8)
Male	91	85.4	106.5	(85.8-130.8)	Female	32	24.1	132.5	(90.6-187.1)
Female	58	52.3	110.9	(84.2-143.3)	<u>Testis</u>				
<u>Larynx</u>					Male	19	29.0	65.5	(39.4-102.3)
Male	18	22.7	79.2	(46.9-125.1)	<u>Thyroid</u>				
Female	11	7.8	141.3	(70.4-252.8)	Male	44	42.5	103.6	(75.3-139.1)
<u>Leukemia</u>					Female	111	133.2	83.3	(68.5-100.3)
Male	61	66.0	92.4	(70.7-118.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	53	51.6	102.6	(76.9-134.3)	Female	159	144.6	110.0	(93.5-128.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	83	52.9	157.0	(125.0-194.6)	Male	2105	2098.1	100.3	(96.1-104.7)
Female	22	18.2	120.9	(75.7-183.0)	Female	2195	2257.4	97.2	(93.2-101.4)
<u>Lung and Bronchus</u>									
Male	333	278.5	119.6	(107.1-133.1)					
Female	357	309.1	115.5	(103.8-128.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.6	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	3	6.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	6.8	87.7	(32.0-190.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.6	nc	(nc-nc)	Male	27	23.2	116.2	(76.5-169.0)
Female	0	0.2	nc	(nc-nc)	Female	17	20.4	83.4	(48.6-133.6)
<u>Lung and Bronchus</u>									
Male	5	3.1	161.2	(52.0-376.3)					
Female	0	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.1	98.7	(49.2-176.7)	Male	5	7.6	65.8	(21.2-153.6)
Female	3	4.3	nc	(nc-nc)	Female	11	6.1	179.0	(89.2-320.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	6.7	148.6	(71.1-273.3)
Female	53	48.1	110.2	(82.6-144.2)	Female	1	5.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	6	2.4	245.7	(89.7-534.7)
Male	20	13.0	153.6	(93.8-237.2)	<u>Ovary</u>				
Female	9	13.7	65.7	(30.0-124.7)	Female	3	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.2	190.2	(69.5-414.0)	Male	4	3.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	56	43.0	130.3	(98.4-169.2)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.7	nc	(nc-nc)
Male	4	6.6	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.4	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	5	8.8	57.0	(18.4-132.9)
Male	3	4.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.5	nc	(nc-nc)	Female	4	10.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.2	nc	(nc-nc)	Male	174	156.5	111.2	(95.3-129.0)
Female	3	1.3	nc	(nc-nc)	Female	145	161.1	90.0	(75.9-105.9)
<u>Lung and Bronchus</u>									
Male	22	20.4	107.8	(67.5-163.2)					
Female	15	21.7	69.0	(38.6-113.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	47.3	110.0	(82.2-144.3)	Male	38	26.4	143.9	(101.9-197.6)
Female	27	17.7	152.3	(100.3-221.6)	Female	45	19.6	230.1	(167.8-307.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	6.4	nc	(nc-nc)	Male	10	8.1	123.4	(59.1-227.0)
Female	8	6.0	132.9	(57.2-261.8)	Female	8	7.2	110.6	(47.6-218.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	28	23.3	120.0	(79.7-173.4)
Female	172	152.6	112.7	(96.5-130.9)	Female	23	21.5	107.1	(67.9-160.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.3	nc	(nc-nc)	Male	22	16.3	135.1	(84.7-204.6)
<u>Colon / Rectum</u>					Female	11	8.5	128.8	(64.2-230.5)
Male	43	47.0	91.5	(66.2-123.2)	<u>Ovary</u>				
Female	45	51.5	87.4	(63.7-117.0)	Female	9	14.4	62.5	(28.5-118.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	19	11.0	172.1	(103.5-268.7)	Male	19	15.0	126.3	(76.0-197.2)
Female	5	3.4	148.7	(47.9-347.0)	Female	13	17.4	74.5	(39.6-127.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.1	234.5	(75.6-547.2)	Male	166	138.6	119.8	(102.3-139.5)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	10.2	58.8	(21.5-128.0)
Male	14	20.1	69.7	(38.1-116.9)	Female	5	6.6	75.7	(24.4-176.7)
Female	11	13.2	83.1	(41.4-148.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.8	nc	(nc-nc)
Male	4	5.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	2.1	nc	(nc-nc)	Male	12	7.5	159.7	(82.4-279.0)
<u>Leukemia</u>					Female	12	21.3	56.3	(29.0-98.3)
Male	29	16.5	176.2	(118.0-253.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	12.5	135.8	(79.1-217.4)	Female	31	35.4	87.5	(59.5-124.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	12.8	109.3	(59.7-183.5)	Male	621	545.6	113.8	(105.0-123.1)
Female	8	4.9	162.4	(69.9-319.9)	Female	611	559.3	109.2	(100.7-118.2)
<u>Lung and Bronchus</u>									
Male	92	81.5	112.9	(91.0-138.4)					
Female	98	88.2	111.1	(90.2-135.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;